

09/180,132

=> d his

(FILE 'HOME' ENTERED AT 11:38:49 ON 02 NOV 2001)

FILE 'REGISTRY' ENTERED AT 11:39:29 ON 02 NOV 2001

L1 STRUCTURE UPLOADED
L2 23 S L1
L3 STRUCTURE UPLOADED
L4 9 S L3
L5 164 S L3 FULL
L6 STRUCTURE UPLOADED
L7 106 S L6 FULL SUB=L5
L8 STRUCTURE UPLOADED
L9 70 S L8 FULL SUB=L7

FILE 'USPATFULL' ENTERED AT 11:48:27 ON 02 NOV 2001

L10 2 S L9

FILE 'CAOLD' ENTERED AT 11:49:25 ON 02 NOV 2001

L11 0 S L9

FILE 'CAPLUS' ENTERED AT 11:49:44 ON 02 NOV 2001


L12 5 S L9

FILE 'MARPAT' ENTERED AT 11:53:24 ON 02 NOV 2001

L13 0 S L9
L14 15 S L9 FULL
L15 12 S L14 NOT L12

L3 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2000 ACS (Continued)
 (Biological study); PROC (Process); USES (Uses)
 (abortifacient effects of antiprogesterins in early pregnancy in
 long-tailed macaque in relation to dose and administration route)
 RN 126784-99-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[(4-
 (dimethylamino)phenyl)-, (11.β.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L3 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1995:985962 CAPLUS
 DOCUMENT NUMBER: 124:22540
 TITLE: Pharmaceutical compositions of antigluccorticoid compounds for treating or preventing symptoms of spontaneous or narcotic-induced withdrawal.
 INVENTOR(S): Petit, Francis; Philibert, Daniel; Ullmann, Andre
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Eur. Pat. Appl., 30 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 676203	A1	19951011	EP 1995-400764	19950406
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
FR 2718354	A1	19951013	FR 1994-4156	19940408
FR 2718354	B1	19960503		
ZA 9502058	A	19960313	ZA 1995-2058	19950313
CA 2146600	AA	19951009	CA 1995-2146600	19950407
FI 9501683	A	19951009	FI 1995-1683	19950407
AU 9516326	A1	19951019	AU 1995-16326	19950407
JP 07278017	A2	19951024	JP 1995-107071	19950407
HU 71468	A2	19951128	HU 1995-1019	19950407
CN 1116929	A	19960221	CN 1995-104015	19950407
			FR 1994-4156	19940408

PRIORITY APPLN. INFO.: MARPAT 124:22540
 OTHER SOURCE(S):
 AB Antigluccorticoid steroids such as mifepristone, onapristone, lilopristone and related steroids are proposed for the prevention or treatment of withdrawal syndromes, either spontaneous or ptpd. by narcotics or mixts. of narcotics. These antigluccorticoids would be useful in the withdrawal from morphinomimetics such as heroin, morphine or methadone as well as cocaine. Pharmacol. activity was demonstrated by the effect of the antigluccorticoids on the stereotypic behavior of mice in response to narcotics. Spontaneous withdrawal syndrome was induced by administration of the opioid antagonist, naloxone. An antiprogesterone activity of the steroids in their action mechanism was eliminated. Results confirmed the involvement of endogenous glucocorticoids in morphine withdrawal since this is inhibited by antigluccorticoids or adrenalectomy.
 IT RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (RU 486 related; antigluccorticoid steroids for treatment or prevention of spontaneous opioid or narcotic-induced drug withdrawal syndrome.)

L3 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2000 ACS (Continued)
 RN 126784-99-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[(4-
 (dimethylamino)phenyl)-, (11.β.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1988:529463 CAPLUS
 DOCUMENT NUMBER: 109:129463
 TITLE: New 11-(alkynylphenyl)-substituted 19-nor and 19-nor-D-homo steroids, their formation and pharmacological activity, and processes for their preparation
 INVENTOR(S): Teutsch, Jean Georges; Klich, Michel; Philibert, Daniel
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Eur. Pat. Appl., 88 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 245170	A1	19871111	EP 1987-401018	19870504
EP 245170	B1	19891129		
R: CH, DE, GB, IT, LI, NL, SE				
FR 2598421	A1	19871113	FR 1986-6517	19860506
FR 2598421	B1	19880819		
US 4912097	A	19900327	US 1987-44958	19870430
HU 44793	A2	19880428	HU 1987-2007	19870505
HU-196224	B	19881028		
JP 62294694	A2	19871222	JP 1987-109059	19870506
			FR 1986-6517	19860506


PRIORITY APPLN. INFO.:
 AB Title steroids I (R1 = C2-8 alkynyl (un)substituted by OH, halo, trialkylsilyl, alkoxy, alkylthio, dialkylamino, or oxo; R2 = C1-3 alkyl; A/B-rings = Q1-Q5; D-ring = Q6, Q7; R3, R4 = H, C1-4 alkyl; R5 = H, OH, acycloxy, (un)substituted C1-6 alkoxy; R6 = H, C1-8 alkyl, C7-15 aralkyl; R7, R8 = H, OH, etc.; R7R8 = lactones and related groups; YZ = CH2CH2, CH:CH, 1,2-cyclopropanediyl, CHR9CH2, CH2CHR10; R9, R10 = C1-4 alkyl)
 are prepd. for use as progestogens, antiprogesterones, and/or antigluccorticoids.
 3,3-Ethylenedioxy-5,10-epoxy-estr-9(11)-en-17-one was treated with 4-(Me3SiC(C)C6H4MgBr and CuCl in THF, and the product treated with CH2:CHCH2MgBr and deprotected and dehydrated (NH4OH in aq. MeOH, then aq. HCl) to give (ethylphenyl)allylhydroxyestradienone
 II. At 10-GM in vitro, II gave 99% reversal of the dexamethasone-induced reduct. of uridine uptake by rat thymocytes (5 .times. 10-8M dexamethasone). Tablets were prepd. from 50 mg of the 17.alpha.-(chloroethynyl) analog of II. and 120 mg of a mixt. of talc, starch, and Mg stearate.
 IT 116421-73-9P 116421-74-OP
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of as drug)

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 19971740250 CAPLUS
 DOCUMENT NUMBER: 1271358992
 TITLE: Preparation of 21-substituted progesterone derivatives
 INVENTOR(S): Kim, Hyun K.; Blye, Richard P.; Rao, Pemmaraju N.;
 Cessac, James W.; Acosta, Carmie K.
 PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA;
 Kim, Hyun K.; Blye, Richard P.; Rao, Pemmaraju N.;
 Cessac, James W.; Acosta, Carmie K.
 SOURCE: PCT Int. Appl., 65 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9741145	A1	19971106	WO 97-US7373	19970430
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LV, LU, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, VZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
EP 9729304	A1	19971119	AU 97-29304	19970430
EP 900234	A1	19900310	EP 97-923523	19970430
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, SI, IE, FI				
PRIORITY APPL. INFO.:			US 96-16628	19960501
			WO 97-US7373	19970430
OTHER SOURCE(S): MARKPAT 1271358992				
AB Progesterone derivs. of formula I (R1 = OMe, SMe, NMe2, NMe, CHO, Ac, CH2CH3; R2 = halo, alkyl, acyl, OH, alkoxy, etc.; R3 = OH, alkyl, alkoxy; R4 = H, alkyl; X = O, (substituted) NH) are prep. as antiprogesterone agents. The present invention provides methods wherein				

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 1999 ACS (Continued)
 the compds. of formula I are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce labor; and for contraception. Thus, it was prep. from 3,3-ethylenedioxy-17 β -cyano-17 α -hydroxyestra-5(10),9(11)-diene and 4-bromo-N,N-dimethylaniline in 9 steps. It showed 2.79 times the antiprogesterone potency in the anti-Clauberger test compared to CDB-2914.
 IT 198414-07-2P 198414-09-4P 198414-31-2P
 RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of progesterone derivs. as antiprogesterone agents)
 RN 198414-07-2P CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17,21-bis(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11 β .)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-09-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetylthio)-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11 β .)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 198414-31-2 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-methoxy-, (11 β .)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 198414-03-8P 198414-05-0P 198414-11-8P
 198414-22-1P 198414-32-3P 198414-33-4P
 198414-34-5P 198414-39-0P 198414-43-6P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of progesterone derivs. as antiprogesterone agents)
 RN 198414-03-8 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-fluoro-, (11 β .)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 1999 ACS (Continued)




RN 198414-05-0 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-chloro-11-[4-(dimethylamino)phenyl]-, (11 β .)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-11-8 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-(acetylthio)-11-[4-(dimethylamino)phenyl]-, (11 β .)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-22-1 CAPLUS
 CN Extra-4,9-dien-3-one, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-1-


L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 1999 ACS (Continued)
oxopropyl)-, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 198414-32-3 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione,
21-(3-cyclopentyl-1-oxopropoxy)-11-[4-(
dimethylamino)phenyl]-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 198414-33-4 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione,
17-(acetyloxy)-21-(3-cyclopentyl-1-
oxopropoxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA
INDEX
NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 198414-43-6 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-bromo-11-[4-(
dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 198413-96-6P 198413-97-7P 198413-98-8P
198413-99-9P 198414-00-5P 198414-21-0P
198414-30-1P 198414-38-9P 198414-42-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of progesterone derivs. as antiprogesterational agents)
RN 198413-96-6 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione,
21-chloro-11-[4-(dimethylamino)phenyl]-
17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 198414-34-5 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(
dimethylamino)phenyl]-21-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-39-0 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(
dimethylamino)phenyl]-21-ethoxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 1999 ACS (Continued)




RN 198413-97-7 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(
dimethylamino)phenyl]-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198413-98-8 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17,21-
dihydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198413-99-9 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione,
11-[4-(dimethylamino)phenyl]-17-hydroxy-
21-[(methylsulfonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 1999 ACS (Continued)

Absolute stereochemistry.



RN 198414-00-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione,
 11-[4-(dimethylamino)phenyl]-21-fluoro-
 17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-21-0 CAPLUS
 CN Extra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-oxopropyl)-, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 198414-42-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione,
 21-bromo-11-[4-(dimethylamino)phenyl]-
 17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 198414-40-3P 198414-41-4P
 RL SPM (Synthetic preparation); PREP (Preparation)
 (pregn. of progesterone derivs. as antiprogesterational agents)
 RN 198414-40-3 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17,21-bis(acetyloxy)-11-[4-(dimethylamino)phenyl]-3-oxime-, (3E,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 198414-30-1 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione,
 11-[4-(dimethylamino)phenyl]-17-hydroxy-
 21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-38-9 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione,
 11-[4-(dimethylamino)phenyl]-21-ethoxy-
 17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 198414-41-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-methoxy-, 3-oxime-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



=> d ibib ab fqhit 1-13

L7 ANSWER 1 OF 13 MARPAT COPYRIGHT 1999 ACS

ACCESSION NUMBER:

129:50105 MARPAT

TITLE:

Uses of anti-glucocorticoid compounds for the treatment of psychoses or addictive behaviors
 Oberlander, Claude; Piazza, Pier Vincenzo
 Hoechst Marion Roussel, Fr.; Oberlander, Claude; Piazza, Pier Vincenzo
 PCT Int. Appl., 41 pp.
 CODEN: PIXXD2

SOURCE:

PCT Int. Appl., 41 pp.

DOCUMENT TYPE:

Patent

LANGUAGE:

French

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9826783	A1	19980625	WO 97-FR2320	19971217
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
FR 2757400	A1	19980626	FR 96-15649	19961219
AU 9855632	A1	19980715	AU 98-55632	19971217
EP 892641	A1	19990127	EP 97-952078	19971217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, NL, SE, MC, PT, IE, FI				
PRIORITY APPLN. INFO.: FR 96-15649 19961219				
WO 97-FR2320 19971217				
AB Glucocorticoid antagonists, except mifepristone, are used as dopamine type II receptor antagonists to treat psychotic or addictive behavior.				
Thus, 17.beta.-hydroxy-10.beta.-[(4-methylphenyl)methyl]-17.alpha.-(1-propenyl)estra-4,9(11)-dien-3-one considerably reduced the response to morphine in vivo.				

MSTR 1

L7 ANSWER 1 OF 13 MARPAT COPYRIGHT 1999 ACS

(Continued)



L7 ANSWER 3 OF 13 MARPAT COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 124:22540 MARPAT
 TITLE: Pharmaceutical compositions of antigluccorticoid compounds for treating or preventing symptoms of spontaneous or narcotic-induced withdrawal.
 INVENTOR(S): Petit, Francis; Philibert, Daniel; Ulmann, Andre
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Eur. Pat. Appl., 30 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 676203	A1	19951011	EP 95-400764	19950406
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT,				

SE	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	FR 2718354	A1	19951013	FR 94-4156	19940408
	FR 2718354	B1	19960503		
	ZA 9502058	A	19960313	ZA 95-2058	19950313
	CA 2146600	AA	19951009	CA 95-2146600	19950407
	FI 9501683	A	19951009	FI 95-1683	19950407
	AU 9516326	A1	19951019	AU 95-16326	19950407
	JP 07278017	A2	19951024	JP 95-107071	19950407
	HU 71468	A2	19951128	HU 95-1019	19950407
	CN 1116929	A	19960221	CN 95-104015	19950407
				FR 94-4156	19940408

PRIORITY APPLN. INFO.:
 AB Antigluccorticoid steroids such as mifepristone, onapristone, lilopristone and related steroids are proposed for the prevention or treatment of withdrawal syndromes, either spontaneous or ptted. by narcotics or mixts. of narcotics. These antigluccorticoids would be useful in the withdrawal from morphinomimetics such as heroin, morphine or methadone as well as cocaine. Pharmacol. activity was demonstrated by the effect of the antigluccorticoids on the stereotypic behavior of mice in response to narcotics. Spontaneous withdrawal syndrome was induced by administration of the opioid antagonist, naloxone. An anti-progesterone activity of the steroids in their action mechanism was eliminated. Results confirmed the involvement of endogenous glucocorticoids in morphine withdrawal since this is inhibited by antigluccorticoids or adrenalectomy.

MFTR 2

L7 ANSWER 4 OF 13 MARPAT COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 123:218391 MARPAT
 TITLE: Steroids for reducing multidrug resistance to cancer
 INVENTOR(S): Cohn, Suzanne Bourgeois; Gruol, Donald J.
 PATENT ASSIGNEE(S): Salk Institute for Biological Studies, USA
 SOURCE: PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9517192	A1	19950629	WO 94-US14624	19941219
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES,				


FI,	GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD,
MG,	MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT,
UA,	US, UZ
RU:	KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT,
LU,	MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE,
SN,	TD, TG

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
AU 9514395	A1	19950710	AU 95-14395	19941219
PRIORITY APPLN. INFO.: US 93-173243 19931222 WO 94-US14624 19941219				

AB Certain steroid-like compds. [I: R1 = H; R2 = OR; or R1R2 = :O; R = H, lower alkyl, Me3Si; R3 = H, Me, or absent if double bond or epoxide bridge joins C9 and C10; R4 = OR', C4-18 cyclic org. group contg. O, N, P, or Si; R' = lower alkyl, Me3Si; R5 = H, OR; or R5C16C17 form a 3-, 5-, 6-, or 7-membered rings; R6 = C(O)CH3, CH(OH)CH3, C(O)CH2OH, (substituted) hydrocarbyl; R9 = H, halo, or absent if double bond or epoxide bridge joins C9 and C10] are capable of inhibiting the P-glycoprotein-associated efflux pump which is considered responsible for multidrug resistance. Chemotherapy can be enhanced by facilitating the accumulation of drug at the target site, with reduced or eliminated competition by the drug efflux system. Thus RU 38486, an anti-progesterin, at 5 .mu.M facilitated killing of multidrug-resistant S7CD-5 murine thymoma cells by 20 .mu.M puromycin.

MFTR 18

L7 ANSWER 3 OF 13 MARPAT COPYRIGHT 1999 ACS (Continued)




G1 = Ph (SO (1-) G2)
 G2 = alkoxy<(6-)>
 G4 = 21

C(O)G5
 21

G5 = alkyl (SR G13)
 G6 = alkyl<(1-12)> (SO (1-) G7)
 G9 = O
 DER: and pharmaceutically acceptable addition salts
 DER: and pharmaceutically acceptable addition salts
 MPL: claim 7

L7 ANSWER 4 OF 13 MARPAT COPYRIGHT 1999 ACS (Continued)



G1 = C(O)
 G3 = loweralkyl
 G10 = Ph (SO (1-2) G16)
 G11 = OH
 G13 = 36

C(O)CH2-OH
 36

G16 = 41

O-G3
 41

MPL: claim 1

L7 ANSWER 5 OF 13 MARPAT COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 122:256423 MARPAT
 TITLE: Antiglucocorticoid steroids for the treatment of anxiety disorders
 INVENTOR(S): Peeters, Bernardus Wynand Machijs Maria
 PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.
 SOURCE: PCT Int. Appl., 25 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9504536	A1	19950216	WO 94-EP2513	19940728
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KG, KP, KR, KZ, LK, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9474968	A1	19950228	AU 94-74968	19940728
AU 687088	B2	19980219		
EP 712311	A1	19960522	EP 94-924819	19940728
EP 712311	B1	19981007		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09501172	T2	19970204	JP 94-506200	19940728
AT 171873	E	19981015	AT 94-924819	19940728
ES 2124905	T3	19990216	ES 94-924819	19940728
US 5741178	A	19980421	US 96-581631	19960118

PRIORITY APPLN. INFO.:
 EP 93-202304 19930804
 EP 94-924819 19940728
 WO 94-EP2513 19940728

AB Antiglucocorticoid steroids are used for the manuf. of a pharmaceutical compn. for the treatment of anxiety disorders. The anxiolytic effect of

11.beta.-(4-dimethylaminophenyl)-17.beta.-hydroxy-17.alpha.-(prop-1-ynyl)-estra-4,9-dien-3-one (RU38486) was demonstrated in animal testing (antagonism of fear-potentiated startle). Prepn. and activity (antagonism of stress-induced hyperthermia) of selected steroids of the invention is also described.

MPTR 1


L7 ANSWER 6 OF 13 MARPAT COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 116:35156 MARPAT
 TITLE: Preparation and use of antiprogesteromimetics for synchronization of parturition in livestock
 INVENTOR(S): Grandadam, Jean Andre
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Eur. Pat. Appl., 13 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 446124	A2	19910911	EP 91-400594	19910305
EP 446124	A3	19920527		
R: AT, BE, CH, DE, DK, FR, GB, GR, IT, LI, LU, NL, SE				
FR 2659233	A1	19910913	FR 90-2783	19900306
FR 2659233	B1	19940121		
CA 2037549	AA	19910907	CA 91-2037549	19910305
AU 9172608	A1	19910912	AU 91-72608	19910305
AU 642975	B2	19931104		
ZA 9101603	A	19920527	ZA 91-1603	19910305
JP 04211610	A2	19920803	JP 91-62496	19910305
RU 2037295	C1	19950619	RU 91-4895041	19910305
CN 1055665	A	19911030	CN 91-102108	19910306
HU 59006	A2	19920428	HU 91-729	19910306


PRIORITY APPLN. INFO.:
 FR 90-2783 19900306

AB The title antiprogesteromimetics are I (R1 = C1-18 hydrocarbyl optionally substituted with .gtoreq.1 heteroatoms and bonded to the steroid by a C; R2 = C1-8 hydrocarbyl; X = remainder of 5- and 6-membered ring optionally substituted and optionally unsatd.; C = A = CNOH, oxo (free or blocked as ketal), etc.; B and C together form a double bond or epoxide bridge) and acid addn. salts thereof. Prepn. of 2 I are described. 17.beta.-Hydroxy-11.beta.-(4-dimethylaminophenyl)-17.alpha.-(prop-1-ynyl)estra-4,9-dien-3-one (II) was more effective at synchronizing parturition than cloprostenol when tested in sows. Injectable pharmaceuticals contg. II are disclosed.


MPTR 1C



L7 ANSWER 5 OF 13 MARPAT COPYRIGHT 1999 ACS (Continued)



G7 = 44




G11 = alkyl<(1-6)> (SO (1-) G12)
 G16 = alkylcarbonyl<(1-5)> (SO (1-) G17)
 G18 = 39




MPL: claim 2


L7 ANSWER 6 OF 13 MARPAT COPYRIGHT 1999 ACS (Continued)



G1 = 30
 G3 = 55-13 57-14



G9 = alkenyl<(2-8)>
 G15 = 61



G1 = C(=O)CH2-OH
 G4 + G17 = O
 DER: and protected derivatives
 DER: and acid addition salts
 MPL: claim 1

L7 ANSWER 7 OF 13 MARPAT COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 115:214857 MARPAT
 TITLE: Injectable microspheres containing
 antiestrogenic and antiprogesteromimetic steroids
 INVENTOR(S): Cohen, Gerard; Dubois, Jean Luc
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Ger. Offen., 15 pp.
 CODEN: GWXXEX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4036425	A1	19910516	DE 90-4036425	19901115
FR 2654337	A1	19910517	FR 89-14976	19891115
SE 9003570	B1	19940805		
BE 1005511	A4	19930831	SE 90-3570	19901109
DK 9002709	A	19910516	BE 90-1062	19901109
CA 2029940	AA	19910516	DK 90-2709	19901113
JP 03294229	A2	19911225	CA 90-2029940	19901114
CH 681691	A	19930514	JP 90-306374	19901114
NL 9002492	A	19910603	CH 90-3611	19901114
GB 2239798	A1	19910717	NL 90-2492	19901115
GB 2239798	B2	19931027	GB 90-24662	19901115
AT 9002313	A	19950415	AT 90-2313	19901115
AT 400298	B	19951127		


PRIORITY APPLN. INFO.: FR 89-14976 19891115
 AB Biodegradable microspheres comprise the title steroids (Markush given) and copolymers of lactic acid with glycolic acid. A mixt. of 250 mL aq. 0.3% hydrolyzed PVA soln., 1 g poly(DL-lactic acid-glycolic acid), 17 g CH2Cl2, and 0.5 g 17.beta.-hydroxy-11.beta.-(4-(dimethylamino)phenyl)-17.alpha.-(1-propenyl)estra-4,9-dien-3-one was emulsified, followed by stirring at 22.degree. and decreasing pressure (gtoreq.400 mm Hg) to give microspheres, which were used for the prepn. of injections.

MSTR 1A


G1—G3

G1 = 3


L7 ANSWER 7 OF 13 MARPAT COPYRIGHT 1999 ACS (Continued)




G2 = Me
 G3 = 24



G5 = 68-26 70-27



G9 = 74



G10 = OH
 G13 = alkenyl<(2-8)>
 MPL: claim 6


L7 ANSWER 8 OF 13 MARPAT COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 115:151901 MARPAT
 TITLE: Use of antiprogesteromimetics for stimulating
 ovulation, and new preparation for use in pharmaceutical
 compositions
 INVENTOR(S): Grandadan, Jean Andre
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Eur. Pat. Appl., 24 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 417003	A2	19910313	EP 90-402449	19900906
EP 417003	A3	19911204		
EP 417003	B1	19940629		
R: AT, EE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE				
FR 2651435	A1	19910308	FR 89-11699	19890907
FR 2651435	B1	19940422		
US 5173493	A	19921222	US 90-578894	19900905
CA 2024728	AA	19910308	CA 90-2024728	19900906
AU 9062259	A1	19910314	AU 90-62259	19900907
AU 623805	B2	19920521		
JP 03099015	A2	19910424	JP 90-236004	19900907

PRIORITY APPLN. INFO.: FR 89-11699 19890907
 AB Anti-progesteromimetic compds., e.g. I [R1 = C1-18 hydrocarbyl with optionally .gtoreq.1 heteroatoms, bonded to the steroid by a C; R2 = C1-8 hydrocarbyl; X = rest of 5- or 6-membered (substituted) (unsatd.) ring; A:C = oxo (free or in ketal), CH(OH), CH(OR3), CH(O2CR3), etc.; R3 = C1-8 alkyl, C7-15 aralkyl; B and C together form a double bond or epoxide bridge] and their acid and base addn. salts, are used for making pharmaceuticals for stimulating ovulation, e.g. in cows. The compds. of the invention are preferably used following treatment with progesterone or a progesteromimetic, e.g. 3-oxo-17.alpha.-allyl-17.beta.-hydroxyestra-4,9,11-triene (II). Thus, heifer cows were 1st administered II for 17 days; on the day following the last administration, the animals were injected with 17.beta.-hydroxy-11.beta.-(4-(dimethylaminophenyl)-17.alpha.-(prop-1-ynyl)estra-4,9-dien-3-one. All of the heifers came to heat after a very short delay period, and LH levels rose very rapidly. Prepn. of 12 anti-progesteromimetics is presented.

MSTR 1B

L7 ANSWER 8 OF 13 MARPAT COPYRIGHT 1999 ACS (Continued)



G1 = 85



G10 = 5Me
 G12 = alkenyl<(2-8)> (50 (1-) X) / 96



G14 = 98



G15 = OH
 G5 + G6 = O
 DER: or acid or base addition salts
 MPL: claim 2
 NTE: oxo formed by G5 and G6 may be protected as a ketal

L7 ANSWER 9 OF 13 MARPAT COPYRIGHT 1999 ACS

ACCESSION NUMBER: 115:9125 MARPAT

TITLE: Preparation of

.omega.-(3-oxoestra-4,9-dien-11.beta.-yl)phenylamino]alkenones as antigluccorticoids

INVENTOR(S): Moguilevsky, Martine; Nedelec, Lucien; Nique, Francois; Philibert, Daniel

PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.

SOURCE: Eur. Pat. Appl., 33 pp.

DOCUMENT TYPE: CODEN: EPXXDW

LANGUAGE: Patent

FAMILY ACC. NUM. COUNT: 1 French

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 414606	A2	19910227	EP 90-402328	19900822
EP 414606	A3	19910724		
EP 414606	B1	19941102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
FR 2651233	A1	19910301	FR 89-11173	19890823
FR 2651233	B1	19911213		
CA 2022648	AA	19910224	CA 90-2022648	19900803
ZA 5006544	A	19911030	ZA 90-6341	19900810
US 5166146	A	19921124	US 90-568597	19900816
JP 63090097	A2	19910416	JP 90-217281	19900820
IL 95451	A1	19950731	IL 90-95451	19900821
AU 9061189	A1	19910228	AU 90-61189	19900822
AU 634569	B2	19930225		
HU 54706	A2	19910328	HU 90-5275	19900822
HU 208154	B	19930830		
ES 2063313	T3	19950101	ES 90-402328	19900822
CN 1051362	A	19910515	CN 90-107161	19900823
CN 1033808	B	19970115		
RU 2041236	C1	19950809	RU 92-5011511	19920518
			FR 89-11173	19890823

PRIORITY APPLN. INFO.:

AB The title compds. (I: R1 = aliph. hydrocarbyl; R2 = H,

(un)substituted alkyl; R5, R6 = H, alkyl; X = atoms to complete an (un)substituted

5- or


6- membered ring; Z = (un)substituted CO2H; n = 1-6) were prepd. Thus, aminophenylestradienone II (R = R5 = R6 = H) was condensed with BrCH2CO2Me

to give, after sapon., II (R = CH2CO2Na, R5 = R6 = H) which at 10-6M

in vitro gave 82% inhibition of uridine incorporation into rat thymocytes.

MSTR 2A

L7 ANSWER 9 OF 13 MARPAT COPYRIGHT 1999 ACS (Continued)

G3 = phenylene
G4 = alkylamino<(1-12)>
G9 = 39-18 37-17

G16-G10-CH2

G10 = (1-2) 45

G11-G12

G13 = alkyl<(2-8)> (50) / 53

G13(O)-CH2-OH

G16 = 68

G13-G13

DER: and protected derivatives
MPL: claim 7

L7 ANSWER 10 OF 13 MARPAT COPYRIGHT 1999 ACS

ACCESSION NUMBER: 114:229227 MARPAT

TITLE: Preparation of 19-nor 3-oxo steroids with an amine

INVENTOR(S):

Lucien;

Philibert, Daniel

Roussel-UCLAF, Fr.

SOURCE: Eur. Pat. Appl., 29 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 389370	A1	19900926	EP 90-400784	19900322
EP 389370	B1	19940427		
R: CH, DE, FR, GB, IT, LI, NL				
FR 2644789	A1	19900928	FR 89-3742	19890322
FR 2644789	B1	19950203		
JP 02273693	A2	19901108	JP 90-68508	19900320
JP 2848907	B2	19990120		
US 5108996	A	19920428	US 90-497562	19900321
			FR 89-3742	19890322

PRIORITY APPLN. INFO.:


AB The title compds. (I: R1, R2 = H, Me; R11 =

(poly) (hetero)hydrocarbyl; one of R17 and R18 is OH or acyloxy and the other is Q; Z = alkylene, alkenylene, alkynylene; P = (substituted) pyrimidinyl, pyridyl) were prepd. via reacting the halo derivs. II or III (X = halo) with the appropriate pyrimidinyl or pyridine deriv. IV. Reaction of

estradienone V [R3 = 3-bromo-1-propynyl, R4 = OH] (prepn. given) was reacted with 2,4-bis(1-pyrrolidinyl)-6-(1-piperazinyl)pyrimidine (prepn. given) in acetone contg. K2CO3 at ambient temp. for 2 h to give V [R3 =


3-[4-[2,6-bis(1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-1-propynyl; R4 = OH]. At 5 .times. 10-4 M this inhibited in vitro the formation of malonyldialdehyde, a measure of lipid peroxidn., in rat brain homogenate by .apprx.47.5%.

MSTR 3



L7 ANSWER 10 OF 13 MARPAT COPYRIGHT 1999 ACS (Continued)

G2 = 107



G4 = OH

G14 = NMe2

MPL: claim 13

NTE: the alkylamino and dialkylamino groups in G11 may be interrupted by oxygen, sulfur, or nitrogen

L7 ANSWER 11 OF 13 MARPAT COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 111:23356 MARPAT
 TITLE: New 11-aryl steroids useful as antiprogestins, their preparation, and pharmaceuticals containing them
 INVENTOR(S): De Jongh, Hendrik Paul; Van Vliet, Nicolaas
 PATENT ASSIGNEE(S): AKZO N. V., Neth.
 SOURCE: Eur. Pat. Appl., 10 pp.
 CODEN: EFXDXW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 321010	A1	19890621	EP 88-202678	19881125
EP 321010	B1	19930203		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
AT 85342	E	19930215	AT 88-202678	19881125
ES 2053714	T3	19940801	ES 88-202678	19881125
ZA 8808996	A	19890830	ZA 88-8996	19881130
AU 8826469	A1	19890615	AU 88-26469	19881201
AU 613433	B2	19910801		
US 4921845	A	19900501	US 88-281582	19881208
CA 1301162	A1	19920519	CA 88-585297	19881208
DK 8806880	A	19890613	DK 88-6880	19881209
DK 168444	B1	19940328		
FI 8805717	A	19890613	FI 88-5717	19881209
FI 89056	E	19930430		
FI 89056	C	19930810		
CN 1034731	A	19890816	CN 88-108484	19881212
CN 1019807	B	19921230		
JP 01211597	A2	19890824	JP 88-313643	19881212
			NL 87-3008	19871212
			EP 88-202678	19881125

PRIORITY APPLN. INFO.:

AB Aryl steroids I [R1 = aryl substituted by -NXY; X, Y = H, Cl-4 hydrocarbyl; or XY = C2-6 hydrocarbyl forming 3- to 7-membered ring; R2 = H, OH, acyloxy, alkoxy, (un)satd. Cl-8 hydrocarbyl with .gtoreq.1 OH, oxo, N3, cyano, and/or halo group; R3 = OH, acyloxy, alkoxy, or acyl optionally substituted by OH, alkoxy, acyloxy, or halo; or R2R3 forms ring; R2 .noteq. H or OH when R3 = OH; R4 = Me, Et], which are strong antiprogestins with little or no antiglucocorticoid activity (no data), are prepd. Thus, 7.beta.-methylster-5-(10)-ene-3,17-dione 3,3-di-Me acetal underwent NaBH4 redn., deketalization, bromination/dehydrobromination, reketalization, and epoxidn., to give 5.alpha., 10.alpha.-epoxy-17.beta.-hydroxy-7.beta.-methylster-9(11)-en-3-

L7 ANSWER 11 OF 13 MARPAT COPYRIGHT 1999 ACS (Continued)
 one 3,3-ethylene acetal. This underwent CuCl-catalyzed coupling with p-(Me2N)C6H4MgBr, Oppenauer oxidn. of 17-OH, alkylation with THP-CH2C.tplbond.CMgBr (THP = tetrahydropyranyl), and deprotection, to give (dimethylaminophenyl)hydroxy(hydroxypropynyl)methylsteradienone II.

MSTR 1



G1 = phenylene
 G3 = 24



G4 = Ak<(1-4)>
 G5 = Ak<(1-8)> (SR (1-) G7)
 G6 = 35



G12 = Ak (SO (1-) G10)
 G14 = 42



MPL: claim 1


L7 ANSWER 12 OF 13 MARPAT COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 110:213172 MARPAT
 TITLE: 13(Alpha)-alkylgonanes, their production, and pharmaceutical preparations containing same
 INVENTOR(S): Neef, Guenter; Wiechert, Rudolf; Beier, Sybille;
 Elger, Walter; Henderson, David
 PATENT ASSIGNEE(S): Schering A.-G., Fed. Rep. Ger.
 SOURCE: U.S., 5 pp. Cont. of U.S. Ser. No. 621,308.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4780461	A	19881025	US 85-810148	19851218
DE 3321826	A1	19841220	DE 83-3321826	19830615
DE 3413036	A1	19851017	DE 84-3413036	19840404
DE 3446661	A1	19860619	DE 84-3446661	19841218

PRIORITY APPLN. INFO.:


AB 13.alpha.-Alkylgonanes [I; R = Cl-4 acyl; X = O, NOH; II; R1 = amino; R2 = H, Me, Et; R3 = (substituted) alkyl; R4 = OH, alkoxy, alkanoyloxy; or R3R4 = Q; R5 = H, alkyl; III; 2 = CH2CH2, CH2CMe2CH2], having antigestagenic activity and useful as postcoital contraceptives, or for triggering abortion and menstruation (no data), are prepd. via photochem. epimerization of the 13.beta.-gonanes IV. 11.beta.-(4-Dimethylaminomethyl)-17.alpha.-hydroxy-13.alpha.-methyl-17.beta.-(3-hydroxypropyl)-4,9-gonadien-3-one (V) was acetylated with Ac2O in pyridine to give 11.beta.-(4-dimethylaminomethyl)-17.alpha.-hydroxy-13.alpha.-methyl-17.beta.-(3-acetoxypropyl)-4,9-gonadien-3-one. A tablet was formulated contg. V 10.0, lactose 140.0, corn starch 69.5, polyvinylpyrrolidone 25 2.5, Aerosil 2.0, and Mg stearate 0.5 mg.

MSTR 2



G1 = OMe
 G4 = 59

L7 ANSWER 12 OF 13 MARPAT COPYRIGHT 1999 ACS (Continued)



G8 = OH
 G11 = OH
 G12 = 66




GGA = 33 <RC (1), RS (1) M5 (1) X6, EC (0-) O (1-) N (0-) S (0) OTHERQ, AN (1) N, BD (ALL) SE>

DER: and acid addition salts
 MPL: claim 18

L7 ANSWER 13 OF 13 MARPAT COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 110:95624 MARPAT
 TITLE: Preparation of novel 11-arylestrane and
 11-arylpregnane derivatives as antiprogestins
 with low or no antiglucocorticoid activity
 INVENTOR(S): Groen, Marinus Bernard; De Jongh, Hendrik Paul
 PATENT ASSIGNEE(S): AKZO N. V., Neth.
 SOURCE: Eur. Pat. Appl., 11 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 289073	A1	19881102	EP 88-200689	19880412
EP 289073	B1	19911127		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
AT 69820	E	19911215	AT 88-200689	19880412
ES 2045082	T3	19940116	ES 88-200689	19880412
ZA 8802643	A	19881130	ZA 88-2643	19880414
FI 8801826	A	19881025	FI 88-1826	19880419
FI 88396	B	19930129		
US 4871224	C	19930510		
US 4871224	A	19891003	US 88-183851	19880420
CA 1297472	A1	19920317	CA 88-564606	19880420
DK 8802218	A	19881025	DK 88-2218	19880422
DK 168294	B1	19940307		
AU 8815072	A1	19881027	AU 88-15072	19880422
AU 608831	B2	19910418		
JP 63280097	A2	19881117	JP 88-100010	19880422
CN 88102416	A	19881214	CN 88-102416	19880423
CN 1019978	B	19930303		
PRIORITY APPL. INFO.:				
NL 87-970 19870424				
EP 88-200689 19880412				
AB The title compds. [1; R1 = aminoaryl; R2 = C1-4 alkyl; R3 = H, OH, substituted (unsatd.) C1-8 hydrocarbyl; R4 = OH, acyloxy, substituted acyl; R3R4 = atoms to complete a ring; R5 = C1-4 hydrocarbyl] useful as antiprogestins (no data) were prepd.				
5.alpha.,6.alpha.-Epoxy-11.beta.-hydroxyestrane-3,17-dione-3,17-diethylene acetal (prepn. given) was treated with MeMgCl in PhMe/THF and the product was dehydrated with POC13/pyridine to give				
6-.beta.-methylestra-5(10),9(11)-diene-3,17-dione-3,17-diethylene acetal. The latter was converted in several steps to				
11.beta.-[4-(dimethylamino)phenyl]-17.beta.-hydroxy-17.alpha.-(3-hydroxy-1-propynyl)-6.beta.-methylestra-4,9-diene-3-one.				

L7 ANSWER 13 OF 13 MARPAT COPYRIGHT 1999 ACS (Continued)
 MSTR 1



G1 = 63 / 64 / 65



G3 = 22



G5 = 25



G6 = Ak<(1-8)> (SR (1-) G9)
 G7 = alkylcarbonyl (SO (1-) G10)
 G20 = Ak<(1-4)>
 GGA = 69 <(1-7)>
 MPL: claim 1

=> d his

(FILE 'HOME' ENTERED AT 11:01:52 ON 16 JUL 1999)

FILE 'REGISTRY' ENTERED AT 11:02:25 ON 16 JUL 1999

L1 STRUCTURE UPLOADED

L2 0 S L1

L3 23 S L1 FULL

FILE 'CAPLUS' ENTERED AT 11:03:21 ON 16 JUL 1999

L4 1 S L3

FILE 'MARPAT' ENTERED AT 11:04:13 ON 16 JUL 1999

L5 0 S L3

L6 14 S L3 FULL

L7 13 S L6 NOT L4

=> d his

(FILE 'HOME' ENTERED AT 11:01:52 ON 16 JUL 1999)

FILE 'REGISTRY' ENTERED AT 11:02:25 ON 16 JUL 1999

L1 STRUCTURE UPLOADED

L2 0 S L1

L3 23 S L1 FULL

FILE 'CAPLUS' ENTERED AT 11:03:21 ON 16 JUL 1999

L4 1 S L3

FILE 'MARPAT' ENTERED AT 11:04:13 ON 16 JUL 1999

L5 0 S L3

L6 14 S L3 FULL

L7 13 S L6 NOT L4

FILE 'REGISTRY' ENTERED AT 11:14:18 ON 16 JUL 1999
SAVE L3 K132/A

FILE 'USPATFULL' ENTERED AT 11:14:41 ON 16 JUL 1999

L8 0 S L3

FILE 'BEILSTEIN' ENTERED AT 11:14:58 ON 16 JUL 1999

L9 0 S L3


09/180,132

Page 1

=> d 1-50

L2 ANSWER 1 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-42-6 REGISTRY
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-bromo-11-[4-(dimethylamino)phenyl]-, (11.β)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C30 H36 Br N O4
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 2 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-42-5 REGISTRY
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-bromo-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11.β)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C28 H34 Br N O3
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 3 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-41-4 REGISTRY
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-methoxy-, 3-oxime, (11.β)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C31 H40 N2 O5
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.
 Double bond geometry unknown.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 4 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-40-3 REGISTRY
 CN 19-Norpregna-4,9-diene-3,20-dione, 17,21-bis(acetyloxy)-11-[4-(dimethylamino)phenyl]-, 3-oxime, (3E,11.β)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C32 H40 N2 O6
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.
 Double bond geometry as shown.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 5 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-39-0 REGISTRY
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-ethoxy-, (11.beta.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C32 H41 N O5
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 6 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-38-9 REGISTRY
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-21-ethoxy-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C30 H39 N O4
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 7 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-37-8 REGISTRY
 CN 19-Norpregn-9-ene-3,20-dione, 11-[4-(dimethylamino)phenyl]-21-ethoxy-5,17-dihydroxy-, cyclic bis(1,2-ethanediyl acetal), (5.alpha.,11.beta.)- (9CI)
 (CA INDEX NAME)
 FS STEREOSEARCH
 MF C34 H49 N O7
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 8 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-36-7 REGISTRY
 CN 19-Norpregn-9(11)-ene-3,20-dione, 5,10-epoxy-21-ethoxy-17-hydroxy-, cyclic bis(1,2-ethanediyl acetal), (5.alpha.,10.alpha.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C26 H38 O7
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 9 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-35-6 REGISTRY
 CN 19-Norpregna-5(10),9(11)-diene-3,20-dione, 21-ethoxy-17-hydroxy-,
 cyclic
 FS bis(1,2-ethanediyl acetal) (9CI) (CA INDEX NAME)
 MF STEREOSEARCH
 MF C26 H38 O6
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 10 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-34-5 REGISTRY
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-(4-(dimethylamino)phenyl)-21-hydroxy-, (11.β.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C30 H37 N O5
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 11 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-33-4 REGISTRY
 CN 19-Norpregna-4,9-diene-3,20-dione,
 17-(acetyloxy)-21-(3-cyclopentyl-1-oxopropoxy)-11-[4-(dimethylamino)phenyl]-, (11.β.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C38 H49 N O6
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 12 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-32-3 REGISTRY
 CN 19-Norpregna-4,9-diene-3,20-dione,
 21-(3-cyclopentyl-1-oxopropoxy)-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11.β.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C36 H47 N O5
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 13 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-31-2 REGISTRY
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-methoxy-, (11.β.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C31 H39 N O5
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 14 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-30-1 REGISTRY
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-hydroxy-21-methoxy-, (11.β.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C29 H37 N O4
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 15 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-29-8 REGISTRY
 CN 19-Norpregn-9-ene-3,20-dione, 11-[4-(dimethylamino)phenyl]-5,17-dihydroxy-21-methoxy-, cyclic bis(1,2-ethanediyl acetal), (5.α.,11.β.)- (9CI)
 (CA INDEX NAME)
 FS STEREOSEARCH
 MF C33 H47 N O7
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 16 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-28-7 REGISTRY
 CN 19-Norpregn-9(11)-ene-3,20-dione, 5,10-epoxy-17-hydroxy-21-methoxy-, cyclic bis(1,2-ethanediyl acetal), (5.α.,10.α.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C25 H36 O7
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 17 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-27-6 REGISTRY
 CN 19-Norpregna-5(10),9(11)-diene-3,20-dione, 17-hydroxy-21-methoxy-, cyclic
 bis(1,2-ethanediyl acetal) (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C25 H36 O6
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 18 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-26-5 REGISTRY
 CN 19-Norpregna-5(10),9(11)-diene-3,20-dione, 17,21-dihydroxy-, cyclic bis(1,2-ethanediyl acetal) (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C24 H34 O6
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 19 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-25-4 REGISTRY
 CN 19-Norpregna-4,9-diene-3,20-dione, 17,21-dihydroxy- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C20 H26 O4
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 20 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-24-3 REGISTRY
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-bromo-17-hydroxy- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C20 H25 Br O3
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 21 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-23-2 REGISTRY
 CN Estr-5(10),9(11)-diene-17-carbonitrile,
 17-[(bromomethyl)dimethylsilyloxy]-3,3-[1,2-ethanediylbis(oxy)]-, (17.alpha.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C24 H34 Br N O3 Si
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 22 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-22-1 REGISTRY
 CN Estr-4,9-dien-3-one, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-(1-oxopropyl)-, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C31 H39 N O4
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry. Rotation (+).



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 23 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-21-0 REGISTRY
 CN Estr-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-oxopropyl)-, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C29 H37 N O3
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 24 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-20-9 REGISTRY
 CN Estr-9-en-3-one, 11-[4-(dimethylamino)phenyl]-5,17-dihydroxy-17-(1-oxopropyl)-, cyclic 3-(1,2-ethanediyl acetal), (5.alpha.,11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C31 H43 N O5
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 25 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-19-6 REGISTRY
 CN Estr-9-en-3-one,
 11-[4-(dimethylamino)phenyl]-5-hydroxy-17-(1-oxopropyl)-
 17-[(trimethylsilyl)oxy]-, cyclic 3-(1,2-ethanediyl acetal),
 (5.alpha.,11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C34 H51 N O5 Si
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 26 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-10-5 REGISTRY
 CN Estr-9(11)-en-3-one,
 5,10-epoxy-17-(1-oxopropyl)-17-[(trimethylsilyl)oxy]-
 , cyclic 3-(1,2-ethanediyl acetal), (5.alpha.,10.alpha.,17.alpha.)-
 (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C26 H40 O5 Si
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 27 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-17-4 REGISTRY
 CN Estr-5(10),9(11)-dien-3-one,
 17-(1-oxopropyl)-17-[(trimethylsilyl)oxy]-,
 cyclic 3-(1,2-ethanediyl acetal), (17.alpha.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C26 H40 O4 Si
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 28 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-16-3 REGISTRY
 CN Estr-5(10),9(11)-dien-3-one, 17-(1-hydroxypropyl)-17-
 [(trimethylsilyl)oxy]-, cyclic 1,2-ethanediyl acetal, (17.alpha.)-
 (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C26 H42 O4 Si
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 29 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-15-2 REGISTRY
 CN Estra-5(10),9(11)-diene-17-carboxaldehyde,
 3,3-[1,2-ethanediylbis(oxy)]-17-
 [(trimethylsilyl)oxy]-, (17.alpha.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C24 H36 O4 Si
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 30 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-13-0 REGISTRY
 CN 19-Norpregna-4,9-diene-3,20-dione,
 11-[4-(dimethylamino)phenyl]-17,21-[(1-
 ethoxyethylidene)bis(oxy)]-, (11.beta.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C32 H41 N O5
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 31 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-11-8 REGISTRY
 CN 19-Norpregna-4,9-diene-3,20-dione,
 17-(acetyloxy)-21-(acetylthio)-11-[4-
 (dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C32 H39 N O5 S
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 32 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-09-4 REGISTRY
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetylthio)-11-[4-
 (dimethylamino)phenyl]-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C30 H37 N O4 S
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 33 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-07-2 REGISTRY
 CN 19-Norpregna-4,9-diene-3,20-dione, 17,21-bis(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C32 H39 N O6
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 34 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-05-0 REGISTRY
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-chloro-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C30 H36 Cl N O4
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 35 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-03-8 REGISTRY
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-fluoro-, (11.beta.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C30 H36 F N O4
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 36 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-01-6 REGISTRY
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17,21-epoxy-, (11.beta.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C28 H33 N O3
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 37 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198414-00-5 REGISTRY
 CN 19-Norpregna-4,9-diene-3,20-dione,
 11-[4-(dimethylamino)phenyl]-21-fluoro-
 17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C28 H34 F N O3
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 38 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198413-99-9 REGISTRY
 CN 19-Norpregna-4,9-diene-3,20-dione,
 11-[4-(dimethylamino)phenyl]-17-hydroxy-
 21-[(methylsulfonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C29 H37 N O6 S
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 39 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198413-98-8 REGISTRY
 CN 19-Norpregna-4,9-diene-3,20-dione,
 11-[4-(dimethylamino)phenyl]-17,21-
 dihydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C28 H35 N O4
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 40 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198413-97-7 REGISTRY
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(
 dimethylamino)phenyl]-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C30 H37 N O5
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 41 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198413-96-6 REGISTRY
 CN 19-Norpregna-4,9-diene-3,20-dione,
 21-chloro-11-[4-(dimethylamino)phenyl]-
 17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C28 H34 Cl N O3
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 42 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198413-95-5 REGISTRY
 CN Estr-4,9-diene-17-carbonitrile,
 17-[[[(bromomethyl)dimethylsilyl]oxy]-11-
 [4-(dimethylamino)phenyl]-3-oxo-, (11.beta.,17.alpha.)- (9CI) (CA
 INDEX NAME)
 FS STEREOSEARCH
 MF C30 H39 Br N2 O2 Si
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 43 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 198413-94-4 REGISTRY
 CN Estr-4,9-diene-17-carbonitrile,
 11-[4-(dimethylamino)phenyl]-17-hydroxy-3-
 oxo-, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C27 H32 N2 O2
 SR CA
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 44 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 91924-94-0 REGISTRY
 CN Estr-9-ene-17-carbonitrile, 11-[4-(dimethylamino)phenyl]-3,3-[1,2-
 ethanediylbis(oxy)]-5-hydroxy-17-[(trimethylsilyl)oxy]-,
 (5.alpha.,11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Spiro[3H-cyclopenta[a]phenanthrene-3,2'-[1,3]dioxolane],
 estr-9-ene-17-carbonitrile deriv.
 FS STEREOSEARCH
 MF C32 H46 N2 O4 Si
 LC STN Files: CA, CAPLUS, USPATFULL


Absolute stereochemistry.



3 REFERENCES IN FILE CA (1967 TO DATE)
 3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 45 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 00097-05-4 REGISTRY
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-17-hydroxy- (9CI)
 (CA INDEX NAME)
 FS STEREOSEARCH
 MF C22 H28 O5
 LC STN Files: CA, CAPLUS, USPATFULL


Absolute stereochemistry.



2 REFERENCES IN FILE CA (1967 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 46 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 54690-63-0 REGISTRY
 CN Estra-5(10),9(11)-diene-17-carbonitrile,
 3,3-[1,2-ethanediylbis(oxy)]-17-
 [(trimethylsilyl)oxy]-, (17.alpha.)- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Spiro[3H-cyclopenta[α]phenanthrene-3,2'-[1,3]dioxolane],
 estra-5(10),9(11)-diene-17-carbonitrile deriv.
 FS STEREOSEARCH
 MF C24 H35 N O3 Si
 LC STN Files: BEILSTEIN*, CA, CAPLUS, USPATFULL
 (*File contains numerically searchable property data)


Absolute stereochemistry.



5 REFERENCES IN FILE CA (1967 TO DATE)
 5 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 47 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 33403-21-3 REGISTRY
 CN Estr-9(11)-ene-17-carbonitrile,
 5,10-epoxy-3,3-[1,2-ethanediylbis(oxy)]-17-
 [(trimethylsilyl)oxy]-, (5.alpha.,10.alpha.,17.alpha.)- (9CI) (CA
 INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 5.alpha.,10.alpha.-Estr-9(11)-ene-17.beta.-carbonitrile,
 5,10-epoxy-3-oxo-17-(trimethylsiloxy)-, cyclic ethylene acetal (8CI)
 CN Spiro[1,3-dioxolane-2,3'-(4'H)]-[5,10]epoxy[6H]cyclopenta[α]phenanthrene],
 estr-9(11)-ene-17-carbonitrile deriv.
 FS STEREOSEARCH
 MF C24 H35 N O4 Si
 LC STN Files: BEILSTEIN*, CA, CAPLUS, IFICDB, IFIPAT, IFIUDB,
 USPATFULL
 (*File contains numerically searchable property data)


Absolute stereochemistry.



19 REFERENCES IN FILE CA (1967 TO DATE)
 19 REFERENCES IN FILE CAPLUS (1967 TO DATE)


L2 ANSWER 48 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 33300-19-5 REGISTRY
 CN Estra-5(10),9(11)-diene-17-carbonitrile,
 3,3-[1,2-ethanediylbis(oxy)]-17-
 hydroxy-, (17.alpha.)- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Estra-5(10),9(11)-diene-17.beta.-carbonitrile, 17-hydroxy-3-oxo-,
 cyclic
 ethylene acetal (8CI)
 CN Spiro[3H-cyclopenta[α]phenanthrene-3,2'-[1,3]dioxolane],
 estra-5(10),9(11)-diene-17-carbonitrile deriv.
 FS STEREOSEARCH
 MF C21 H27 N O3
 LC STN Files: CA, CAPLUS, IFICDB, IFIPAT, IFIUDB

Absolute stereochemistry.




6 REFERENCES IN FILE CA (1967 TO DATE)
 6 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 49 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 506-77-6 REGISTRY
 CN Benzenamine, 4-bromo-N,N-dimethyl- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Aniline, p-bromo-N,N-dimethyl- (6CI, 8CI)
 OTHER NAMES:
 CN 1-Bromo-4-(dimethylamino)benzene
 CN 4-(Dimethylamino)phenyl bromide
 CN 4-Bromo-N,N-dimethylaniline
 CN 4-Bromo-N,N-dimethylbenzenamine
 CN 4-Dimethylamino-1-bromobenzene
 CN 4-Dimethylaminobromobenzene
 CN N,N-Dimethyl-4-bromoaniline
 CN N,N-Dimethyl-p-bromoaniline
 CN p-(Dimethylamino)phenyl bromide
 CN p-Bromo(dimethylamino)benzene
 CN p-Bromo-N,N-dimethylaniline
 CN p-Dimethylaminobromobenzene
 CN p-N,N-Dimethylaminobromobenzene
 FS 3D CONCORD
 MF C9 H10 Br N
 CI COM
 LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHM, DETHERM*, GMLIN*, HODOC*, IFICDB, IFIPAT, IFIUB, MSDS-OHS, RTECS*, SPECINFO, TOXLIT, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS*, NDSL*, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)



517 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 518 REFERENCES IN FILE CAPLUS (1967 TO DATE)
 35 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L2 ANSWER 50 OF 50 REGISTRY COPYRIGHT 1999 ACS
 RN 104-97-2 REGISTRY
 CN Cyclopentanepropionyl chloride (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Cyclopentanepropionyl chloride (8CI)
 OTHER NAMES:
 CN 3-Cyclopentanepropionyl chloride
 CN 3-Cyclopentylpropionyl chloride
 CN 3-Cyclopentylpropionyl chloride
 FS 3D CONCORD
 MF C8 H13 Cl O
 LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHM, HODOC*, IFICDB, IFIPAT, IFIUB, TOXLIT, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS**
 (**Enter CHEMLIST File for up-to-date regulatory information)



64 REFERENCES IN FILE CA (1967 TO DATE)
 64 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> d his

(FILE 'HOME' ENTERED AT 10:32:36 ON 29 JUL 1999)

FILE 'CAPLUS' ENTERED AT 10:32:42 ON 29 JUL 1999
E WO9741145/PN

L1 1 S E3
SEL RN

L2 FILE 'REGISTRY' ENTERED AT 10:33:08 ON 29 JUL 1999
50 S E1-E50


L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1999:576939 CAPLUS
 DOCUMENT NUMBER: 131:199885
 TITLE: Preparation of 20-keto-11.beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties
 INVENTOR(S): Cook, C. Edgar; Kepler, John A.; Zhang, Ping-sheng;
 PATENT ASSIGNEE(S): Lee, Yue-wei; Tallent, C. Ray
 SOURCE: Research Triangle Institute, USA
 PCT Int. Appl., 95 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9945022	A1	19990910	WO 1999-US3732	19990305
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TH				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.: US 1998-35949 19980306				
OTHER SOURCE(S): MARPAT 131:199885				
AB 20-Keto-11.beta.-arylsteroids of formula I [X = O, (substituted) NOH, H2, OH, etc.; R1 = dialkylamino, imidazolyl, pyrrolyl, piperidino, etc.; R2 = H, halo; R3 = H, Me, halo; R4 = H, acyloxy, (substituted) OH, alkyl, etc.; R5 = H, alkyl, halo, acyloxy, etc.] are prepd. which exhibit potent antiprogesterational activity. Thus, II was prepd. from 17.alpha.-hydroxymethyl-3-methoxy-19-norpregna-1,3,5(10)-trien-20-one and 4-bromo-N,N-dimethylaniline in several steps. The affinity of II for the progesterone hormone receptor was IC50 of 0.7 nM.				
IT 240806-28-4P				
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)				

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1997:740250 CAPLUS
 DOCUMENT NUMBER: 127:358992
 TITLE: Preparation of 21-substituted progesterone derivatives as new antiprogesterational agents
 INVENTOR(S): Kim, Hyun K.; Blye, Richard P.; Rao, Pemmaraju N.; Cessac, James W.; Acosta, Carmie K.
 PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA;
 SOURCE: Kim, Hyun K.; Blye, Richard P.; Rao, Pemmaraju N.; Cessac, James W.; Acosta, Carmie K.
 PCT Int. Appl., 65 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9741145	A1	19971106	WO 1997-US7373	19970430
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TH				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2253673 AA 19971106 19970430				
AU 9729304 A1 19971119 19970430				
EP 900234 A1 19990310 19970430				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRIORITY APPLN. INFO.: US 1996-16628 19960501				
WO 1997-US7373 19970430				
OTHER SOURCE(S): MARPAT 127:358992				
AB Progesterone derivs. of formula I [R1 = OMe, SMe, NMe2, NMe, CHO, Ac, CHOHCH3; R2 = halo, alkyl, acyl, OH, alkoxy, etc.; R3 = OH, alkyl, alkoxy, acyloxy; R4 = H, alkyl; X = O, (substituted) NOH] are prepd. as antiprogesterational agents. The present invention provides methods wherein the compds. of formula I are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce labor; and for contraception. Thus, II was				


L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2000 ACS (Continued)
 (prepn. of 20-keto-11.beta.-arylsteroids with antiprogesterational activity)
 RN 240806-28-4 CAPLUS
 CN 19,21-Dinorchola-4,9-dien-24-oic acid, 11-[4-(dimethylamino)phenyl]-17-hydroxy-3,20-dioxo-, ethyl ester, (11.beta.)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)
 CM 1
 CRN 240806-27-3
 CMF C32 H41 N O5
 Absolute stereochemistry.



CM 2
 CRN 76-05-1
 CMF C2 H F3 O2




L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2000 ACS (Continued)
 prepd. from 3,3-ethylenedioxy-17.beta.-cyano-17.alpha.-hydroxyestra-5(10),9(11)-diene and 4-bromo-N,N-dimethylaniline in 9 steps. II showed 2.79 times the antiprogesterational potency in the antiClauberg test compared to CDB-2914.
 IT 198414-07-2P 198414-09-4P 198414-31-2P
 RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of progesterone derivs. as antiprogesterational agents)
 RN 198414-07-2 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17,21-bis(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



RN 198414-09-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetylthio)-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-31-2 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2000 ACS (Continued)



IT 198414-03-8P 198414-05-0P 198414-11-8P
 198414-22-1P 198414-32-3P 198414-33-4P
 198414-34-5P 198414-39-0P 198414-43-6P
 RL: BAC (Biological activity or effector, except adverse); SPN
 (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (prepn. of progesterone derivs. as antiprogesterone agents)
 RN 198414-03-8 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-fluoro-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-05-0 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-chloro-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 198414-11-8 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-(acetylthio)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-22-1 CAPLUS
 CN Estradiol-4,9-dien-3-one, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-(1-oxopropyl)-, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 198414-32-3 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(3-cyclopentyl-1-oxopropoxy)-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-33-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-(3-cyclopentyl-1-oxopropoxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2000 ACS (Continued)




RN 198414-34-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-39-0 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-ethoxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-43-6 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-bromo-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2000 ACS (Continued)
(dimethylamino)phenyl]-, (11.β.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 198413-96-6F 198413-97-7F 198413-98-8P
198413-99-9P 198414-00-5P 198414-21-0P
198414-30-1P 198414-38-9P 198414-42-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of progesterone derivs. as antiprogesterone agents)
RN 198413-96-6 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione,
21-chloro-11-[4-(dimethylamino)phenyl]-
17-hydroxy-, (11.β.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198413-97-7 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(
(dimethylamino)phenyl]-17-hydroxy-, (11.β.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 198413-98-8 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17,21-
dihydroxy-, (11.β.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198413-99-9 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione,
11-[4-(dimethylamino)phenyl]-17-hydroxy-
21-[(methylsulfonyl)oxy]-, (11.β.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2000 ACS (Continued)




RN 198414-00-5 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione,
11-[4-(dimethylamino)phenyl]-21-fluoro-
17-hydroxy-, (11.β.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-21-0 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-
oxopropyl)-, (11.β.,17.α.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-30-1 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione,
11-[4-(dimethylamino)phenyl]-17-hydroxy-


L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2000 ACS (Continued)
21-methoxy-, (11.β.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 198414-38-9 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione,
11-[4-(dimethylamino)phenyl]-21-ethoxy-
17-hydroxy-, (11.β.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-42-5 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione,
21-bromo-11-[4-(dimethylamino)phenyl]-
17-hydroxy-, (11.β.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



LS ANSWER 2 OF 2 CAPLUS COPYRIGHT 2000 ACS (Continued)


IT 198414-40-3P 198414-41-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of progesterone derivs. as antiprogesterational agents)

RN 198414-40-3 CAPLUS

CN 19-Norpregna-4,9-diene-3,20-dione, 17,21-bis(acetyloxy)-11-[4-(dimethylamino)phenyl]-, 3-oxime, (3E,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 198414-41-4 CAPLUS

CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-methoxy-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



=> log h


COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	8.55	136.55
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	-1.11	-1.11

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:20:00 ON 07 JAN 2000

L9 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1999:576939 CAPLUS
 DOCUMENT NUMBER: 131:199885
 TITLE: Preparation of 20-keto-11.beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties
 INVENTOR(S): Cook, C. Edgar; Kepler, John A.; Zhang, Ping-sheng;
 PATENT ASSIGNEE(S): Lee, Yue-wei; Tallent, C. Ray
 SOURCE: Research Triangle Institute, USA
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9945022	A1	19990910	WO 1999-US3732	19990305
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TH, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, RW, GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.: MARPAT 131:199885 OTHER SOURCE(S): AB 20-Keto-11.beta.-arylsteroids of formula I [X = O, (substituted) NOH, HZ, OH, etc.; R1 = dialkylamino, imidazolyl, pyrrolyl, piperidino, etc.; R2 = H, halo; R3 = H, Me, halo; R4 = H, acyloxy, (substituted) OH, alkyl, etc.; R5 = H, alkyl, halo, acyloxy, etc.] are prep'd. which exhibit potent antiprogesterational activity. Thus, II was prep'd. from 17.alpha.-hydroxymethyl-3-methoxy-19-norpregna-1,3,5(10)-trien-20-one and 4-bromo-N,N-dimethylaniline in several steps. The affinity of II for the progesterone hormone receptor was IC50 of 0.7 nM.				
IT 240805-96-3P 240805-97-4P 240805-98-5P 240805-99-6P 240806-00-2P 240806-01-3P				

L9 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)
 Absolute stereochemistry.




RN 240805-99-6 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(benzoyloxy)-11-[(4-(dimethylamino)phenyl)]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 240806-00-2 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(1-oxopropoxy)-11-[(4-(1-methyl-1H-indol-5-yl)]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 240806-01-3 CAPLUS

L9 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)
 240806-02-4P 240806-03-5P 240806-04-6P
 240806-05-7P 240806-06-8P 240806-12-6P
 240806-44-4P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of 20-keto-11.beta.-arylsteroids with antiprogesterational activity)
 RN 240805-96-3 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[(4-(1-piperidinyl)phenyl)]-, (11.beta.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



RN 240805-97-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[(4-(dimethylamino)phenyl)]-17-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 240805-98-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[(4-(dimethylamino)phenyl)]-17-[(phenylacetyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


L9 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-(1-methyl-1H-indol-5-yl)-17-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 240806-02-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-(2,3-dihydro-1-methyl-1H-indol-5-yl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 240806-03-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-(4-methoxyphenyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 240806-04-6 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(1-methyl-1H-indol-5-yl)]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 240806-05-7 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(1-methyl-1H-indol-5-yl)]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 240806-06-8 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)-3-fluorophenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 240806-12-6 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(1-oxopropoxy)-11-[4-(1-piperidinyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 240806-44-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-(2,3-dihydro-1-methyl-1H-indol-5-yl)-17-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1999:416361 CAPLUS
 DOCUMENT NUMBER: 131:243453
 TITLE: Synthesis of N-desmethyl derivatives of

17.alpha.-acetoxy-11.beta.-(4-N,N-dimethylaminophenyl)-
 19-norpregna-4,9-diene-3,20-dione and

mifepristone:
 substrates for the synthesis of radioligands
 Rao, Femmaraju N.; Acosta, C. Kirk; Cessac, James W.;

Bahr, Martin L.; Kim, Hyun K.
 CORPORATE SOURCE: Department of Organic Chemistry, Southwest
 Foundation for Biomedical Research, San Antonio, TX,
 78245-0549,
 USA

SOURCE: Steroids (1999), 64(3), 205-212

CODEN: STERAM; ISSN: 0039-128X

PUBLISHER: Elsevier Science Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The syntheses of N-desmethyl derivs. of CDB-2914 and the
 mono-N-desmethyl
 deriv. of mifepristone are described. We also describe the use of the
 mono-desmethyl derivs. as substrates for the synthesis of
 N-tritiumethyl
 derivs. of CDB-2914 and mifepristone with high specific activity (ca.

80 Ci/mmol), which serve as radioligands for RIA.

IT 126784-99-4, CDB-2914


RL: RCT (Reactant)

(synthesis of N-desmethyl derivs. of CDB-2914 and mifepristone as
 substrates for synthesis of radioligands)

RN 126784-99-4 CAPLUS

CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 159681-66-0P, CDB 3877 244206-53-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (synthesis of N-desmethyl derivs. of CDB-2914 and mifepristone as
 substrates for synthesis of radioligands)


L9 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)
 RN 159681-66-0 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(methylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 244206-53-9 CAPLUS
 CN Acetamide,
 N-[4-[(11.beta.)-17-(acetyloxy)-3,20-dioxo-19-norpregna-4,9-dien-11-yl]phenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 244206-49-3P 244206-50-6P 244206-56-2P
 RL: SPN (Synthetic preparation), PREP (Preparation)
 (synthesis of N-desmethyl deriva. of CDB-2914 and mifepristone as
 substrates for synthesis of radioligands)
 RN 244206-49-3 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-(4-aminophenyl)-,
 (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)

L9 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 244206-50-6 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione,
 17-(acetyloxy)-11-[4-(methylmethyl-5-
 amino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244206-56-2 CAPLUS
 CN Acetamide,
 N-[4-[(11.beta.)-17-(acetyloxy)-3,20-dioxo-19-norpregna-4,9-dien-11-yl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L9 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1999:154103 CAPLUS
 DOCUMENT NUMBER: 1301291788
 TITLE: The novel progesterone receptor antagonists RTI 3021-012 and RTI 3021-022 exhibit complex glucocorticoid receptor antagonist activities: implications for the development of dissociated antiprogesterins
 AUTHOR(S): Wagner, B. L.; Pollio, G.; Giangrande, P.; Webster, J.
 Vedeckis, C.; Breslin, M.; Mais, D. E.; Cook, C. E.;
 CORPORATE SOURCE: W. V. Cidlowski, J. A.; McDonnell, D. P.
 Department of Pharmacology and Cancer Biology,
 Duke University Medical Center, Durham, NC, 27710, USA
 SOURCE: Endocrinology (1999), 140(3), 1449-1458
 CODEN: ENDOAO; ISSN: 0013-7227
 PUBLISHER: Endocrine Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The authors have identified two novel compds. (RTI 3021-012 and RTI 3021-022) that demonstrate similar affinities for human progesterone receptor (PR) and display equiv. antiprogesteric activity. As with most antiprogesterins, such as RU486, RTI 3021-012, and RTI 3021-022 also bind to the glucocorticoid receptor (GR) with high affinity. Unexpectedly, when compared with RU486, the RTI antagonists manifest significantly less GR antagonist activity. This finding indicates that, with respect to antiglucocorticoid function, receptor binding affinity is not a good predictor of biol. activity. The authors have detd. that the lack of a clear correlation between the GR binding affinity of the RTI compds. and their antagonist activity reflects the unique manner in which they modulate GR signaling. Previously, the authors proposed a two step "active inhibition" model to explain steroid receptor antagonism: (1) competitive inhibition of agonist binding; and (2) competition of the antagonist bound receptor with that activated by agonists for DNA response elements within target gene promoters. Accordingly, the authors obsd. that RU486, RTI 3021-012, and RTI 3021-022, when assayed for PR antagonist activity, accomplished both of these steps. Thus, all three compds. are "active antagonists" of PR function. When assayed on GR, however, RU486 alone functioned as an active antagonist. RTI 3021-012 and RTI 3021-022, functioned solely as "competitive antagonists" since they were capable of high affinity GR binding, but the resulting ligand receptor complex was unable to bind DNA. These results have important pharmaceutical


L9 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)
 implications supporting the use of mechanism based approaches to
 identify nuclear receptor modulators. Of equal importance, RTI 3021-012 and
 RTI 3021-022 are two new antiprogesterins that may have clin. utility and
 are likely to be useful as research reagents with which to sep. the
 effects of antiprogesterins and antiglucocorticoids in physiol. systems.
 IT 126784-99-4, RTI 3021-012
 RL: BAC (Biological activity or effector, except adverse); BIOL
 (Biological study)
 (progesterone receptor antagonists RTI 3021-012 and RTI 3021-022
 exhibit complex glucocorticoid receptor antagonist activities)
 RN 126784-99-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[(4-
 (dimethylamino)phenyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)
 RL: BAC (Biological activity or effector, except adverse); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antioviulatory and postcoital antifertility activity of
 antiprogesterin CDB-2914 compared to mifepristone as single, multiple, or
 continuous doses to rats)
 RN 126784-99-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[(4-
 (dimethylamino)phenyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1998:646581 CAPLUS
 DOCUMENT NUMBER: 130:20723
 TITLE: Antioviulatory and postcoital antifertility activity of
 the antiprogesterin CDB-2914 when administered as single, multiple, or continuous doses to rats
 Reel, Jerry R.; Hild-Petito, Sheri; Blye, Richard P.
 CORPORATE SOURCE: BIOQUAL, Inc., Rockville, MD, 20852-3336, USA
 SOURCE: Contraception (1998), 58(2), 129-136
 CODEN: CCTAY; ISSN: 0010-7824
 PUBLISHER: Elsevier Science Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The present studies in rats were undertaken to investigate the potential of a new antiprogesterin, CDB-2914, for use as an emergency postcoital contraceptive for women. When given orally at noon on the day of proestrus, both CDB-2914 and mifepristone displayed dose-dependent antioviulatory activity; however, CDB-2914 was about eight times more potent than mifepristone. Both antiprogesterins were considerably less potent in blocking ovulation when injected s.c. To evaluate antioviulatory activity during continuous low dose administration, rats were dosed orally with 0.5 mg of either CDB-2914 or mifepristone daily, commencing on the day of estrus and continuing for 24 days. Females were cohabited with proven fertile males on day 8 of treatment and were removed 1-3 days later after confirmed mating. The pregnancy rate was significantly reduced only in the CDB-2914-treated females; however, the mean no. of normal implantation sites per pregnant rat was significantly reduced by mifepristone as compared with the vehicle control group. CDB-2914 was also found to prevent pregnancy when administered orally after mating from days 0-3 during tubal egg transport, or from days 4-6 during the pre- and peri-implantation periods. To det. the day of maximal sensitivity to CDB-2914, a single 2-mg dose per rat was given orally on days 0, 1, 2, 3, 4, or 5 postmating. This dose of CDB-2914 was without effect on pregnancy at days 0, 1, 2, or 3 postmating. In contrast, 2 mg CDB-2914 per rat was highly effective in blocking pregnancy when given on either day 4 or 5 postmating. Collectively, these data demonstrate that CDB-2914 is an orally active postcoital antifertility agent that is more potent than mifepristone in the rat. Hence, CDB-2914 may prove to be an effective emergency postcoital contraceptive in women.
 IT 126784-99-4, CDB-2914


L9 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1998:424125 CAPLUS
 DOCUMENT NUMBER: 129:50105
 TITLE: Uses of anti-glucocorticoid compounds for the treatment of psychoses or addictive behaviors
 Oberlander, Claude; Piazza, Pier Vincenzo
 INVENTOR(S): Hoechst Marion Roussel, Fr.; Oberlander, Claude;
 PATENT ASSIGNER(S): Piazza, Pier Vincenzo
 SOURCE: PCT Int. Appl., 41 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9826783	A1	19980625	WO 1997-FR2320	19971217
IL,	W:	AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GW, HU, ID,		
PL,		IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ,		
KG,		RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY,		
FI,		KZ, MD, RU, TJ, TM		
CH,	FW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES,		
		FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,		
		GA, GN, ML, MR, NE, SN, TD, TG		
FR 2757400	A1	19980626	FR 1996-15649	19961219
FR 2757400	B1	19991217		
AU 9855632	A1	19980715	AU 1998-55632	19971217
EP 892641	A1	19990127	EP 1997-952078	19971217
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,		
PT,		IE, FI		
PRIORITY APPLN. INFO.:			FR 1996-15649	19961219
			WO 1997-FR2320	19971217

OTHER SOURCE(S): MARPAT 129:50105
 AB Glucocorticoid antagonists, except mifepristone, are used as dopamine type II receptor antagonists to treat psychotic or addictive behavior.
 Thus, 17.beta.-hydroxy-10.beta.-[(4-methylphenyl)methyl]-17.alpha.-(1-propenyl)estra-4,9(11)-dien-3-one considerably reduced the response to morphine in vivo.
 IT 126784-99-4
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (use of anti-glucocorticoid compds. as dopamine type II receptor blocking agents for the treatment of psychoses or addictive behaviors)
 RN 126784-99-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[(4-
 (dimethylamino)phenyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)



L9 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2000 ACS


ACCESSION NUMBER: 1998:13308 CAPLUS
 DOCUMENT NUMBER: 128:128177
 TITLE: 11.beta.-substituted 13.beta.-ethyl gonane derivatives exhibit reversal of antiprogesterational activity
 AUTHOR(S): Rao, Pemmaraju N.; Cessac, James W.; Blye, Richard P.; Kim, Hyun K.
 CORPORATE SOURCE: Department of Organic Chemistry Southwest Foundation for Biomedical Research, San Antonio, TX, 78245-0549, USA
 SOURCE: Steroids (1998), 63(1), 50-57
 CODEN: STEDAM; ISSN: 0039-128X
 PUBLISHER: Elsevier Science Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The syntheses of three 17.alpha.-acetoxy-13.beta.-ethyl-11.beta.-acryl-18,19-dinorpregna-4,9-diene-3,20-diones from levonorgestrel are described. Despite their close structural similarity to the antiprogesterone CDB-2914, one of the compds. exhibits agonistic progesterational activity, and the other two compds. are totally inactive.
 IT 202062-92-0P 202062-93-0P 202062-94-0P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (prepn. of acetoxyethylaryldinorpregnadienediones with reversal of antiprogesterational activity)
 RN 202062-92-8 CAPLUS
 CN 18,19-Dinorpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-13-ethyl-, (11.beta.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry. Rotation (+).




RN 202062-93-9 CAPLUS
 CN 18,19-Dinorpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-13-ethyl-11-[4-

L9 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)

(methylthio)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry. Rotation (+).



RN 202062-94-0 CAPLUS
 CN 18,19-Dinorpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(acetylphenyl)-13-ethyl-, (11.beta.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry. Rotation (+).



L9 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2000 ACS


ACCESSION NUMBER: 1997:745947 CAPLUS
 DOCUMENT NUMBER: 128:19047
 TITLE: Improvement of implantation rates after in vitro fertilization by administering a nitric oxide substrate and/or donor
 INVENTOR(S): Chwalsz, Krzysztof; Garfield, Robert E.
 PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany
 SOURCE: PCT Int. Appl., 38 pp.
 CODEN: P1XXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9741866	A1	19971113	WO 1997-EP2371	19970507
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TH, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9728947	A1	19971126	AU 1997-28947	19970507
EP 906105	A1	19990407	EP 1997-923032	19970507
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1218402	A	19990602	CN 1997-194452	19970507
NO 9805204	A	19990106	NO 1998-5204	19981106
PRIORITY APPL. INFO.: US 1996-646518 19960507				
WO 1997-EP2371 19970507				

AB A method is provided for the improvement of implantation rates and/or pregnancy rates in a female mammal, comprising administering to a female mammal in whom pregnancy is desired an effective amt. of: (a) a nitric oxide synthase substrate, a nitric oxide donor, or both, optionally in combination with, (b) a progestin, and, (c) optionally, in further combination with an estrogen. A method is also provided for fertility control for a female mammal, comprising administering to a female mammal in whom pregnancy is not desired and at risk of becoming pregnant an effective amt. of nitric oxide synthase inhibitor in combination with an antiprogesterin. Pharmaceutical compns. are also provided.
 IT 126784-99-4, CDB2914
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

L9 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)
 (fertility control using a nitric oxide synthase inhibitor in
 combination with an antiprogesterin)
 RN 126784-99-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-
 (dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 19971740250 CAPLUS
 DOCUMENT NUMBER: 127:358992
 TITLE: Preparation of 21-substituted progesterone
 derivatives
 as new antiprogesterational agents
 INVENTOR(S): Kim, Hyun K.; Blye, Richard P.; Rao, Pemmaraju N.;
 Cessac, James W.; Acosta, Carmie K.
 PATENT ASSIGNEE(S): United States Dept. of Health and Human Services,
 USA
 Kim, Hyun K.; Blye, Richard P.; Rao, Pemmaraju N.;
 Cessac, James W.; Acosta, Carmie K.
 SOURCE: PCT Int. Appl., 65 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9741145	A1	19971106	WO 1997-US7373	19970430
W: AL, AM, AT, AU, AZ, BA, BE, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, ES, FI, FR, GB, GR, IE, IL, LU, MC, NL, PT, SE, EF, BJ, CF, CG, CI, CH, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2253673	AA	19971106	CA 1997-2253673	19970430
AU 9729304	A1	19971113	AU 1997-29304	19970430
EP 900234	A1	19990310	EP 1997-923523	19970430
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRIORITY APPLN. INFO.: US 1996-16628 19960501 WO 1997-US7373 19970430				
OTHER SOURCE(S): MARPAT 127:358992				
AB Progesterone derivs. of formula I [R1 = OMe, SMe, NMe2, NMe, CHO, Ac, CHOHCH3; R2 = halo, alkyl, acyl, OH, alkoxy, etc.; R3 = OH, alkyl, alkoxy; R4 = H, alkyl; X = O, (substituted) NOH] are prepd. as antiprogesterational agents. The present invention provides methods wherein the compds. of formula I are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat				


L9 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)
 endometriosis; to treat dysmenorrhea; to treat endocrine
 hormone-dependent
 tumors; to treat uterine fibroids; to inhibit uterine endometrial
 proliferation; to induce labor; and for contraception. Thus, II was
 prepd. from 3,3-ethylenedioxy-17.beta.-cyano-17.alpha.-hydroxyestra-
 5(10),9(11)-diene and 4-bromo-N,N-dimethylaniline in 9 steps. II
 showed
 2.79 times the antiprogesterational potency in the antiClauberg test
 compared to CDB-2914.
 IT 198414-07-2P 198414-31-2P
 RL: BAC (Biological activity or effector, except adverse); RCT
 (Reactant);
 SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
 study); PREP (Preparation); USES (Uses)
 RN 198414-07-2 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17,21-bis(acetyloxy)-11-[4-
 (dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-31-2 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-
 (dimethylamino)phenyl]-21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 198414-03-8P 198414-05-0P 198414-11-8P
 198414-22-1P 198414-33-4P 198414-34-5P
 198414-39-0P 198414-43-6P


L9 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)
 RL: BAC (Biological activity or effector, except adverse); SPN
 (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (prepn. of progesterone derivs. as antiprogesterational agents)
 RN 198414-03-8 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-
 (dimethylamino)phenyl]-21-fluoro-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-05-0 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-chloro-11-[4-
 (dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-11-8 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione,
 17-(acetyloxy)-21-(acetylthio)-11-[4-
 (dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 198414-22-1 CAPLUS
 CN 19-Norpregna-4,9-diene-3-one,
 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-(1-oxopropyl)-, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 198414-33-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-(3-cyclopentyl-1-oxopropoxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 198414-34-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-39-0 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-ethoxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)




RN 198414-43-6 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-bromo-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 198414-40-3P 198414-41-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of progesterone derivs. as antiprogesterational agents)
 RN 198414-40-3 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17,21-bis(acetyloxy)-11-[4-(dimethylamino)phenyl]-, 3-oxime, (3E,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Double bond geometry as shown.



L9 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)

RN 198414-41-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-methoxy-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.



L9 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1996:705614 CAPLUS
 DOCUMENT NUMBER: 125:329114
 TITLE: improved preparation of
 17.alpha.-acetoxy-11.beta.-(4-

N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione and its intermediates

INVENTOR(S): Kim, Hyun K.; Rao, Pemmaraju Narasinha; Burdett, James

PATENT ASSIGNEE(S): E., Jr.; Acosta, Carmie Kirk
 United States Dept. of Health and Human Services, USA

SOURCE: PCT Int. Appl., 40 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9630390	A2	19961003	WO 1996-US3660	19960318
WO 9630390	A3	19970109		

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CH, GA, GN, ML, US 5929262 A 19990727 US 1995-413755 19950330
 CA 2216737 AA 19961003 CA 1996-2216737 19960318
 AU 9653145 A1 19961016 AU 1996-53145 19960318
 EP 817793 A2 19980114 EP 1996-909749 19960318
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
 PRIORITY APPLN. INFO.: US 1995-413755 19950330
 WO 1996-US3660 19960318
 OTHER SOURCE(S): CASREACT 125:329114; MARPAT 125:329114
 AB Improved method for prepn. of 19-norprogesterone (I) and its intermediates, in cryst. and amorphous forms is given. I is prepd. in seven steps by silylation of 3-ethylenedioxy-17.beta.-cyano-17.alpha.-hydroxyestra-5(10),9(11)-diene followed by oxidn., ketalization, epoxidn., arylation, deprotection and acetylation.
 IT 126784-99-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (improved prepn. of 17.alpha.-acetoxy-11.beta.-(4-N,N-

L9 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)
 dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione and its intermediates
 RN 126784-99-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L9 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1996:540408 CAPLUS
 DOCUMENT NUMBER: 125:238950
 TITLE: Effects of two antiprogestins on early pregnancy in the long-tailed macaque (Macaca fascicularis)
 AUTHOR(S): Tarantal, Alice F.; Hendrickx, Andrew G.; Matlin, Stephen A.; Lasley, Bill L.; Gu, Quin-Quin; Thomas, Charles A.A.; Vince, Pamela M.; Van Look, Paul F.A.
 CORPORATE SOURCE: California Regional Primate Research Center, University of California, Davis, CA, 95616, USA
 SOURCE: Contraception (1996), 54(2), 107-115
 CODEN: CCTAY; ISSN: 0010-7824
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The abortifacient effects of mifepristone and HRP 2000 were compared in gravid long-tailed macaques. Thirty-six animals were studied with treatment administered either by the oral (0.5 or 5.0 mg/kg; N = 5 per antiprogesterin per dose) or i.m. (IM) routes (0.5 mg/kg; N = 5 per antiprogesterin) on gestational days (GD) 23-26; six vehicle controls were included. Blood samples were collected for assay of progesterone (P4) and each of the antiprogestins (pre-treatment, daily GD 23-28, every other day GD 30-40), and animals were monitored sonog. throughout gestation. Results of these studies indicated high rates of abortion with IM administration (3/5 mifepristone, 4/5 HRP 2000) and 5.0 mg/kg oral route (4/5, 2/5, resp.), with less effects noted at oral doses of 0.5 mg/kg (2/5, 0/5, resp.). No early abortions were obsd. in the control groups. Following daily IM treatment, peak levels of 8-16 ng/mL mifepristone were detected whereas 6-10 ng/mL of HRP 2000 were noted (GD 26-27). No serum levels of mifepristone were detected following either of the oral doses whereas serum levels of 2-6 ng/mL HRP 2000 were noted with high dose oral administration. Results of these studies suggest: (1) both antiprogestins are roughly comparable in terminating early pregnancy although HRP 2000 may be more efficacious when administered IM whereas mifepristone may be more effective when administered orally; (2) similar levels of biol. activity are seen with the IM and high dose oral dosing regimens, with little or no activity with the oral low dose; and (3) infants resulting from surviving pregnancies were not affected by early gestation exposure.
 IT 126784-99-4
 RL: BPR (Biological process); THU (Therapeutic use); BIOL (Biological


L9 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)
 study); PROC (Process); USES (Uses)
 (abortifacient effects of antiprogestins in early pregnancy in long-tailed macaque in relation to dose and administration route)
 RN 126784-99-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1996:498851 CAPLUS
 DOCUMENT NUMBER: 125:238820
 TITLE: 16.alpha.-substituted analogs of the antiprogesterin RU486 induce a unique conformation in the human progesterone receptor resulting in mixed agonist activity
 AUTHOR(S): Wagner, Brandee L.; Pollio, Giuseppe; Leonhardt, Susan; Wani, Mansukh C.; Lee, David Y.-W.; Imhof, Markus O.; Edwards, Dean P.; Cook, C. Edgar; McDonnell, Donald P.
 CORPORATE SOURCE: Department Pharmacology Molecular Cancer Biology, Duke University Medical Center, Durham, NC, 27710, USA
 SOURCE: Proc. Natl. Acad. Sci. U. S. A. (1996), 93(16), 8739-8744
 CODEN: PNASA6; ISSN: 0027-8424
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Previously, the authors have shown that agonists and antagonists interact with distinct, though overlapping regions within the human progesterone receptor (hPR) resulting in the formation of structurally different complexes. Thus, a link was established between the structure of a ligand-receptor complex and biol. activity. In this study, the authors have utilized a series of in vitro assays with which to study hPR pharmacol. and have identified a third class of hPR ligands that induce a receptor conformation which is distinct from that induced by agonists or antagonists. Importantly, when assayed on PR-responsive target genes these compds. were shown to exhibit partial agonist activity; an activity that was influenced by cell context. Thus, as has been shown previously for estrogen receptor, the overall structure of the ligand-receptor complex is influenced by the nature of the ligand. It appears, therefore, that the obsd. differences in the activity of some PR and estrogen receptor ligands reflect the ability of the cellular transcription machinery to discriminate between the structurally different complexes that result following ligand interaction. These data support the increasingly favored hypothesis that different ligands can interact with different regions within the hormone binding domains of steroid hormone receptors resulting in different biologies.
 IT 126784-99-4, RTI 3021-012
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); PRP (Properties); BIOL (Biological study); PROC (Process)

L9 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)
 (16.alpha.-substituted analogs of the antiprogesterin RU486 induce a unique conformation in the human progesterone receptor resulting in mixed agonist activity)
 RN 126784-99-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




L9 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1995:985962 CAPLUS
 DOCUMENT NUMBER: 124:22540
 TITLE: Pharmaceutical compositions of antigluccorticoid compounds for treating or preventing symptoms of spontaneous or narcotic-induced withdrawal.
 INVENTOR(S): Petit, Francis; Philibert, Daniel; Ulmann, Andre
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Eur. Pat. Appl., 30 pp.
 CODEN: EPXIXW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 676203	A1	19951011	EP 1995-400764	19950406
FR 2718354	A1	19951013	FR 1994-4156	19940408
FR 2718354	B1	19960503		
ZA 9502058	A	19960313	ZA 1995-2058	19950313
CA 2146600	AA	19951009	CA 1995-2146600	19950407
FI 9501683	A	19951009	FI 1995-1683	19950407
AU 9516326	A1	19951019	AU 1995-16326	19950407
JP 07278017	A2	19951024	JP 1995-107871	19950407
HU 71468	A2	19951128	HU 1995-1019	19950407
CN 1116929	A	19960221	CN 1995-104015	19950407
			FR 1994-4156	19940408

PRIORITY APPLN. INFO.:
 OTHER SOURCE(S): MARPAT 124:22540
 AB Antigluccorticoid steroids such as mifepristone, onapristone, lilopristone and related steroids are proposed for the prevention or treatment of withdrawal syndromes, either spontaneous or ptpd. by narcotics or mixts. of narcotics. These antigluccorticoids would be useful in the withdrawal from morphinomimetics such as heroin, morphine or methadone as well as cocaine. Pharmacol. activity was demonstrated by the effect of the antigluccorticoids on the stereotypic behavior of mice in response to narcotics. Spontaneous withdrawal syndrome was induced by administration of the opioid antagonist, naloxone. An antiprogesterone activity of the steroids in their action mechanism was eliminated. Results confirmed the involvement of endogenous glucocorticoids in morphine withdrawal since this is inhibited by antigluccorticoids or adrenalectomy.
 IT 126784-99-4
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (RU 486 related; antigluccorticoid steroids for treatment or prevention of spontaneous opioid or narcotic-induced drug withdrawal syndrome.)
 RN 126784-99-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


L9 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)
 Absolute stereochemistry.



L9 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1995:499191 CAPLUS
 DOCUMENT NUMBER: 122:256542
 TITLE: The anti-progestin CDB 2914 has no antifertility effect in male rats
 AUTHOR(S): Wang, Christina; Sinha-Hikim, Amiya; Leung, Andrew
 CORPORATE SOURCE: Department of Medicine, Cedars-Sinai Medical Center,
 Los Angeles, CA, USA
 SOURCE: Contraception (1995), 51(3), 215-18
 CODEN: CCPTAY; ISSN: 0010-7824
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB This study examines the effect of an anti-progestin (CDB 2914) with anti-progestational potencies similar to RU 486 on spermatogenesis, sperm maturation, and fertility in male rats. Adult male rats of proven fertility were administered the anti-progestin (10 mg/kg/day) or vehicle (control group) for 14, 35, and 70 days to study the possible effect of this compd. on epididymal sperm maturation, post-meiotic sperm development, spermatogenesis, and fertility, resp. Fertility rates of the rats were detd. by mating studies. The anti-progestin, CDB 2914, had no effect on testis or accessory organ wts., epididymal sperm content or motility, testicular sperm count, spermatogenesis, and fertility of male rats. This study suggests that anti-progestins, when administered even at higher doses than those used in humans, have no contraceptive effect in adult male rats.
 IT 126784-99-4, CDB 2914
 RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
 (anti-progestin CDB 2914 has no antifertility effect in male rats)
 RN 126784-99-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)



L9 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1995:86211 CAPLUS
 DOCUMENT NUMBER: 122:31745
 TITLE: Oxidative demethylation of 4-substituted N,N-dimethylanilines with iodine and calcium oxide in the presence of methanol
 AUTHOR(S): Acosta, Kirk; Cessac, James W.; Rao, P. Narasimha; Kim, Kyun K.
 CORPORATE SOURCE: Dep. Org. Chem., Southwest Foundation Biomed. Res.,
 San Antonio, TX, 78228-0147, USA
 SOURCE: J. Chem. Soc., Chem. Commun. (1994), (17), 1985-6
 CODEN: JOCCAT; ISSN: 0022-4936
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 122:31745
 AB Reaction of p-substituted N,N-dimethylarylamines with iodine-calcium oxide in tetrahydrofuran-methanol affords N-methylarylamines in good yield.
 IT 126784-99-4
 RL: RCT (Reactant)
 (oxidative demethylation of 4-substituted N,N-dimethylanilines with iodine and calcium oxide in methanol)
 RN 126784-99-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




IT 159681-66-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (oxidative demethylation of 4-substituted N,N-dimethylanilines with iodine and calcium oxide in methanol)
 RN 159681-66-0 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(methylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)




L9 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1994:290311 CAPLUS
 DOCUMENT NUMBER: 120:290311
 TITLE: A comparison of the pregnancy-terminating
 potencies of three anti-progestins in guinea pigs, and the
 effects of sulprostone
 AUTHOR(S): Poyser, N. L.; Forcelledo, M. L.
 CORPORATE SOURCE: Med. Sch., Univ. Edinburgh, Edinburgh, EH8 9JZ, UK
 SOURCE: Prostaglandins, Leukotrienes Essent. Fatty Acids
 (1994), 50(5), 245-7
 CODEN: PLEAEU; ISSN: 0952-3278
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The anti-progestins mifepristone, lilopristone (2K 98734) and HRP 2000
 were equipotent at terminating the pregnancy of guinea-pigs during
 mid-gestation, although mifepristone was more effective at low doses.
 Sulprostone administration on the day following anti-progestin
 treatment tended to increase the effectiveness of mifepristone and HRP 2000,
 without affecting the time interval between the start of the antiprogesterin
 treatment and the day of abortion. It is concluded that, of the three
 afferent anti-progestins used, none is more potent than the other two
 at terminating pregnancy in the animal model used. The
 co-administration of a PGE2 analog tends to increase the effectiveness of the
 anti-progestin.
 IT 126784-99-4
 RI: BIOL (Biological study)
 (abortion from, sulprostone enhancement of)
 RN 126784-99-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-
 (dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




L9 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)

L9 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1993:73787 CAPLUS
 DOCUMENT NUMBER: 118:73787
 TITLE: Reversal of activity profile in analogs of the
 antiprogesterin RU 486: effect of a
 16.alpha.-substituent on progestational (agonist)
 activity
 AUTHOR(S): Cook, C. Edgar; Wani, Mansukh C.; Lee, Yue Wei;
 Fail,
 CORPORATE SOURCE: Patricia A.; Petrow, Vladimir
 Research Triangle Inst., Research Triangle Park,
 NC, 27709-2194, USA
 SOURCE: Life Sci. (1993), 52(2), 155-62
 CODEN: LIFSAR; ISSN: 0024-3205
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB RU 486 analogs (I, R = H, OAc; R1 = H, Et; R2 = H, Me) were tested for
 binding to progesterone receptors and for progestational and
 antiprogesterational activity. The 17.beta.-acetoxy analogs showed
 antiprogesterational activity, whereas the 16.alpha.-Et analogs were
 progestogenic. The analog I (R = R1 = R2 = H) exhibited mixed
 activity.
 Examm. of structure-activity relationships in combination with
 computer aided mol. modeling suggests that a binding interaction of the
 16.alpha.-Et group with the progesterone receptor (PR) or the
 PR-progestin response element complex may play the major role in this reversal of
 activity profile.
 IT 126690-26-4 126784-99-4
 RI: BAC (Biological activity or effector, except adverse); BIOL
 (Biological study)
 (antiprogesterogenic activity of, mol. structure in relation to)
 RN 126690-26-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-
 (dimethylamino)phenyl]-6-methyl-, (6.alpha.,11.beta.)- (9CI) (CA
 INDEX NAME)
 Absolute stereochemistry.



L9 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)
 RN 126784-99-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-
 (dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1990:198892 CAPLUS
 DOCUMENT NUMBER: 112:198892
 TITLE: Preparation of 11.beta.-acyl-19-norsteroids as antiglucocorticoids, progestogens, and antiprogestogens
 INVENTOR(S): Cook, C. Edgar; Wani, Mansukh C.; Lee, Yue Wei; Reel, Jerry R.; Rector, Douglas
 PATENT ASSIGNEE(S): Research Triangle Institute, USA
 SOURCE: PCT Int. Appl., 50 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8912448	A1	19891228	WO 1989-US2706	19890623
US 4954490	A	19900904	US 1988-210503	19880623
CA 1338906	A1	19970211	CA 1989-603686	19890622
AU 8938906	A1	19900112	AU 1989-38506	19890623
EP 422100	B2	19930318	EP 1989-907924	19890623
EP 422100	A1	19910417	JP 1989-507392	19890623
JP 03505582	T2	19911205	AT 1989-907924	19890623
JP 2953729	B2	19990927	US 1990-504129	19900403
AT 149839	E	19970315	NO 1990-5546	19901221
US 5073548	A	19911217	DK 1990-3053	19901221
NO 9005546	A	19901221	US 1988-210503	19880623
NO 178264	B	19951113	WO 1989-US2706	19890623
NO 178264	C	19960221		
DK 9003053	A	19901221		

PRIORITY APPLN. INFO.:
 OTHER SOURCE(S): MARPAT 112:198892
 AB The title compds. [I: R1 = H, alkyl, alkenyl, etc.; R2 = H, R3 = H, alkyl, alkenyl, alkynyl; R4 = H, Me, F, Cl; R6 = H, Me2N, MeO, MeCO, MeS, etc.; X = O, MeON; or R1R2 = bonds or R1R3 = CH2, N:CH2; or R2R3 = CH2] were prepd. Gignard reaction of 5.alpha.,6.alpha.-epoxy-6.alpha.-methyl-3,3:20,20-bis(ethylenedioxy)-19-norpregn-9(11)-en-17.alpha.-ol (prepn. given) with p-Me2NC6H4MgBr followed by 17-O-acetylation and deketalization gave I [R1 = AcO, R2 = R3 = H, R4 = Me, R6 = Me2N, X = O]. The binding affinity of I for progesterone receptor in cytosol obtained from estrogen-primed immature rabbit uterus was 8-80% that of progesterone.


L9 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)
 (dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)
 Several I had glucocorticoid receptor binding affinities up to 2.5-fold that of dexamethasone, and one compd. had in vivo antiprogestational activity comparable to that of RU-486.
 IT 126690-26-4P 126690-29-7P 126784-99-4P
 RI: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as antiglucocorticoid and/or (anti)progestogen)
 RN 126690-26-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-6-methyl-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 126690-29-7 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 126784-99-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-


L9 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1989:213172 CAPLUS
 DOCUMENT NUMBER: 110:213172
 TITLE: 13(Alpha)-alkylgonanes, their production, and pharmaceutical preparations containing same
 INVENTOR(S): Neef, Guenter; Wiechert, Rudolf; Beier, Sybille; Elger, Walter; Henderson, David
 PATENT ASSIGNEE(S): Schering A.-G., Fed. Rep. Ger.
 SOURCE: U.S., 5 pp. Cont. of U.S. Ser. No. 621,308.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4780461	A	19881025	US 1985-810148	19851218
DE 3321826	A1	19841220	DE 1983-3321826	19830615
DE 3413036	A1	19851017	DE 1984-3413036	19840404
DE 3446661	A1	19860619	DE 1984-3446661	19841218

PRIORITY APPLN. INFO.:
 OTHER SOURCE(S): MARPAT 110:213172
 AB 13.alpha.-Alkylgonanes [I: R = Cl-4 acyl; X = O, NOH; II: R1 = amino; R2 = H, Me, Et; R3 = (substituted) alkyl; R4 = OH, alkoxy, alkanoyloxy; or R3R4 = Q; R5 = H, alkyl; III: Z = CH2CH2, CH2CHMe2CH2], having antigestagenic activity and useful as postcoital contraceptives, or for triggering abortion and menstruation (no data), are prepd. via photochem. epimerization of the 13.beta.-gonanes IV. 11.beta.-(4-Dimethylaminomethyl)-17.alpha.-hydroxy-13.alpha.-methyl-17.beta.-(3-hydroxypropyl)-4,9-gonadien-3-one (V) was acetylated with Ac2O in pyridine to give 11.beta.-(4-dimethylaminomethyl)-17.alpha.-hydroxy-13.alpha.-methyl-17.beta.-(3-acetoxypentyl)-4,9-gonadien-3-one. A tablet was formulated contg. V 10.0, lactose 140.0, corn starch 69.5, polyvinylpyrrolidone 25 2.5, Aerosil 2.0, and Mg stearate 0.5 mg.
 IT 96285-40-4P 96285-50-6P
 RI: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as postcoital contraceptive)
 RN 96285-40-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.,13.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)




RN 96285-50-6 CAPLUS
 CN 18,19-Dinorpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-13-ethyl-, (11.beta.,13.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)
 IT 116421-73-99 116421-74-0P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of, as drug)
 RN 116421-73-9 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(1-propynyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 116421-74-0 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(1-propynyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1988:529463 CAPLUS
 DOCUMENT NUMBER: 109:129463
 TITLE: New 11-(alkynylphenyl)-substituted 19-nor and 19-nor-0-homo steroids, their formation and pharmacological activity, and processes for their preparation
 INVENTOR(S): Teutsch, Jean Georges; Klich, Michel; Philibert, Daniel
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Eur. Pat. Appl., 88 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 245170	A1	19871111	EP 1987-401018	19870504
EP 245170	B1	19891129		
R: CH, DE, GB, IT, LI, NL, SE				
FR 2598421	A1	19871113	FR 1986-6517	19860506
FR 2598421	B1	19880819		
US 4912097	A	19900327	US 1987-44958	19870430
HU 44793	A2	19880428	HU 1987-2007	19870505
HU 196224	B	19881028		
JP 62294694	A2	19871222	JP 1987-109059	19870506

PRIORITY APPL. INFO.:
 AS Title steroids I [R1 = C2-8 alkynyl (un)substituted by OH, halo, trialkylsilyl, alkoxy, alkylthio, dialkylamino, or oxo; R2 = C1-3 alkyl; A/B-rings = Q1-Q5; D-ring = Q6; Q7; R3, R4 = H, C1-4 alkyl; R5 = H, OH, acyloxy, (un)substituted C1-6 alkoxy; R6 = H, C1-8 alkyl, C7-15 alkyl; R7, R8 = H, OH, etc.; R7R8 = lactones and related groups; YZ = CH2CH2, CH:CH, 1,2-cyclopropanediyl, CHNCH2, CH2CHN10; R9, R10 = C1-4 alkyl] are prepd. for use as progestogens, antiprogestogens, and/or antiglucocorticoids.
 3,3-Ethyleneedioxy-5,10-epoxy-estr-9(11)-en-17-one was treated with 4-(Me3SiC(C)CH4MgBr and CuCl in THF, and the product treated with CH2:CHCH2MgBr and deprotected and dehydrated (NH4OH in aq. MeOH, then aq. HCl) to give (ethynylphenyl)allylhydroxyestradiene II.
 At 10⁻⁶M in vitro, II gave 98% reversal of the dexamethasone-induced redn. of uridine uptake by rat thymocytes (5 times. 10⁻⁸M dexamethasone). Tablets were prepd. from 50 mg of the 17.alpha.-(chloroethynyl) analog of II, and 120 mg of a mixt. of talc, starch, and Mg stearate.

L9 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1987:5324 CAPLUS
 DOCUMENT NUMBER: 106:5324
 TITLE: 11.beta.-Phenylgonanes and pharmaceutical compositions containing them
 INVENTOR(S): Neef, Guenter; Wiechert, Rudolf; Ottow, Eckard; Rohde, Ralph; Beier, Sybille; Elger, Walter; Henderson, David
 PATENT ASSIGNEE(S): Schering A.-G., Fed. Rep. Ger.
 SOURCE: Eur. Pat. Appl., 55 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 190759	A2	19860813	EP 1986-101548	19860206
EP 190759	A3	19861120		
EP 190759	B1	19890830		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
DE 3504421	A1	19860807	DE 1985-3504421	19850207
DE 3527517	A1	19870129	DE 1985-3527517	19850729
AT 45956	E	19890915	AT 1986-101548	19860206

PRIORITY APPL. INFO.:
 DE 1985-3504421 19850207
 DE 1985-3527517 19850729
 EP 1986-101548 19860206
 AS 11.beta.-Phenylgonane derivs. I [Z = O, CH2, bond; X = O, NOH; R1 = 3- or 4-hydrocarbyl contg. C:X; R2 = .alpha.- or .beta.-Me or -Et; R3 and R4 = various group combinations (e.g. R3 or R4 = OH, acyloxy, other = (un)substituted C.tpbond.CH, R3R4 = CH2CH2CO2); R5-8 = H, OH, alkyl, alkoxy, acyloxy, halo] were prepd. as antigestagens and antiglucocorticoids, with a notable disson. of the two activities.
 Thus, 4-BrCH4Ac was ketalized with Me2C(CH2OH)2, and the ketal was coupled with epoxystrenol deriv. II by a Cu-catalyzed Grignard reaction. The resulting arylgonane deriv. III (R3 = OH, R4 = H) was oxidized to give III (R3R4 = O), which underwent alkylation by LiC.tpbond.CMe or LiC.tpbond.CCH2OTHP (THP = 2-tetrahydropyranyl) to give III (R3 = OH, R4 = C.tpbond.CR9, R9 = Me or CH2OTHP). The former was hydrolyzed by aq. HOAc, and the latter was hydrogenated and then hydrolyzed, to give IV (R4 = C.tpbond.CMe) (V) and (Z)-IV (R4 = CH:CHCH2OH) (VI). V and VI showed, resp., 10- and 30-fold the abortifacient activity of the known compd. RU-38486 in gravid rats, while showing 30% and <1% of its antiglucocorticoid activity.

IT 105114-79-2P

L9 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)
 RL: BAC (Biological activity or effector, except adverse); SPN
 (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prepn. of, as antigestagen and antigluocorticoid)
 RN 105114-79-2 CAPLUS
 CN Benzaldehyde, 4-[(11.beta.,13.alpha.)-17-(acetyloxy)-3,20-dioxo-19-norpregna-4,9-dien-11-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1987:5323 CAPLUS
 DOCUMENT NUMBER: 106:5323
 TITLE: 11.beta.-Phenylgonanes
 INVENTOR(S): Neef, Guenter; Beier, Sybille; Elger, Walter;
 Henderson, David; Ottow, Eckhard; Rhode, Ralph
 PATENT ASSIGNEE(S): Schering A.-G., Fed. Rep. Ger.
 SOURCE: Ger. Offen., 40 pp.
 CODEN: GWXXEX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3504421	A1	19860807	DE 1985-3504421	19850207
AU 8652913	A1	19860814	AU 1986-52913	19860131
AU 580843	B2	19890202		
IL 77762	A1	19920818	IL 1986-77762	19860202
CN 86100994	A	19861008	CN 1986-100994	19860203
CN 1033753	B	19970108		
ES 551625	A1	19861216	ES 1986-551625	19860204
DK 8600560	A	19860808	DK 1986-560	19860205
DK 161709	B	19910805		
DK 161709	C	19920113		
NO 8600425	A	19860808	NO 1986-425	19860206
NO 171994	B	19930215		
NO 171994	C	19930526		
EP 190759	A2	19860813	EP 1986-101548	19860206
EP 190759	A3	19861120		
EP 190759	B1	19890830		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
HU 40453	A2	19861228	HU 1986-499	19860206
HU 194904	B	19880328		
DD 261166	A5	19881019	DD 1986-268660	19860206
AT 45956	E	19890915	AT 1986-101548	19860206
CA 1310630	A1	19921124	CA 1986-501252	19860206
FI 8600559	A	19860808	FI 1986-559	19860207
FI 85377	B	19911231		
FI 85377	C	19920410		
JP 61183296	A2	19860815	JP 1986-24260	19860207
JP 04037080	B4	19920618		
ZA 8600936	A	19860924	ZA 1986-936	19860207
US 5089635	A	19920218	US 1986-827050	19860207
NO 8604209	A	19860808	NO 1986-4209	19861021
NO 170285	B	19920622		
NO 170285	C	19920930		


PRIORITY APPLN. INFO.:

DE 1985-3504421	19850207
DE 1985-3527517	19850729
EP 1986-101548	19860206
NO 1986-425	19860206

AB Gonanes I [AB = O, CH2, bond; X = O, NOH; n = 0, 1; R1 = H, C1-4 alkyl; R2


L9 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)
 alkyl, = Me, Et; R3, R4 = OH, acyloxy, alkynyl, acyl, Me, H, (substituted)
 alkenyl, tetrahydrofuran-5-on-2-yl], useful as contraceptives,
 antiprogestins, and antigluocorticoids (data given), were prep.
 17.alpha.-Ethinyl-11.beta.-(4-formylphenyl)-17.beta.-hydroxy-4,9-estradien-
 3-one was prep. in 5 steps from 4-BrC6H4CHO, (HOCH2)2CMe2, HC(OMe)3,
 and
 4-MeC6H4SO3H.
 IT 105114-79-2P
 RL: BAC (Biological activity or effector, except adverse); SPN
 (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prepn. of, as antigestagen and antigluocorticoid)
 RN 105114-79-2 CAPLUS
 CN Benzaldehyde, 4-[(11.beta.,13.alpha.)-17-(acetyloxy)-3,20-dioxo-19-norpregna-4,9-dien-11-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1986:34230 CAPLUS
 DOCUMENT NUMBER: 104:34230
 TITLE: New steroids with antiprogestational and
 antigluocorticoid activities
 AUTHOR(S): Neef, Guenter; Beier, Sybille; Elger, Walter;
 Henderson, David; Wiechart, Rudolf
 CORPORATE SOURCE: Res. Lab., Schering A.-G./Bergkamen, Berlin,
 D-1000/65, Fed. Rep. Ger.
 SOURCE: Steroids (1984), 44(4), 349-72
 CODEN: STEDAM; ISSN: 0039-128X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB C-11 substituted 19-norsteroids I and-II (R = MeO, F, Me2N; R1 = HO,
 AcO,
 HC.tplbond.C, MeC.tplbond.C, HOCH2CH2CH2; R2 = HO, Ac, HC.tplbond.C,
 HOCH2CH2CH2, HOCH2CH:CH) with inverse configuration at C-13 were
 synthesized. 11.beta.-Aryl compds. possess antiprogestational and
 antigluocorticoid activities.
 IT 96285-40-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and antigluocorticoid activity of)
 RN 96285-40-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(
 dimethylamino)phenyl]-, (11.beta.,13.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L9 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1985:06617 CAPLUS
 DOCUMENT NUMBER: 103:6617
 TITLE: 13.alpha.-Alkylgonanes and pharmaceutical compositions
 INVENTOR(S): containing them
 Neef, Guenter; Sauer, Gerhard; Wiechert, Rudolf;
 Baier, Sybille; Elger, Walter; Henderson, David;
 Rohde, Ralph
 PATENT ASSIGNEE(S): Schering A.-G., Fed. Rep. Ger.
 SOURCE: Eur. Pat. Appl., 34 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 129499	A2	19841227	EP 1984-730062	19840613
EP 129499	A3	19851009		
EP 129499	B1	19871209		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
DE 3321826	A1	19841220	DE 1983-3321826	19830615
DE 3413036	A1	19851017	DE 1984-3413036	19840404
AT 31313	E	19871215	AT 1984-730062	19840613
PRIORITY AFFIL. INFO.:				
AB Phenylalkylgonanes I [R = H, alkyl; R1 = amino, alkylamino, 5- or 6-membered heterocycle ring radical, alkoxy; R2 = H, Me, Et; R3 = alkyl, alkylsulfonfylalkyl, alkoxyalkenyl, alkynyl, cyanoalkyl, Ac, HOCH2CO; R4 = HO, alkoxy, acyloxy; R3R4 = 5-oxodihydrofuran-2(3H)-ylidene] were prepd. via epimerization of estrene derivs. and possessed antigestagenic and post-coital contraceptive activities. Thus, the (aminophenyl)estrenone ketal II was photolyzed in THF using a Hg high-pressure lamp to give the C-13 epimer of II, which underwent successive addn. reaction with LiC.tpbond.OCH2O-THP (THP = tetrahydropyranyl), hydrogenation, and hydrolysis to give the (hydroxypropyl)gonadiene III. At 10 mg/animal/day III had a 100% abortion rate in rats.				
IT 96285-40-4F 96285-50-6F				
RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)				
RN 96285-40-4 CAPLUS				
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.,13.alpha.)- (9CI) (CA INDEX NAME)				

L9 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2000 ACS (Continued)
 Absolute stereochemistry.



RN 96285-50-6 CAPLUS
 CN 18,19-Dinorpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-13-ethyl-, (11.beta.,13.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d ibib ab fqhit 1-18

L10 ANSWER 1 OF 18 MARPAT COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 131:199885 MARPAT
 TITLE: Preparation of 20-keto-11.beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties
 INVENTOR(S): Cook, C. Edgar; Kepler, John A.; Zhang, Lee, Yue-wei; Tallent, C. Ray
 PATENT ASSIGNEE(S): Research Triangle Institute, USA
 SOURCE: PCT Int. Appl., 95 pp.
 DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: 1 English
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9945022	A1	19990910	WO 1999-US3732	19990305
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 1998-35949 19980306
 AB 20-Keto-11.beta.-arylsteroids of formula I [X = O, (substituted) NOH, H2, OH, etc.; R1 = dialkylamino, imidazolyl, pyrrolyl, piperidino, etc.; R2 = H, halo; R3 = H, Me, halo; R4 = H, acyloxy, (substituted) OH, alkyl, etc.; R5 = H, alkyl, halo, acyloxy, etc.] are prepd. which exhibit potent antiprogesterational activity. Thus, II was prepd. from 17.alpha.-hydroxymethyl-3-methoxy-19-norpregna-1,3,5(10)-trien-20-one and 4-bromo-N,N-dimethylaniline in several steps. The affinity of II for the progesterone hormone receptor was IC50 of 0.7 nM.


MPFR 1A

L10 ANSWER 2 OF 18 MARPAT COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 130:282222 MARPAT
 TITLE: Method for the preparation and pharmaceutical formulation of 11.beta.-benzaloxime-9.alpha.,10.alpha.-epoxy-estr-4-ene derivatives
 INVENTOR(S): Schubert, Gerd; Ring, Sven; Kaufmann, Guenter; Schneider, Birgitt; Elger, Walter
 PATENT ASSIGNEE(S): Jenapharm G.m.b.H. und Co. K.-G., Germany
 SOURCE: Ger. Offen., 16 pp.
 DOCUMENT TYPE: CODEN: GWXXEX
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: 1 German
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19745085	A1	19990415	DE 1997-19745085	19971011
EP 909764	A1	19990421	EP 1998-118613	19981001
EP 909764	B1	19990929		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
 AT 185145 E 19991015 AT 1998-118613 19981001
 PRIORITY APPLN. INFO.: DE 1997-19745085 19971011
 AB 11.beta.-Benzaloxime-9.alpha.,10.alpha.-epoxy-estr-4-ene derivs., e.g. I (R1 = H, C1-6-alkyl; R2 = H, C1-10-alkyl, aryl, aralkyl, alkylaryl, C1-10-acyl, CONHR4, CO2R4; R3 = H, C1-10-alkyl, aryl, aralkyl, alkylaryl, (CH2)nCH2Y; R4 = H, C1-10-alkyl, aryl, aralkyl, alkylaryl; Y = F, Cl, Br, I, CN, N3, SCN, OR5, SR5; n = 0-2; R5 = H, C1-10-alkyl, aryl, aralkyl, alkylaryl, C1-10-acyl), are described. Thus, (E)-I (R1 = R2 = Me, R3 = CH2OMe, Z = H) was prepd. via regioselective epoxidn. of estradienone II (R1 = R2 = Me, R3 = CH2OMe, Z = H) with m-chloroperbenzoic acid in CH2Cl2. (E)-I (R1 = R2 = Me, R3 = CH2OMe, Z = H) showed 88% affinity for the progesterone receptor but only 12% affinity for the glucocorticoid receptor.

MPFR 2



L10 ANSWER 1 OF 18 MARPAT COPYRIGHT 2000 ACS (Continued)



G2 = phenylene (SO (1) G3)
 G14 = 128

128 = G15

G27 = OCHO
 DER: and pharmaceutically acceptable salts
 MPL: claim 1
 NTE: substitution is restricted; also incorporates claim 3

L10 ANSWER 2 OF 18 MARPAT COPYRIGHT 2000 ACS (Continued)

G2 = 30

30 = G3

G3 = 33

The structure shows a steroid nucleus with a side chain at C17 containing a double bond and a nitrogen atom. A substituent G4 is indicated at C14.

G8 = 51

The structure shows a steroid nucleus with a side chain at C17 containing a double bond and a nitrogen atom. A substituent G12 is indicated at C14.

G12 = alkyl<(1-10)>
 DER: or pharmaceutically acceptable salts
 MPL: claim 1

L10 ANSWER 3 OF 18 MARPAT COPYRIGHT 2000 ACS

ACCESSION NUMBER: 129:50105 MARPAT

TITLE: Uses of anti-glucocorticoid compounds for the treatment of psychoses or addictive behaviors
 INVENTOR(S): Oberlander, Claude; Piazza, Pier Vincenzo
 PATENT ASSIGNEE(S): Hoechst Marion Roussel, Fr.; Oberlander, Claude; Piazza, Pier Vincenzo
 SOURCE: PCT Int. Appl., 41 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9826783	A1	19980625	WO 1997-FR2320	19971217
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
FR 2757400	A1	19980626	FR 1996-15649	19961219
FR 2757400	B1	19991217		
AU 9855632	A1	19980715	AU 1998-55632	19971217
EP 892641	A1	19990127	EP 1997-952078	19971217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: FR 1996-15649 19961219
 WO 1997-FR2320 19971217
 AB Glucocorticoid antagonists, except mifepristone, are used as dopamine type II receptor antagonists to treat psychotic or addictive behavior.

Thus, 17.beta.-hydroxy-10.beta.-[(4-methylphenyl)methyl]-17.alpha.-(1-propynyl)estra-4,9(11)-dien-3-one considerably reduced the response to morphine in vivo.

MYSTR 7

L10 ANSWER 3 OF 18 MARPAT COPYRIGHT 2000 ACS (Continued)



G1 = OCOMe
 DER: and pharmaceutically acceptable acid or basic addition salts
 MPL: claim 18

L10 ANSWER 4 OF 18 MARPAT COPYRIGHT 2000 ACS

ACCESSION NUMBER: 128:188869 MARPAT

TITLE: Mixed agonists of the progesterone receptor and assays
 for them


INVENTOR(S): McDonnell, Donald P.; Wagner, Brandee L.
 PATENT ASSIGNEE(S): Duke University, USA
 SOURCE: PCT Int. Appl., 62 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9805679	A2	19980212	WO 1997-US13754	19970805
W: CA				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

PRIORITY APPLN. INFO.: US 1996-23206 19960805
 AB A third class of PR-ligand (i.e. mixed agonist) is identified which induces a progesterone receptor conformation distinct from that induced by a PR agonist or antagonist; the agonists are estradiol-4,9-dien-3-one derivatives. PR mixed agonists exhibit partial agonist activity which is influenced by cell context. These compds. provide useful pharmacol. profiles for treating progesterone related diseases and/or conditions, such as uterine proliferation from estrogen administration, endometriosis, breast cancer, fibroids, endometrial cancer, and brain meningiomas. The agonists can also be used as contraceptives. Assays are provided to screen for PR mixed agonists. Mol. designs are provided to convert a PR antagonist to a PR mixed agonist.

MYSTR 2



G2 = COMe


L10 ANSWER 4 OF 18 MARPAT COPYRIGHT 2000 ACS (Continued)

G3 = OCOMe
 MPL: claim 9

L10 ANSWER 5 OF 18 MARPAT COPYRIGHT 2000 ACS
ACCESSION NUMBER: 127:358992 MARPAT
TITLE: Preparation of 21-substituted progesterone
derivatives
as new antiprostegestational agents
INVENTOR(S): Kim, Hyun K.; Blye, Richard P.; Rao, Pemmaraju N.;
Cessac, James W.; Acosta, Carmie K.
PATENT ASSIGNEE(S): United States Dept. of Health and Human Services,
USA;
Kim, Hyun K.; Blye, Richard P.; Rao, Pemmaraju N.;
Cessac, James W.; Acosta, Carmie K.
SOURCE: PCT Int. Appl., 65 pp.
CODING: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9741145	A1	19971106	NO 1997-US7373	19970430
DE,	W: AL, AM, AT, AU, AZ, BA, BB,	VG, BR, BY, CA, CH, CN, CZ,		
KZ,	DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR,			
PL,	LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ,			
UZ,	PT, RO, RU, SD, SE, SG, SI, SK, TJ, TH, TR, TT, UA, UG, US,			
GB,	VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
GN,	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR,			
	GR, IE, IT, LU, MC, NL, PT, SE, BF, BG, CF, CG, CI, CM, GA,			
	ML, MR, NE, SN, TD, TG			
CA 2253673	AA	19971106	CA 1997-2253673	19970430
AU 9729304	A1	19971119	AU 1997-29304	19970430
EP 900234	A1	19990310	EP 1997-923523	19970430
	R: AT, BE, CH, DE, DK, ES, FR, BG, GR, IT, LI, LU, NL, SE, MC,			
PT,	IE, FI			
PRIORITY APPLN. INFO.:			US 1996-16628	19960501
			WO 1997-US7373	19970430
AB	Progesterone derivs. of formula I [R1 = OMe, SMe, NMe2, NMe3, CHO, Ac, CHORCH3; R2 = halo, alkyl, acyl, OH, alkoxy, etc.; R3 = OH, alkyl, alkoxy; R4 = H, alkyl; X = O, (substituted) NOH] are prepd. as antiprostaglandin agents. The present invention provides methods wherein			
	the compds. of formula I are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent			


L10 ANSWER 5 OF 8 MARPAT COPYRIGHT 2000 ACS (Continued)
tumors; to treat uterine fibroids; to inhibit uterine endometrial
proliferation; to induce labor; and for contraception. Thus, II was
prepared from 3,3-ethylenedioxy-17-beta.-cyano-17.alpha.-hydroxyestra-
5(10),9(11)-diene and 4-bromo-N,N-dimethylaniline in 9 steps. II
showed
2.79 times the antiprogesterational potency in the antiClauberg test
compared to CDB-2914.



110 ANSWER 6 OF 18 MARPAT COPYRIGHT 2000 ACS
ACCESSION NUMBER: 122:256423 MARPAT
TITLE: Antiglucoocorticoid steroids for the treatment of
anxiety disorders
INVENTOR(S): Peeters, Bernardus Wynand Machijs Maria
PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXX02
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE
WO 9504546	A1 19950216	WO 1994-EP2513	19940728
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KG, KP,			
KR,	KZ, LK, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ,		
TT,	UA, US, UZ, VN		
MC,	RW: XE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU,		
TD, TG	NL, PT, SE, BF, BI, CF, CG, CI, CH, GA, GN, ML, MR, NE, SN,		
AU 9474968	A1 19950228	AU 1994-74968	19940728
AU 687088	B2 19980219		
EP 712311	A1 19960522	EP 1994-924819	19940728
EP 712311	B1 19981007		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL,			
PT, SE			
JP 09501172	T2 19970204	JP 1994-506200	19940728
AT 718973	E 19981015	AT 1994-924819	19940728
ES 2124905	T3 19990216	ES 1994-924819	19940728
US 5741787	A 19980421	US 1996-581631	19960118
PRIORITY APPLN. INFO.:		EP 1993-202304	19930804
		EP 1994-924819	19940728
		WO 1994-EP2513	19940728
AB	Antiglucocorticoid steroids are used for the manuf. of a pharmaceutical compn. for the treatment of anxiety disorders. The anxiolytic effect of		
11.beta.-(4-dimethylaminophenyl)-17.beta.-hydroxy-17.alpha.-(prop-1-ynyl)-estra-4,9-dien-3-one (RU38486)	was demonstrated in animal testing (antagonism of fear-potentiated startle). Prepn. and activity		
(antagonism of stress-induced hyperthermia) of selected steroids of the invention	is also described.		

L10 ANSWER 6 OF 18 MARPAT COPYRIGHT 2000 ACS (Continued)



MPL: claim 2

MYTR 1

L10 ANSWER 7 OF 18 MARPAT COPYRIGHT 2000 ACS

ACCESSION NUMBER: 116:35156 MARPAT
 TITLE: Preparation and use of antiprogestomimetics for
 synchronization of parturition in livestock
 INVENTOR(S): Grandadam, Jean Andre
 PATENT ASSIGNER(S): Roussel-UCLAF, Fr.
 SOURCE: Eur. Pat. Appl., 13 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 446124	A2	19910911	EP 1991-400594	19910305
EP 446124	A3	19920527		
R: AT, BE, CH, DE, DK, FR, GB, GR, IT, LI, LU, NL, SE				
FR 2659233	A1	19910913	FR 1990-2783	19900306
FR 2659233	B1	19940121		
CA 2037549	AA	19910907	CA 1991-2037549	19910305
AU 9172608	A1	19910912	AU 1991-72608	19910305
AU 642975	B2	19931104		
ZA 9101603	A	19920527	ZA 1991-1603	19910305
JP 04211610	A2	19920803	JP 1991-62496	19910305
RU 2037295	C1	19950619	RU 1991-4895041	19910305
CN 1055665	A	19911030	CN 1991-102108	19910306
HU 59006	A2	19920428	HU 1991-729	19910306
			FR 1990-2783	19900306

PRIORITY APPLN. INFO.:

AB The title antiprogestomimetics are I (R1 = C1-18 hydrocarbyl optionally substituted with .gtoreq.1 heteroatoms and bonded to the steroid by a C; R2 = C1-8 hydrocarbyl; X = remainder of 5- and 6-membered ring optionally substituted and optionally unsatd.; C = A = CNOH, oxo (free or blocked as ketal), etc.; B and C together form a double bond or epoxide bridge) and acid addn. salts thereof. Prepn. of 2 I are described.
 17.beta.-Hydroxy-11.beta.-(4-dimethylaminophenyl)-17.alpha.-(prop-1-ynyl)estra-4,9-dien-3-one (II) was more effective at synchronizing parturition than cloprostenol when tested in sows. Injectable pharmaceuticals contg. II are disclosed.

MPTR 1C

L10 ANSWER 8 OF 18 MARPAT COPYRIGHT 2000 ACS

ACCESSION NUMBER: 115:214857 MARPAT
 TITLE: Injectable microspheres containing antiestrogenic and antiprogestomimetic steroids
 INVENTOR(S): Cohen, Gerard; Dubois, Jean Luc
 PATENT ASSIGNER(S): Roussel-UCLAF, Fr.
 SOURCE: Ger. Offen., 15 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4036425	A1	19910516	DE 1990-4036425	19901115
FR 2654337	A1	19910517	FR 1989-14976	19891115
FR 2654337	B1	19940805		
SE 9003570	A	19910516	SE 1990-3570	19901109
BE 1005511	A4	19930831	BE 1990-1062	19901109
DK 9002709	A	19910516	DK 1990-2709	19901113
CA 2029940	AA	19910516	CA 1990-2029940	19901114
JP 03294229	A2	19911225	JP 1990-306374	19901114
CH 681691	A	19930514	CH 1990-3611	19901114
NL 9002492	A	19910603	NL 1990-2492	19901115
GB 2239798	A1	19910717	GB 1990-24862	19901115
GB 2239798	B2	19931027		
AT 9002313	A	19950415	AT 1990-2313	19901115
AT 400298	B	19951127		


PRIORITY APPLN. INFO.:

AB Biodegradable microspheres comprise the title steroids (Markush given) and copolymers of lactic acid with glycolic acid. A mixt. of 250 mL aq. 0.3% hydrolyzed PVA soln., 1 g poly(DL-lactic acid-glycolic acid), 17 g CH2Cl2, and 0.5 g 17.beta.-hydroxy-11.beta.-(4-(dimethylamino)phenyl)-17.alpha.-(1-propynyl)estra-4,9-dien-3-one was emulsified, followed by stirring at 22.degree. and decreasing pressure (.gtoreq.400 mm Hg) to give microspheres, which were used for the prepn. of injections.


MPTR 1A

G1—G3


G1 = 3




L10 ANSWER 7 OF 18 MARPAT COPYRIGHT 2000 ACS (Continued)



G1 = 30



G3 = 55-13 57-14




G9 = 40




G15 = alkylcarbonyloxy<(1-8)>
 DER: and protected derivatives
 DER: and acid addition salts
 MPL: claim 1

L10 ANSWER 8 OF 18 MARPAT COPYRIGHT 2000 ACS (Continued)


G3 = 24



G5 = 68-26 70-27



G9 = 74




G13 = alkylcarbonyloxy<(1-8)>
 MPL: claim 6

L10 ANSWER 9 OF 18 MARPAT COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 115:151901 MARPAT
 TITLE: Use of antiprogesteronimetics for stimulating ovulation,
 and new preparation for use in pharmaceutical compositions
 INVENTOR(S): Grandadam, Jean Andre
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Eur. Pat. Appl., 24 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 417003	A2	19910313	EP 1990-402449	19900906
EP 417003	A3	19911204		
EP 417003	B1	19940629		
R: AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE				
FR 2651435	A1	19910308	FR 1989-11699	19890907
FR 2651435	B1	19940422		
US 5173483	A	19921222	US 1990-578894	19900905
CA 2024728	AA	19910308	CA 1990-2024728	19900906
AU 9062259	A1	19910314	AU 1990-62259	19900907
AU 623805	B2	19920521		
JP 03099015	A2	19910424	JP 1990-236004	19900907
FR 1989-11699 19890907				

PRIORITY APPLN. INFO.:
 AB Anti-progesteronimetic compds., e.g. I [R1 = C1-18 hydrocarbyl with optionally .gtoreq.1 heteroatoms, bonded to the steroid by a C; R2 = C1-8 hydrocarbyl; X = rest of 5- or 6-membered (substituted) (unsatd.) ring; A1C = oxo (free or in ketal), CH(OH), CH(OR3), CH(O2CR3), etc.; R3 = alkyl, C7-15 aralkyl; B and C together form a double bond or epoxide bridge] and their acid and base addn. salts, are used for making pharmaceuticals for stimulating ovulation, e.g. in cows. The compds. of the invention are preferably used following treatment with progesterone or a progestomimetic, e.g. 3-oxo-17.alpha.-allyl-17.beta.-hydroxyestra-4,9,11-triene (II). Thus, heifer cows were 1st administered II for 17 days; on the day following the last administration, the animals were injected with 17.beta.-hydroxy-11.beta.-(4-dimethylaminophenyl)-17.alpha.-(prop-1-ynyl)estra-4,9-dien-3-one. All of the heifers came to heat after a very short delay period, and LH levels rose very rapidly. Prepn. of 12 anti-progesteronimetics is presented.

L10 ANSWER 9 OF 18 MARPAT COPYRIGHT 2000 ACS (Continued)
 MSTR 1A




L10 ANSWER 11 OF 18 MARPAT COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 114:229227 MARPAT
 TITLE: Preparation of 19-nor 3-oxo steroids with an amine substituted 17-chain as antioxidants and antiinflammatories: their use as medicines and pharmaceutical composition containing them
 INVENTOR(S): Claussner, Andre; Leclaire, Jacques; Nedelec, Lucien;
 PATENT ASSIGNEE(S): Philibert, Daniel
 SOURCE: Roussel-UCLAF, Fr.
 Eur. Pat. Appl., 29 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 389370	A1	19900926	EP 1990-400784	19900322
EP 389370	B1	19940427		
R: CH, DE, FR, GB, IT, LI, NL				
FR 2644789	A1	19900928	FR 1989-3742	19890322
FR 2644789	B1	19950203		
JP 02273693	A2	19901108	JP 1990-68508	19900320
JP 2848907	B2	19900120		
US 5108996	A	19920428	US 1990-497562	19900321
			FR 1989-3742	19890322


PRIORITY APPL. INFO.:
 AB The title compds. [I; R1, R2 = H, Me; R11 = (poly)(hetero)hydrocarbyl; one of R17 and R18 is OH or acyloxy and the other is Q; Z = alkylene, alkenylene, alkynylene; P = (substituted) pyrimidinyl, pyridyl] were prepd. via reacting the halo derivs. II or III (X = halo) with the appropriate pyrimidinyl or pyridine deriv. IV. Reaction of estradienone V [R3 = 3-bromo-1-propynyl, R4 = OH] (prepn. given) was reacted with 2,4-bis(1-pyrrolidinyl)-6-(1-piperazinyl)pyrimidine (prepn. given) in acetone contg. K2CO3 at ambient temp. for 2 h to give V [R3 = 3-[4-[2,6-bis(1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-1-propynyl; R4 = OH]. At 5 times. 10-4 M this inhibited in vitro the formation of malonyldialdehyde, a measure of lipid peroxidn., in rat brain homogenate by .apprx.47.5%.

MPTR 1c

L10 ANSWER 11 OF 18 MARPAT COPYRIGHT 2000 ACS (Continued)



G2 = 97



G4 = 33



DER: and salts
 MPL: claim 1
 NTE: the alkylamino and dialkylamino groups in G11 may be interrupted by oxygen, sulfur, or nitrogen

L10 ANSWER 12 OF 18 MARPAT COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 113:115677 MARPAT
 TITLE: Preparation of androstanone derivatives as drugs
 INVENTOR(S): Scholz, Stefan; Neef, Guenter; Ottow, Eckhard; Elger,
 PATENT ASSIGNEE(S): Walter; Beier, Sybille; Chwalisz, Krzysztof
 SOURCE: Schering A.-G., Fed. Rep. Ger.
 Eur. Pat. Appl., 38 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 360369	A1	19900328	EP 1989-250040	19890920
EP 360369	B1	19950503		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DE 3832303	A1	19900412	DE 1988-3832303	19880920
IL 91672	A1	19941229	IL 1989-91672	19890918
WO 9003385	A1	19900405	WO 1989-EP1090	19890920
W: AU, DK, FI, HU, JP, NO, US				
AU 8943049	A1	19900418	AU 1989-43049	19890920
AU 640616	B2	19930902		
ZA 8907191	A	19901031	ZA 1989-7191	19890920
DD 284682	A5	19901121	DD 1989-332836	19890920
HU 56851	A2	19911028	HU 1989-5541	19890920
HU 208151	B	19930830		
JP 04501712	T2	19920326	JP 1989-509963	19890920
JP 2760870	B2	19980604		
AT 122052	E	19950515	AT 1989-250040	19890920
ES 2074073	T3	19950901	ES 1989-250040	19890920
NO 9101102	A	19910319	NO 1991-1102	19910319
DK 9100504	A	19910320	DK 1991-504	19910320
US 5244886	A	19930914	US 1991-663819	19910320
NO 9104772	A	19910319	NO 1991-4772	19911204
			DE 1988-3832303	19880920
			WO 1989-EP1090	19890920
			NO 1991-1102	19910319

PRIORITY APPL. INFO.:
 AB The title compds. [I; Z = O, hydroxyimino; LM = bond, or L = H and M = -alpha.-OH; AB = bond and D = H and R1 = heteroaryl; or A = H and BD = CH2 and Z = H2; R3, R4 = tetrahydropyranyloxyalkyl, tetrahydropyranyloxyalkenyl, etc.], useful as antiglucoocorticoids, neoplasm inhibitors (esp. for breast cancer), progestogen inhibitors, and antiproliferative agents, were prepd. 3-(Tetrahydropyran-2-yloxy)-1-propyne was lithiated with BuLi in THF-hexane and the product treated with 14.beta.-androstan-17-one II (R3R4 = O) (prepn. given) to give II (R3 = Q, R4 = OH) treated with 4N HCl to give I [R1 = OMe, R2 = Me, R3 = (CH2)3OH, BD = CH2, LM = bond, Z = O, A = H] (III). III had higher affinity for the gestagen receptor than the known EP-A 0277676 [11.beta.-[4-


L10 ANSWER 12 OF 18 MARPAT COPYRIGHT 2000 ACS (Continued)

(dimethylamino)phenyl]-17.alpha.-hydroxy-17-(3-hydroxypropyl)-14.beta.-estra-4,9-dien-3-one].

MPTR 1a



G20 = 45



G29 = OCHO
 MPL: claim 1


L10 ANSWER 13 OF 18 MARPAT COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 112:235680 MARPAT
 TITLE: Preparation of 13-alkyl-11.beta.-phenylgonanes as
 antigestagens and antigluccorticoids
 INVENTOR(S): Scholz, Stefan; Ottow, Eckhard; Neef, Guenter;
 Elger,
 PATENT ASSIGNEE(S): Walter; Beier, Sybille; Chwalisz, Krzysztof
 Schering A.-G., Fed. Rep. Ger.
 SOURCE: Ger. Offen., 22 pp.
 CODEN: GWGXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3822770	A1	19900104	DE 1988-3822770	19880701
IL 90826	A1	19940624	IL 1989-90826	19890630
CA 1334668	A1	19950307	CA 1989-604596	19890630
EP 349481	A1	19900103	EP 1989-730155	19890703
EP 349481	B1	19951102		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
WO 9000174	A1	19900111	WO 1989-DE443	19890703
W: AU, FI, HU, JP, NO				
AU 8938568	A1	19900123	AU 1989-38568	19890703
AU 644060	B2	19931202		
ZA 8905058	A	19900425	ZA 1989-5058	19890703
DD 287511	A5	19910228	DD 1989-330342	19890703
HU 56114	A2	19910729	HU 1989-4130	19890703
HU 208021	B	19930728		
DD 295638	A5	19911107	DD 1989-341722	19890703
JP 03505727	T2	19911212	JP 1989-507188	19890703
JP 2956776	B2	19910004		
US 5273971	A	19931228	US 1989-374809	19890703
AT 129717	E	19951115	AT 1989-730155	19890703
ES 2080079	T3	19960201	ES 1989-730155	19890703
NO 9005609	A	19910228	NO 1990-5609	19901227
NO 180451	B	19970113		
NO 180451	C	19970423		
US 5446036	A	19950829	US 1993-144474	19931102
FI 9504856	A	19951012	FI 1995-4856	19951012
NO 9600829	A	19910228	NO 1996-829	19960229
PRIORITY APPLN. INFO.:				
DE 1988-3822770 19880701				
US 1989-374809 19890703				
WO 1989-DE443 19890703				
NO 1990-5609 19901227				
FI 1990-6441 19901228				

AB The title compds. [I; R1 = heterocyclyl, cycloalkyl, cycloalkenyl, alkenyl, etc.; R2 = .alpha.-, .beta.-Me, -Et; R3, R4 = alkoxy, acyl, oxofuryl, alkynyl, etc.; Z = O, NOH], antigestagens and antigluccorticoids useful for induction of abortion, were prepd. via Grignard reaction of the corresponding 5.alpha.,10.alpha.-epoxy-9(11)

L10 ANSWER 13 OF 18 MARPAT COPYRIGHT 2000 ACS (Continued)
 unsatd. steroids with p-R1C6H4X (X = halo). Grignard reaction of epoxy steroid II (prepn. given) with p-CH2:CHC6H4X (X = Br, iodo) gave I [R1 = CH2:CH, R2 = .beta.-Me, R3 = OH, R4 = C.tplbond.CMe, Z = OCH2CMe2CH2O], which was hydrolyzed to give I [Z = O, R1-R4 same as above]. This at 3.0 mg s.c./day induced abortion in 100% of rats tested.

MYR 1A



G4 = 37

G5 = CH2-G10

G7 = 32

G8 = CHO

MPL: claim 1

NTE: substitution is restricted


L10 ANSWER 14 OF 18 MARPAT COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 112:198892 MARPAT
 TITLE: Preparation of 11.beta.-aryl-19-norsteroids as
 antigluccorticoids, progestogens, and
 antiprogesterones
 INVENTOR(S): Cook, C. Edgar; Wani, Mansukh C.; Lee, Yue Wei;
 Reel,
 PATENT ASSIGNEE(S): Research Triangle Institute, USA
 SOURCE: PCT Int. Appl., 50 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8912448	A1	19891228	WO 1989-US2706	19890623
W: AU, DK, JP, KR, NO				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
US 4954490	A	19900904	US 1988-210503	19880623
CA 1338906	A1	19970211	CA 1989-603686	19890622
AU 8938506	A1	19900112	AU 1989-38506	19890623
AU 635211	B2	19930318		
EP 422100	A1	19910417	EP 1989-907924	19890623
EP 422100	B1	19970312		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 03505582	T2	19911205	JP 1989-507392	19890623
JP 2953725	B2	19990927		
AT 149839	E	19970315	AT 1989-907924	19890623
US 5073548	A	19911217	US 1990-504129	19900403
NO 9005546	A	19901221	NO 1990-5546	19901221
NO 178264	B	19951113		
NO 178264	C	19960221		
DK 9003053	A	19901221	DK 1990-3053	19901221
PRIORITY APPLN. INFO.:				
US 1988-210503 19880623				
WO 1989-US2706 19890623				

AB The title compds. [I; R1 = H, alkyl, alkenyl, etc.; R2 = H, R3 = H, alkyl, alkenyl, alkynyl; R4 = H, Me, F, Cl; R6 = H, Me2N, MeO, MeCO, MeS, etc.; X = O, MeON; or R1R2 = bond; or R1R3 = CH2, N:CH2; or R2R3 = CH2] were prepd. Grignard reaction of 5.alpha.,6.alpha.-epoxy-6.alpha.-methyl-3,3:20,20-bis(ethylenedioxy)-19-norpregn-9(11)-en-17.alpha.-ol (prepn. given) with p-Me2NC6H4MgBr followed by 17-O-acetylation and deketalization gave I [R1 = AcO, R2 = R3 = H, R4 = Me, R6 = Me2N, X = O]. The binding affinity of I for progesterone receptor in cytosol obtained from estrogen-primed immature rabbit uterus was 8-80% that of progesterone. Several I had glucocorticoid receptor binding affinities up to 2.5-fold that of dexamethasone, and one compd. had in vivo antiprogesterational activity comparable to that of RU-486.

MYR 1A

L10 ANSWER 14 OF 18 MARPAT COPYRIGHT 2000 ACS (Continued)



G1 = OCOMe

MPL: claim 1

L10 ANSWER 15 OF 18 MARPAT COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 111:233356 MARPAT
 TITLE: New 11-aryl steroids useful as antiprogesterins,
 their
 INVENTOR(S): preparation, and pharmaceuticals containing them
 De Jongh, Hendrik Paul; Van Vliet, Nicolaas Pieter
 PATENT ASSIGNEE(S): AKZO N. V., Neth.
 SOURCE: Eur. Pat. Appl., 10 pp.
 CODEN: EPXKXOW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 321010	A1	19890621	EP 1988-202678	19881125
EP 321010	B1	19930203		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
AT 85342	E	19930215	AT 1988-202678	19881125
ES 2053714	T3	19940801	ES 1988-202678	19881125
ZA 8808996	A	19890830	ZA 1988-8996	19881130
AU 8826469	A1	19890615	AU 1988-26469	19881201
AU 613433	B2	19910801		
US 4921845	A	19900501	US 1988-281582	19881208
CA 1301162	A1	19920519	CA 1988-585297	19881208
DK 8806880	A	19890613	DK 1988-6880	19881209
DK 168444	B1	19940328		
FI 8805717	A	19890613	FI 1988-5717	19881209
FI 89056	B	19930430		
FI 89056	C	19930810		
CN 1034731	A	19890816	CN 1988-108484	19881212
CN 1019807	B	19921230		
JP 01211597	A2	19890824	JP 1988-313643	19881212


PRIORITY APPLN. INFO.:
 AB Aryl steroids I [R1 = aryl substituted by -NXY; X, Y = H, Cl-4
 hydrocarbyl; or XY = C2-6 hydrocarbyl forming 3- to 7-membered ring;
 R2 = H, OH, acyloxy, alkoxy, (unsatd. C1-8 hydrocarbyl with .gtoreq.1 OH,
 oxo,
 N3, cyano, and/or halo group; R3 = OH, acyloxy, alkoxy, or acyl
 optionally
 substituted by OH, alkoxy, acyloxy, or halo; or R2R3 forms ring; R2
 .noteq. H or OH when R3 = OH; R4 = Me, Et], which are strong
 antiprogesterins with little or no antiglucocorticoid activity (no
 data),
 are prepd. Thus, 7.beta.-methylester-5-(10)-ene-3,17-dione 3,3-di-Me
 acetal underwent NaBH4 redn., deketalization,
 bromination/dehydrobromination, reketalization, and epoxidn., to give
 5.alpha.,
 10.alpha.-epoxy-17.beta.-hydroxy-7.beta.-methylester-9(11)-en-3-
 one 3,3-ethylene acetal. This underwent CuCl-catalyzed coupling with

L10 ANSWER 16 OF 18 MARPAT COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 110:213172 MARPAT
 TITLE: 13(Alpha)-alkylgonanes, their production, and
 pharmaceutical preparations containing same
 INVENTOR(S): Neef, Guenter; Wiechert, Rudolf; Beier, Sybille;
 Elger, Walter; Henderson, David
 PATENT ASSIGNEE(S): Schering A.-G., Fed. Rep. Ger.
 SOURCE: U.S., 5 pp. Cont. of U.S. Ser. No. 621,308.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4780461	A	19881025	US 1985-810148	19851218
DE 3321826	A1	19841220	DE 1983-3321826	19830615
DE 3413036	A1	19851017	DE 1984-3413036	19840404
DE 3446661	A1	19860619	DE 1984-3446661	19841218

PRIORITY APPLN. INFO.:
 AB 13.alpha.-Alkylgonanes [I; R = C1-4 acyl; X = O, NOH; II; R1 = amino;
 R2 = H, Me, Et; R3 = (substituted) alkyl; R4 = OH, alkoxy, alkanoyloxy; or
 R3R4 = O; R5 = H, alkyl; III; Z = CH2CH2, CH2CH=2CH2], having
 antigestagenic
 activity and useful as postcoital contraceptives, or for triggering
 abortion and menstruation (no data), are prepd. via photochem.
 epimerization of the 13.beta.-gonanes IV. 11.beta.-(4-
 Dimethylaminomethyl)-17.alpha.-hydroxy-13.alpha.-methyl-17.beta.-(3-
 hydroxypropyl)-4,9-gonadien-3-one (V) was acetylated with Ac2O in
 pyridine
 to give 11.beta.-(4-dimethylaminomethyl)-17.alpha.-hydroxy-13.alpha.-
 methyl-17.beta.-(3-acetoxypyl)-4,9-gonadien-3-one. A tablet was
 formulated contg. V 10.0, lactose 140.0, corn starch 69.5,
 polyvinylpyrrolidone 25 2.5, Aerosil 2.0, and Mg stearate 0.5 mg.


MSTR 2



G4 = 59

L10 ANSWER 15 OF 18 MARPAT COPYRIGHT 2000 ACS (Continued)
 p-(Me2N)C6H4NgBr, Oppenauer oxidn. of 17-OH, alkylation with
 THP-OGH2C.tpbond.CNgBr (THP = tetrahydropyranyl), and deprotection,
 to
 give (dimethylaminophenyl)hydroxy(hydroxypropynyl)methylestradienone
 II.

MSTR 1



G1 = phenylene
 G5 = 31

31-C(O)-G11

G6 = 31 / 35

31-C(O)-G11 35(O)-G12

G10 = 31

31-C(O)-G11

G12 = Ak (S0 (1-) G10)

G14 = 42



MPL: claim 1

L10 ANSWER 16 OF 18 MARPAT COPYRIGHT 2000 ACS (Continued)

59(O)CH2-G11

G8 = alkylcarbonyloxy<(1-3)>

G12 = 66



GGA = 33 <RC (1), RS (1) M5 (1) X6, EC (0-) O (1-) N (0-) S (0)

OTHERQ, AM (1) N, BD (ALL) SE>

DER: and acid addition salts

MPL: claim 18

L10 ANSWER 17 OF 18 MARPAT COPYRIGHT 2000 ACS

ACCESSION NUMBER: 110:95624 MARPAT
 TITLE: Preparation of novel 11-arylestrane and
 11-arylpregnane derivatives as antiprogestins

with low

or no antiglucocorticoid activity
 INVENTOR(S): Groen, Marinus Bernard; De Jongh, Hendrik Paul
 PATENT ASSIGNEE(S): AKZO N. V., Neth.
 SOURCE: Eur. Pat. Appl., 11 pp.
 CODEN: EPXXDW

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 289073	A1	19881102	EP 1988-200689	19880412
EP 289073	B1	19911127		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
AT 69820	E	19911215	AT 1988-200689	19880412
ES 2045082	T3	19940116	ES 1988-200689	19880412
ZA 8802643	A	19881130	ZA 1988-2643	19880414
FI 8801826	A	19881025	FI 1988-1826	19880419
FI 88396	B	19930129		
FI 88396	C	19930510		
US 4871724	A	19891003	US 1988-183851	19880420
CA 1297472	A1	19920317	CA 1988-564606	19880420
DK 8802218	A	19881025	DK 1988-2218	19880422
DK 168294	B1	19940307		
AU 8815072	A1	19881027	AU 1988-15072	19880422
AU 608831	B2	19910418		
JP 63280097	A2	19881117	JP 1988-100010	19880422
CN 88102416	A	19881214	CN 1988-102416	19880423
CN 1019978	B	19930303		
PRIORITY APPLN. INFO.:			NL 1987-970	19870424
			EP 1988-200689	19880412
AB The title compds. [I; R1 = aminoaryl; R2 = C1-4 alkyl; R3 = H, OH, substituted (unsatd.) C1-8 hydrocarbyl; R4 = OH, acyloxy, substituted acyl; R3R4 = atoms to complete a ring; R5 = C1-4 hydrocarbyl] useful as antiprogestins (no data) were prepd.				
5.alpha.,6.alpha.-Epoxy-11.beta.-hydroxysterane-3,17-dione-3,17-diethylene acetal (prepn. given) was treated with MeHgCl in PhMe/THF and the product was dehydrated with POC13/pyridine to give				
6-.beta.-methylene-5(10),9(11)-diene-3,17-dione-3,17-diethylene acetal. The latter was converted in several steps to				
11.beta.-[4-(dimethylamino)phenyl]-17.beta.-hydroxy-17.alpha.-(3-hydroxy-1-propynyl)-6.beta.-methylene-4,9-diene-3-one.				

MSTR 1


L10 ANSWER 18 OF 18 MARPAT COPYRIGHT 2000 ACS

ACCESSION NUMBER: 109:170799 MARPAT
 TITLE: Antiprogestinic
 11.beta.-aryl-14.beta.-estra-4,9-dien-3-one derivatives, a process for their preparation,

and pharmaceuticals containing them
 INVENTOR(S): Loozen, Hubert Jan Jozef
 PATENT ASSIGNEE(S): AKZO N. V., Neth.
 SOURCE: Eur. Pat. Appl., 15 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 277676	A1	19880810	EP 1988-200071	19880118
EP 277676	B1	19920304		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
CA 1339570	A1	19971209	CA 1988-556625	19880115
ZA 8800317	A	19880928	ZA 1988-317	19880118
AT 73137	E	19920315	AT 1988-200071	19880118
ES 2031991	T3	19930101	ES 1988-200071	19880118
FI 8800257	A	19880724	FI 1988-257	19880121
FI 89054	B	19930430		
FI 89054	C	19930810		
AU 8810669	A1	19880728	AU 1988-10669	19880121
AU 603637	B2	19901122		
DK 8800304	A	19880724	DK 1988-304	19880122
DK 163307	B	19920217		
DK 163307	C	19920706		
CN 88100979	A	19880817	CN 1988-100979	19880122
CN 1030081	B	19951018		
JP 63216895	A2	19880909	JP 1988-12431	19880122
US 5272140	A	19931221	US 1990-488391	19900227
PRIORITY APPLN. INFO.:			NL 1987-157	19870123
			EP 1988-200071	19880118
			US 1988-146895	19880122
AB Title steroids I [R1 = monosubstituted homo- or heterocyclic aryl; R2 = C1-4 alkyl; R3, R4 = H, OH, C1-18 acyloxy, C2-8 alkoxyalkyl, C1-8 acyl, C1-12 alkoxy, (un)satd. (un)substituted C1-8 hydrocarbyl; R3R4 = C1-6 alkylidene, or atoms needed to form ring; .DELTA.16 optionally present, with R3 or R4 absent], having strong antiprogestinic activity, are prepd.				
Estrone 3-Me ether was brominated, dehydrobrominated, and hydrogenated to give the isomeric 14.beta.-estrone 3-Me ether. This underwent NaBH4 redn., Birch redn., hydrolysis, and bromination-dehydrobromination to give 17.alpha.-hydroxy-14.beta.-estra-4,9-dien-3-one. The latter was ketalized at the 3-position, oxidized to the 17-one, alkynylated at the 17-position				

L10 ANSWER 17 OF 18 MARPAT COPYRIGHT 2000 ACS (Continued)



G1 = 63 / 64 / 65




G5 = 25




G6 = alkylcarbonyloxy (SR (1-) G12)
 G7 = alkylcarbonyl (SO (1-) G10)
 GGA = 69 <(1-7)>
 MPL: claim 1

L10 ANSWER 18 OF 18 MARPAT COPYRIGHT 2000 ACS (Continued)
 by the tetrahydropyranyl ether of propargyl alc., epoxidized to the 5.alpha.,10.alpha.-epoxide, coupled with 4-(Me2N)C6H4MgBr in the presence of CuCl, hydrogenated in the side chain, hydrolyzed and dehydrated, and cyclized in the sidechain by tosylation in pyridine to give (dimethylaminophenyl)dihydrospiro(estradienefuran)one II. At 1 mg orally, twice daily in pregnant rats on days 6-10, II caused 100% pregnancy interception, but only slightly reversed dexamethasone-induced thymus wt. redn. in rats.

MSTR 1B



G1 = biphenyl (SR)
 G6 = 37 / 39



G10 = O
 GGA = 27 31 <(1-10)>
 GGA = 37 <(1-8)>
 MPL: claim 1

=> d ibib ab hitstr 1-6

L11 ANSWER 1 OF 6 USPATFULL

ACCESSION NUMBER: 1999:85613 USPATFULL

TITLE: Method for preparing

17.alpha.-acetoxy-11.beta.-(4-N,

INVENTOR(S): N-dimethylaminophenyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
Kim, Hyun K., Bethesda, MD, United States
Rao, Pemmaraju Narasinha, San Antonio, TX, United States
Burdett, Jr., James E., Somerset, TX, United States
Acosta, Carmie K., San Antonio, TX, United States
PATENT ASSIGNEE(S): The United States of America as represented by the Department of Health and Human Services,
Washington, DC, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5929262	19990727
APPLICATION INFO.:	US 1995-413755	19950330 (8)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Dees, Jose G.	
ASSISTANT EXAMINER:	Badio, Barbara	
LEGAL REPRESENTATIVE:	Leydig, Voit & Mayer	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	777	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for the preparation of the 19-norprogesterone of formula I ##STR1## and its intermediates, in crystalline and amorphous forms

are disclosed. The process is performed by (1) protecting the hydroxyl group

of a compound of formula II ##STR2## (2) reacting the protected compound

with an alkali or alkaline earth metal anion radical, (3)

hydrolyzing the resulting compound, (4) ketalizing the carbonyl groups, (5)

epoxidizing the compound, (6) opening the epoxide ring and

introducing an N,N-dimethylamino-phenyl functional group into the axial position of

C.sub.11, (7) deketalizing and dehydrating the resulting compound, and

(8) acetylating to provide 17.alpha.-acetoxy-11.beta.-(4-N,N-

dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione (I).


IT 126784-99-4P
(improved prepn. of 17.alpha.-acetoxy-11.beta.-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione and its intermediates)

RN 126784-99-4 USPATFULL

L11 ANSWER 1 OF 6 USPATFULL (Continued)

CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[(4-(dimethylamino)phenyl)-, (11.beta.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 2 OF 6 USPATFULL

ACCESSION NUMBER: 92:13091 USPATFULL

TITLE: 11 .beta.-phenyl-gonanes, their manufacture and pharmaceutical preparations containing them
Neef, Gunter, Berlin, Germany, Federal Republic of
Beier, Sybille, Berlin, Germany, Federal Republic

of Elger, Walter, Berlin, Germany, Federal Republic of
Henderson, David, Berlin, Germany, Federal

Republic of Otto, Eckard, Berlin, Germany, Federal Republic of
Rohde, Ralph, Berlin, Germany, Federal Republic of
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Berlin and Bergkamen,
Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5089635	19920218
APPLICATION INFO.:	US 1986-827050	19860207 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1985-3504421	19850207
	DE 1985-3527517	19850729

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Killos, Paul J.

LEGAL REPRESENTATIVE: Millen, White & Zelano

NUMBER OF CLAIMS: 45

EXEMPLARY CLAIM: 1

LINE COUNT: 1284

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 13-alkyl-11.beta.-phenyl-gonanes of general formula I ##STR1##

wherein A

and B together stand for an oxygen atom, a CH.sub.2 group or a second bond between carbon atoms 9 and 10,

X is an oxygen atom or the hydroxyimino grouping N.about.OH,

R.sub.1 is a straight-chained or branched, saturated or unsaturated alkyl radical with up to 8 carbon atoms, which contains the grouping ##STR2## with X as described above, R.sub.2 is a methyl or ethyl radical in the .alpha. or .beta. position,

R.sub.9, R.sub.10, R.sub.11 and R.sub.12 each stand for a hydrogen atom,

a hydroxy, alkyl, alkoxy or acyloxy group with 1 to 4 carbon atoms respectively or a halogen atom and R.sub.3 and R.sub.4 have a variety of

meanings, have antigestagenic and antigluccorticoid effects.


IT 105114-79-2P
(prepn. of, as antigestagen and antigluccorticoid)

RN 105114-79-2 USPATFULL

CN Benzaldehyde, 4-[(11.beta.,13.alpha.)-17-(acetyloxy)-3,20-dioxo-19-norpregna-4,9-dien-11-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 2 OF 6 USPATFULL (Continued)




L11 ANSWER 3 OF 6 USPATFULL

ACCESSION NUMBER: 91:102214 USPATFULL
 TITLE: 11. beta.-substituted progesterone analogs
 INVENTOR(S): Cook, C. Edgar, Durham, NC, United States
 Wani, Mansukh C., Durham, NC, United States
 Lee, Yun W., Chapel Hill, NC, United States
 Reel, Jerry R., Cary, NC, United States
 Rector, Douglas, Mobile, AL, United States
 Research Triangle Institute, Research Triangle Park,
 NC, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5073548	19911217
APPLICATION INFO.:	US 1990-504129	19900403 (7)
RELATED APPLN. INFO.:	Division of Ser. No. US 1988-210503, filed on 23 Jun	


1988, now patented, Pat. No. US 4954490
 DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Shah, Mukund J.
 ASSISTANT EXAMINER: Ward, E. C.
 LEGAL REPRESENTATIVE: Oblon, Spivak, McClelland, Maier & Neustadt
 NUMBER OF CLAIMS: 16
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
 LINE COUNT: 177
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A 11. beta.-aryl-19-norprogesterone steroid of the formula: ##STR1##
 wherein (i) R.sub.1 is H, C.sub.1-4 alkyl, C.sub.2-4 alkenyl,
 C.sub.2-4 alkynyl, OH, OC(O)CH.sub.3, or OC(O)R.sub.5, wherein R.sub.5 is
 C.sub.2-8 alkyl, C.sub.2-8 alkenyl, C.sub.2-8 alkynyl or aryl,
 R.sub.2
 is H, R.sub.3 is H, C.sub.1-4 alkyl, C.sub.2-4 alkenyl or C.sub.2-4
 alkynyl, R.sub.4 is H, CH.sub.3, F or Cl, R.sub.6 is H,
 (CH.sub.3).sub.2
 N, CH.sub.3 O, CH.sub.3 CO, CH.sub.3 S, CH.sub.3 SO, CH.sub.3
 SO.sub.2,
 and X is O or NOCH.sub.3 ; or
 (ii) R.sub.1 and R.sub.2 taken together are a carbon-carbon bond and
 R.sub.3, R.sub.4, R.sub.6 and X are as defined above; or
 (iii) R.sub.1 and R.sub.3 taken together are --CH.sub.2 -- or
 --N.dbd.N--CH.sub.2 --, R.sub.2 is H and R.sub.4, R.sub.6 and X are
 as
 defined above; or
 (iv) R.sub.2 and R.sub.3 taken together are .dbd.CH.sub.2 and
 R.sub.1,
 R.sub.4, R.sub.6 and X are as defined above.
 IT 126690-26-4P 126690-29-7P 126784-99-4P

L11 ANSWER 3 OF 6 USPATFULL (Continued)




L11 ANSWER 3 OF 6 USPATFULL (Continued)

(prepn. of, as antilucocorticoid and/or (anti)progestogen)
 RN 126690-26-4 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-6-methyl-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



RN 126690-29-7 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



RN 126784-99-4 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L11 ANSWER 4 OF 6 USPATFULL


ACCESSION NUMBER: 90:69718 USPATFULL
 TITLE: 11. beta.-substituted progesterone analogs
 INVENTOR(S): Cook, C. Edgar, Durham, NC, United States
 Wani, Mansukh C., Research Triangle Park, NC,
 United States
 Lee, Y.-W., Chapel Hill, NC, United States
 Reel, Jerry R., Delmar, NY, United States
 Rector, Douglas, Raleigh, NC, United States
 Research Triangle Institute, Research Triangle Park,
 NC, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4954490	19900904
APPLICATION INFO.:	US 1988-210503	19880623 (7)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Lipovsky, Joseph A.	
LEGAL REPRESENTATIVE:	Oblon, Spivak, McClelland, Maier & Neustadt	
NUMBER OF CLAIMS:	31	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	1259	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB A 11. beta.-aryl-19-norprogesterone steroid of the formula: ##STR1## wherein (i) R.sub.1 is H, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, OH, OC(O)CH.sub.3, or OC(O)R.sub.5, wherein R.sub.5 is C.sub.2-8 alkyl, C.sub.2-8 alkenyl, C.sub.2-8 alkynyl or aryl, R.sub.2 is H, R.sub.3 is H, C.sub.1-4 alkyl, C.sub.2-4 alkenyl or C.sub.2-4 alkynyl, R.sub.4 is H, CH.sub.3, F or Cl, R.sub.6 is H, (CH.sub.3).sub.2 N, CH.sub.3 O, CH.sub.3 CO, CH.sub.3 S, CH.sub.3 SO, CH.sub.3 SO.sub.2, and X is O or NOCH.sub.3 ; or (ii) R.sub.1 and R.sub.2 taken together are a carbon-carbon bond and R.sub.3, R.sub.4, R.sub.6 and X are as defined above; or (iii) R.sub.1 and R.sub.3 taken together are --CH.sub.2 -- or --N.dbd.N--CH.sub.2 --, R.sub.2 is H and R.sub.4, R.sub.6 and X are as defined above; or (iv) R.sub.2 and R.sub.3 taken together are .dbd.CH.sub.2 and R.sub.1, R.sub.4, R.sub.6 and X are as defined above.		

IT 126690-26-4P 126690-29-7P 126784-99-4P
 (prepn. of, as antilucocorticoid and/or (anti)progestogen)
 RN 126690-26-4 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-6-methyl-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


L11 ANSWER 4 OF 6 USPATFULL (Continued)

Absolute stereochemistry.



RN 126690-29-7 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione,
 17-(acetyloxy)-11-(4-(dimethylamino)phenyl)-,
 (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 126784-99-4 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 4 OF 6 USPATFULL (Continued)



L11 ANSWER 5 OF 6 USPATFULL

ACCESSION NUMBER: 90:23597 USPATFULL
 TITLE: Novel 11 .beta.-alkynylphenyl-10-nor-steroids
 INVENTOR(S): Teutsch, Jean-Georges, Pantin, France
 Klich, Michel, Villemomble, France
 Philibert, Daniel, La Varenne-Saint-Hilaire, France
 PATENT ASSIGNEE(S): Roussel Uclaf, Paris, France (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4912097	19900327
APPLICATION INFO.:	US 1987-44958	19870430 (7)


	NUMBER	DATE
PRIORITY INFORMATION:	FR 1986-6517	19860506
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Berch, Mark L.	
LEGAL REPRESENTATIVE:	Bierman & Musserlian	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1,9	
LINE COUNT:	2174	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Novel 11.beta.-alkynylphenyl-19-nor-steroids of the formula ##STR1##
 wherein R.sub.1 is alkynyl of 2 to 8 carbon atoms optionally
 substituted
 with at least one member of the group consisting of --OH halogen,
 trialkylsilyl of 1 to 6 alkyl carbon atoms, alkoxy and alkylthio of
 1 to 6 carbon atoms and dialkylamino of 1 to 6 alkyl carbon atoms having
 remarkably antiprogesterone mimetic and antigluocorticoid activity.

IT 116421-73-9P 116421-74-0P
 (prepn. of, as drug)

RN 116421-73-9 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(1-propynyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 116421-74-0 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione,
 17-(acetyloxy)-11-(4-ethynylphenyl)-,
 (11.beta.)- (9CI) (CA INDEX NAME)

L11 ANSWER 5 OF 6 USPATFULL (Continued)

Absolute stereochemistry.



L11 ANSWER 6 OF 6 USPATFULL
 ACCESSION NUMBER: 88:69168 USPATFULL
 TITLE: 13.alpha.-alkyl-gonanes, their production, and pharmaceutical preparations containing same
 INVENTOR(S): Neef, Gunter, Berlin, Germany, Federal Republic of
 Republic of Wiechert, Rudolf, Berlin, Germany, Federal
 of Beier, Sybille, Berlin, Germany, Federal Republic
 Republic of Elger, Walter, Berlin, Germany, Federal Republic of
 PATENT ASSIGNEE(S): Henderson, David, Berlin, Germany, Federal
 Schering Aktiengesellschaft, Berlin and Bergkamen,
 Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4780461	19881025
APPLICATION INFO.:	US 1985-810148	19851218 (6)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1984-621308, filed on 15 Jun 1984, now abandoned	

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1983-3321826	19830615
	DE 1984-3413036	19840404
	DE 1984-3446661	19841218

DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Schenkman, Leonard
 ASSISTANT EXAMINER: Lipovsky, Joseph A.
 LEGAL REPRESENTATIVE: Millen & White
 NUMBER OF CLAIMS: 41
 EXEMPLARY CLAIM: 18
 LINE COUNT: 310

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB 13.alpha.-alkylgonanes of formula I ##STR1## where R is an acyl
 radical
 with as many as 10 C-atoms, and

X is an oxygen atom or the grouping N--OH,

have a strong antigestagenic effect and can be used for postcoital
 fertility control.


IT 96285-40-4P 96285-50-6P
 (prepn. of, as postcoital contraceptive)

RN 96285-40-4 USPATFULL

CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-
 (dimethylamino)phenyl]-, (11.beta.,13.alpha.)- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.

L11 ANSWER 6 OF 6 USPATFULL (Continued)



RN 96285-50-6 USPATFULL
 CN 18,19-Dinorpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-
 (dimethylamino)phenyl]-13-ethyl-, (11.beta.,13.alpha.)- (9CI) (CA
 INDEX
 NAME)

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 12:17:50 ON 07 JAN 2000)

FILE 'REGISTRY' ENTERED AT 12:17:55 ON 07 JAN 2000
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 25 S L1 FULL

FILE 'USPATFULL' ENTERED AT 12:18:43 ON 07 JAN 2000
L4 0 S L3

FILE 'CAPLUS' ENTERED AT 12:18:54 ON 07 JAN 2000
L5 2 S L3

FILE 'REGISTRY' ENTERED AT 12:57:23 ON 07 JAN 2000
L6 STRUCTURE UPLOADED
L7 1 S L6
L8 41 S L6 FULL

FILE 'CAPLUS' ENTERED AT 12:58:14 ON 07 JAN 2000
L9 23 S L8

FILE 'MARPAT' ENTERED AT 13:01:43 ON 07 JAN 2000
L10 18 S L8 FULL

FILE 'USPATFULL' ENTERED AT 13:04:11 ON 07 JAN 2000
L11 6 S L8

Printed by EAST

UserID: BBadio

Computer: WS06692

Date: 01/07/2000

Time: 13:10

Document Listing

Document	Image pages	Text pages	Error pages
US 4780461 A	6	2	0
Total	6	2	0


=> d ibib ab hitstr 1-8

L3 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1999:576939 CAPLUS
 DOCUMENT NUMBER: 131:199885
 TITLE: Preparation of 20-keto-11.beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties
 INVENTOR(S): Cook, C. Edgar; Kepler, John A.; Zhang, Ping-sheng;
 PATENT ASSIGNEE(S): Lee, Yue-wei; Tallent, C. Ray
 SOURCE: Research Triangle Institute, USA
 PCT Int. Appl., 95 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9945022	A1	19990910	WO 1999-US3732	19990305


DE, W: AL, AM, AT, AU, A2, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TH RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 PRIORITY APPLN. INFO.: US 1998-35949 19980306
 OTHER SOURCE(S): MARPAT 131:199885
 AB 20-Keto-11.beta.-arylsteroids of formula I [X = O, (substituted) NOH, H2, OH, etc.; R1 = dialkylamino, imidazolyl, pyrrolyl, piperidino, etc.; R2 = H, halo; R3 = H, Me, halo; R4 = H, acyloxy, (substituted) OH, alkyl, etc.; R5 = H, alkyl, halo, acyloxy, etc.] are prepd. which exhibit potent antiprogesterone activity. Thus, II was prepd. from 17.alpha.-hydroxymethyl-3-methoxy-19-norpregna-1,3,5(10)-trien-20-one and 4-bromo-N,N-dimethylaniline in several steps. The affinity of II for the progesterone hormone receptor was IC50 of 0.7 nM.
 IT 240805-94-3P 240805-97-4P 240805-98-5P 240805-99-6P 240806-00-2P 240806-01-3P

L3 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2000 ACS (Continued)
 Absolute stereochemistry.




RN 240805-99-6 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(benzoyloxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 240806-00-2 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(1-oxopropoxy)-11-[4-(1-pyrrolidinyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 240806-01-3 CAPLUS

L3 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2000 ACS (Continued)
 240806-02-4P 240806-03-5P 240806-04-6P
 240806-05-7P 240806-06-8P 240806-12-6P
 240806-44-4P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of 20-keto-11.beta.-arylsteroids with antiprogesterone activity)


RN 240805-96-3 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(1-piperidinyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 240805-97-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 240805-98-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-[(phenylacetyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2000 ACS (Continued)
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-(1-methyl-1H-indol-5-yl)-17-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 240806-02-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-(2,3-dihydro-1-methyl-1H-indol-5-yl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 240806-03-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-(4-methoxyphenyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 240806-04-6 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[(1-pyrrolidinyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 240806-05-7 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[(1-methyl-1H-indol-5-yl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 240806-06-8 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)-3-fluorophenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 240806-12-6 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(1-oxopropoxy)-11-[4-(1-piperidinyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 240806-44-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-(2,3-dihydro-1-methyl-1H-indol-5-yl)-17-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2000 ACS


ACCESSION NUMBER: 1998:646581 CAPLUS
 DOCUMENT NUMBER: 130:20723
 TITLE: Antioviulatory and postcoital antifertility activity of the antiprogesterin CDB-2914 when administered as single, multiple, or continuous doses to rats
 AUTHOR(S): Reel, Jerry R.; Hild-Petito, Sheri; Blye, Richard P.
 CORPORATE SOURCE: BIOQUAL, Inc., Rockville, MD, 20852-3336, USA
 SOURCE: Contraception (1998), 58(2), 129-136
 CODEN: CCTAY; ISSN: 0010-7824
 PUBLISHER: Elsevier Science Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The present studies in rats were undertaken to investigate the potential of a new antiprogesterin, CDB-2914, for use as an emergency postcoital contraceptive for women. When given orally at noon on the day of proestrus, both CDB-2914 and mifepristone displayed dose-dependent antioviulatory activity; however, CDB-2914 was about eight times more potent than mifepristone. Both antiprogesterins were considerably less potent in blocking ovulation when injected s.c. To evaluate antioviulatory activity during continuous low dose administration, rats were dosed orally with 0.5 mg of either CDB-2914 or mifepristone daily, commencing on the day of estrus and continuing for 24 days. Females were cohoused with proven fertile males on day 8 of treatment and were removed 1-3 days later after confirmed mating. The pregnancy rate was significantly reduced only in the CDB-2914-treated females; however, the mean no. of normal implantation sites per pregnant rat was significantly reduced by mifepristone as compared with the vehicle control group. CDB-2914 was also found to prevent pregnancy when administered orally after mating from days 0-3 during tubal egg transport, or from days 4-6 during the pre- and peri-implantation periods. To det. the day of maximal sensitivity to CDB-2914, a single 2-mg dose per rat was given orally on days 0, 1, 2, 3, 4, or 5 postmating. This dose of CDB-2914 was without effect on pregnancy at days 0, 1, 2, or 3 postmating. In contrast, 2 mg CDB-2914 per rat was highly effective in blocking pregnancy when given on either day 4 or 5 postmating. Collectively, these data demonstrate that CDB-2914 is an orally active postcoital antifertility agent that is more potent than mifepristone in the rat. Hence, CDB-2914 may prove to be an effective emergency postcoital contraceptive in women.
 IT 126784-99-4, CDB-2914
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USRS (Uses)
 (antioviulatory and postcoital antifertility activity of antiprogesterin

L3 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2000 ACS (Continued)
CDB-2914 compared to mifepristone as single, multiple, or
continuous

RN 126784-99-4 CAPLUS


CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11 β .)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2000 ACS (Continued)
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11 β .)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1998:424125 CAPLUS

DOCUMENT NUMBER: 129:50105

TITLE:

Uses of anti-glucocorticoid compounds for the treatment of psychoses or addictive behaviors

INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9826783	A1	19980625	WO 1997-FR2320	19971217
IL,	W:	AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GW, HU, ID,		
PL,		IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ,		
KG,		RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY,		
FI,		KZ, MD, RU, TJ, TM		
CH,	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES,		
		FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,		
		GA, GN, ML, MR, NE, SN, TD, TG		
FR 2757400	A1	19980626	FR 1996-15649	19961219
FR 2757400	B1	19991217		
AU 9855632	A1	19980715	AU 1998-55632	19971217
EP 892641	A1	19990127	EP 1997-952078	19971217
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,		
PT,		IE, FI		
PRIORITY APPL. INFO.:			FR 1996-15649	19961219
			WO 1997-FR2320	19971217

OTHER SOURCE(S):

MARPAT 129:50105

AB Glucocorticoid antagonists, except mifepristone, are used as dopamine type II receptor antagonists to treat psychotic or addictive behavior.

Thus, 17 β -hydroxy-10 β -[4-(4-methylphenyl)methyl]-17 α -(1-propynyl)estra-4,9(11)-dien-3-one considerably reduced the response to morphine in vivo.

IT 126784-99-4

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of anti-glucocorticoid compds. as dopamine type II receptor blocking agents for the treatment of psychoses or addictive behaviors)

RN 126784-99-4 CAPLUS

L3 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1997:745947 CAPLUS

DOCUMENT NUMBER: 128:19047

TITLE:

Improvement of implantation rates after in vitro fertilization by administering a nitric oxide substrate and/or donor

INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9741866	A1	19971113	WO 1997-EP2371	19970507
EE,	W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK,		
LS,		ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR,		
SD,		LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU,		
KG,		SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY,		
GB,		KZ, MD, RU, TJ, TM		
GN,	RW:	GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR,		
		GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,		
		ML, MR, NE, SN, TD, TG		
AU 9728947	A1	19971126	AU 1997-28947	19970507
EP 906105	A1	19990407	EP 1997-923032	19970507
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,		
PT,		IE, FI		
		CN 1218402	CN 1997-194452	19970507
		NO 9805204	NO 1998-5204	19981106
PRIORITY APPL. INFO.:			US 1996-646518	19960507
			WO 1997-EP2371	19970507


AB A method is provided for the improvement of implantation rates and/or pregnancy rates in a female mammal, comprising administering to a female mammal in whom pregnancy is desired an effective amt. of: (a) a nitric oxide synthase substrate, a nitric oxide donor, or both, optionally in combination with, (b) a progestin, and, (c) optionally, in further combination with an estrogen. A method is also provided for fertility control for a female mammal, comprising administering to a female mammal in whom pregnancy is not desired and at risk of becoming pregnant an effective amt. of nitric oxide synthase inhibitor in combination with an antiprogesterone. Pharmaceutical compns. are also provided.

IT 126784-99-4, CDB2914

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

L3 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2000 ACS (Continued)
 (fertility control using a nitric oxide synthase inhibitor in
 combination with an antiprogesterin)
 RN 126784-99-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-
 (dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L3 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2000 ACS
 ACCSSION NUMBER: 1997:740250 CAPLUS
 DOCUMENT NUMBER: 127:358992
 TITLE: Preparation of 21-substituted progesterone derivatives
 as new antiprogesterational agents
 INVENTOR(S): Kim, Hyun K.; Blye, Richard P.; Rao, Pemmaraju N.;
 Cessac, James W.; Acosta, Carmie K.
 PATENT ASSIGNEE(S): United States Dept. of Health and Human Services,
 USA;
 Kim, Hyun K.; Blye, Richard P.; Rao, Pemmaraju N.;
 Cessac, James W.; Acosta, Carmie K.
 SOURCE: PCT Int. Appl., 65 pp.
 CODEN: FIKX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9741145	A1	19971106	WO 1997-US7373	19970430
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2253673	AA	19971106	CA 1997-2253673	19970430
AU 9729304	A1	19971119	AU 1997-29304	19970430
EP 900234	A1	19990310	EP 1997-923523	19970430
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRIORITY APPLN. INFO.:			US 1996-16628	19960501
			WO 1997-US7373	19970430
OTHER SOURCE(S):				
AB: Progesterone derivs. of formula I [R1 = OMe, SMe, NMe2, NMe, CHO, Ac, CHOHCH3; R2 = halo, alkyl, acyl, OH, alkoxy, etc.; R3 = OH, alkyl, alkoxy, acyloxy; R4 = H, alkyl; X = O, (substituted) NOH] are prep. as antiprogesterational agents. The present invention provides methods wherein the comds. of formula I are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat				


L3 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2000 ACS (Continued)
 endometriosis; to treat dysmenorrhea; to treat endocrine
 hormone-dependent
 tumors; to treat uterine fibroids; to inhibit uterine endometrial
 proliferation; to induce labor; and for contraception. Thus, II was
 prep. from 3,3-ethylenedioxy-17.beta.-cyano-17.alpha.-hydroxyestra-
 5(10),9(11)-diene and 4-bromo-N,N-dimethylaniline in 9 steps. II
 showed
 2.79 times the antiprogesterational potency in the antiClauberg test
 compared to CDB-2914.
 IT 198414-07-2P 198414-31-2P
 RL: BAC (Biological activity or effector, except adverse); RCT
 (Reactant);
 SPN (Synthetic preparation); THU (Therapeutic use); BIOL
 (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of progesterone derivs. as antiprogesterational agents)
 RN 198414-07-2 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17,21-bis(acetyloxy)-11-[4-
 (dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-31-2 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-
 (dimethylamino)phenyl]-21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 198414-03-8P 198414-05-0P 198414-11-8P
 198414-22-1P 198414-33-4P 198414-34-5P
 198414-39-0P 198414-43-6P


L3 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2000 ACS (Continued)
 RL: BAC (Biological activity or effector, except adverse); SPN
 (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study);
 PREP (Preparation); USES (Uses)
 (prepn. of progesterone derivs. as antiprogesterational agents)
 RN 198414-03-8 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-
 (dimethylamino)phenyl]-21-fluoro-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-05-0 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-chloro-11-[4-
 (dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-11-8 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione,
 17-(acetyloxy)-21-(acetylthio)-11-[4-
 (dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 198414-22-1 CAPLUS
 CN Estra-4,9-dien-3-one,
 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-(1-oxopropyl)-, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 198414-33-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-(3-cyclopentyl-1-oxopropoxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 198414-34-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-39-0 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-ethoxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2000 ACS (Continued)



RN 198414-43-6 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-bromo-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1996:540408 CAPLUS
 DOCUMENT NUMBER: 125:238850
 TITLE: Effects of two antiprogestins on early pregnancy in

AUTHOR(S): the long-tailed macaque (*Macaca fascicularis*)
 Tarantal, Alice F.; Hendrickx, Andrew G.; Matlin, Stephen A.; Lasley, Bill L.; Gu, Quin-Quin;
 Thomas,

Charles A.A.; Vince, Pamela M.; Van Look, Paul

F.A.
 CORPORATE SOURCE: California Regional Primate Research Center,
 University of California, Davis, CA, 95616, USA
 SOURCE: Contraception (1996), 54(2); 107-115
 CODEN: CPTAY; ISSN: 0010-7824

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The abortifacient effects of mifepristone and HRP 2000 were compared in

gravid long-tailed macaques. Thirty-six animals were studied with treatment administered either by the oral (0.5 or 5.0 mg/kg; N = 5 per antiprogesterin per dose) or i.m. (IM) routes (0.5 mg/kg; N = 5 per antiprogesterin) on gestational days (GD) 23-26; six vehicle controls

were included. Blood samples were collected for assay of progesterone (P4) and each of the antiprogestins (pre-treatment, daily GD 23-28, every other day GD 30-40), and animals were monitored sonog. throughout gestation. Results of these studies indicated high rates of abortion with IM administration (3/5 mifepristone, 4/5 HRP 2000) and 5.0 mg/kg oral route (4/5, 2/5, resp.), with less effects noted at oral doses of 0.5 mg/kg (2/5, 0/5, resp.). No early abortions were obsd. in the control groups.

Following daily IM treatment, peak levels of 8-16 ng/mL mifepristone were detected whereas 6-10 ng/mL of HRP 2000 were noted (GD 26-27). No serum

levels of mifepristone were detected following either of the oral doses whereas serum levels of 2-6 ng/mL HRP 2000 were noted with high dose

oral administration. Results of these studies suggest: (1) both antiprogestins are roughly comparable in terminating early pregnancy although HRP 2000

may be more efficacious when administered IM whereas mifepristone may

be more effective when administered orally; (2) similar levels of biol. activity are seen with the IM and high dose oral dosing regimens, with little or no activity with the oral low dose; and (3) infants

resulting from surviving pregnancies were not affected by early gestation exposure.

IT 126784-99-4


RL: BPR (Biological process); THU (Therapeutic use); BIOL

L3 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2000 ACS (Continued)

RN 116421-73-9 CAPLUS

CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(1-propynyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 116421-74-0 CAPLUS

CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-ethynylphenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d all 1-6

L4 ANSWER 1 OF 6 BEILSTEIN COPYRIGHT 2000 BEILSTEIN CD4S


Beilstein Reg. No. (BRN): 7958451 Beilstein
 Molecular Formula (MF): C31 H39 N O4
 Autonom Name (AUN): acetic acid
 17-acetyl-11-(4-dimethylamino-phenyl)-
 13-ethyl-3-oxo-2,3,6,7,8,11,12,13,14,15,16,17-
 dodecahydro-1H-cyclopenta<a>phenanthren-17-yl

ester
 Beilstein Reference (SO): 6-14
 General Comments (NTE): Stereo compound
 Formula Weight (FW): 489.65
 Lawson Number (LN): 15935; 2817; 1155

Ring System Data:

Number of Rings (CNR): 5
 Ring Systems (CNRS): 2
 Diff. Ring Systems (CNDRS): 2
 Ring Heteros (CNRH): 0
 Acyclic Heteros (CNAH): 5

Beilstein Ring Index (BRIX)	Ring System Formula (RF)	BRIX Count
17.4.32-0.0-2.20	C17	1
6.1.0-0.0-3.1	C6	1



Atom/Bond Notes:
 1. CIP Descriptor: R
 2. CIP Descriptor: S

Biological Function:
 BF in vitro relative binding affinities for progesterone and glucocorticoid

L4 ANSWER 1 OF 6 BEILSTEIN COPYRIGHT 2000 BEILSTEIN CD4S (Continued)

Len: 10.0 nm
 Solv: CHCl3
 Wavel: 589.00 nm
 Temp: 26.0 Cel

Reference(s):
 1. Rao, Pemmaraju N.; Cessac, James W.; Blye, Richard P.; Kim, Hyun

K., Steroids, 63 <1998> 1, 50-57, LA: EN, CODEN: STEDAM

NMR Absorption:

NMRA

Nucl: 1H
 Solv: CDCl3

Reference(s):
 1. Rao, Pemmaraju N.; Cessac, James W.; Blye, Richard P.; Kim, Hyun

K., Steroids, 63 <1998> 1, 50-57, LA: EN, CODEN: STEDAM

Infrared Maximum:

IRM 2943 - 1610 cm⁻¹

Solv: KBr

Reference(s):
 1. Rao, Pemmaraju N.; Cessac, James W.; Blye, Richard P.; Kim, Hyun

K., Steroids, 63 <1998> 1, 50-57, LA: EN, CODEN: STEDAM

L4 ANSWER 1 OF 6 BEILSTEIN COPYRIGHT 2000 BEILSTEIN CD4S (Continued)

receptors; in vivo progestational (Clausberg), and antiprogesterone (anti-Clausberg) no activity in immature New Zealand white rabbits (p.o)

Reference(s):
 1. Rao, Pemmaraju N.; Cessac, James W.; Blye, Richard P.; Kim, Hyun

K., Steroids, 63 <1998> 1, 50-57, LA: EN, CODEN: STEDAM

Preparation:

PRE

Start: BRN=506007 acetic acid, BRN=7954622

13.beta.-ethyl-11.beta.-<4-

(N,N-dimethylamino)phenyl)-17.alpha.-hydroxy-18,19-dinorpregna-4,9-
 diene-3,20-dione

Reag: 1.) trifluoroacetic anhydride, 2.) p-TsOH*H2O

Detail: 1.) CH2Cl2, RT, 30 min, 2.) CH2Cl2, 0 deg C, 1 h

Reference(s):

1. Rao, Pemmaraju N.; Cessac, James W.; Blye, Richard P.; Kim, Hyun

K., Steroids, 63 <1998> 1, 50-57, LA: EN, CODEN: STEDAM

Note(s):

2. Yield given. Multistep reaction

CTCPL Coupling Phenomena: Spin-spin coupling constants

Reference(s):

1. Rao, Pemmaraju N.; Cessac, James W.; Blye, Richard P.; Kim, Hyun

K., Steroids, 63 <1998> 1, 50-57, LA: EN, CODEN: STEDAM

Note(s):

2. 1H-1H. Solvent(s): CDCl3

Melting Point:

Value	Solv.	Ref.	Note
(MP)	(.SOL)		
(Cal)			
233.00 - 236.00	CH2Cl2	1	1

Reference(s):

1. Rao, Pemmaraju N.; Cessac, James W.; Blye, Richard P.; Kim, Hyun K.,
 Steroids, 63 <1998> 1, 50-57, LA: EN, CODEN: STEDAM

Note(s):

1. Crystallization with 0.25 Mol(s) H2O

Optical Rotatory Power:

ORP 210.730 deg

Type: <alpha>

Conc: 1.03 g/100ml

L4 ANSWER 2 OF 6 BEILSTEIN COPYRIGHT 2000 BEILSTEIN CD4S

Beilstein Reg. No. (BRN): 7958075 Beilstein
 Molecular Formula (MF): C30 H36 O4 S
 Autonom Name (AUN): acetic acid
 17-acetyl-13-ethyl-11-(4-methylsulfonyl-
 phenyl)-3-oxo-2,3,6,7,8,11,12,13,14,15,16,17-
 dodecahydro-1H-cyclopenta<a>phenanthren-17-yl


ester

Beilstein Reference (SO): 6-08
 General Comments (NTE): Stereo compound
 Formula Weight (FW): 492.67
 Lawson Number (LN): 9938; 1155; 292

Ring System Data:

Number of Rings (CNR): 5
 Ring Systems (CNRS): 2
 Diff. Ring Systems (CNDRS): 2
 Ring Heteros (CNRH): 0
 Acyclic Heteros (CNAH): 5

Beilstein Ring Index (BRIX)	Ring System Formula (RF)	BRIX Count
17.4.32-0.0-2.20	C17	1
6.1.0-0.0-3.1	C6	1



Atom/Bond Notes:
 1. CIP Descriptor: R
 2. CIP Descriptor: S

Biological Function:

BF in vitro relative binding affinities for progesterone and glucocorticoid
 receptors; in vivo progestational activity (Clausberg), and in vivo
 antiprogesterone (anti-Clausberg) no activity in immature New Zealand
 white rabbits (p.o)

Reference(s):

1. Rao, Pemmaraju N.; Cessac, James W.; Blye, Richard P.; Kim, Hyun

K.,

L4 ANSWER 2 OF 6 BEILSTEIN COPYRIGHT 2000 BEILSTEIN CD&S (Continued)
Steroids, 63 <1998> 1, 50-57, LA: EN, CODEN: STEDAM

Preparation:

PRE

Start: BRN=506007 acetic acid, BRN=7953710

13.beta.-ethyl-11.beta.-<4-

(methylthio)phenyl)-17.alpha.-hydroxy-18,19-dinorpregna-4,9-diene-3,20-dione

Reag: 1.) trifluoroacetic anhydride, 2.) p-TsOH*H₂O

Detail: 1.) CH₂Cl₂, RT, 30 min, 2.) CH₂Cl₂, 0 deg C, 1 h

Reference(s):

1. Rao, Pemmaraju N.; Cessac, James W.; Blye, Richard P.; Kim, Hyun

K.,

Steroids, 63 <1998> 1, 50-57, LA: EN, CODEN: STEDAM

Note(s):

2. Yield given. Multistep reaction

CTCPL Coupling Phenomena: Spin-spin coupling constants

Reference(s):

1. Rao, Pemmaraju N.; Cessac, James W.; Blye, Richard P.; Kim, Hyun

K.,

Steroids, 63 <1998> 1, 50-57, LA: EN, CODEN: STEDAM

Note(s):

2. 1H-1H. Solvent(s): CDCl₃

Melting Point:

Value	Solv.	Ref.	Note
(MP)	(.SOL)		
(Cel)			

270.00 - 275.00	ethyl acetate	1	1

Reference(s):

1. Rao, Pemmaraju N.; Cessac, James W.; Blye, Richard P.; Kim, Hyun K.,
Steroids, 63 <1998> 1, 50-57, LA: EN, CODEN: STEDAM

Notes(s):

1. Crystallization with 0.125 Mol(s) H₂O

Optical Rotatory Power:

ORP

213.900 deg
Type: <alpha>
Conc: 1.01 g/100ml
Len: 10.0 nm
Solv: CHCl₃
Wavel: 589.00 nm
Temp: 26.0 Cel
Reference(s):

L4 ANSWER 3 OF 6 BEILSTEIN COPYRIGHT 2000 BEILSTEIN CD&S

Beilstein Reg. No. (BRN): 7957866 Beilstein

Molecular Formula (MF): C₃₁H₃₆O₅

Synonym (SY): 17.alpha.-acetoxy-13.beta.-ethyl-11.beta.-<4-acetylphenyl)-18,19-dinorpregna-4,9-diene-3,20-dione

Autonom Name (AUN):

17-acetyl-11-(4-acetyl-phenyl)-13-ethyl-

3-oxo-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta<a>phenanthren-17-yl ester

Beilstein Reference (SO):

6-08

General Comments (NTE): Stereo compound


Formula Weight (FW): 488.62

Lawson Number (LN): 9954 1155

Ring System Data:

Number of Rings (CNR): 5
Ring Systems (CNRS): 2
Diff. Ring Systems (CNDRS): 2
Ring Heteros (CNRH): 0
Acyclic Heteros (CNAH): 5

Beilstein Ring Index (BRIX)	Ring System Formula (RF)	BRIX Count
17.4.32-0.0-2.20	C17	1
6.1.0-0.0-3.1	C6	1



Atom/Bond Notes:

1. CIP Descriptor: R
2. CIP Descriptor: S

Biological Function:

BF in vitro relative binding affinities for progesterone and glucocorticoid

L4 ANSWER 2 OF 6 BEILSTEIN COPYRIGHT 2000 BEILSTEIN CD&S (Continued)
1. Rao, Pemmaraju N.; Cessac, James W.; Blye, Richard P.; Kim, Hyun

K.,

Steroids, 63 <1998> 1, 50-57, LA: EN, CODEN: STEDAM

NMR Absorption:

NMRA

Nucl: 1H

Solv: CDCl₃

Reference(s):

1. Rao, Pemmaraju N.; Cessac, James W.; Blye, Richard P.; Kim, Hyun

K.,

Steroids, 63 <1998> 1, 50-57, LA: EN, CODEN: STEDAM

Infrared Maximum:

IRM 2948 - 1595 cm⁻¹-1

Solv: KBr

Reference(s):

1. Rao, Pemmaraju N.; Cessac, James W.; Blye, Richard P.; Kim, Hyun

K.,

Steroids, 63 <1998> 1, 50-57, LA: EN, CODEN: STEDAM

L4 ANSWER 3 OF 6 BEILSTEIN COPYRIGHT 2000 BEILSTEIN CD&S (Continued)
receptors; in vivo progestational (Clausberg), and antiprogesterone (anti-Clausberg) no activity in immature New Zealand withe rabbits (p.o)

Reference(s):

1. Rao, Pemmaraju N.; Cessac, James W.; Blye, Richard P.; Kim, Hyun

K.,

Steroids, 63 <1998> 1, 50-57, LA: EN, CODEN: STEDAM

Preparation:

PRE

Start: BRN=506007 acetic acid, BRN=7953599

13.beta.-ethyl-11.beta.-<4-

acetylphenyl)-17.alpha.-hydroxy-18,19-dinorpregna-4,9-diene-3,20-dione

Reag: 1.) trifluoroacetic anhydride, 2.) p-TsOH*H₂O

Detail: 1.) CH₂Cl₂, RT, 30 min, 2.) CH₂Cl₂, 0 deg C, 45 min

Reference(s):

1. Rao, Pemmaraju N.; Cessac, James W.; Blye, Richard P.; Kim, Hyun

K.,

Steroids, 63 <1998> 1, 50-57, LA: EN, CODEN: STEDAM

Note(s):

2. Yield given. Multistep reaction

CTCPL Coupling Phenomena: Spin-spin coupling constants

Reference(s):

1. Rao, Pemmaraju N.; Cessac, James W.; Blye, Richard P.; Kim, Hyun

K.,

Steroids, 63 <1998> 1, 50-57, LA: EN, CODEN: STEDAM

Note(s):

2. 1H-1H. Solvent(s): CDCl₃

Melting Point:

Value	Solv.	Ref.	Note
(MP)	(.SOL)		
(Cel)			

268.00 - 270.00	CH ₂ Cl ₂ , diethyl ether	1	1

Reference(s):

1. Rao, Pemmaraju N.; Cessac, James W.; Blye, Richard P.; Kim, Hyun K.,
Steroids, 63 <1998> 1, 50-57, LA: EN, CODEN: STEDAM

Notes(s):

1. Decomposition

Optical Rotatory Power:

ORP

184.400 deg
Type: <alpha>
Conc: 1.03 g/100ml
Len: 10.0 nm
Solv: CHCl₃
Wavel: 589.00 nm

L4 ANSWER 3 OF 6 BEILSTEIN COPYRIGHT 2000 BEILSTEIN CD&S (Continued)

Temp: 26.0 Cel

Reference(s):

1. Rao, Pemmaraju N.; Cessac, James W.; Blye, Richard P.; Kim, Hyun

Steroids, 63 <1998> 1, 50-57, LA: EN, CODEN: STEDAM

NMR Absorption:

NMRA

Nucl: 1H

Solv: CDCl3

Reference(s):

1. Rao, Pemmaraju N.; Cessac, James W.; Blye, Richard P.; Kim, Hyun

Steroids, 63 <1998> 1, 50-57, LA: EN, CODEN: STEDAM

Infrared Maximum:

IRM 2951 - 1596 cm⁻¹

Solv: KBr

Reference(s):

1. Rao, Pemmaraju N.; Cessac, James W.; Blye, Richard P.; Kim, Hyun

Steroids, 63 <1998> 1, 50-57, LA: EN, CODEN: STEDAM

L4 ANSWER 4 OF 6 BEILSTEIN COPYRIGHT 2000 BEILSTEIN CD&S

Beilstein Reg. No. (BRN): 6946364 Beilstein

Molecular Formula (MF): C30 H37 N O4

Autonom Name (AUN): acetic acid

17-acetyl-11-(4-dimethylamino-phenyl)-13-methyl-3-oxo-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[*a*]phenanthren-17-yl

ester

Beilstein Reference (SO): 6-14

General Comments (NTE): Stereo compound

Rtd. Stereoisomers (RSI): 5673666

Formula Weight (FW): 475.63

Lawson Number (LN): 15934; 2817; 1155

Ring System Data:

Number of Rings (CNR): 5


Ring Systems (CNRS): 2

Diff. Ring Systems (CNDRS): 2

Ring Heteros (CNRH): 0

Acyclic Heteros (CNAH): 5

Beilstein Ring Index (BRIX)	Ring System Formula (RF)	BRIX Count
17.4.32-0.0-2.20	C17	1
6.1.0-0.0-3.1	C6	1



Atom/Bond Notes:

1. CIP Descriptor: R

L4 ANSWER 4 OF 6 BEILSTEIN COPYRIGHT 2000 BEILSTEIN CD&S (Continued)

2. CIP Descriptor: S

Biological Function:

BF in vitro relative binding affinities for progesterone and glucocorticoid

receptors; in vivo antiprogesterational activity (anti-Clauberger) in

immature New Zealand white rabbits (p.o)

Reference(s):

1. Rao, Pemmaraju N.; Cessac, James W.; Blye, Richard P.; Kim, Hyun

Steroids, 63 <1998> 1, 50-57, LA: EN, CODEN: STEDAM

BF agonistic activity in female breast cancer cells BT-474 and T47-D (by

measuring amount of prostate-specific antigen (PSA) gene);

antagonistic activity in T47-D cells (blocking of norgestrel, norgestimate and

dihydrotestosterone activities)

Reference(s):

1. Rao, Pemmaraju N.; Wang, Zhiqiang; Cessac, James W.; Rosenberg,

S.; Jenkins, David J. A.; Diamandis, Eleftherios P.; Steroids, 63

<1998> 10, 523-530, LA: EN, CODEN: STEDAM

L4 ANSWER 5 OF 6 BEILSTEIN COPYRIGHT 2000 BEILSTEIN CD&S

Beilstein Reg. No. (BRN): 6945949 Beilstein

Molecular Formula (MF): C29 H35 N O4

Synonym (SY): 17-acetoxy-11.β.-(4-N-methylaminophenyl)-19-

norpregna-4,9-diene-3,20-dione

acetic acid

17-acetyl-13-methyl-11-(4-methylamino-

phenyl)-3-oxo-2,3,6,7,8,11,12,13,14,15,16,17-

dodecahydro-1H-cyclopenta[*a*]phenanthren-17-yl

ester

Beilstein Reference (SO): 6-14

General Comments (NTE): Stereo compound

Formula Weight (FW): 461.60

Lawson Number (LN): 15934; 2817; 1155

Ring System Data:

Number of Rings (CNR): 5


Ring Systems (CNRS): 2

Diff. Ring Systems (CNDRS): 2

Ring Heteros (CNRH): 0

Acyclic Heteros (CNAH): 5

Beilstein Ring Index (BRIX)	Ring System Formula (RF)	BRIX Count
17.4.32-0.0-2.20	C17	1
6.1.0-0.0-3.1	C6	1



Atom/Bond Notes:

1. CIP Descriptor: R

2. CIP Descriptor: S

Preparation:

PRE

Start: BRN=6946364

17-acetoxy-11.β.-(4-N,N-dimethylaminophenyl)-19-

L4 ANSWER 5 OF 6 BEILSTEIN COPYRIGHT 2000 BEILSTEIN CD&S (Continued)
 norpregna-4,9-diene-3,20-dione
 Reag: I2, CaO
 Solv: tetrahydrofuran, methanol
 Reference(s):
 1. Acosta, Kirk; Cessac, James W.; Rao, P. Narasimha; Kim, Hyun K.,
 J.Chem.Soc.Chem.Comm., <1994> 17, 1985-1986, LA: EN, CODEN:
 JCCCAT


L4 ANSWER 6 OF 6 BEILSTEIN COPYRIGHT 2000 BEILSTEIN CD&S
 Beilstein Reg. No. (BRN): 5673666 Beilstein
 Molecular Formula (MF): C30 H37 N O4
 Synonym (SY):
 17.alpha.-acetoxy-11.beta.-(4-dimethylaminophenyl)-
 13.alpha.-methyl-18,19-dinor-pregna-4,9-diene-3,20-
 dione
 Autonom Name (AUN): acetic acid
 17-acetyl-11-(4-dimethylamino-phenyl)-
 13-methyl-3-oxo-2,3,6,7,8,11,12,13,14,15,16,17-
 dodecahydro-1H-cyclopenta<a>phenanthren-17-yl
 ester
 Beilstein Reference (SO): 6-14
 General Comments (NTE): Stereo compound
 CAS Reg. No. (RN): 96285-40-4; 126784-99-4
 Rltd. Stereoisomers (RSI): 6946364
 Formula Weight (FW): 475.63
 Lawson Number (LN): 15934; 2817; 1155

Ring System Data:

Number of Rings (CNR): 5
 Ring Systems (CNR5): 2
 Diff. Ring Systems (CNDRS): 2
 Ring Heteros (CNRH): 0
 Acyclic Heteros (CNAH): 5

Beilstein Ring Index (BRIX)	Ring System Formula (RF)	BRIX Count
17.4.32-0.0-2.20	C17	1
6.1.0-0.0-3.1	C6	1

L4 ANSWER 6 OF 6 BEILSTEIN COPYRIGHT 2000 BEILSTEIN CD&S (Continued)



Atom/Bond Notes:
 1. CIP Descriptor: R
 2. CIP Descriptor: S

Biological Function:
 BF reversal of dexamethasone induced tyrosine aminotransferase activity
 in rat hepatoma cells (antiglucocorticoid activity)
 Reference(s):
 1. Neef, Guenter; Beier, Sybille; Elger, Walter; Henderson, David;
 Wiechert, Rudolf, Steroids, 44 <1984> 4, 349-372, LA: EN, CODEN:
 STEDAM

Preparation:
 PRE

Start: BRN=5657948
 11.beta.-(4-dimethylaminophenyl)-17.alpha.-hydroxy-
 13.alpha.-methyl-18,19-dinor-pregna-4,9-diene-3,20-dione
 BRN=385737 acetic acid anhydride
 Reag: 4-dimethylaminopyridine
 Time: 14 hour(s)
 Yield: 93.00 %
 Solv: toluene
 Ambient Temperature
 Reference(s):
 1. Neef, Guenter; Beier, Sybille; Elger, Walter; Henderson, David;
 Wiechert, Rudolf, Steroids, 44 <1984> 4, 349-372, LA: EN, CODEN:
 STEDAM

Melting Point:
 Value | Solv. | Ref.
 (MP) | (SOL) |

L4 ANSWER 6 OF 6 BEILSTEIN COPYRIGHT 2000 BEILSTEIN CD&S (Continued)

(Cel) | |

 194.00 - 195.00 | ethyl acetate, 11
 | hexane |

Reference(s):
 1. Neef, Guenter; Beier, Sybille; Elger, Walter; Henderson, David;
 Wiechert, Rudolf, Steroids, 44 <1984> 4, 349-372, LA: EN, CODEN:
 STEDAM

Optical Rotatory Power:
 ORP 372.300 deg

Type: <alpha>
 Conc: 0.39 g/100ml
 Solv: CHCl3
 Wavel: 589.00 nm
 Temp: 25.0 Cel

Reference(s):
 1. Neef, Guenter; Beier, Sybille; Elger, Walter; Henderson, David;
 Wiechert, Rudolf, Steroids, 44 <1984> 4, 349-372, LA: EN, CODEN:
 STEDAM

NMR Absorption:

NMRA
 Nucl: 1H
 Solv: CDCl3
 Reference(s):
 1. Neef, Guenter; Beier, Sybille; Elger, Walter; Henderson, David;
 Wiechert, Rudolf, Steroids, 44 <1984> 4, 349-372, LA: EN, CODEN:
 STEDAM

Infrared Maximum:
 IRM 1736 - 1612 cm⁻¹

Solv: KBr
 Reference(s):
 1. Neef, Guenter; Beier, Sybille; Elger, Walter; Henderson, David;
 Wiechert, Rudolf, Steroids, 44 <1984> 4, 349-372, LA: EN, CODEN:
 STEDAM

=> d his

(FILE 'HOME' ENTERED AT 13:14:23 ON 07 JAN 2000)

FILE 'REGISTRY' ENTERED AT 13:14:38 ON 07 JAN 2000
ACTIVATE K2132/A

L1 STR
L2 41 SEA FILE=REGISTRY SSS FUL L1

FILE 'CAPLUS' ENTERED AT 13:15:01 ON 07 JAN 2000
L3 8 S L2/THU

FILE 'BEILSTEIN' ENTERED AT 13:16:58 ON 07 JAN 2000
L4 6 S L1 FULL

=> log y

09/180,132

Page 1

=> d ibib ab hitstr 1-3 16

L6 ANSWER 1 OF 3 USPATFULL

ACCESSION NUMBER: 2002:43584 USPATFULL
 TITLE: 21-SUBSTITUTED PROGESTERONE DERIVATIVES AS NEW
 ANTIPROGESTATIONAL AGENTS
 INVENTOR(S): KIM, HYUN K., BETHESDA, MD, UNITED STATES
 BLYE, RICHARD P., HIGHLAND, MD, UNITED STATES
 RAO, PEDMARAJU N., SAN ANTONIO, TX, UNITED STATES
 CESSAC, JAMES W., SAN ANTONIO, TX, UNITED STATES
 ACOSTA, CARMIE K., SAN ANTONIO, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002025951	A1	20020228
APPLICATION INFO.:	US 1999-180132	A1	19990524 (9)
	WO 1997-US7373		19970430
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	EUGENIA GARRETT WACKOWSKI, TOWNSEND AND TOWNSEND AND CREW, TWO EMBARCADERO CENTER, 8TH FLOOR, SAN FRANCISCO, CA, 94111		
NUMBER OF CLAIMS:	36		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Page(s)		
LINE COUNT:	2185		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	A compound having the general formula: ##STR1##		

in which: R_{sup.1} is a member selected from the group consisting of --CH₃.sub.3, --SCH₃.sub.3, --N(CH₃.sub.3).sub.2, --NHCH₃.sub.3, --CHO, --COCH₃.sub.3 and --CHOCH₃.sub.3; R_{sup.2} is a member selected from the group consisting of halogen, alkyl, acyl, hydroxy, alkoxy, acyloxy, alkyl carbonate, cyponyloxy, S-alkyl and S-acyl; R_{sup.3} is a member selected from the group consisting of alkyl, hydroxy, alkoxy and acyloxy; R_{sup.4} is a member selected from the group consisting of hydrogen and alkyl; and X is a member selected from the group consisting of .sub.3, .dbd.O and .sub.3, .dbd.N--OR_{sup.5}, wherein R_{sup.5} is a member selected from the group consisting of hydrogen and alkyl.

In addition to providing the compounds of Formula I, the present invention provides methods wherein the compounds of Formula I are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce labor; and for contraception.


IT 198414-07-2P 198414-09-4P 198414-31-2P
 (prepn. of progesterone derivs. as antiprogesterational agents)
 RN 198414-07-2 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 17,21-bis(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 1 OF 3 USPATFULL (Continued)


RN 198414-03-8 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-fluoro-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 198414-05-0 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-chloro-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 198414-11-8 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-(acetylthio)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 198414-22-1 USPATFULL
 CN Extra-4,9-dien-3-one, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-(1-oxopropyl)-, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

L6 ANSWER 1 OF 3 USPATFULL (Continued)




RN 198414-09-4 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetylthio)-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-31-2 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 198414-03-8P 198414-05-0P 198414-11-8P
 198414-22-1P 198414-32-3P 198414-33-4P
 198414-34-5P 198414-39-0P 198414-43-6P
 (prepn. of progesterone derivs. as antiprogesterational agents)


L6 ANSWER 1 OF 3 USPATFULL (Continued)

Absolute stereochemistry. Rotation (+).




RN 198414-32-3 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(3-cyclopentyl-1-oxopropoxy)-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-33-4 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-(3-cyclopentyl-1-oxopropoxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-34-5 USPATFULL


L6 ANSWER 1 OF 3 USPATFULL (Continued)
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 198414-39-0 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-ethoxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 198414-43-6 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-bromo-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L6 ANSWER 1 OF 3 USPATFULL (Continued)




RN 198413-99-9 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-hydroxy-21-[(methylsulfonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-00-5 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-21-fluoro-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 198414-21-0 USPATFULL
 CN Estradiol, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-oxopropyl)-, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L6 ANSWER 1 OF 3 USPATFULL (Continued)
 IT 198413-96-6P 198413-97-7P 198413-98-8P
 198413-99-9P 198414-00-5P 198414-21-0P
 198414-30-1P 198414-38-9P 198414-42-5P
 (prepn. of progesterone derivs. as antiprogesterone agents)
 RN 198413-96-6 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-chloro-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198413-97-7 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 198413-98-8 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17,21-dihydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L6 ANSWER 1 OF 3 USPATFULL (Continued)




RN 198414-30-1 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-hydroxy-21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-38-9 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-21-ethoxy-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-42-5 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-bromo-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 1 OF 3 USPATFULL (Continued)




IT 198414-40-3P 198414-41-4P

(prepn. of progesterone derivs. as antiprogesterational agents)


RN 198414-40-3 USPATFULL

CN 19-Norpregna-4,9-diene-3,20-dione, 17,21-bis(acetyloxy)-11-[4-(dimethylamino)phenyl]-, 3-oxime, (3E,11.β.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 198414-41-4 USPATFULL

CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-methoxy-, 3-oxime, (11.β.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L6 ANSWER 2 OF 3 USPATFULL

ACCESSION NUMBER:

2001:4726 USPATFULL

TITLE:

17.β.-acyl-17.α.-propynyl-11.β.-arylsteroids and their derivatives having agonist or antagonist hormonal properties

INVENTOR(S):

Cook, C. Edgar, Staunton, VA, United States
Kepler, John A., Raleigh, NC, United States
O'Reilly, Jill M., Durham, NC, United States
Research Triangle Institute, Research Triangle Park, NC, United States (U.S. corporation)

PATENT ASSIGNEE(S):


Research Triangle Institute, Research Triangle Park, NC, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6172052	B1	20010109
US 1998-205395		19981204 (9)

PATENT INFORMATION:
 APPLICATION INFO.:
 DOCUMENT TYPE:
 FILE SEGMENT:
 PRIMARY EXAMINER:
 ASSISTANT EXAMINER:
 LEGAL REPRESENTATIVE:
 NUMBER OF CLAIMS:
 EXEMPLARY CLAIM:
 NUMBER OF DRAWINGS:
 LINE COUNT:
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The invention is directed to a novel class of 17.β.-acyl-17.β.-propynyl steroids which exhibit potent antiprogesterational activity.
 IT 273208-59-6P 273208-60-9P 273208-61-0P
 273208-62-1P 273208-63-2P 273208-64-3P
 273208-65-4P 273208-66-5P 273208-67-6P
 273208-68-7P 273208-69-8P 273208-70-9P
 273208-71-0P 273208-72-1P 273208-73-2P
 273208-74-3P 273208-75-4P 273208-76-5P
 273208-77-6P 273208-78-7P 273208-79-8P
 273208-80-9P 273208-81-0P 273208-82-1P
 273208-83-2P 273208-84-3P 273208-85-4P
 273208-86-5P 273208-87-6P 273208-88-7P
 273208-89-8P 273208-90-9P 273208-91-0P
 273208-92-1P 273208-93-2P 273208-94-3P
 273208-95-4P 273208-96-5P 273208-97-6P
 273208-98-7P 273208-99-8P 273208-100-9P
 273209-01-0P 273209-02-1P 273209-03-2P
 273209-04-3P 273209-05-4P 273209-06-5P
 273209-07-6P 273209-08-7P 273209-09-8P
 273209-10-9P 273209-11-0P 273209-12-1P
 273209-13-2P 273209-14-3P 273209-15-4P
 273209-16-5P 273209-17-6P 273209-18-7P
 273209-19-8P 273209-20-9P 273209-21-0P
 273209-22-1P 273209-23-2P 273209-24-3P
 273209-25-4P 273209-26-5P 273209-27-6P
 273209-28-7P 273209-29-8P 273209-30-9P
 273209-31-0P 273209-32-1P 273209-33-2P
 273209-34-3P 273209-35-4P 273209-36-5P
 273209-37-6P 273209-38-7P 273209-39-8P
 273209-40-9P 273209-41-0P 273209-42-1P
 273209-43-2P 273209-44-3P 273209-45-4P
 273209-46-5P 273209-47-6P 273209-48-7P
 273209-49-8P 273209-50-9P 273209-51-0P
 273209-52-1P 273209-53-2P 273209-54-3P
 273209-55-4P 273209-56-5P 273209-57-6P
 273209-58-7P 273209-59-8P 273209-60-9P
 273209-61-0P 273209-62-1P 273209-63-2P
 273209-64-3P 273209-65-4P 273209-66-5P
 273209-67-6P 273209-68-7P 273209-69-8P
 273209-70-9P 273209-71-0P 273209-72-1P
 273209-73-2P 273209-74-3P 273209-75-4P
 273209-76-5P 273209-77-6P 273209-78-7P
 273209-79-8P 273209-80-9P 273209-81-0P
 273209-82-1P 273209-83-2P 273209-84-3P
 273209-85-4P 273209-86-5P 273209-87-6P
 273209-88-7P 273209-89-8P 273209-90-9P
 273209-91-0P 273209-92-1P 273209-93-2P
 273209-94-3P 273209-95-4P 273209-96-5P
 273209-97-6P 273209-98-7P 273209-99-8P
 273209-100-9P 273210-01-0P 273210-02-1P
 273210-03-2P 273210-04-3P 273210-05-4P
 273210-06-5P 273210-07-6P 273210-08-7P
 273210-09-8P 273210-10-9P 273210-11-0P
 273210-12-1P 273210-13-2P 273210-14-3P
 273210-15-4P 273210-16-5P 273210-17-6P
 273210-18-7P 273210-19-8P 273210-20-9P
 273210-21-0P 273210-22-1P 273210-23-2P
 273210-24-3P 273210-25-4P 273210-26-5P
 273210-27-6P 273210-28-7P 273210-29-8P
 273210-30-9P 273210-31-0P 273210-32-1P
 273210-33-2P 273210-34-3P 273210-35-4P
 273210-36-5P 273210-37-6P 273210-38-7P
 273210-39-8P 273210-40-9P 273210-41-0P
 273210-42-1P 273210-43-2P 273210-44-3P
 273210-45-4P 273210-46-5P 273210-47-6P
 273210-48-7P 273210-49-8P 273210-50-9P
 273210-51-0P 273210-52-1P 273210-53-2P
 273210-54-3P 273210-55-4P 273210-56-5P
 273210-57-6P 273210-58-7P 273210-59-8P
 273210-60-9P 273210-61-0P 273210-62-1P
 273210-63-2P 273210-64-3P 273210-65-4P
 273210-66-5P 273210-67-6P 273210-68-7P
 273210-69-8P 273210-70-9P 273210-71-0P
 273210-72-1P 273210-73-2P 273210-74-3P
 273210-75-4P 273210-76-5P 273210-77-6P
 273210-78-7P 273210-79-8P 273210-80-9P
 273210-81-0P 273210-82-1P 273210-83-2P
 273210-84-3P 273210-85-4P 273210-86-5P
 273210-87-6P 273210-88-7P 273210-89-8P
 273210-90-9P 273210-91-0P 273210-92-1P
 273210-93-2P 273210-94-3P 273210-95-4P
 273210-96-5P 273210-97-6P 273210-98-7P
 273210-99-8P 273210-100-9P 273211-01-0P
 273211-02-1P 273211-03-2P 273211-04-3P
 273211-05-4P 273211-06-5P 273211-07-6P
 273211-08-7P 273211-09-8P 273211-10-9P
 273211-11-0P 273211-12-1P 273211-13-2P
 273211-14-3P 273211-15-4P 273211-16-5P
 273211-17-6P 273211-18-7P 273211-19-8P
 273211-20-9P 273211-21-0P 273211-22-1P
 273211-23-2P 273211-24-3P 273211-25-4P
 273211-26-5P 273211-27-6P 273211-28-7P
 273211-29-8P 273211-30-9P 273211-31-0P
 273211-32-1P 273211-33-2P 273211-34-3P
 273211-35-4P 273211-36-5P 273211-37-6P
 273211-38-7P 273211-39-8P 273211-40-9P
 273211-41-0P 273211-42-1P 273211-43-2P
 273211-44-3P 273211-45-4P 273211-46-5P
 273211-47-6P 273211-48-7P 273211-49-8P
 273211-50-9P 273211-51-0P 273211-52-1P
 273211-53-2P 273211-54-3P 273211-55-4P
 273211-56-5P 273211-57-6P 273211-58-7P
 273211-59-8P 273211-60-9P 273211-61-0P
 273211-62-1P 273211-63-2P 273211-64-3P
 273211-65-4P 273211-66-5P 273211-67-6P
 273211-68-7P 273211-69-8P 273211-70-9P
 273211-71-0P 273211-72-1P 273211-73-2P
 273211-74-3P 273211-75-4P 273211-76-5P
 273211-77-6P 273211-78-7P 273211-79-8P
 273211-80-9P 273211-81-0P 273211-82-1P
 273211-83-2P 273211-84-3P 273211-85-4P
 273211-86-5P 273211-87-6P 273211-88-7P
 273211-89-8P 273211-90-9P 273211-91-0P
 273211-92-1P 273211-93-2P 273211-94-3P
 273211-95-4P 273211-96-5P 273211-97-6P
 273211-98-7P 273211-99-8P 273211-100-9P
 273212-01-0P 273212-02-1P 273212-03-2P
 273212-04-3P 273212-05-4P 273212-06-5P
 273212-07-6P 273212-08-7P 273212-09-8P
 273212-10-9P 273212-11-0P 273212-12-1P
 273212-13-2P 273212-14-3P 273212-15-4P
 273212-16-5P 273212-17-6P 273212-18-7P
 273212-19-8P 273212-20-9P 273212-21-0P
 273212-22-1P 273212-23-2P 273212-24-3P
 273212-25-4P 273212-26-5P 273212-27-6P
 273212-28-7P 273212-29-8P 273212-30-9P
 273212-31-0P 273212-32-1P 273212-33-2P
 273212-34-3P 273212-35-4P 273212-36-5P
 273212-37-6P 273212-38-7P 273212-39-8P
 273212-40-9P 273212-41-0P 273212-42-1P
 273212-43-2P 273212-44-3P 273212-45-4P
 273212-46-5P 273212-47-6P 273212-48-7P
 273212-49-8P 273212-50-9P 273212-51-0P
 273212-52-1P 273212-53-2P 273212-54-3P
 273212-55-4P 273212-56-5P 273212-57-6P
 273212-58-7P 273212-59-8P 273212-60-9P
 273212-61-0P 273212-62-1P 273212-63-2P
 273212-64-3P 273212-65-4P 273212-66-5P
 273212-67-6P 273212-68-7P 273212-69-8P
 273212-70-9P 273212-71-0P 273212-72-1P
 273212-73-2P 273212-74-3P 273212-75-4P
 273212-76-5P 273212-77-6P 273212-78-7P
 273212-79-8P 273212-80-9P 273212-81-0P
 273212-82-1P 273212-83-2P 273212-84-3P
 273212-85-4P 273212-86-5P 273212-87-6P
 273212-88-7P 273212-89-8P 273212-90-9P
 273212-91-0P 273212-92-1P 273212-93-2P
 273212-94-3P 273212-95-4P 273212-96-5P
 273212-97-6P 273212-98-7P 273212-99-8P
 273212-100-9P 273213-01-0P 273213-02-1P
 273213-03-2P 273213-04-3P 273213-05-4P
 273213-06-5P 273213-07-6P 273213-08-7P
 273213-09-8P 273213-10-9P 273213-11-0P
 273213-12-1P 273213-13-2P 273213-14-3P
 273213-15-4P 273213-16-5P 273213-17-6P
 273213-18-7P 273213-19-8P 273213-20-9P
 273213-21-0P 273213-22-1P 273213-23-2P
 273213-24-3P 273213-25-4P 273213-26-5P
 273213-27-6P 273213-28-7P 273213-29-8P
 273213-30-9P 273213-31-0P 273213-32-1P
 273213-33-2P 273213-34-3P 273213-35-4P
 273213-36-5P 273213-37-6P 273213-38-7P
 273213-39-8P 273213-40-9P 273213-41-0P
 273213-42-1P 273213-43-2P 273213-44-3P
 273213-45-4P 273213-46-5P 273213-47-6P
 273213-48-7P 273213-49-8P 273213-50-9P
 273213-51-0P 273213-52-1P 273213-53-2P
 273213-54-3P 273213-55-4P 273213-56-5P
 273213-57-6P 273213-58-7P 273213-59-8P
 273213-60-9P 273213-61-0P 273213-62-1P
 273213-63-2P 273213-64-3P 273213-65-4P
 273213-66-5P 273213-67-6P 273213-68-7P
 273213-69-8P 273213-70-9P 273213-71-0P
 273213-72-1P 273213-73-2P 273213-74-3P
 273213-75-4P 273213-76-5P 273213-77-6P
 273213-78-7P 273213-79-8P 273213-80-9P
 273213-81-0P 273213-82-1P 273213-83-2P
 273213-84-3P 273213-85-4P 273213-86-5P
 273213-87-6P 273213-88-7P 273213-89-8P
 273213-90-9P 273213-91-0P 273213-92-1P
 273213-93-2P 273213-94-3P 273213-95-4P
 273213-96-5P 273213-97-6P 273213-98-7P
 273213-99-8P 273213-100-9P 273214-01-0P
 273214-02-1P 273214-03-2P 273214-04-3P
 273214-05-4P 273214-06-5P 273214-07-6P
 273214-08-7P 273214-09-8P 273214-10-9P
 273214-11-0P 273214-12-1P 273214-13-2P
 273214-14-3P 273214-15-4P 273214-16-5P
 273214-17-6P 273214-18-7P 273214-19-8P
 273214-20-9P 273214-21-0P 273214-22-1P
 273214-23-2P 273214-24-3P 273214-25-4P
 273214-26-5P 273214-27-6P 273214-28-7P
 273214-29-8P 273214-30-9P 273214-31-0P
 273214-32-1P 273214-33-2P 273214-34-3P
 273214-35-4P 273214-36-5P 273214-37-6P
 273214-38-7P 273214-39-8P 273214-40-9P
 273214-41-0P 273214-42-1P 273214-43-2P
 273214-44-3P 273214-45-4P 273214-46-5P
 273214-47-6P 273214-48-7P 273214-49-8P
 273214-50-9P 273214-51-0P 273214-52-1P
 273214-53-2P 273214-54-3P 273214-55-4P
 273214-56-5P 273214-57-6P 273214-58-7P
 273214-59-8P 273214-60-9P 273214-61-0P
 273214-62-1P 273214-63-2P 273214-64-3P
 273214-65-4P 273214-66-5P 273214-67-6P
 273214-68-7P 273214-69-8P 273214-70-9P
 273214-71-0P 273214-72-1P 273214-73-2P
 273214-74-3P 273214-75-4P 273214-76-5P
 273214-77-6P 273214-78-7P 273214-79-8P
 273214-80-9P 273214-81-0P 273214-82-1P
 273214-83-2P 273214-84-3P 273214-85-4P
 273214-86-5P 273214-87-6P 273214-88-7P
 273214-89-8P 273214-90-9P 273214-91-0P
 273214-92-1P 273214-93-2P 273214-94-3P
 273214-95-4P 273214-96-5P 273214-97-6P
 273214-98-7P 273214-99-8P 273214-100-9P
 273215-01-0P 273215-02-1P 273215-03-2P
 273215-04-3P 273215-05-4P 273215-06-5P
 273215-07-6P 273215-08-7P 273215-09-8P
 273215-10-9P 273215-11-0P 273215-12-1P
 273215-13-2P 273215-14-3P 273215-15-4P
 273215-16-5P 273215-17-6P 273215-18-7P
 273215-19-8P 273215-20-9P 273215-21-0P
 273215-22-1P 273215-23-2P 273215-24-3P
 273215-25-4P 273215-26-5P 273215-27-6P
 273215-28-7P 273215-29-8P 273215-30-9P
 273215-31-0P 273215-32-1P 273215-33-2P
 273215-34-3P 273215-35-4P 273215-36-5P
 273215-37-6P 273215-38-7P 273215-39-8P
 273215-40-9P 273215-41-0P 273215-42-1P
 273215-43-2P 273215-44-3P 273215-45-4P
 273215-46-5P 273215-47-6P 273215-48-7P
 273215-49-8P 273215-50-9P 273215-51-0P
 273215-52-1P 273215-53-2P 273215-54-3P
 273215-55-4P 273215-56-5P 273215-57-6P
 273215-58-7P 273215-59-8P 273215-60-9P
 273215-61-0P 273215-62-1P 273215-63-2P
 273215-64-3P 273215-65-4P 273215-66-5P
 273215-67-6P 273215-68-7P 273215-69-8P
 273215-70-9P 273215-71-0P 273215-72-1P
 273215-73-2P 273215-74-3P 273215-75-4P
 273215-76-5P 273215-77-6P 273215-78-7P
 273215-79-8P 273215-80-9P 273215-81-0P
 273215-82-1P 273215-83-2P 273215-84-3P
 273215-85-4P 273215-86-5P 273215-87-6P
 273215-88-7P 273215-89-8P 273215-90-9P
 273215-91-0P 273215-92-1P 273215-93-2P
 273215-94-3P 273215-95-4P 273215-96-5P
 273215-97-6P 273215-98-7P 27321

L6 ANSWER 2 OF 3 USPATFULL (Continued)




RN 273208-63-2 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-(4-aminophenyl)-21-methoxy-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 273208-64-3 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-(4-aminophenyl)-17-(3-hydroxy-1-propynyl)-21-methoxy-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 273208-77-8 USPATFULL
 CN 19-Norpregna-4,9-dien-3-one, 11-(4-aminophenyl)-17-(1-oxopropyl)-17-(1-propynyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


L6 ANSWER 2 OF 3 USPATFULL (Continued)
 CN 19-Norpregna-4,9-dien-3-one, 11-(4-aminophenyl)-17-(1-oxopropyl)-17-(1-propynyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 273208-81-4 USPATFULL
 CN 19-Norpregna-4,9-dien-3-one, 11-(4-aminophenyl)-17-(1-oxopropyl)-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 273208-82-5 USPATFULL
 CN 19-Norpregna-4,9-dien-3-one, 11-(4-aminophenyl)-17-(3-hydroxy-1-propynyl)-17-(1-oxopropyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




L6 ANSWER 2 OF 3 USPATFULL (Continued)
 , (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273208-78-9 USPATFULL
 CN 19-Norpregna-4,9-dien-3-one, 11-(4-aminophenyl)-17-(1-oxopropyl)-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273208-79-0 USPATFULL
 CN 19-Norpregna-4,9-dien-3-one, 11-(4-aminophenyl)-17-(3-hydroxy-1-propynyl)-17-(1-oxopropyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273208-80-3 USPATFULL

L6 ANSWER 2 OF 3 USPATFULL (Continued)


273209-12-4 USPATFULL
 CN 19-Norpregna-4,9-dien-3,20-dione, 11-[4-(dimethylamino)phenyl]-21-methoxy-17-(1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273209-13-5 USPATFULL
 CN 19-Norpregna-4,9-dien-3,20-dione, 11-[4-(dimethylamino)phenyl]-21-methoxy-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273209-14-6 USPATFULL
 CN 19-Norpregna-4,9-dien-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-(3-hydroxy-1-propynyl)-21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273209-15-7 USPATFULL
 CN 19-Norpregna-4,9-dien-3,20-dione, 11-[4-(dimethylamino)phenyl]-21-methoxy-17-(1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

L6 ANSWER 2 OF 3 USPATFULL (Continued)


Absolute stereochemistry.
Double bond geometry unknown.



RN 273209-16-8 USPATFULL

CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-(1-methoxy-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 273209-17-9 USPATFULL

CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-(3-hydroxy-1-propynyl)-21-methoxy-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L6 ANSWER 2 OF 3 USPATFULL (Continued)


Absolute stereochemistry.



RN 273209-33-9 USPATFULL

CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-(1-oxopropyl)-17-(1-propynyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 273209-34-0 USPATFULL

CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-(1-oxopropyl)-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 273209-35-1 USPATFULL

CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-(3-hydroxy-1-propynyl)-17-(1-oxopropyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


L6 ANSWER 2 OF 3 USPATFULL (Continued)



RN 273209-30-6 USPATFULL

CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-(1-oxopropyl)-17-(1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273209-31-7 USPATFULL

CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-(1-oxopropyl)-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273209-32-8 USPATFULL

CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-(3-hydroxy-1-propynyl)-17-(1-oxopropyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

L6 ANSWER 2 OF 3 USPATFULL (Continued)


Absolute stereochemistry.
Double bond geometry unknown.



RN 273209-67-9 USPATFULL

CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(methylamino)phenyl]-17-(1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273209-68-0 USPATFULL

CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(methylamino)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273209-69-1 USPATFULL


CN 19-Norpregna-4,9-diene-3,20-dione, 17-(3-hydroxy-1-propynyl)-21-methoxy-11-[4-(methylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

L6 ANSWER 2 OF 3 USPATFULL (Continued)
Absolute stereochemistry.




RN 273209-70-4 USPATFULL
CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(methylamino)phenyl]-17-(1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 273209-71-5 USPATFULL
CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(methylamino)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




L6 ANSWER 2 OF 3 USPATFULL (Continued)




RN 273209-87-3 USPATFULL
CN 19-Norpregna-4,9-dien-3-one, 17-(3-hydroxy-1-propynyl)-11-[4-(methylamino)phenyl]-17-(1-oxopropyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273209-88-4 USPATFULL
CN 19-Norpregna-4,9-dien-3-one, 11-[4-(methylamino)phenyl]-17-(1-oxopropyl)-17-(1-propynyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 273209-89-5 USPATFULL
CN 19-Norpregna-4,9-dien-3-one, 11-[4-(methylamino)phenyl]-17-(1-oxopropyl)-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L6 ANSWER 2 OF 3 USPATFULL (Continued)


RN 273209-72-6 USPATFULL
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(3-hydroxy-1-propynyl)-21-methoxy-11-[4-(methylamino)phenyl]-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 273209-85-1 USPATFULL
CN 19-Norpregna-4,9-dien-3-one, 11-[4-(methylamino)phenyl]-17-(1-oxopropyl)-17-(1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273209-86-2 USPATFULL
CN 19-Norpregna-4,9-dien-3-one, 11-[4-(methylamino)phenyl]-17-(1-oxopropyl)-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L6 ANSWER 2 OF 3 USPATFULL (Continued)




RN 273209-90-8 USPATFULL
CN 19-Norpregna-4,9-dien-3-one, 17-(3-hydroxy-1-propynyl)-11-[4-(methylamino)phenyl]-17-(1-oxopropyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 273210-18-7 USPATFULL
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(aminophenyl)-17-(1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273210-19-8 USPATFULL
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(aminophenyl)-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L6 ANSWER 2 OF 3 USPATFULL (Continued)




RN 273210-20-1 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-(4-aminophenyl)-17-(3-hydroxy-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273210-21-2 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-(4-aminophenyl)-17-(1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


RN 273210-22-3 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-(4-aminophenyl)-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

L6 ANSWER 2 OF 3 USPATFULL (Continued)




RN 273210-37-0 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-(4-(dimethylamino)phenyl)-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273210-38-1 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-(4-(dimethylamino)phenyl)-17-(3-hydroxy-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273210-39-2 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-(4-(dimethylamino)phenyl)-17-(1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L6 ANSWER 2 OF 3 USPATFULL (Continued)
NAME)Absolute stereochemistry.
Double bond geometry unknown.

RN 273210-23-4 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-(4-aminophenyl)-17-(3-hydroxy-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

RN 273210-36-9 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-(4-(dimethylamino)phenyl)-17-(1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L6 ANSWER 2 OF 3 USPATFULL (Continued)
Double bond geometry unknown.

RN 273210-40-5 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-(4-(dimethylamino)phenyl)-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


RN 273210-41-6 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-(4-(dimethylamino)phenyl)-17-(3-hydroxy-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 273210-54-1 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-(4-(dimethylamino)phenyl)-17-(1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

L6 ANSWER 2 OF 3 USPATFULL (Continued)


Absolute stereochemistry.



RN 273210-55-2 USPATFULL

CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(methylamino)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 273210-56-3 USPATFULL

CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-17-(3-hydroxy-1-propynyl)-11-[4-(methylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 2 OF 3 USPATFULL (Continued)




L6 ANSWER 2 OF 3 USPATFULL (Continued)

RN 273210-57-4 USPATFULL

CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(methylamino)phenyl]-17-(1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 273210-58-5 USPATFULL

CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(methylamino)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 273210-59-6 USPATFULL

CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-17-(3-hydroxy-1-propynyl)-11-[4-(methylamino)phenyl]-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L6 ANSWER 3 OF 3 USPATFULL

2000:12791 USPATFULL

TITLE: 20-keto-11.beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties
INVENTOR(S): Cook, C. Edgar, Staunton, VA, United States
Kepler, John A., Raleigh, NC, United States
Zhang, Ping-sheng, Millbrae, CA, United States
Lee, Yue-wei, Chapel Hill, NC, United States
Tallent, C. Ray, Raleigh, NC, United States
PATENT ASSIGNEE(S): Research Triangle Institute, Research Triangle Park, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6020328		20000201
APPLICATION INFO.:	US 1998-35949		19980306 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Dees, Jose' G.		
ASSISTANT EXAMINER:	Badio, Barbara		
LEGAL REPRESENTATIVE:	Obion, Spivak, McClelland, Maier & Neustadt, P.C.		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 10 Drawing Page(s)		
LINE COUNT:	2399		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is directed to 20-keto-11.beta.-arylsteroids of formula I: CC1=C(C(=O)C2=CC=CC=C2C3=C1C(=O)CC[C@H]4[C@@H]5C=C[C@H](C(=O)OCC)C[C@H]5[C@@H](C(=O)OCC)C[C@H]4C)C=C[C@H]3C wherein R.sup.1, R.sup.6, R.sup.7, R.sup.9, R.sup.12 and X are as defined by the specification. The compounds exhibit progestational and antiprogestational activities.

IT 240806-28-4P

(prepn. of 20-keto-11.beta.-arylsteroids with antiprogestational activity)

RN 240806-28-4 USPATFULL


CN 19,21-Dinorchola-4,9-dien-24-oic acid, 11-[4-(dimethylamino)phenyl]-17-hydroxy-3,20-dioxo-, ethyl ester, (11.beta.)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CH 1

CRN 240806-27-3

CHF C32 H41 N O5

Absolute stereochemistry.



L6 ANSWER 3 OF 3 USPATFULL (Continued)
CM 2

CRN 76-05-1
CMF C2 H F3 O2



=> d ibib ab fqhit 1-15

L12 ANSWER 1 OF 15 MARPAT COPYRIGHT 2002 ACS

ACCESSION NUMBER:

TITLE:

INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT:


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19745085	A1	19990415	DE 1997-19745085	19971011
EP 909764	A1	19990421	EP 1998-118613	19981001
EP 909764	B1	19990929		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AT 185145	E	19991015	AT 1998-118613	19981001
DE 1997-19745085 19971011				

PRIORITY APPLN. INFO.:

AB 11.beta.-Benzaldoxime-9.alpha.,10.alpha.-epoxy-estr-4-ene derivs., e.g. I (R1 = H, C1-6-alkyl; R2 = H, C1-10-alkyl, aryl, aralkyl, alkylaryl, C1-10-acyl, CONHR4, CO2R4; R3 = H, C1-10-alkyl, aryl, aralkyl, alkylaryl, (CH2)nCH2Y; R4 = H, C1-10-alkyl, aryl, aralkyl, alkylaryl; Y = F, Cl, Br, I, CN, R3, SCN, OR5, SR5; n = 0 - 2; R5 = H, C1-10-alkyl, aryl, aralkyl, alkylaryl, C1-10-acyl), are described. Thus, (E)-I (R1 = R2 = Me, R3 = CH2OMe, Z = H) was prepd. via regioselective epoxidn. of estradienone II (R1 = R2 = Me, R3 = CH2OMe, Z = H) with m-chloroparbenzoic acid in CH2Cl2. (E)-I (R1 = R2 = Me, R3 = CH2OMe, Z = H) showed 88% affinity for the progesterone receptor but only 12% affinity for the glucocorticoid receptor.

MSTR 2



G8 = 51



L12 ANSWER 1 OF 15 MARPAT COPYRIGHT 2002 ACS (Continued)

G12 = alkyl(1-10)

DER: or pharmaceutically acceptable salts

MPL: claim 1

L12 ANSWER 2 OF 15 MARPAT COPYRIGHT 2002 ACS

ACCESSION NUMBER:

TITLE:

INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE:


FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9826783	A1	19980625	WO 1997-FR2320	19971217
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DE, DK, EE, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, BF, BY, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
FR 2757400	A1	19980626	FR 1996-15649	19961219
FR 2757400	B1	19991217		
AU 9855632	A1	19980715	AU 1998-55632	19971217
EP 192641	A1	19990127	EP 1997-952078	19971217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRIORITY APPLN. INFO.:				
FR 1996-15649 19961219				
WO 1997-FR2320 19971217				

AB Glucocorticoid antagonists, except mifepristone, are used as dopamine type II receptor antagonists to treat psychotic or addictive behavior. Thus, 17.beta.-hydroxy-10.beta.-[(4-methylphenyl)methyl]-17.alpha.-(1-propynyl)estra-4,9(11)-dien-3-one considerably reduced the response to morphine in vivo.

MSTR 1



G1 = FR (SO (1-)) G11)
G3 = 35-13 37-14



G4 = C(O)

L12 ANSWER 2 OF 15 MARPAT COPYRIGHT 2002 ACS (Continued)

G12 = 41

C(O)CH2-OH

DER: and pharmaceutically acceptable acid addition salts

MPL: claim 4


NTE: substitution is restricted

L12 ANSWER 3 OF 15 MARPAT COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 128:18869 MARPAT
 TITLE: Mixed agonists of the progesterone receptor and assays for them
 INVENTOR(S): McDonnell, Donald P.; Wagner, Brandee L.
 PATENT ASSIGNEE(S): Duke University, USA
 SOURCE: PCT Int. Appl., 62 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9805679	A2	19980212	WO 1997-US13754	19970805
W: CA				

RV: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
 PRIORITY APPL. INFO.: US 1996-23206P 19960805
 AB A third class of PR-ligand (i.e. mixed agonist) is identified which induces a progesterone receptor conformation distinct from that induced by a PR agonist or antagonist; the agonists are estra-4,9-dien-3-one deriva. PR mixed agonists exhibit partial agonist activity which is influenced by cell context. These compds. provide useful pharmacol. profiles for treating progesterone related diseases and/or conditions, such as uterine proliferation from estrogen administration, endometriosis, breast cancer, fibroids, endometrial cancer, and brain meningiomas. The agonists can also be used as contraceptives. Assays are provided to screen for PR mixed agonists. Mol. designs are provided to convert a PR antagonist to a PR mixed agonist.

MSTR 1



G2 = 30

30(O)G3

G3 = alkyl(1-6) (50)
G9 = 52

L12 ANSWER 3 OF 15 MARPAT COPYRIGHT 2002 ACS (Continued)




MPL: claim 4

L12 ANSWER 4 OF 15 MARPAT COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 124:22540 MARPAT
 TITLE: Pharmaceutical compositions of antiglucocorticoid compounds for treating or preventing symptoms of spontaneous or narcotic-induced withdrawal.
 INVENTOR(S): Petit, Francis; Philibert, Daniel; Ulmann, Andre
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Eur. Pat. Appl., 30 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 676203	A1	19951011	EP 1995-400764	19950406
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
FR 2718354	A1	19951013	FR 1994-4156	19940408
FR 2718354	B1	19960503		
ZA 9502058	A	19960313	ZA 1995-2058	19950313
CA 2146600	AA	19951009	CA 1995-2146600	19950407
FI 9501683	A	19951009	FI 1995-1683	19950407
AU 9516326	A1	19951019	AU 1995-16326	19950407
JP 07278017	A2	19951024	JP 1995-107071	19950407
HU 71469	A2	19951128	HU 1995-1013	19950407
CN 1116929	A	19960221	CN 1995-104015	19950407
FR 1994-4156 19940408				

PRIORITY APPL. INFO.:
 AB Antiglucocteric steroids such as mifepristone, onapristone, lilopristone and related steroids are proposed for the prevention or treatment of withdrawal syndromes, either spontaneous or pptrd. by narcotics or mixts. of narcotics. These antiglucoctericoids would be useful in the withdrawal from morphinomimetics such as heroin, morphine or methadone as well as cocaine. Pharmacol. activity was demonstrated by the effect of the antiglucoctericoids on the stereotypic behavior of mice in response to narcotics. Spontaneous withdrawal syndrome was induced by administration of the opioid antagonist, naloxone. An antiprogesterone activity of the steroids in their action mechanism was eliminated. Results confirmed the involvement of endogenous glucocorticoids in morphine withdrawal since this is inhibited by antiglucoctericoids or adrenalectomy.

MSTR 2

G1 = Ph (50 (1-) G2)
G4 = 21

21(O)G5


L12 ANSWER 4 OF 15 MARPAT COPYRIGHT 2002 ACS (Continued)

G5 = alkyl (SR G13)
 G9 = O
 DER: and pharmaceutically acceptable addition salts
 DER: and pharmaceutically acceptable addition salts
 MPL: claim 7

L12 ANSWER 5 OF 15 MARPAT COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 123:218391 MARPAT
 TITLE: Steroids for reducing multidrug resistance to cancer
 chemotherapeutic agents
 INVENTOR(S): Cohn, Suzanne Bourgeois; Gruol, Donald J.
 PATENT ASSIGNEE(S): Salk Institute for Biological Studies, USA
 SOURCE: PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9517192	A1	19950629	WO 1994-US14624	19941219
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9514395	A1	19950710	AU 1995-14395	19941219
US 1993-173243 19931222				
WO 1994-US14624 19941219				
PRIORITY APPLN. INFO.: AB Certain steroid-like compds. (I); R1 = H; R2 = OR; or R1R2 = :O; R = H, lower alkyl, Me3Si; R3 = H, Me, or absent if double bond or epoxide bridge joins C9 and C10; R4 = OR', C4-18 cyclic org. group contg. O, N, P, or Si; R' = lower alkyl, Me3Si; R5 = H, OR; or R5C16C17 form a 3-, 5-, 6-, or 7-membered ring; R6 = C(O)CH3, CH(OH)CH3, C(O)CH2OH, (substituted) hydrocarbyl; R9 = H, halo, or absent if double bond or epoxide bridge joins C9 and C10] are capable of inhibiting the P-glycoprotein-assocd. efflux pump which is considered responsible for multidrug resistance. Chemotherapy can be enhanced by facilitating the accumulation of drug at the target site, with reduced or eliminated competition by the drug efflux system. Thus RU 38486, an antiprogesterin, at 5 .mu.M facilitated killing of multidrug-resistant S7CD-8 murine thymoma cells by 20 .mu.M puromycin.				

MYSTR 1B




G1 = C(O)
 G10 = Ph (SO (1-2) G16)
 G13 = 36


L12 ANSWER 6 OF 15 MARPAT COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 122:256423 MARPAT
 TITLE: Antiglucocorticoid steroids for the treatment of anxiety disorders
 INVENTOR(S): Peeters, Bernardus Wynand Machijs Maria
 PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.
 SOURCE: PCT Int. Appl., 25 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9504536	A1	19950216	WO 1994-EP2513	19940728
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KG, KP, KR, KZ, LK, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9474968	A1	19950228	AU 1994-74968	19940728
AU 687088	B2	19980219		
EP 712311	A1	19960522	EP 1994-924819	19940728
EP 712311	B1	19981007		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09501172	T2	19970204	JP 1994-506200	19940728
AT 171873	E	19981015	AT 1994-924819	19940728
ES 2124905	T3	19990216	ES 1994-924819	19940728
US 5741787	A	19980421	US 1996-581631	19960118
PRIORITY APPLN. INFO.: AB Antiglucocorticoid steroids are used for the manuf. of a pharmaceutical compn. for the treatment of anxiety disorders. The anxiolytic effect of 11.beta.-(4-dimethylaminophenyl)-17.beta.-hydroxy-17.alpha.-(prop-1-ynyl)-estra-4,9-dien-3-one (RU38486) was demonstrated in animal testing (antagonism of fear-potentiated startle). Prep'n. and activity (antagonism of stress-induced hyperthermia) of selected steroids of the invention is also described.				

MYSTR 1



G7 = 44



L12 ANSWER 5 OF 15 MARPAT COPYRIGHT 2002 ACS (Continued)

36 C(O)CH2-OH

MPL: claim 1

L12 ANSWER 6 OF 15 MARPAT COPYRIGHT 2002 ACS (Continued)

G16 = alkylcarbonyl<(1-5)> (SO (1-) G17)
 G18 = 39



MPL: claim 2

L12 ANSWER 7 OF 15 MARPAT COPYRIGHT 2002 ACS


ACCESSION NUMBER: 116:35156 MARPAT
 TITLE: Preparation and use of antiprogesteronimetics for synchronization of parturition in livestock
 INVENTOR(S): Grandadam, Jean Andre
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Eur. Pat. Appl., 13 pp.
 CODEN: EPOXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 446124	A2	19910911	EP 1991-400594	19910305
EP 446124	A3	19920527		
FR 2659233	A1	19910913	FR 1990-2783	19900306
FR 2659233	B1	19940121		
CA 2037549	AA	19910907	CA 1991-2037549	19910305
AU 9172608	A1	19910912	AU 1991-72608	19910305
AU 642975	B2	19931104		
ZA 9101603	A	19920527	ZA 1991-1603	19910305
JP 04211610	A2	19920803	JP 1991-62496	19910305
RU 2037295	C1	19950619	RU 1991-4895041	19910305
CN 1055665	A	19911030	CN 1991-102108	19910306
HU 59006	A2	19920428	HU 1991-729	19910306
			FR 1990-2783	19900306

PRIORITY APPLN. INFO.:


AB The title antiprogesteronimetics are I (R1 = C1-18 hydrocarbyl optionally substituted with .gtoreq.1 heteroatoms and bonded to the steroid by a C; R2 = C1-8 hydrocarbyl; X = remainder of 5- and 6-membered ring optionally substituted and optionally unsatd.; C = A = CNOH, oxo (free or blocked as ketal), etc.; B and C together form a double bond or epoxide bridge) and acid addn. salts thereof. Prepn. of 2 I are described.
 17.beta.-Hydroxy-11.beta.-[4-(dimethylaminophenyl)-17.alpha.-(prop-1-vinyl)estra-4,9-dien-3-one (II)] was more effective at synchronizing parturition than cloprostenol when tested in sows. Injectable pharmaceuticals contg. II are disclosed.

MSTR 1C




G1 = 30

L12 ANSWER 7 OF 15 MARPAT COPYRIGHT 2002 ACS (Continued)



G3 = 55-13 57-14



G15 = 61



G4 + G17 = 0

DER: and protected derivatives
 DER: and acid addition salts
 MPL: claim 1

L12 ANSWER 8 OF 15 MARPAT COPYRIGHT 2002 ACS

ACCESSION NUMBER: 115:214857 MARPAT
 TITLE: Injectable microspheres containing antiestrogenic and antiprogesteronimetic steroids
 INVENTOR(S): Cohen, Gerard; Dubois, Jean Luc
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Ger. Offen., 15 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4036425	A1	19910516	DE 1990-4036425	19901115
FR 2654337	A1	19910517	FR 1989-14976	19891115
FR 2654337	B1	19940805		
SE 9003570	A	19910516	SE 1990-3570	19901109
BE 1005511	A4	19930831	BE 1990-1062	19901109
DK 9002709	A	19910516	DK 1990-2709	19901113
CA 2029940	AA	19910516	CA 1990-2029940	19901114
JP 03294229	A2	19911225	JP 1990-306374	19901114
CH 681691	A	19930514	CH 1990-3611	19901114
NL 9002492	A	19910603	NL 1990-2492	19901115
GB 2239798	A1	19910717	GB 1990-24862	19901115
GB 2239798	B2	19931027		
AT 9002313	A	19950415	AT 1990-2313	19901115
AT 400298	B	19951127		


PRIORITY APPLN. INFO.:

AB Biodegradable microspheres comprise the title steroids (Markush given) and copolymers of lactic acid with glycolic acid. A mixt. of 250 mL aq. 0.3% hydrolyzed PVA soln., 1 g poly(DL-lactic acid-glycolic acid), 17 g CH₂Cl₂, and 0.5 g 17.beta.-hydroxy-11.beta.-[4-(dimethylamino)phenyl]-17.alpha.-(1-propynyl)estra-4,9-dien-3-one was emulsified, followed by stirring at 22.degree. and decreasing pressure (.gtoreq.400 mm Hg) to give microspheres, which were used for the prepn. of injections.

MSTR 1A


G1—G3

G1 = 3




G3 = 24


L12 ANSWER 8 OF 15 MARPAT COPYRIGHT 2002 ACS (Continued)



G5 = 68-26 70-27



G9 = 74



G10 = OH

MPL: claim 6


L12 ANSWER 9 OF 15 MARPAT COPYRIGHT 2002 ACS

ACCESSION NUMBER: 115:151901 MARPAT
 TITLE: Use of antiprogestomimetics for stimulating ovulation, and new preparation for use in pharmaceutical compositions
 INVENTOR(S): Grandadam, Jean Andre
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Eur. Pat. Appl., 24 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 417003	A2	19910313	EP 1990-402449	19900906
EP 417003	A3	19911204		
EP 417003	B1	19940629		
FR 2651435	A1	19910308	FR 1989-11699	19890907
FR 2651435	B1	19940422		
US 5173483	A	19921222	US 1990-578894	19900905
CA 2024728	AA	19910308	CA 1990-2024728	19900906
AU 9062259	A1	19910314	AU 1990-62259	19900907
AU 623805	B2	19920521		
JP 03099015	A2	19910424	JP 1990-236004	19900907
JP 3032258	B2	20000410		

PRIORITY APPLN. INFO.: FR 1989-11699 19890907
 AB Anti-progestomimetic compds., e.g. I [R1 = C1-18 hydrocarbyl with optionally .gtoreq.1 heteroatoms, bonded to the steroid by a C; R2 = C1-8 hydrocarbyl; X = rest of 5- or 6-membered (substituted) (unsatd.) ring; A:C = oxo (free or in ketal), CH(OH), CH(OR3), CH(O2CR3), etc.; R3 = C1-8 alkyl, C7-15 aralkyl; B and C together form a double bond or epoxide bridge] and their acid and base addn. salts, are used for making pharmaceuticals for stimulating ovulation, e.g. in cows. The compds. of the invention are preferably used following treatment with progesterone or a progestomimetic, e.g. 3-oxo-17.alpha.-allyl-17.beta.-hydroxyestra-4,9,11-triene (II). Thus, heifer cows were 1st administered II for 17 days; on the day following the last administration, the animals were injected with 17.beta.-hydroxy-11.beta.-(4-dimethylaminophenyl)-17.alpha.-(prop-1-ynyl)estra-4,9-dien-3-one. All of the heifers came to heat after a very short delay period, and LH levels rose very rapidly. Prepn. of 12 anti-progestomimetics is presented.

MSTR 1B




L12 ANSWER 10 OF 15 MARPAT COPYRIGHT 2002 ACS

ACCESSION NUMBER: 115:9125 MARPAT
 TITLE: Preparation of .omega.-[(3-oxoestra-4,9-dien-11.beta.-yl)phenylamino]alkanoates as antiglucocorticoids
 INVENTOR(S): Moguilevsky, Martine; Nedelec, Lucien; Nique, Francois; Philibert, Daniel
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Eur. Pat. Appl., 33 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 414606	A2	19910227	EP 1990-402328	19900822
EP 414606	A3	19910724		
EP 414606	B1	19941102		
FR 2651233	A1	19910301	FR 1989-11173	19890823
FR 2651233	B1	19911213		
CA 2022648	AA	19910224	CA 1990-2022648	19900803
ZA 9006341	A	19911030	ZA 1990-6341	19900810
US 5166146	A	19921124	US 1990-568597	19900816
JP 03090097	A2	19910416	JP 1990-217281	19900820
JP 3026997	B2	20000327		
IL 95451	A1	19950731	IL 1990-95451	19900821
AU 9061189	A1	19910228	AU 1990-61189	19900822
AU 634569	B2	19930225		
HU 54706	A2	19910328	HU 1990-5275	19900822
HU 208154	B	19930830		
ES 2063313	T3	19950101	ES 1990-402328	19900822
CN 1051362	A	19910515	CN 1990-107161	19900823
CN 1033808	B	19970115		
RU 2041236	C1	19950809	RU 1992-5011511	19920518

PRIORITY APPLN. INFO.: FR 1989-11173 19890823
 OTHER SOURCE(S): CASREACT 115:9125
 AB The title compds. [I: R1 = aliph. hydrocarbyl; R2 = H, (un)substituted alkyl; R5, R6 = H, alkyl; X = atoms to complete an (un)substituted 5- or 6- membered ring; Z = (un)satified CO2H; n = 1-6] were prepd. Thus, aminophenyl estradienone II (R = R5 = R6 = H) was condensed with BrCH2CO2Me to give, after sapon., II (R = CH2CO2Na, R5 = R6 = H) which at 10-6M in vitro gave 82% inhibition of uridine incorporation into rat thymocytes.

MSTR 1A



G3 = phenylene
 G9 = 39-18 37-17

L12 ANSWER 9 OF 15 MARPAT COPYRIGHT 2002 ACS (Continued)

G1 = 85
 G5 = 6H4G10
 G12 = 96
 G14 = 98
 G15 = OH
 G5 + G6 = O
 DER: or acid or base addition salts
 MPL: claim 2
 NTE: oxo formed by G5 and G6 may be protected as a ketal

L12 ANSWER 10 OF 15 MARPAT COPYRIGHT 2002 ACS (Continued)


G16 = G10-CH2
 G10 = (1-2) 45
 G11 = G12
 G13 = 53
 G16 = 68
 G13 = G13
 MPL: claim 1

L12 ANSWER 11 OF 15 MARPAT COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 114:229227 MARPAT
 TITLE: Preparation of 19-nor 3-oxo steroids with an amine substituted 17-chain as antioxidants and antiinflammatories: their use as medicines and pharmaceutical composition containing them
 INVENTOR(S): Claussner, Andre; Leclaire, Jacques; Nedelec, Lucien; Philibert, Daniel
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Eur. Pat. Appl., 29 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 389370	A1	19900926	EP 1990-400784	19900322
EP 389370	B1	19940427		
R: CH, DE, FR, GB, IT, LI, NL				
FR 2644789	A1	19900928	FR 1989-3742	19890322
FR 2644789	B1	19950203		
JP 02273693	A2	19901108	JP 1990-68508	19900320
JP 2848907	B2	19950120		
US 5108996	A	19920428	US 1990-497562	19900321
			FR 1989-3742	19890322

PRIORITY APPLN. INFO.:
 OTHER SOURCE(S): CASREACT 114:229227
 AB The title compds. [I; R1, R2 = H, Me; R11 = (poly)(hetero)hydrocarbyl; one of R17 and R18 is OH or acyloxy and the other is Q; Z = alkylene, alkenylene, alkynylene; P = (substituted) pyrimidinyl, pyridyl] were prepd. via reacting the halo derivs. II or III (X = halo) with the appropriate pyrimidinyl or pyridine deriv. IV. Reaction of estradienone V [R3 = 3-bromo-1-propynyl, R4 = OH] (prepn. given) was reacted with 2,4-bis(1-pyrrolidinyl)-6-(1-piperazinyl)pyrimidine (prepn. given) in acetone contg. K2CO3 at ambient temp. for 2 h to give V [R3 = 3-{4-[2,6-bis(1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl}-1-propynyl; R4 = OH]. At 5 times. 10-4 M this inhibited in vitro the formation of malonyldialdehyde, a measure of lipid peroxidn., in rat brain homogenate by approx. 47.5%.

MSTR 3



G2 = 97


L12 ANSWER 12 OF 15 MARPAT COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 113:115677 MARPAT
 TITLE: Preparation of androstane derivatives as drugs
 INVENTOR(S): Scholz, Stefan; Neef, Guenter; Ottow, Eckhard; Elger, Walter; Beier, Sybille; Chwalisz, Krzysztof
 PATENT ASSIGNEE(S): Schering A.-G., Fed. Rep. Ger.
 SOURCE: Eur. Pat. Appl., 38 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 360369	A1	19900328	EP 1989-250040	19890920
EP 360369	B1	19950503		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DE 3832303	A1	19900412	DE 1988-3832303	19880920
IL 91672	A1	19941229	IL 1989-91672	19890918
WO 9003385	A1	19900405	WO 1989-EP1090	19890920
V: AU, DK, FI, HU, JP, NO, US				
AU 8943049	A1	19900418	AU 1989-43049	19890920
AU 640616	B2	19930902		
ZA 8907191	A	19901031	ZA 1989-7191	19890920
DD 284682	A5	19901121	DD 1989-332836	19890920
HU 56851	A2	19911028	HU 1989-5541	19890920
HU 208151	B	19930830		
JP 04501712	T2	19920326	JP 1989-509963	19890920
JP 2760870	B2	19980604		
AT 122052	E	19950515	AT 1989-250040	19890920
ES 2074073	T3	19950901	ES 1989-250040	19890920
NO 9101102	A	19910319	NO 1991-1102	19910319
DK 9100504	A	19910320	DK 1991-504	19910320
US 5244886	A	19930914	US 1991-663819	19910320
NO 9104772	A	19910319	NO 1991-4772	19911204
PRIORITY APPLN. INFO.:			DE 1988-3832303	19880920
			WO 1989-EP1090	19890920
			NO 1991-1102	19910319

OTHER SOURCE(S): CASREACT 113:115677
 AB The title compds. [I; Z = O, hydroxyimino; LM = bond, or L = H and M = α -alkoxy-OH; AB = bond and D = H and R1 = heteroaryl; or A = H and BD = CH2 and Z = HZ; R3, R4 = tetrahydropranyloxyalkyl, tetrahydropranyloxyalkyl, useful as antigluocorticoids, neoplasm inhibitors (esp. for breast cancer), progestogen inhibitors, and antiproliferative agents, were prepd. 3-(Tetrahydropranyloxy)-1-propyne was lithiated with BuLi in THF-hexane and the product treated with 14. β -androstane-17-one II (R3R4 = O) (prepn. given) to give II (R3 = Q, R4 = OH) treated with 4N HCl to give I [R1 = OMe, R2 = Me, R3 = (CH2)3OH, BD = CH2, LM = bond, Z = O, A = H] (III). III had higher affinity for the estrogen receptor than the known EP-A 0277676 [11. β -[4-(dimethylamino)phenyl]-17. α -hydroxy-17-(3-hydroxypropyl)-14. β -estra-4,9-dien-3-one].


MSTR 1A

L12 ANSWER 11 OF 15 MARPAT COPYRIGHT 2002 ACS (Continued)




MPL: claim 13
 NTE: the alkylamino and dialkylamino groups in G11 may be interrupted by oxygen, sulfur, or nitrogen

L12 ANSWER 12 OF 15 MARPAT COPYRIGHT 2002 ACS (Continued)



G1 = O
 G20 = 45



G28 = alkyl<(1-4)>
 MPL: claim 1

L12 ANSWER 13 OF 15 MARPAT COPYRIGHT 2002 ACS

ACCESSION NUMBER: 112:235680 MARPAT
 TITLE: Preparation of 13-alkyl-11.beta.-phenylgonanes as
 antigestagens and antigluccorticoids
 INVENTOR(S): Scholz, Stefan; Ottow, Eckhard; Neef, Guenter; Elger,
 Walter; Beier, Sybille; Chwalisz, Krzysztof
 PATENT ASSIGNEE(S): Schering A.-G., Fed. Rep. Ger.
 SOURCE: Ger. Offen., 22 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3822770	A1	19900104	DE 1988-3822770	19880701
IL 90826	A1	19940624	IL 1989-90826	19890630
CA 1334668	A1	19950307	CA 1989-604596	19890630
EP 349481	A1	19900109	EP 1989-730155	19890703
EP 349481	B1	19951102		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
WO 9000174	A1	19900111	WO 1989-DE443	19890703
W: AU, FI, HU, JP, NO				
AU 8938568	A1	19900123	AU 1989-38568	19890703
AU 644060	B2	19931202		
ZA 8905058	A	19900425	ZA 1989-5058	19890703
DD 287511	A5	19910228	DD 1989-330342	19890703
HU 56114	A2	19910728	HU 1989-4130	19890703
HU 208021	B	19930728		
DD 295638	A5	19911107	DD 1989-341722	19890703
JP 03505727	T2	19911212	JP 1989-507188	19890703
JP 2956776	B2	19991004		
US 5273971	A	19931228	US 1989-374809	19890703
AT 129717	E	19951115	AT 1989-730155	19890703
ES 2080079	T3	19960201	ES 1989-730155	19890703
NO 9005609	A	19910228	NO 1990-5609	19901227
NO 180451	B	19970113		
NO 180451	C	19970423		
US 5446036	A	19950829	US 1993-144474	19931102
FI 9504856	A	19951012	FI 1995-4856	19951012
NO 9600829	A	19910228	NO 1996-829	19960229

PRIORITY APPLN. INFO.:

AB The title compds. [1; R1 = heterocyclyl, cyclyalkyl, cycloalkenyl, alkenyl, etc.; R2 = .alpha.-, .beta.-Me, Et; R3,R4 = alkoxy, acyl, oxofuryl, alkynyl, etc.; Z = O, NOH], antigestagens and antigluccorticoids useful for induction of abortion, were prepd. via Grignard reaction of the corresponding 5.alpha.,10.alpha.-epoxy-9(11) unsatd. steroids with p-RC6H4X (X = halo). Grignard reaction of epoxy steroid II (prepn. given) with p-CH2:CHC6H4X (X = Br, iodo) gave I [R1 = CH2:CH, R2 = .beta.-Me, R3 = OH, R4 = C.tlplbond.CMe, Z = OCH2CMe2CH2O], which was hydrolyzed to give I [Z = O, R1-R4 same as above]. This at 3.0 mg s.c./day induced abortion in 100% of rats tested.

L12 ANSWER 13 OF 15 MARPAT COPYRIGHT 2002 ACS (Continued)

MSTR 1A



G1 = 0
 G4 = 37

37(O)CH2-G10

G10 = alkyl<(1-4)>
 MPL: claim 1
 NTE: substitution is restricted

L12 ANSWER 14 OF 15 MARPAT COPYRIGHT 2002 ACS


ACCESSION NUMBER: 110:213172 MARPAT
 TITLE: 13(Alpha)-alkylgonanes, their production, and
 pharmaceutical preparations containing same
 INVENTOR(S): Neef, Guenter; Wiechert, Rudolf; Beier, Sybille;
 Elger, Walter; Henderson, David
 PATENT ASSIGNEE(S): Schering A.-G., Fed. Rep. Ger.
 SOURCE: U.S., 5 pp. Cont. of U.S. Ser. No. 621,308.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4780461	A	19881025	US 1985-810148	19851218
DE 3321826	A1	19841220	DE 1983-3321826	19830615
DE 3413036	A1	19851017	DE 1984-3413036	19840404
DE 3446661	A1	19860619	DE 1984-3446661	19841218
PRIORITY APPLN. INFO.:			DE 1983-3321826	19830615
			DE 1984-3413036	19840404
			US 1984-621308	19840615
			DE 1984-3446661	19841218

OTHER SOURCE(S):

CASREACT 110:213172
 AB 13.alpha.-Alkylgonanes [I; R = C1-4 acyl; X = O, NOH; II; R1 = amino; R2 = H, Me, Et; R3 = (substituted) alkyl; R4 = OH, alkoxy, alkanyloxy; or R3R4 = O; R5 = H, alkyl; III; Z = CH2CH2, CH2CMe2CH2], having antigestagenic activity and useful as postcoital contraceptives, or for triggering abortion and menstruation (no data), are prepd. via photochem. epimerization of the 13.beta.-gonanes IV. 11.beta.-(4-Dimethylaminomethyl)-17.alpha.-hydroxy-13.alpha.-methyl-17.beta.-(3-hydroxypropyl)-4,9-gonadien-3-one (V) was acetylated with Ac2O in pyridine to give 11.beta.-(4-dimethylaminomethyl)-17.alpha.-hydroxy-13.alpha.-methyl-17.beta.-(3-acetoxypropyl)-4,9-gonadien-3-one. A tablet was formulated contg. V 10.0, lactose 140.0, corn starch 69.5, polyvinylpyrrolidone 25 2.5, Aerosil 2.0, and Mg stearate 0.5 mg.

MSTR 2



G4 = 59

59(O)CH2-G11

G11 = OH
 G12 = 66

L12 ANSWER 14 OF 15 MARPAT COPYRIGHT 2002 ACS (Continued)



GGA = 33 <RC (1), RS (1) MS (1) X6, EC (0-) O (1-) N (0-) S (0)
 DER: OTHERQ, AM (1) N, BD (ALL) SE>
 MPL: and acid addition salts
 claim 18


L12 ANSWER 15 OF 15 MARPAT COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 109:170799 MARPAT
 TITLE: Antiprogesterinic 11.beta.-aryl-14.beta.-estra-4,9-dien-3-one derivatives, a process for their preparation, and pharmaceuticals containing them
 INVENTOR(S): Loozen, Hubert Jan Jozef
 PATENT ASSIGNEE(S): AKZO N. V., Neth.
 SOURCE: Eur. Pat. Appl., 15 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 277676	A1	19880810	EP 1988-200071	19880118
EP 277676	B1	19920304		
CA 1339570	A1	19971209	CA 1988-556625	19880115
ZA 8800317	A	19880928	ZA 1988-317	19880118
AT 73137	E	19920315	AT 1988-200071	19880118
ES 2031991	T3	19930101	ES 1988-200071	19880118
FI 8800257	A	19880724	FI 1988-257	19880121
FI 89054	B	19930430		
FI 89054	C	19930810		
AU 8810669	A1	19880728	AU 1988-10669	19880121
AU 603637	B2	19901122		
DK 8800304	A	19880724	DK 1988-304	19880122
DK 163307	B	19920217		
DK 163307	C	19920706		
CN 88100979	A	19880817	CN 1988-100979	19880122
CN 1030081	B	19951018		
JP 63216895	A2	19880909	JP 1988-12431	19880122
US 5272140	A	19931221	US 1990-488391	19900227

PRIORITY APPLN. INFO.:

AB Title steroids I [R1 = monosubstituted homo- or heterocyclic aryl; R2 = C1-4 alkyl; R3, R4 = H, OH, C1-18 acyloxy, C2-8 alkoxyalkyl, C1-8 acyl, C1-12 alkoxy, (un)satd. (un)substituted C1-8 hydrocarbyl; R3R4 = C1-6 alkylidene, or atoms needed to form ring; DELTA.16 optionally present, with R3 or R4 absent], having strong antiprogesterinic activity, are prepd. Estrone 3-Me ether was brominated, dehydrobrominated, and hydrogenated to give the isomeric 14.beta.-estrone 3-Me ether. This underwent NaBH4 redn., Birch redn., hydrolysis, and bromination-dehydrobromination to give 17.alpha.-hydroxy-14.beta.-estra-4,9-dien-3-one. The latter was ketalized at the 3-position, oxidized to the 17-one, alkynylated at the 17-position by the tetrahydropyranyl ether of propargyl alc., epoxidized to the 5.alpha.,10.alpha.-epoxide, coupled with 4-(Me2N)C6H4MgBr in the presence of CuCl, hydrogenated in the side chain, hydrolyzed and dehydrated, and cyclized in the sidechain by tosylation in pyridine to give (dimethylaminophenyl)dihydrospiro(estradiene-furan)one II. At 1 mg orally, twice daily in pregnant rats on days 6-10, II caused 100% pregnancy interception, but only slightly reversed dexamethasone-induced thymus wt. redn. in rats.

L12 ANSWER 15 OF 15 MARPAT COPYRIGHT 2002 ACS (Continued)
 MSTR 18



G1 = biphenyl (SR)
 G6 = 37



GGA = 27 31 <(1-10)>
 GGA = 37 <(1-8)>
 MPL: claim 1

=> d his

(FILE 'HOME' ENTERED AT 12:02:25 ON 09 AUG 2002)

FILE 'REGISTRY' ENTERED AT 12:02:30 ON 09 AUG 2002

L1 STRUCTURE UPLOADED

L2 23 S L1

L3 STRUCTURE UPLOADED

L4 12 S L3

L5 176 S L3 FULL

FILE 'USPATFULL' ENTERED AT 12:05:46 ON 09 AUG 2002

L6 3 S L5

FILE 'CAPLUS' ENTERED AT 12:07:33 ON 09 AUG 2002

L7 7 S L5

L8 0 S L7 NOT L6

FILE 'USPATFULL' ENTERED AT 12:10:05 ON 09 AUG 2002

FILE 'BEILSTEIN' ENTERED AT 12:11:15 ON 09 AUG 2002

L9 0 S L3 FULL

FILE 'CAOLD' ENTERED AT 12:11:34 ON 09 AUG 2002

L10 0 S L5

FILE 'MARPAT' ENTERED AT 12:11:43 ON 09 AUG 2002

L11 20 S L5 FULL

L12 15 S L11 NOT L7

L9 ANSWER 1 OF 12 MARPAT COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 131:199885 MARPAT
 TITLE: Preparation of 20-keto-11.beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties
 INVENTOR(S): Cook, C. Edgar; Kepler, John A.; Zhang, Ping-sheng;
 PATENT ASSIGNEE(S): Lee, Yue-wei; Tallent, C. Ray
 SOURCE: Research Triangle Institute, USA
 PCT Int. Appl., 95 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9945022	A1	19990910	WO 1999-US3732	19990305

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1998-35949 19980306
 AB 20-Keto-11.beta.-arylsteroids of formula I [X = O, (substituted) NOH, H2, OH, etc.; R1 = dialkylamino, imidazolyl, pyrrolyl, piperidino, etc.; R2 = H, halo; R3 = H, Me, halo; R4 = H, acyloxy, (substituted) OH, alkyl, etc.; R5 = H, alkyl, halo, acyloxy, etc.] are prepd. which exhibit potent antiprogesterational activity. Thus, II was prepd. from 17.alpha.-hydroxymethyl-3-methoxy-19-norpregna-1,3,5(10)-trien-20-one and 4-bromo-N,N-dimethylaniline in several steps. The affinity of II for the progesterone hormone receptor was IC50 of 0.7 nM.

MPTR 1A

L9 ANSWER 1 OF 12 MARPAT COPYRIGHT 2000 ACS (Continued)



G2 = phenylene (SO (1) G3)
 G14 = 128

G15

G27 = OCHO
 G29 = OCHO
 DER: and pharmaceutically acceptable salts
 MPL: claim 1
 NTE: substitution is restricted; also incorporates claim 3

L9 ANSWER 2 OF 12 MARPAT COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 127:358992 MARPAT
 TITLE: Preparation of 21-substituted progesterone derivatives as new antiprogesterational agents
 INVENTOR(S): Kim, Hyun K.; Blye, Richard P.; Rao, Pemmaraju N.; Cessac, James W.; Acosta, Carmie K.
 PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA
 SOURCE: Kim, Hyun K.; Blye, Richard P.; Rao, Pemmaraju N.; Cessac, James W.; Acosta, Carmie K.
 PCT Int. Appl., 65 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9741145	A1	19971106	WO 1997-US7373	19970430

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG


CA 2253673 AA 19971106 CA 1997-2253673 19970430
 AU 9729304 A1 19971119 AU 1997-29304 19970430
 EP 900234 A1 19990310 EP 1997-923523 19970430
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

PRIORITY APPLN. INFO.: US 1996-16628 19960501
 WO 1997-US7373 19970430

AB Progesterone derivs. of formula I [R1 = OMe, SMe, NMe2, NMe3, CHO, Ac, CHOHCH3; R2 = halo, alkyl, acyl, OH, alkoxy, etc.; R3 = OH, alkyl, alkoxy, acyloxy; R4 = H, alkyl; X = O, (substituted) NOH] are prepd. as antiprogesterational agents. The present invention provides methods wherein the compds. of formula I are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce labor; and for contraception. Thus, II was prepd. from 3,3-ethylenedioxy-17.beta.-cyano-17.alpha.-hydroxyestra-5(10),9(11)-diene and 4-bromo-N,N-dimethylaniline in 9 steps. II showed

L9 ANSWER 2 OF 12 MARPAT COPYRIGHT 2000 ACS (Continued)
 2.79 times the antiprogesterational potency in the antiClauberg test compared to CDB-2914.

MPTR 1



G2 = 29

G3

G3 = alkyl<(1-6)> (SO)
 G8 = 46

G6

MPL: claim 1

L9 ANSWER 3 OF 12 MARPAT COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 122:256423 MARPAT
 TITLE: Antigluco corticoid steroids for the treatment of anxiety disorders
 INVENTOR(S): Peeters, Bernardus Wynand Machijs Maria
 PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.
 SOURCE: PCT Int. Appl., 25 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9504536	A1	19950216	WO 1994-EP2513	19940728
V: AM, AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KG, KP, KR, KZ, LX, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, UA, US, UZ, VN				
RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9474968	A1	19950228	AU 1994-74968	19940728
AU 687088	B2	19980219		
EP 712311	A1	19960522	EP 1994-924819	19940728
EP 712311	B1	19981007		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, JP 09501172 T2 19970204 JP 1994-506200 19940728				
AT 171873	E	19981015	AT 1994-924819	19940728
ES 2124905	T3	19990216	ES 1994-924819	19940728
US 5741787	A	19980421	US 1996-581631	19960118

PRIORITY APPLN. INFO.:
 AB Antigluco corticoid steroids are used for the manuf. of a pharmaceutical compn. for the treatment of anxiety disorders. The anxiolytic effect of 11.beta.-(4-dimethylaminophenyl)-17.beta.-hydroxy-17.alpha.-(prop-1-ynyl)-estra-4,9-dien-3-one (RU38486) was demonstrated in animal testing (antagonism of fear-potentiated startle). Prepn. and activity of stress-induced hyperthermia) of selected steroids of the invention is also described.


MYSTR 1

L9 ANSWER 4 OF 12 MARPAT COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 116:35156 MARPAT
 TITLE: Preparation and use of antiprogesteromimetics for synchronization of parturition in livestock
 INVENTOR(S): Grandadam, Jean Andre
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Eur. Pat. Appl., 13 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 446124	A2	19910911	EP 1991-400594	19910305
EP 446124	A3	19920527		
R: AT, BE, CH, DE, DK, FR, GB, GR, IT, LI, LU, NL, SE				
FR 2659233	A1	19910913	FR 1990-2783	19900306
FR 2659233	B1	19940121		
CA 2037549	AA	19910907	CA 1991-2037549	19910305
AU 9172608	A1	19910912	AU 1991-72608	19910305
AU 642975	B2	19931104		
ZA 9101603	A	19920527	ZA 1991-1603	19910305
JP 04211610	A2	19920803	JP 1991-62496	19910305
RU 2037295	C1	19950619	RU 1991-4895041	19910305
CN 1055665	A	19911030	CN 1991-102108	19910306
HU 59006	A2	19920428	HU 1991-729	19910306
FR 1990-2783 19900306				

PRIORITY APPLN. INFO.:
 AB The title antiprogesteromimetics are I (R1 = C1-18 hydrocarbyl optionally substituted with .gtoreq.1 heteroatoms and bonded to the steroid by a C, R2 = C1-8 hydrocarbyl; X = remainder of 5- and 6-membered ring optionally substituted and optionally unsatd.; C = A = CNOH, oxo (free or blocked as ketal), etc.; B and C together form a double bond or epoxide bridge) and acid addn. salts thereof. Prepn. of 2 I are described. 17.beta.-Hydroxy-11.beta.-(4-dimethylaminophenyl)-17.alpha.-(prop-1-ynyl)estra-4,9-dien-3-one (II) was more effective at synchronizing parturition than cloprostenol when tested in sows. Injectable pharmaceuticals contg. II are disclosed.


MYSTR 1c



L9 ANSWER 3 OF 12 MARPAT COPYRIGHT 2000 ACS (Continued)



G7 = 44




G11 = OCHO
 G16 = alkylcarbonyl<(1-5)> (SO (1-) G17)
 G17 = alkoxy<(1-6)>
 G18 = 39



MPL: claim 2


L9 ANSWER 4 OF 12 MARPAT COPYRIGHT 2000 ACS (Continued)



G3 = 55-13 57-14



G9 = 43



G15 = alkylcarbonyloxy<(1-8)> and protected derivatives
 DER: and acid addition salts
 MPL: claim 1

L9 ANSWER 5 OF 12 MARPAT COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 115:214857 MARPAT
 TITLE: Injectable microspheres containing antiestrogenic and antiprogesteromimetic steroids
 INVENTOR(S): Cohen, Gerard; Dubois, Jean Luc
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Ger. Offen., 15 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4036425	A1	19910516	DE 1990-4036425	19901115
FR 2654337	A1	19910517	FR 1989-14976	19891115
FR 2654337	B1	19940805		
SE 9003570	A	19910516	SE 1990-3570	19901109
BE 1005511	A4	19930831	BE 1990-1062	19901109
DK 9002709	A	19910516	DK 1990-2709	19901113
CA 2029940	AA	19910516	CA 1990-2029940	19901114
JP 03294229	A2	19911225	JP 1990-306374	19901114
CH 681691	A	19930514	CH 1990-3611	19901114
NL 9002492	A	19910603	NL 1990-2492	19901115
GB 2239798	A1	19910717	GB 1990-24862	19901115
GB 2239798	B2	19931027		
AT 9002313	A	19950415	AT 1990-2313	19901115
AT 400298	B	19951127		

PRIORITY APPLN. INFO.: FR 1989-14976 19891115
 AB Biodegradable microspheres comprise the title steroids (Markush given) and copolymers of lactic acid with glycolic acid. A mixt. of 250 mL aq. 0.3% hydrolyzed PVA soln., 1 g poly(DL-lactic acid-glycolic acid), 17 g CH₂Cl₂, and 0.5 g 17.β-hydroxy-11.β-[(4-(dimethylamino)phenyl)-17.α-(1-propenyl)estra-4,9-dien-3-one was emulsified, followed by stirring at 22.degree. and decreasing pressure (.gtoreq.400 mm Hg) to give microspheres, which were used for the prepn. of injections.

NOTR 1A

G1—G3

G1 = 3


L9 ANSWER 6 OF 12 MARPAT COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 115:151901 MARPAT
 TITLE: Use of antiprogesteromimetics for stimulating ovulation, and new preparation for use in pharmaceutical compositions
 INVENTOR(S): Grandadam, Jean Andre
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Eur. Pat. Appl., 24 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 417003	A2	19910313	EP 1990-402449	19900906
EP 417003	A3	19911204		
EP 417003	B1	19940629		
R: AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE				
FR 2651435	A1	19910308	FR 1989-11699	19890907
FR 2651435	B1	19940422		
US 5173483	A	19921222	US 1990-578894	19900905
CA 2024728	AA	19910308	CA 1990-2024728	19900906
AU 9062259	A1	19910314	AU 1990-62259	19900907
AU 623805	B2	19920521		
JP 03099015	A2	19910424	JP 1990-236004	19900907
			FR 1989-11699	19890907


PRIORITY APPLN. INFO.:
 AB Anti-progesteromimetic compds., e.g. I [R1 = C1-18 hydrocarbyl with optionally .gtoreq.1 heteroatoms, bonded to the steroid by a C; R2 = C1-8 hydrocarbyl; X = rest of 5- or 6-membered (substituted) (unsatd.) ring; A:C = oxo (free or in ketal), CH(OH), CH(OR3), CH(O2CR3), etc.; R3 = alkyl, C7-15 aralkyl; B and C together form a double bond or epoxide bridge] and their acid and base addn. salts, are used for making pharmaceuticals for stimulating ovulation, e.g. in cows. The compds. of the invention are preferably used following treatment with progesterone or a progesteromimetic, e.g. 3-oxo-17.α-allyl-17.β-hydroxyestra-4,9,11-triene (II). Thus, heifer cows were 1st administered II for 17 days; on the day following the last administration, the animals were injected with 17.β-hydroxy-11.β-[(4-(dimethylaminophenyl)-17.α-(prop-1-ynyl)estra-4,9-dien-3-one. All of the heifers came to heat after a very short delay period, and LH levels rose very rapidly. Prepn. of 12 anti-progesteromimetics is presented.

NOTR 1B


L9 ANSWER 5 OF 12 MARPAT COPYRIGHT 2000 ACS (Continued)




G3 = 24



G5 = 68-26 70-27




G9 = 74



G10 = alkylcarbonyloxy<(1-8)> (50)
 G13 = alkylcarbonyloxy<(1-8)>
 MPL: claim 6

L9 ANSWER 6 OF 12 MARPAT COPYRIGHT 2000 ACS (Continued)



G1 = 85



G12 = alkylcarbonyloxy<(1-8)> (50 (1-) aryl) / 96



G14 = 98



G15 = alkylcarbonyloxy<(1-8)> (50 (1-) aryl)
 DER: or acid or base addition salts
 MPL: claim 2
 NTE: oxo formed by G5 and G6 may be protected as a ketal

L9 ANSWER 7 OF 12 MARPAT COPYRIGHT 2000 ACS

ACCESSION NUMBER: 115:9125 MARPAT

TITLE: Preparation of

.omega.-[3-oxoestra-4,9-dien-11.beta.-

yl)phenylamino]alkanoates as antiglucoocorticoids

INVENTOR(S): Moguilevsky, Martine; Nedelec, Lucien; Nique,

Francois; Philibert, Daniel

PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.

SOURCE: Eur. Pat. Appl., 33 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 414606	A2	19910227	EP 1990-402328	19900822
EP 414606	A3	19910724		
EP 414606	B1	19941102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
FR 2651233	A1	19910301	FR 1989-11173	19890823
FR 2651233	B1	19911213		
CA 2022648	AA	19910224	CA 1990-2022648	19900803
ZA 9006341	A	19911030	ZA 1990-6341	19900810
US 5166146	A	19921124	US 1990-568597	19900816
JP 03090097	A2	19910416	JP 1990-217281	19900820
IL 95451	A1	19950731	IL 1990-95451	19900821
AU 9061189	A1	19910228	AU 1990-61189	19900822
AU 634569	B2	19930225		
HU 54706	A2	19910328	HU 1990-5275	19900822
HU 208154	B	19930830		
ES 2063313	T3	19950101	ES 1990-402328	19900822
CN 1051362	A	19910515	CN 1990-107161	19900823
CN 1033808	B	19970115		
RU 2041236	C1	19950809	RU 1992-501511	19920518
			FR 1989-11173	19890823

PRIORITY APPLN. INFO.:

AB The title compds. [I]: R1 = aliph. hydrocarbyl; R2 = H, (un)substituted alky; R5, R6 = H, alky; X = atoms to complete an (un)substituted 5-


or

6- membered ring; Z = (un)salified CO₂H; n = 1-6] were prep'd. Thus, aminophenylestradienone II (R = R5 = R6 = H) was condensed with BrCH₂CO₂Meto give, after sapon., II (R = CH₂CO₂Na, R5 = R6 = H) which at 10-6M

in vitro gave 82% inhibition of uridine incorporation into rat thymocytes.

MSTR 1A

L9 ANSWER 7 OF 12 MARPAT COPYRIGHT 2000 ACS (Continued)

G3 = phenylene
G9 = 39-18 37-17G16-G10-CH₂

G10 = (1-2) 45

G11-G12

G13 = alkylcarbonyloxy<(1-8)> / 56

G5(O)CH₂-O-C(O)G14

G16 = 68

G13-G13

MPL: claim 1

L9 ANSWER 8 OF 12 MARPAT COPYRIGHT 2000 ACS

ACCESSION NUMBER: 113:115677 MARPAT

TITLE: Preparation of androstanone derivatives as drugs

INVENTOR(S): Scholz, Stefan; Neef, Guenter; Ottow, Eckhard;

Elger,

Walter; Beier, Sybille; Chwalisz, Krzysztof

Schering A.-G., Fed. Rep. Ger.

SOURCE: Eur. Pat. Appl., 38 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 360369	A1	19900328	EP 1989-250040	19890920
EP 360369	B1	19950503		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DE 3832303	A1	19900412	DE 1988-3832303	19880920
IL 91672	A1	19941229	IL 1989-91672	19890918
WO 9003385	A1	19900405	WO 1989-EP1090	19890920
W: AU, DK, FI, HU, JP, NO, US				
AU 8943049	A1	19900418		
AU 640616	B2	19930902	AU 1989-43049	19890920
ZA 8907191	A	19901031	ZA 1989-7191	19890920
DD 284682	A5	19901121	DD 1989-332836	19890920
HU 56851	A2	19911028	HU 1989-5541	19890920
HU 208151	B	19930830		
JP 04501712	T2	19920326	JP 1989-509963	19890920
JP 2760870	B2	19980604		
AT 122052	E	19950515	AT 1989-250040	19890920
ES 2074073	T3	19950901	ES 1989-250040	19890920
NO 9101102	A	19910319	NO 1991-1102	19910319
DK 9100504	A	19910320	DK 1991-504	19910320
US 5244886	A	19930914	US 1991-663819	19910320
NO 9104772	A	19910319	NO 1991-4772	19911204
			DE 1988-3832303	19880920
			WO 1989-EP1090	19890920
			NO 1991-1102	19910319

PRIORITY APPLN. INFO.:

AB The title compds. [I]: Z = O, hydroxylmino; LM = bond, or L = H and M = .alpha.-OH; AB = bond and O = H and R1 = heteroaryl; or A = H and BD = CH₂and Z = H₂; R3, R4 = tetrahydropyranyloxyalkyl, tetrahydropyranyloxyalkynyl, etc.), useful as antiglucoocorticoids, neoplasm inhibitors (esp. for breast cancer), progestogen inhibitors,

and antiproliferative agents, were prep'd. 3-(Tetrahydropyran-2-yloxy)-1-propyne was lithiated with BuLi in THF-hexane and the product treated

with 14.beta.-androstan-17-one II (R3R4 = O) (prepn. given) to give II (R3

= O,

R4 = OH) treated with 4N HCl to give I [R1 = OMe, R2 = Me, R3 =

(CH₂)₃OH,BD = CH₂, LM = bond, Z = O, A = H] (III). III had higher affinity


for the

gestagen receptor than the known EP-A 0277676 [11.beta.-[4-

L9 ANSWER 8 OF 12 MARPAT COPYRIGHT 2000 ACS (Continued)

(dimethylamino)phenyl]-17.alpha.-hydroxy-17-(3-hydroxypropyl)-14.beta.-estra-4,9-dien-3-one].

MSTR 1A



G20 = 45

G29

G24 = 81

G1-G30

G27 = 81

G1-G30

G28 = 81

G1-G30

G29 = OCHO

G30 = CHO

MPL: claim 1

L9 ANSWER 9 OF 12 MARPAT COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 112:235680 MARPAT
 TITLE: Preparation of 13-alkyl-11.beta.-phenylgonanes as
 antiestrogens and antigluccorticoids
 INVENTOR(S): Scholz, Stefan; Ottow, Eckhard; Neef, Guenter;
 Elger,
 PATENT ASSIGNEE(S): Walter; Beier, Sybille; Chwalisz, Krzysztof
 Schering A.-G., Fed. Rep. Ger.
 SOURCE: Ger. Offen., 22 pp.
 CODEN: GWXXEX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3822770	A1	19900104	DE 1988-3822770	19880701
IL 90826	A1	19940624	IL 1989-90826	19890630
CA 1334668	A1	19950307	CA 1989-604596	19890630
EP 349481	A1	19900103	EP 1989-730155	19890703
EP 349481	B1	19951102		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
WO 9000174	A1	19900111	WO 1989-DE443	19890703
W: AU, FI, HU, JP, NO				
AU 8938568	A1	19900123	AU 1989-38568	19890703
AU 644060	B2	19931202		
ZA 8905058	A	19900425	ZA 1989-5058	19890703
DD 287511	A5	19910228	DD 1989-330342	19890703
HU 56114	A2	19910729	HU 1989-4130	19890703
HU 208021	B	19930728		
DD 295638	A5	19911107	DD 1989-341722	19890703
JP 03505727	T2	19911212	JP 1989-507188	19890703
JP 2956776	B2	19991004		
US 5273971	A	19931228	US 1989-374809	19890703
AT 129717	E	19951115	AT 1989-730155	19890703
ES 2080079	T3	19960201	ES 1989-730155	19890703
NO 9005609	A	19910228	NO 1990-5609	19901227
NO 180451	B	19970113		
NO 180451	C	19970423		
US 5446036	A	19950829	US 1993-144474	19931102
FI 9504856	A	19951012	FI 1995-4856	19951012
NO 9600829	A	19910228	NO 1996-829	19960229
			DE 1988-3822770	19880701
			US 1989-374809	19890703
			WO 1989-DE443	19890703
			NO 1990-5609	19901227
			FI 1990-6441	19901228

PRIORITY APPLN. INFO.:

AB The title compds. [I: R1 = heterocyclyl, cyclyalkyl, cycloalkenyl, alkenyl, etc.; R2 = .alpha.-, .beta.-Me, -Et; R3, R4 = alkoxy, acyl, oxofuryl, alkynyl, etc.; Z = O, NOH], antiestrogens and antigluccorticoids useful for induction of abortion, were prepd. via Grignard reaction of the corresponding 5.alpha.,10.alpha.-epoxy-9(11)

L9 ANSWER 9 OF 12 MARPAT COPYRIGHT 2000 ACS (Continued)
 unsatd. steroids with p-R1C6H4X (X = halo). Grignard reaction of epoxy steroid II (prepn. given) with p-CH2:CHC6H4X (X = Br, iodo) gave I [R1 = CH2:CH, R2 = .beta.-Me, R3 = OH, R4 = C.tplbond.CMe, Z = OCH2CMe2CH2O], which was hydrolyzed to give I [Z = O, R1-R4 same as above]. This at 3.0 mg s.c./day induced abortion in 100% of rats tested.

MYTR 1A



G4 = 37

37(O)-CH2-G10

G7 = 32

32-G8

G8 = CHO

G10 = alkoxy<(1-4)>

MPL: claim 1

NTE: substitution is restricted

L9 ANSWER 10 OF 12 MARPAT COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 111:233356 MARPAT
 TITLE: New 11-aryl steroids useful as antiprogestins,
 their
 INVENTOR(S): De Jongh, Hendrik Paul; Van Vliet, Nicolaas Pieter
 PATENT ASSIGNEE(S): AKZO N. V., Neth.
 SOURCE: Eur. Pat. Appl., 10 pp.
 CODEN: EPXXEW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 321010	A1	19890621	EP 1988-202678	19881125
EP 321010	B1	19930203		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
AT 85342	E	19930215	AT 1988-202678	19881125
ES 2053714	T3	19940801	ES 1988-202678	19881125
ZA 8808996	A	19890830	ZA 1988-8996	19881130
AU 8826469	A1	19890615	AU 1988-26469	19881201
AU 613433	B2	19910801		
US 4921845	A	19900501	US 1988-281582	19881208
CA 1301162	A1	19920519	CA 1988-585297	19881208
DK 8806880	A	19890613	DK 1988-6880	19881209
DK 168444	B1	19940328		
FI 8805717	A	19890613	FI 1988-5717	19881209
FI 89056	B	19930430		
FI 89056	C	19930810		
CN 1034731	A	19890816	CN 1988-108484	19881212
CN 1019807	B	19921230		
JP 01211597	A2	19890824	JP 1988-313643	19881212
			NL 1987-3008	19871212
			EP 1988-202678	19881125

PRIORITY APPLN. INFO.:

AB Aryl steroids I [R1 = aryl substituted by -NXY; X, Y = H, Cl-4 hydrocarbyl; or XY = C2-6 hydrocarbyl forming 3- to 7-membered ring; R2 = H, OH, acyloxy, alkoxy, (un)satd. C1-8 hydrocarbyl with .gtoreq.1 OH, oxo, N3, cyano, and/or halo group; R3 = OH, acyloxy, alkoxy, or acyl optionally substituted by OH, alkoxy, acyloxy, or halo; or R2R3 forms ring; R2 .noteq. H or OH when R3 = OH; R4 = Me, Et], which are strong antiprogestins with little or no antigluccorticoid activity (no data), are prepd. Thus, 7.beta.-methylene-5-(10)-ene-3,17-dione 3,3-di-Me acetal underwent NaBH4 redn., deketalization, bromination/dehydrobromination, reketalization, and epoxidn., to give 5.alpha.,10.alpha.-epoxy-17.beta.-hydroxy-7.beta.-methylester-9(11)-en-3-one 3,3-ethylene acetal. This underwent CuCl-catalyzed coupling with p-(Me2N)C6H4MgBr, Oppenauer oxidn. of 17-OH, alkynylation with THP-OCH2C.tplbond.CMeBr (THP = tetrahydropyranyl), and deprotection, to give (dimethylaminophenyl) hydroxy(hydroxypropynyl) methylestradienone II.

L9 ANSWER 10 OF 12 MARPAT COPYRIGHT 2000 ACS (Continued)

MYTR 1



G1 = phenylene

G5 = 31

31-C(O)-G11

G6 = 31 / 35

31-C(O)-G11 35(O)-G12

G10 = 31

31-C(O)-G11

G12 = Ak (SO (1-) G10)

G14 = 42



MPL: claim 1

L9 ANSWER 11 OF 12 MARPAT COPYRIGHT 2000 ACS


ACCESSION NUMBER: 110:213172 MARPAT
 TITLE: 13(Alpha)-alkylgonanes, their production, and pharmaceutical preparations containing same
 INVENTOR(S): Neef, Guenter; Wischert, Rudolf; Beier, Sybille; Elger, Walter; Henderson, David
 PATENT ASSIGNEE(S): Schering A.-G., Fed. Rep. Ger.
 SOURCE: U.S., 5 pp. Cont. of U.S. Ser. No. 621,308.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4780461	A	19881025	US 1985-810148	19851218
DE 3321826	A1	19841220	DE 1983-3321826	19830615
DE 3413036	A1	19851017	DE 1984-3413036	19840404
DE 3446661	A1	19860619	DE 1984-3446661	19841218

PRIORITY APPLN. INFO.:
 DE 1983-3321826 19830615
 DE 1984-3413036 19840404
 US 1984-621308 19840615
 DE 1984-3446661 19841218

AB 13.alpha.-Alkylgonanes [I; R = C1-4 acyl; X = O, NOH; II; R1 = amino; R2 = H, Me, Et; R3 = (substituted) alkyl; R4 = OH, alkoxy, alkanoyloxy; or R3R4 = Q; R5 = H, alkyl; III; Z = CH2CH2, CH2CMe2CH2], having antiegestagenic activity and useful as postcoital contraceptives, or for triggering abortion and menstruation (no data), are prepd. via photochem. epimerization of the 13.beta.-gonanes IV. 11.beta.-(4-Dimethylaminomethyl)-17.alpha.-hydroxy-13.alpha.-methyl-17.beta.-(3-hydroxypropyl)-4,9-gonadien-3-one (V) was acetylated with Ac2O in pyridine to give 11.beta.-(4-dimethylaminomethyl)-17.alpha.-hydroxy-13.alpha.-methyl-17.beta.-(3-acetoxypyl)-4,9-gonadien-3-one. A tablet was formulated contg. V 10.0, lactose 140.0, corn starch 69.5, polyvinylpyrrolidone 25 2.5, Aerosil 2.0, and Mg stearate 0.5 mg.

MOTR 2



L9 ANSWER 12 OF 12 MARPAT COPYRIGHT 2000 ACS

ACCESSION NUMBER: 110:95624 MARPAT
 TITLE: Preparation of novel 11-arylestrane and 11-arylpregnane derivatives as antiprogesterins
 with low or no antigluccorticoid activity
 INVENTOR(S): Groen, Marinus Bernard; De Jongh, Hendrik Paul
 PATENT ASSIGNEE(S): AKZO N. V., Neth.
 SOURCE: Eur. Pat. Appl., 11 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 289073	A1	19881102	EP 1988-200689	19880412
EP 289073	B1	19911127		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
AT 69820	E	19911215	AT 1988-200689	19880412
ES 2045082	T3	19940116	ES 1988-200689	19880412
ZA 8802643	A	19881130	ZA 1988-2643	19880414
FI 8801826	A	19881025	FI 1988-1826	19880419
FI 88396	B	19930129		
FI 88396	C	19930510		
US 4871724	A	19891003	US 1988-183851	19880420
CA 1297472	A1	19920317	CA 1988-564606	19880420
DK 8802218	A	19881025	DK 1988-2218	19880422
DK 168294	B1	19940307		
AU 8815072	A1	19881027	AU 1988-15072	19880422
AU 608831	B2	19910418		
JP 63280097	A2	19881117	JP 1988-100010	19880422
CN 88102416	A	19881214	CN 1988-102416	19880423
CN 1019978	B	19930303		

PRIORITY APPLN. INFO.:
 NL 1987-970 19870424
 EP 1988-200689 19880412

AB The title compds. [I; R1 = aminoaryl; R2 = C1-4 alkyl; R3 = H, OH, substituted (unsatd.) C1-8 hydrocarbyl; R4 = OH, acyloxy, substituted acyl; R3R4 = atoms to complete a ring; R5 = C1-4 hydrocarbyl] useful as antiprogesterins (no data) were prepd.
 5.alpha.,6.alpha.-Epoxy-11.beta.-hydroxyestrane-3,17-dione-3,17-diethylene acetal (prepn. given) was treated with MeMgCl in PhMe/THF and the product was dehydrated with POCl3/pyridine to give
 6.alpha.,17.alpha.-methylene-5(10),9(11)-diene-3,17-dione-3,17-diethylene acetal. The latter was converted in several steps to
 11.beta.-(4-(dimethylamino)phenyl)-17.beta.-hydroxy-17.alpha.-(3-hydroxy-1-propynyl)-6.alpha.-methylene-4,9-diene-3-one.

MOTR 1


L9 ANSWER 11 OF 12 MARPAT COPYRIGHT 2000 ACS (Continued)

G4 = 59
 59(0)-CH2-G11
 G8 = alkylcarbonyloxy (1-3)
 G11 = alkoxy (1-4)
 G12 = 66



GGA = 33 <RC (1), RS (1) M5 (1) X6, EC (0-) O (1-) N (0-) S (0) OTHERQ, AN (1) N, BD (ALL) SE>
 DER: and acid addition salts
 MPL: claim 18

L9 ANSWER 12 OF 12 MARPAT COPYRIGHT 2000 ACS (Continued)



G1 = 63 / 64 / 65



G5 = 25



G6 = alkylcarbonyloxy (SR (1-) G12)
 G7 = alkylcarbonyl (SO (1-) G10)
 G10 = alkylcarbonyloxy (SR (1-) G12)
 GGA = 69 <1-7>
 MPL: claim 1

=> d his

(FILE 'HOME' ENTERED AT 14:34:24 ON 07 JAN 2000)

FILE 'REGISTRY' ENTERED AT 14:34:49 ON 07 JAN 2000
ACTIVATE

L1 STR
L2 41 SEA FILE=REGISTRY SSS FUL L1

L3 STRUCTURE UPLOADED
L4 0 S L3
L5 6 S L3 FULL

FILE 'CAPLUS' ENTERED AT 14:36:30 ON 07 JAN 2000
L6 1 S L5

FILE 'USPATFULL' ENTERED AT 14:36:48 ON 07 JAN 2000
L7 0 S L5

FILE 'BEILSTEIN' ENTERED AT 14:37:03 ON 07 JAN 2000
L8 0 S L3 FULL

FILE 'MARPAT' ENTERED AT 14:37:24 ON 07 JAN 2000
L9 12 S L5 FULL
L10 12 S L9 NOT PY>=1996

09/180,132

Page 1

=> d ibib ab hitstr 1-7

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:211446 CAPLUS

DOCUMENT NUMBER: 137:28399

TITLE: CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogesterins with reduced antigluccorticoid activity: in vitro comparison to mifepristone and CDB-2914

AUTHOR(S): Attardi, Barbara J.; Burgenson, Janet; Hild, Sheri A.; Reel, Jerry R.; Blye, Richard P.

CORPORATE SOURCE: Molecular Endocrinology Laboratory, BIOQUAL, Inc., Rockville, MD, 20850, USA

SOURCE: Molecular and Cellular Endocrinology (2002), 188 (1-2), 111-123

CODEN: MCEND6; ISSN: 0303-7207

PUBLISHER: Elsevier Science Ireland Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB To obtain selective antiprogesterins, we have examd. the in vitro antiprogesterational/antigluccorticoid properties of two novel compds., CDB-4124 and the putative monodemethylated metabolite, CDB-4453, in transcription and receptor binding assays and compared them to CDB-2914 and mifepristone. All four antiprogesterins bound with high affinity to rabbit uterine progesterin receptors (PR) and recombinant human PR-A and PR-B (rhPR-A, rhPR-B) and were potent inhibitors of R5020-induced transactivation of the PRE2-tk-luciferase (PRE2-tk-LUC) reporter plasmid and endogenous alk. phosphatase prodn. in T47D-CO human breast cancer cells. None of these compds. exhibited agonist activity in these cells. Induction of luciferase activity was potentiated about five-fold by 8-Br-cAMP under basal conditions and to the same extent in the presence of the PR antagonists. Mifepristone bound to rabbit thymic glucocorticoid receptors (GR) with approx. twice the avidity of the CDB antiprogesterins. Inhibition of GR-mediated transcription of PRE2-tk-LUC was assessed in HepG2 human hepatoblastoma cells. Mifepristone exhibited greater antigluccorticoid activity than CDB-2914, 4124, and 4453, about 12-, 22-, and 185-fold, resp. Thus, while there was a good correlation between binding to PR and functional activity of these antiprogesterins, GR binding was not predictive of their glucocorticoid antagonist activity. In agreement with our in vivo results, CDB-4124 and CDB-4453, as well as CDB-2914, are potent antiprogesterins in vitro, but show considerably less antigluccorticoid activity than mifepristone.

IT 198414-31-2, CDB-4124 365416-28-0, CDB 4453

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(CDB-4124 and putative monodemethylated metabolite, CDB-4453, are potent antiprogesterins with reduced antigluccorticoid activity in transcription and receptor binding assays)

RN 198414-31-2 CAPLUS

CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 365416-28-0 CAPLUS

CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-methoxy-11-[4-(methylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:747811 CAPLUS

DOCUMENT NUMBER: 135:304062

TITLE: Preparation of 17.alpha.-substituted-11.beta.-substituted-4-aryl and 21-substituted 19-norpregna-4,9-diene-3,20-dione derivatives as new antiprogesterational agents

INVENTOR(S): Kim, Hyun K.; Blye, Richard P.; Rao, Pemmaraju N.; Cessac, James W.; Acosta, Carmie K.; Simmons, Anne Marie

PATENT ASSIGNEE(S): Secretary of Health and Human Services, USA

SOURCE: PCT Int. Appl., 171 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001074840	A2	20011011	WO 2001-US8681	20010316
WO 2001074840	A3	20020502		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, FI, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, T2, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001045849	A5	20011015	AU 2001-45849	20010316
EP 1265911	A2	20021218	EP 2001-918912	20010316
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, NO, HK, CY, AL, TR				
PRIORITY APPLN. INFO.: US 2000-526855 A 20000317				
WO 2001-US8681 W 20010316				

OTHER SOURCE(S): MARPAT 135:304062

AB 19-Norpregna-4,9-diene-3,20-dione derivs. [1: R1 = OMe, SMe, NMe2, NHMe, NC4H8, NCSH10, NC4H8O, CHO, CH(OH)Me, C(O)Me, O(CH2)2NMe2, and -O(CH2)2NCSH10; R2 = H, halogen, alkyl, acyl, hydroxy, alkoxy, acyloxy, alkylcarbonate, cyplonyloxy, S-alkyl, -SCN, S-acyl and -OC(O)R6; R6 = alkyl, alkoxy ester, alkoxy; R3 = alkyl, hydroxy, alkoxy and acyloxy; R4 = H, alkyl; X = O, (substituted) NOH] were prep'd as antiprogesterational agents. The present invention provides methods wherein I were advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat meningiomas; to treat uterine leiomyomas; to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce cervical ripening; to induce labor; and for contraception. Thus, norpregnadienedione deriv. II was prep'd from 3,3-ethylenedioxy-17.beta.-cyano-17.alpha.-hydroxyestra-5(10),9(11)-diene and 4-bromo-N,N-dimethylaniline in 9 steps which showed 2.79 times the antiprogesterational potency in the antiClauberg test compared to CDB-2914.

IT 198414-09-4P, CDB 4102 198414-31-2P, CDB 4124

198414-39-0P, CDB 4167 365416-60-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of 17.alpha.-substituted-11.beta.-substituted-4-aryl and


L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)

21-substituted 19-norpregnadienedione as new antiprogesterational agents)

RN 198414-09-4 CAPLUS

CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetylthio)-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-31-2 CAPLUS

CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-39-0 CAPLUS

CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-ethoxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365416-60-0 CAPLUS

CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17,21-

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)
dimethoxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 198414-03-8P, CDB 4058 198414-05-0P, CDB 3876
198414-07-2P, CDB 4059 198414-11-8P, CDB 4101
198414-22-1P, CDB 4030 198414-33-4P, CDB 4125
198414-34-5P, CDB 4152 198414-41-4P 198414-43-6P
, CDB 4031 365415-80-1P 365416-26-8P
365416-28-0P 365416-50-8P 365416-51-9P
365416-52-0P 365416-53-1P 365416-58-6P
365416-59-7P 365416-61-1P 365416-62-2P
365416-63-3P 365416-64-4P 365416-65-5P
365416-66-6P 365416-67-7P 365416-68-8P
365416-69-9P 365416-70-2P 365416-71-3P
365416-72-4P 365416-73-5P 365416-74-6P
365416-75-7P

RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREF (Preparation); USES (Uses)
(prepn. of 17.alpha.-substituted-11.beta.-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogesterational agents)

RN 198414-03-8 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-fluoro-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-05-0 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-chloro-11-[4-


L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN Extra-4,9-dien-3-one, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-(1-oxopropyl)-, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 198414-33-4 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-(3-cyclopentyl-1-oxopropoxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-34-5 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-41-4 CAPLUS


L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)
(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 198414-07-2 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17,21-bis(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-11-8 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-(acetylthio)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-22-1 CAPLUS


L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-methoxy-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 198414-43-6 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-bromo-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365415-80-1 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17,21-bis(acetyloxy)-11-[4-(dimethylamino)phenyl]-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 365416-26-8 CAPLUS


L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[(4-(dimethylamino)phenyl)-17,21-dimethoxy-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 365416-26-0 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-methoxy-11-[4-(methylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365416-50-8 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(acetylthio)-21-(acetylthio)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 365416-58-6 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17,21-bis(acetyloxy)-11-[4-(1-piperidinyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365416-59-7 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17,21-bis(acetyloxy)-11-[4-(acetylphenyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365416-61-1 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-ethoxy-21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 365416-51-9 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, -11-(4-acetylphenyl)-17,21-dimethoxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365416-52-0 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-[2-(dimethylamino)ethoxy]phenyl]-21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365416-53-1 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-methoxy-11-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 365416-62-2 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17,21-dimethoxy-11-[4-(1-pyrrolidinyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365416-63-3 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17,21-dimethoxy-11-[4-(1-piperidinyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365416-64-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-methoxy-11-[4-(1-piperidinyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 365416-65-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365416-66-6 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-methoxy-11-[4-(2-(1-pyrrolidinyl)ethoxy)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365416-67-7 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 365416-70-2 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-(ethenyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365416-71-3 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-21-(ethenyl)-17-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365416-72-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-21-(ethenyl)-17-ethoxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry.



RN 365416-68-8 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-[(methoxycarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365416-69-9 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-[(methoxycarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 365416-73-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-thiocyanato-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365416-74-6 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17,21-bis(formyloxy)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365416-75-7 CAPLUS
 CN Glycine, N,N-dimethyl-, (11.beta.)-17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-3,20-dioxo-19-norpregna-4,9-dien-21-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)



IT 198413-96-6P 198413-97-7P 198413-98-8P
 198413-99-9P 198414-00-5P 198414-21-0P
 198414-30-1P 198414-32-3P 198414-38-9P
 198414-42-5P 365416-07-5P 365416-08-6P
 365416-17-7P 365416-18-8P 365416-19-9P
 365416-20-2P 365416-21-3P 365416-22-4P
 365416-33-7P 365416-34-8P 365416-35-9P
 365416-45-1P 365416-46-2P 365416-47-3P
 365416-48-4P 365416-49-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of 17.alpha.-substituted-11.beta.-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents)
 RN 198413-96-6 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-chloro-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 198413-97-7 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry.




RN 198414-21-0 CAPLUS
 CN Extra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-oxopropyl)-, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-30-1 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-hydroxy-21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-32-3 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(3-cyclopentyl-1-oxopropoxy)-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 198413-98-8 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17,21-dihydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198413-99-9 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-hydroxy-21-[(methylsulfonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry..



RN 198414-00-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-21-fluoro-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry.




RN 198414-38-9 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-21-ethoxy-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-42-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-bromo-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365416-07-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-chloro-17-hydroxy-11-[4-(1-piperidinyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 365416-08-6 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-17-hydroxy-11-[(1-piperidinyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365416-17-7 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-hydroxy-21-methoxy-11-[(1-piperidinyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 365416-18-8 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[(4-(dimethylamino)phenyl)-17-hydroxy-21-(1-oxopropoxy)]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365416-19-9 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-[(chloroacetyl)oxy]-11-[(4-(dimethylamino)phenyl)-17-hydroxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 365416-20-2 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-[(chloroacetyl)oxy]-11-[(4-(dimethylamino)phenyl)]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365416-21-3 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[(4-(dimethylamino)phenyl)-21-(iodoacetyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365416-22-4 CAPLUS


L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[(4-(dimethylamino)phenyl)-17-hydroxy-21-thiocyanato]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365416-33-7 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[(4-(dimethylamino)phenyl)-21-bromo-17-hydroxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365416-34-8 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[(4-(dimethylamino)phenyl)-17-hydroxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365416-35-9 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[(4-(dimethylamino)phenyl)-17-hydroxy-21-(acetylthio)]-, (11.beta.)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)
Absolute stereochemistry.




RN 365416-45-1 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[(4-acetylphenyl)-17-hydroxy-21-methoxy-], (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365416-46-2 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[(2-(dimethylamino)ethoxy)phenyl]-17-hydroxy-21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365416-47-3 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17-hydroxy-21-methoxy-11-[(2-(1-piperidinyl)ethoxy)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)




IT 365416-23-5P 365416-27-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of 17.alpha.-substituted-11.beta.-substituted-4-aryl and
21-substituted 19-norpregnadienedione as new antiprogesterational agents)
RN 365416-23-5 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[(4-(dimethylamino)phenyl)-21-
(formyloxy)-17-hydroxy-], (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365416-27-9 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17,21-bis(acetyloxy)-11-[(4-(dimethylamino)phenyl)-21-methoxy-19-norpregna-4,9-diene-3,20-dione, intermediates useful in the process, and processes for preparing such intermediates)

Absolute stereochemistry.




L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry.



RN 365416-48-4 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[(4-(dimethylamino)phenyl)-17-hydroxy-21-[(methoxycarbonyloxy)-], (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365416-49-5 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[(4-(dimethylamino)phenyl)-17-hydroxy-21-[(methoxycarbonyloxy)-], (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:489415 CAPLUS
DOCUMENT NUMBER: 135:61476
TITLE: Process for the preparation of 17.alpha.-acetoxy-11.beta.-[4-N,N-(dimethylamino)phenyl]-21-methoxy-19-norpregna-4,9-diene-3,20-dione, intermediates useful in the process, and processes for preparing such intermediates
INVENTOR(S): Kim, Hyun Koo; Rao, Pannaraju N.; Cessac, James W.; Simmons, Anne Marie
PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001047945	A1	20010705	WO 2000-US35479	20001229
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TN			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2001026048	A5	20010709	AU 2001-26048	20001229
EP 1242444	A1	20020925	EP 2000-989551	20001229
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MX, CY, AL, TR			
US 2003060646	A1	20030327	US 2002-169139	20020627
PRIORITY APPLN. INFO.:			US 1999-173470P	19991229
			WO 2000-US35479	W 20001229

OTHER SOURCE(S): CASREACT 135:61476
AB A process for prep. the antiprogesterational agent, 17.alpha.-acetoxy-11.beta.-[4-N,N-(dimethylamino)phenyl]-21-methoxy-19-norpregna-4,9-diene-3,20-dione (I), intermediates useful in the process, and processes for prep. such intermediates was described. I was prep. via a multistep synthetic sequence starting from cynachydrin II. The synthetic sequence involved replacing the cyanohydrin group of II with a chloroacetyl group and a hydroxyl group; replacing the chloro group of the resulting compd. with an acetoxy group; deacetylating the resulting compd.; selectively ketalizing the resulting compd.; selectively methylating the 21-hydroxy group of the resulting compd.; reducing the 20-keto group of the resulting compd.; epoxidizing the resulting compd.; introducing a N,N-dimethylaminophenyl group at the 11-position and opening the epoxide; dealkalizing the resulting compd.; selectively oxidizing the 20-hydroxyl group to a keto group; and acetylating the resulting compd.

IT 198414-30-1P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for the prep. of 17.alpha.-acetoxy-11.beta.-[4-N,N-(dimethylamino)phenyl]-21-methoxy-19-norpregna-4,9-diene-3,20-dione, intermediates useful in the process, and processes for prep. such intermediates)
RN 198414-30-1 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[(4-(dimethylamino)phenyl)-17-hydroxy-

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)
21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 198414-31-2P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(process for the prepn. of 17.alpha.-acetoxy-11.beta.-[4-N,N-(dimethylamino)phenyl]-21-methoxy-19-norpregna-4,9-diene-3,20-dione, intermediates useful in the process, and processes for prepn. such intermediates)

RN 198414-31-2 CAPLUS

CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetoxy)-11-[4-(dimethylamino)phenyl]-21-methoxy-, (11.beta.)- (9CI). (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:185774 CAPLUS

DOCUMENT NUMBER: 134:208009

TITLE: Preparation of 17.beta.-acyl-17.alpha.-propynyl-11.beta.-[cyclic amino]aryl steroids and their derivatives having antagonist hormonal properties

INVENTOR(S): Cook, C. Edgar; Kepler, John A.; O'Reilly, Jill M.

PATENT ASSIGNEE(S): Research Triangle Institute, USA

SOURCE: PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001018025	A2	20010315	WO 2000-US24274	20000905
WO 2001018025	A3	20010920		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GR, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SO, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000071113	A5	20010410	AU 2000-71113	20000905
EP 1208113	A2	20020529	EP 2000-959867	20000905
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003508540	T2	20030304	JP 2001-522248	20000905
NO 2002001037	A	20020405	NO 2002-1037	20020301
PRIORITY APPLN. INFO.: US 1999-389212 A 19990903				
WO 2000-US24274 W 20000905				

OTHER SOURCE(S): MARPAT 134:208009


AB The invention is directed to the prepn. of 17.beta.-acyl-17.alpha.-propynyl steroids of formula I (R1 = heterocycle; R2 = Me, CF3, CH2OH; R3 = H, Me, OMe, OAc; halo; R4 = H, Me, F, Cl; X = O, H2, NOH, NOME) which exhibit potent antiprogesterone activity. Thus, II was prepd. from 17.beta.-cyano-3,3-(ethanedithioloxo)-17.alpha.-trimethylsilyloxy-5(10),9(11)-diene in 8 steps. The anti-McGinty assay for antiprogesterone activity shows II to be an exceptionally potent antiprogesterone agent with a marked effect at 0.3 .mu.g dose.

IT 328535-36-OP 328535-37-1P 328535-38-2P
328535-39-3P 328535-40-6P 328535-41-7P
328535-42-8P 328535-43-9P 328535-44-0P
328535-45-1P 328535-46-2P 328535-47-3P
328535-48-4P 328535-49-5P 328535-50-6P
328535-51-7P 328535-52-8P 328535-53-9P
328535-54-0P 328535-55-1P 328535-56-2P
328535-57-3P 328535-58-4P 328535-59-5P
328535-60-6P 328535-61-7P 328535-62-8P
328535-63-9P 328535-64-0P 328535-65-1P
328535-66-2P 328535-67-3P 328535-68-4P
328535-69-5P 328535-70-6P 328535-71-7P
328535-72-8P 328535-73-9P 328535-74-0P
328535-75-1P 328535-76-2P 328535-77-3P
328535-78-4P 328535-79-5P 328535-80-6P
328535-81-7P 328535-82-8P 328535-83-9P
328535-84-0P 328535-85-1P 328535-86-2P
328535-87-3P 328535-88-4P 328535-89-5P
328535-90-6P 328535-91-7P 328535-92-8P
328535-93-9P 328535-94-0P 328535-95-1P
328535-96-2P 328535-97-3P 328535-98-4P
328535-99-5P 328535-100-6P 328535-101-7P
328535-102-8P 328535-103-9P 328535-104-0P
328535-105-1P 328535-106-2P 328535-107-3P
328535-108-4P 328535-109-5P 328535-110-6P
328535-111-7P 328535-112-8P 328535-113-9P
328535-114-0P 328535-115-1P 328535-116-2P
328535-117-3P 328535-118-4P 328535-119-5P
328535-120-6P 328535-121-7P 328535-122-8P
328535-123-9P 328535-124-0P 328535-125-1P
328535-126-2P 328535-127-3P 328535-128-4P
328535-129-5P 328535-130-6P 328535-131-7P
328535-132-8P 328535-133-9P 328535-134-0P
328535-135-1P 328535-136-2P 328535-137-3P
328535-138-4P 328535-139-5P 328535-140-6P
328535-141-7P 328535-142-8P 328535-143-9P
328535-144-0P 328535-145-1P 328535-146-2P
328535-147-3P 328535-148-4P 328535-149-5P
328535-150-6P 328535-151-7P 328535-152-8P
328535-153-9P 328535-154-0P 328535-155-1P
328535-156-2P 328535-157-3P 328535-158-4P
328535-159-5P 328535-160-6P 328535-161-7P
328535-162-8P 328535-163-9P 328535-164-0P
328535-165-1P 328535-166-2P 328535-167-3P
328535-168-4P 328535-169-5P 328535-170-6P
328535-171-7P 328535-172-8P 328535-173-9P
328535-174-0P 328535-175-1P 328535-176-2P
328535-177-3P 328535-178-4P 328535-179-5P
328535-180-6P 328535-181-7P 328535-182-8P
328535-183-9P 328535-184-0P 328535-185-1P
328535-186-2P 328535-187-3P 328535-188-4P
328535-189-5P 328535-190-6P 328535-191-7P
328535-192-8P 328535-193-9P 328535-194-0P
328535-195-1P 328535-196-2P 328535-197-3P
328535-198-4P 328535-199-5P 328535-200-6P
328535-201-7P 328535-202-8P 328535-203-9P
328535-204-0P 328535-205-1P 328535-206-2P
328535-207-3P 328535-208-4P 328535-209-5P
328535-210-6P 328535-211-7P 328535-212-8P
328535-213-9P 328535-214-0P 328535-215-1P
328535-216-2P 328535-217-3P 328535-218-4P
328535-219-5P 328535-220-6P 328535-221-7P
328535-222-8P 328535-223-9P 328535-224-0P
328535-225-1P 328535-226-2P 328535-227-3P
328535-228-4P 328535-229-5P 328535-230-6P
328535-231-7P 328535-232-8P 328535-233-9P
328535-234-0P 328535-235-1P 328535-236-2P
328535-237-3P 328535-238-4P 328535-239-5P
328535-240-6P 328535-241-7P 328535-242-8P
328535-243-9P 328535-244-0P 328535-245-1P
328535-246-2P 328535-247-3P 328535-248-4P
328535-249-5P 328535-250-6P 328535-251-7P
328535-252-8P 328535-253-9P 328535-254-0P
328535-255-1P 328535-256-2P 328535-257-3P
328535-258-4P 328535-259-5P 328535-260-6P
328535-261-7P 328535-262-8P 328535-263-9P
328535-264-0P 328535-265-1P 328535-266-2P
328535-267-3P 328535-268-4P 328535-269-5P
328535-270-6P 328535-271-7P 328535-272-8P
328535-273-9P 328535-274-0P 328535-275-1P
328535-276-2P 328535-277-3P 328535-278-4P
328535-279-5P 328535-280-6P 328535-281-7P
328535-282-8P 328535-283-9P 328535-284-0P
328535-285-1P 328535-286-2P 328535-287-3P
328535-288-4P 328535-289-5P 328535-290-6P
328535-291-7P 328535-292-8P 328535-293-9P
328535-294-0P 328535-295-1P 328535-296-2P
328535-297-3P 328535-298-4P 328535-299-5P
328535-300-6P 328535-301-7P 328535-302-8P
328535-303-9P 328535-304-0P 328535-305-1P
328535-306-2P 328535-307-3P 328535-308-4P
328535-309-5P 328535-310-6P 328535-311-7P
328535-312-8P 328535-313-9P 328535-314-0P
328535-315-1P 328535-316-2P 328535-317-3P
328535-318-4P 328535-319-5P 328535-320-6P
328535-321-7P 328535-322-8P 328535-323-9P
328535-324-0P 328535-325-1P 328535-326-2P
328535-327-3P 328535-328-4P 328535-329-5P
328535-330-6P 328535-331-7P 328535-332-8P
328535-333-9P 328535-334-0P 328535-335-1P
328535-336-2P 328535-337-3P 328535-338-4P
328535-339-5P 328535-340-6P 328535-341-7P
328535-342-8P 328535-343-9P 328535-344-0P
328535-345-1P 328535-346-2P 328535-347-3P
328535-348-4P 328535-349-5P 328535-350-6P
328535-351-7P 328535-352-8P 328535-353-9P
328535-354-0P 328535-355-1P 328535-356-2P
328535-357-3P 328535-358-4P 328535-359-5P
328535-360-6P 328535-361-7P 328535-362-8P
328535-363-9P 328535-364-0P 328535-365-1P
328535-366-2P 328535-367-3P 328535-368-4P
328535-369-5P 328535-370-6P 328535-371-7P
328535-372-8P 328535-373-9P 328535-374-0P
328535-375-1P 328535-376-2P 328535-377-3P
328535-378-4P 328535-379-5P 328535-380-6P
328535-381-7P 328535-382-8P 328535-383-9P
328535-384-0P 328535-385-1P 328535-386-2P
328535-387-3P 328535-388-4P 328535-389-5P
328535-390-6P 328535-391-7P 328535-392-8P
328535-393-9P 328535-394-0P 328535-395-1P
328535-396-2P 328535-397-3P 328535-398-4P
328535-399-5P 328535-400-6P 328535-401-7P
328535-402-8P 328535-403-9P 328535-404-0P
328535-405-1P 328535-406-2P 328535-407-3P
328535-408-4P 328535-409-5P 328535-410-6P
328535-411-7P 328535-412-8P 328535-413-9P
328535-414-0P 328535-415-1P 328535-416-2P
328535-417-3P 328535-418-4P 328535-419-5P
328535-420-6P 328535-421-7P 328535-422-8P
328535-423-9P 328535-424-0P 328535-425-1P
328535-426-2P 328535-427-3P 328535-428-4P
328535-429-5P 328535-430-6P 328535-431-7P
328535-432-8P 328535-433-9P 328535-434-0P
328535-435-1P 328535-436-2P 328535-437-3P
328535-438-4P 328535-439-5P 328535-440-6P
328535-441-7P 328535-442-8P 328535-443-9P
328535-444-0P 328535-445-1P 328535-446-2P
328535-447-3P 328535-448-4P 328535-449-5P
328535-450-6P 328535-451-7P 328535-452-8P
328535-453-9P 328535-454-0P 328535-455-1P
328535-456-2P 328535-457-3P 328535-458-4P
328535-459-5P 328535-460-6P 328535-461-7P
328535-462-8P 328535-463-9P 328535-464-0P
328535-465-1P 328535-466-2P 328535-467-3P
328535-468-4P 328535-469-5P 328535-470-6P
328535-471-7P 328535-472-8P 328535-473-9P
328535-474-0P 328535-475-1P 328535-476-2P
328535-477-3P 328535-478-4P 328535-479-5P
328535-480-6P 328535-481-7P 328535-482-8P
328535-483-9P 328535-484-0P 328535-485-1P
328535-486-2P 328535-487-3P 328535-488-4P
328535-489-5P 328535-490-6P 328535-491-7P
328535-492-8P 328535-493-9P 328535-494-0P
328535-495-1P 328535-496-2P 328535-497-3P
328535-498-4P 328535-499-5P 328535-500-6P
328535-501-7P 328535-502-8P 328535-503-9P
328535-504-0P 328535-505-1P 328535-506-2P
328535-507-3P 328535-508-4P 328535-509-5P
328535-510-6P 328535-511-7P 328535-512-8P
328535-513-9P 328535-514-0P 328535-515-1P
328535-516-2P 328535-517-3P 328535-518-4P
328535-519-5P 328535-520-6P 328535-521-7P
328535-522-8P 328535-523-9P 328535-524-0P
328535-525-1P 328535-526-2P 328535-527-3P
328535-528-4P 328535-529-5P 328535-530-6P
328535-531-7P 328535-532-8P 328535-533-9P
328535-534-0P 328535-535-1P 328535-536-2P
328535-537-3P 328535-538-4P 328535-539-5P
328535-540-6P 328535-541-7P 328535-542-8P
328535-543-9P 328535-544-0P 328535-545-1P
328535-546-2P 328535-547-3P 328535-548-4P
328535-549-5P 328535-550-6P 328535-551-7P
328535-552-8P 328535-553-9P 328535-554-0P
328535-555-1P 328535-556-2P 328535-557-3P
328535-558-4P 328535-559-5P 328535-560-6P
328535-561-7P 328535-562-8P 328535-563-9P
328535-564-0P 328535-565-1P 328535-566-2P
328535-567-3P 328535-568-4P 328535-569-5P
328535-570-6P 328535-571-7P 328535-572-8P
328535-573-9P 328535-574-0P 328535-575-1P
328535-576-2P 328535-577-3P 328535-578-4P
328535-579-5P 328535-580-6P 328535-581-7P
328535-582-8P 328535-583-9P 328535-584-0P
328535-585-1P 328535-586-2P 328535-587-3P
328535-588-4P 328535-589-5P 328535-590-6P
328535-591-7P 328535-592-8P 328535-593-9P
328535-594-0P 328535-595-1P 328535-596-2P
328535-597-3P 328535-598-4P 328535-599-5P
328535-600-6P 328535-601-7P 328535-602-8P
328535-603-9P 328535-604-0P 328535-605-1P
328535-606-2P 328535-607-3P 328535-608-4P
328535-609-5P 328535-610-6P 328535-611-7P
328535-612-8P 328535-613-9P 328535-614-0P
328535-615-1P 328535-616-2P 328535-617-3P
328535-618-4P 328535-619-5P 328535-620-6P
328535-621-7P 328535-622-8P 328535-623-9P
328535-624-0P 328535-625-1P 328535-626-2P
328535-627-3P 328535-628-4P 328535-629-5P
328535-630-6P 328535-631-7P 328535-632-8P
328535-633-9P 328535-634-0P 328535-635-1P
328535-636-2P 328535-637-3P 328535-638-4P
328535-639-5P 328535-640-6P 328535-641-7P
328535-642-8P 328535-643-9P 328535-644-0P
328535-645-1P 328535-646-2P 328535-647-3P
328535-648-4P 328535-649-5P 328535-650-6P
328535-651-7P 328535-652-8P 328535-653-9P
328535-654-0P 328535-655-1P 328535-656-2P
328535-657-3P 328535-658-4P 328535-659-5P
328535-660-6P 328535-661-7P 328535-662-8P
328535-663-9P 328535-664-0P 328535-665-1P
328535-666-2P 328535-667-3P 328535-668-4P
328535-669-5P 328535-670-6P 328535-671-7P
328535-672-8P 328535-673-9P 328535-674-0P
328535-675-1P 328535-676-2P 328535-677-3P
328535-678-4P 328535-679-5P 328535-680-6P
328535-681-7P 328535-682-8P 328535-683-9P
328535-684-0P 328535-685-1P 328535-686-2P
328535-687-3P 328535-688-4P 328535-689-5P
328535-690-6P 328535-691-7P 328535-692-8P
328535-693-9P 328535-694-0P 328535-695-1P
328535-696-2P 328535-697-3P 328535-698-4P
328535-699-5P 328535-700-6P 328535-701-7P
328535-702-

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 328535-41-7 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(3-hydroxy-1-propynyl)-21-methoxy-11-[4-(4-morpholinyl)phenyl]-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 328535-54-2 CAPLUS
 CN Estr-4,9-dien-3-one, 11-[4-(4-morpholinyl)phenyl]-17-(1-oxopropyl)-17-(1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 328535-55-3 CAPLUS
 CN Estr-4,9-dien-3-one, 11-[4-(4-morpholinyl)phenyl]-17-(1-oxopropyl)-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 328535-58-6 CAPLUS
 CN Estr-4,9-dien-3-one, 11-[4-(4-morpholinyl)phenyl]-17-(1-oxopropyl)-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 328535-59-7 CAPLUS
 CN Estr-4,9-dien-3-one, 17-(3-hydroxy-1-propynyl)-11-[4-(4-morpholinyl)phenyl]-17-(1-oxopropyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 328535-56-4 CAPLUS
 CN Estr-4,9-dien-3-one, 17-(3-hydroxy-1-propynyl)-11-[4-(4-morpholinyl)phenyl]-17-(1-oxopropyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 328535-57-5 CAPLUS
 CN Estr-4,9-dien-3-one, 11-[4-(4-morpholinyl)phenyl]-17-(1-oxopropyl)-17-(1-propynyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 328535-89-3 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(1-piperidiny)phenyl]-17-(1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328535-90-6 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(1-piperidiny)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 328535-91-7 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(3-hydroxy-1-propynyl)-21-methoxy-11-


L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)
[4-(1-piperidinyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328535-92-8 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(1-piperidinyl)phenyl]-17-(1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 328535-94-0 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(1-piperidinyl)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 328536-22-7 CAPLUS
CN Estr-4,9-dien-3-one, 17-(1-oxopropyl)-11-[4-(1-piperidinyl)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 328536-23-8 CAPLUS
CN Estr-4,9-dien-3-one, 17-(3-hydroxy-1-propynyl)-17-(1-oxopropyl)-11-[4-(1-piperidinyl)phenyl]-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 328536-24-9 CAPLUS
CN Estr-4,9-dien-3-one, 17-(1-oxopropyl)-11-[4-(1-piperidinyl)phenyl]-17-(1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 328535-96-2 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(3-hydroxy-1-propynyl)-21-methoxy-11-[4-(1-piperidinyl)phenyl]-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 328536-20-5 CAPLUS
CN Estr-4,9-dien-3-one, 17-(1-oxopropyl)-11-[4-(1-piperidinyl)phenyl]-17-(1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)
propynyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 328536-25-0 CAPLUS
CN Estr-4,9-dien-3-one, 17-(1-oxopropyl)-11-[4-(1-piperidinyl)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 328536-26-1 CAPLUS
CN Estr-4,9-dien-3-one, 17-(3-hydroxy-1-propynyl)-17-(1-oxopropyl)-11-[4-(1-piperidinyl)phenyl]-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 328536-56-7 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-17-(1-propynyl)-11-[(4-(1-pyrrolidinyl)phenyl)]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 328536-57-8 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-17-(1-propynyl)-11-[(4-(1-pyrrolidinyl)phenyl)]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 328536-61-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(3-hydroxy-1-propynyl)-21-methoxy-11-[(4-(1-pyrrolidinyl)phenyl)]-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 328536-74-9 CAPLUS
 CN Estr-4,9-dien-3-one, 17-(1-oxopropyl)-17-(1-propynyl)-11-[(4-(1-pyrrolidinyl)phenyl)]-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 328536-75-0 CAPLUS
 CN Estr-4,9-dien-3-one, 17-(1-oxopropyl)-11-[(4-(1-pyrrolidinyl)phenyl)]-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 328536-58-9 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(3-hydroxy-1-propynyl)-21-methoxy-11-[(4-(1-pyrrolidinyl)phenyl)]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328536-59-0 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-17-(1-propynyl)-11-[(4-(1-pyrrolidinyl)phenyl)]-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

RN 328536-60-3 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-17-(1-propynyl)-11-[(4-(1-pyrrolidinyl)phenyl)]-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry.




RN 328536-76-1 CAPLUS
 CN Estr-4,9-dien-3-one, 17-(3-hydroxy-1-propynyl)-17-(1-oxopropyl)-11-[(4-(1-pyrrolidinyl)phenyl)]-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 328536-77-2 CAPLUS
 CN Estr-4,9-dien-3-one, 17-(1-oxopropyl)-17-(1-propynyl)-11-[(4-(1-pyrrolidinyl)phenyl)]-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 328536-78-3 CAPLUS
 CN Estr-4,9-dien-3-one, 17-(1-oxopropyl)-11-[(4-(1-pyrrolidinyl)phenyl)]-17-


L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)
(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 328536-79-4 CAPLUS
CN 19-Norpregna-4,9-dien-3-one, 17-(3-hydroxy-1-propynyl)-17-(1-oxopropyl)-11-[4-(1-pyrrolidinyl)phenyl]-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 328537-07-1 CAPLUS
CN 19-Norpregna-4,9-dien-3,20-dione, 21-(acetyloxy)-11-[4-(4-morpholinyl)phenyl]-17-(1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 328537-08-2 CAPLUS
CN 19-Norpregna-4,9-dien-3,20-dione, 21-(acetyloxy)-11-[4-(4-morpholinyl)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 328537-09-3 CAPLUS
CN 19-Norpregna-4,9-dien-3,20-dione, 21-(acetyloxy)-17-(3-hydroxy-1-propynyl)-11-[4-(4-morpholinyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 328537-10-6 CAPLUS
CN 19-Norpregna-4,9-dien-3,20-dione, 21-(acetyloxy)-11-[4-(4-morpholinyl)phenyl]-17-(1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 328537-11-7 CAPLUS
CN 19-Norpregna-4,9-dien-3,20-dione, 21-(acetyloxy)-11-[4-(4-morpholinyl)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 328537-12-8 CAPLUS
CN 19-Norpregna-4,9-dien-3,20-dione, 21-(acetyloxy)-17-(3-hydroxy-1-propynyl)-11-[4-(4-morpholinyl)phenyl]-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 328537-25-3 CAPLUS
CN 19-Norpregna-4,9-dien-3,20-dione, 21-(acetyloxy)-11-[4-(1-piperidinyl)phenyl]-17-(1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 328537-27-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(1-piperidinyl)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328537-29-7 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-17-(3-hydroxy-1-propynyl)-11-[4-(1-piperidinyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 328537-31-1 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(1-piperidinyl)phenyl]-17-(1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 328537-33-3 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(1-piperidinyl)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 328537-35-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-17-(3-hydroxy-1-propynyl)-11-[4-(1-piperidinyl)phenyl]-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 328537-48-0 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-17-(1-propynyl)-11-[4-(1-pyrrolidinyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328537-49-1 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(1-pyrrolidinyl)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 328537-50-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-17-(3-hydroxy-1-propynyl)-11-[4-(1-pyrrolidinyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry.




RN 328537-51-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-17-(1-propynyl)-11-[4-(1-pyrrolidinyl)phenyl]-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 328537-52-6 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(1-pyrrolidinyl)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 328537-53-7 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-17-(3-hydroxy-1-propynyl)-11-[4-(1-pyrrolidinyl)phenyl]-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:401850 CAPLUS
 DOCUMENT NUMBER: 133:17687
 TITLE: Preparation of 17.beta.-acyl-17.alpha.-propynyl-11.beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties
 INVENTOR(S): Cook, C. Edgar; Kepler, John A.; O'Reilly, Jill M.
 PATENT ASSIGNEE(S): Research Triangle Institute, USA
 SOURCE: PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000034306	A1	20000615	WO 1999-US28535	19991203
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GE, GH, GM, GR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6172052	B1	20010109	US 1998-205395	19981204
CA 2358466	AA	20000615	CA 1999-2358466	19991203
EP 1135403	A1	20010926	EP 1999-964047	19991203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NZ 512697	A	20030131	NZ 1999-512697	19991203
PRIORITY APPLN. INFO.: US 1998-205395 A 19981204 WO 1999-US28535 W 19991203				

OTHER SOURCE(S): MARPAT 133:17687
 AB Novel 17.beta.-acyl-17.alpha.-propynyl steroids of formula I [R1 = NMe2, HMe, NH2; R2 = H, Me, CF3, CH2OH; R3 = H, Me, OMe, OAc; R4 = H, Me, F, Cl; X = O, H2, NOH, NONE] are prepd. which exhibit potent antiprogesterone activity. Thus, II was prepd. from estrone in many steps. The relative progesterone binding activity of II was 3131 of promegestone.


IT 273208-59-6P 273208-60-9P 273208-61-0P
 273208-62-1P 273208-63-2P 273208-64-3P
 273208-77-8P 273208-78-9P 273208-79-0P
 273208-80-3P 273208-81-4P 273208-82-5P
 273209-12-4P 273209-13-5P 273209-14-6P
 273209-15-7P 273209-16-8P 273209-17-9P
 273209-30-6P 273209-31-7P 273209-32-8P
 273209-33-9P 273209-34-0P 273209-35-1P
 273209-67-9P 273209-68-0P 273209-69-1P
 273209-70-4P 273209-71-5P 273209-72-6P
 273209-85-1P 273209-86-2P 273209-87-3P
 273209-88-4P 273209-89-5P 273209-90-6P
 273210-18-7P 273210-19-8P 273210-20-1P
 273210-21-2P 273210-22-3P 273210-23-4P
 273210-36-9P 273210-37-0P 273210-38-1P
 273210-39-2P 273210-40-5P 273210-41-6P

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)

273210-54-1P 273210-55-2P 273210-56-3P
 273210-57-4P 273210-58-5P 273210-59-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of 17.beta.-acyl-17.alpha.-propynyl-11.beta.-arylsteroids with antiprogesterone activity)


RN 273208-59-6 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-(4-aminophenyl)-21-methoxy-17-(1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273208-60-9 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-(4-aminophenyl)-21-methoxy-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273208-61-0 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-(4-aminophenyl)-17-(3-hydroxy-1-propynyl)-21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 273208-62-1 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-(4-aminophenyl)-21-methoxy-17-(1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 273208-63-2 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-(4-aminophenyl)-21-methoxy-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 273208-64-3 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-(4-aminophenyl)-17-(3-hydroxy-1-propynyl)-21-methoxy-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 273208-77-8 CAPLUS
 CN Estradiol-4,9-dien-3-one, 11-(4-aminophenyl)-17-(1-oxopropyl)-17-(1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273208-78-9 CAPLUS
 CN Estradiol-4,9-dien-3-one, 11-(4-aminophenyl)-17-(1-oxopropyl)-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273208-79-0 CAPLUS
 CN Estradiol-4,9-dien-3-one, 11-(4-aminophenyl)-17-(3-hydroxy-1-propynyl)-17-(1-oxopropyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 273208-82-5 CAPLUS
 CN Estradiol-4,9-dien-3-one, 11-(4-aminophenyl)-17-(3-hydroxy-1-propynyl)-17-(1-oxopropyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


RN 273209-12-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-21-methoxy-17-(1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273209-13-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-21-methoxy-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 273209-14-6 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-(3-

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)
Absolute stereochemistry.


RN 273208-80-3 CAPLUS
 CN Estradiol-4,9-dien-3-one, 11-(4-aminophenyl)-17-(1-oxopropyl)-17-(1-propynyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


RN 273208-81-4 CAPLUS
 CN Estradiol-4,9-dien-3-one, 11-(4-aminophenyl)-17-(1-oxopropyl)-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)
hydroxy-1-propynyl)-21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273209-15-7 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-21-methoxy-17-(1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


RN 273209-16-8 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-21-methoxy-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 273209-17-9 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-(3-


L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)
 hydroxy-1-propynyl)-21-methoxy-, 3-oxime, (11.β.,17.β.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 273209-30-6 CAPLUS
 CN Estradiol-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-(1-oxopropynyl)-17-(1-propynyl)-, (11.β.,17.β.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273209-31-7 CAPLUS
 CN Estradiol-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-(1-oxopropynyl)-17-(3,3,3-trifluoro-1-propynyl)-, (11.β.,17.β.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 273209-35-1 CAPLUS
 CN Estradiol-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-(3-hydroxy-1-propynyl)-17-(1-oxopropynyl)-, 3-oxime, (11.β.,17.β.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 273209-67-9 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(methylamino)phenyl]-17-(1-propynyl)-, (11.β.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273209-68-0 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(methylamino)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, (11.β.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 273209-32-8 CAPLUS
 CN Estradiol-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-(3-hydroxy-1-propynyl)-17-(1-oxopropynyl)-, (11.β.,17.β.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273209-33-9 CAPLUS
 CN Estradiol-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-(1-oxopropynyl)-17-(1-propynyl)-, 3-oxime, (11.β.,17.β.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 273209-34-0 CAPLUS
 CN Estradiol-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-(1-oxopropynyl)-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.β.,17.β.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 273209-69-1 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(3-hydroxy-1-propynyl)-21-methoxy-11-[4-(methylamino)phenyl]-, (11.β.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273209-70-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(methylamino)phenyl]-17-(1-propynyl)-, 3-oxime, (11.β.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 273209-71-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(methylamino)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.β.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 273209-72-6 CAPLUS


CN 19-Norpregna-4,9-diene-3,20-dione, 17-(3-hydroxy-1-propynyl)-21-methoxy-11-[4-(methylamino)phenyl]-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 273209-85-1 CAPLUS

CN Estr-4,9-dien-3-one, 11-[4-(methylamino)phenyl]-17-(1-oxopropyl)-17-(1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273209-86-2 CAPLUS

CN Estr-4,9-dien-3-one, 11-[4-(methylamino)phenyl]-17-(1-oxopropyl)-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)

(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 273209-90-8 CAPLUS


CN Estr-4,9-dien-3-one, 17-(3-hydroxy-1-propynyl)-11-[4-(methylamino)phenyl]-17-(1-oxopropyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 273210-18-7 CAPLUS

CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-(4-aminophenyl)-17-(3-hydroxy-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273210-19-8 CAPLUS

CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-(4-aminophenyl)-17-

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)


Absolute stereochemistry.



RN 273209-87-3 CAPLUS


CN Estr-4,9-dien-3-one, 17-(3-hydroxy-1-propynyl)-11-[4-(methylamino)phenyl]-17-(1-oxopropyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273209-88-4 CAPLUS

CN Estr-4,9-dien-3-one, 11-[4-(methylamino)phenyl]-17-(1-oxopropyl)-17-(1-propynyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


RN 273209-89-5 CAPLUS

CN Estr-4,9-dien-3-one, 11-[4-(methylamino)phenyl]-17-(1-oxopropyl)-17-

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)

(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273210-20-1 CAPLUS


CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-(4-aminophenyl)-17-(3-hydroxy-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273210-21-2 CAPLUS


CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-(4-aminophenyl)-17-(1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 273210-22-3 CAPLUS


CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-(4-aminophenyl)-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)
Absolute stereochemistry.
Double bond geometry unknown.




RN 273210-23-4 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(4-aminophenyl)-17-(3-hydroxy-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 273210-36-9 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-(1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 273210-40-5 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 273210-41-6 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-(3-hydroxy-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 273210-54-1 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(methylamino)phenyl]-17-(1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)
RN 273210-37-0 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273210-38-1 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-(3-hydroxy-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273210-39-2 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-(1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)
Absolute stereochemistry.




RN 273210-55-2 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(methylamino)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273210-56-3 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-17-(3-hydroxy-1-propynyl)-11-[4-(methylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273210-57-4 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(methylamino)phenyl]-17-(1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)
Double bond geometry unknown.




RN 273210-58-5 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(methylamino)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 273210-59-6 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-17-(3-hydroxy-1-propynyl)-11-[4-(methylamino)phenyl]-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:576939 CAPLUS
DOCUMENT NUMBER: 131:199885
TITLE: Preparation of 20-keto-11.beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties
INVENTOR(S): Cook, C. Edgar; Kepler, John A.; Zhang, Ping-sheng;
PATENT ASSIGNEE(S): Lee, Yue-wei; Tallent, C. Ray
SOURCE: Research Triangle Institute, USA
PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9945022	A1	19990910	WO 1999-US3732	19990305
V: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6020328	A	20000201	US 1998-35949	19980306
CA 2322862	AA	19990910	CA 1999-2322862	19990305
AU 9928715	A1	19990920	AU 1999-28715	19990305
EP 1060186	A1	20001220	EP 1999-909531	19990305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9908598	A	20011002	BR 1999-9598	19990305
JP 2002505334	T2	20020219	JP 2000-534564	19990305
PRIORITY APPLN. INFO.: US 1998-35949 A 19980306 WO 1999-US3732 W 19990305				

OTHER SOURCE(S): MARPAT 131:199885
AB 20-Keto-11.beta.-arylsteroids of formula I [X = O, (substituted) NOH, H2, OH, etc.; R1 = dialkylamino, imidazolyl, pyrrolyl, piperidino, etc.; R2 = H, halo; R3 = H, Me, halo; R4 = H, acyloxy, (substituted) OH, alkyl, etc.; R5 = H, alkyl, halo, acyloxy, etc.] are prepd. which exhibit potent antiprogesterational activity. Thus, II was prepd. from 17.alpha.-hydroxymethyl-3-methoxy-19-norpregna-1,3,5(10)-trien-20-one and 4-bromo-N,N-dimethylaniline in several steps. The affinity of II for the progesterone hormone receptor was IC50 of 0.7 nM.

IT 240806-28-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 20-keto-11.beta.-arylsteroids with antiprogesterational activity)

RN 240806-28-4 CAPLUS
CN 19,21-Dinorchola-4,9-dien-24-oic acid, 11-[4-(dimethylamino)phenyl]-17-hydroxy-3,20-dioxo-, ethyl ester, (11.beta.)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CH 1

CRN 240806-27-3
CMF C32 H41 N O5

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)
Absolute stereochemistry.



CH 2

CRN 76-05-1
CMF C2 H F3 O2




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1997:740250 CAPLUS
 DOCUMENT NUMBER: 127:358992
 TITLE: Preparation of 21-substituted progesterone derivatives as new antiprogesterational agents
 INVENTOR(S): Kim, Hyun K.; Blye, Richard P.; Rao, Pemmaraju N.; Cessac, James W.; Acosta, Carmie K.
 PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA; Kim, Hyun K.; Blye, Richard P.; Rao, Pemmaraju N.; Cessac, James W.; Acosta, Carmie K.
 SOURCE: PCT Int. Appl., 65 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9741145	A1	19971106	WO 1997-US7373	19970430
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GR, HU, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, BG, KG, KZ, MD, RU, TJ, TM				
CA 2253673	AA	19971106	CA 1997-2253673	19970430
AU 9729304	A1	19971119	AU 1997-29304	19970430
EP 710139	B2	19990916		
EP 900234	A1	19990310	EP 1997-923523	19970430
EP 900234	B1	20000705		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 194358	E	20000715	AT 1997-923523	19970430
JP 2000509396	T2	20000725	JP 1997-539232	19970430
ES 2152611	T3	20010201	ES 1997-923523	19970430
US 2002025951	A1	20020228	US 1999-180132	19990524
PRIORITY APPL. INFO.: US 1996-16628P P 19960501 WO 1997-US7373 W 19970430				


OTHER SOURCE(S): MARPAT 127:358992
 AB Progesterone derivs. of formula I [R1 = OMe, SMe, NMe2, NHMe, CHO, Ac, CHOHCH3; R2 = halo, alkyl, acyl, OH, alkoxy, etc.; R3 = OH, alkyl, alkoxy, acyloxy; R4 = H, alkyl; X = O, (substituted) NOH] are prepd. as antiprogesterational agents. The present invention provides methods wherein the compds. of formula I are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce labor; and for contraception. Thus, II was prepd. from 3,3-ethylenedioxy-17 β .cyano-17 α .hydroxyestra-5(10),9(11)-diene and 4-bromo-N,N-dimethylaniline in 9 steps. II showed 2.79 times the antiprogesterational potency in the antiClauberg test compared to CDB-2914.
 IT 198414-07-2P 198414-09-4P 198414-31-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)




IT 198414-03-8P 198414-05-0P 198414-11-8P
 198414-22-1P 198414-32-3P 198414-33-4P
 198414-34-5P 198414-39-0P 198414-43-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of progesterone derivs. as antiprogesterational agents)
 RN 198414-03-8 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-fluoro-, (11 β .)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-05-0 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-chloro-11-[4-(dimethylamino)phenyl]-, (11 β .)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-11-8 CAPLUS


L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)
 study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of progesterone derivs. as antiprogesterational agents)
 RN 198414-07-2 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17,21-bis(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11 β .)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-09-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetylthio)-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11 β .)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 198414-31-2 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-methoxy-, (11 β .)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11 β .)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 198414-22-1 CAPLUS
 CN Estra-4,9-dien-3-one, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-(1-oxopropyl)-, (11 β .), 17 α .)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 198414-32-3 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(3-cyclopentyl-1-oxopropoxy)-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11 β .)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-33-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-(3-cyclopentyl-1-


L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)
oxopropoxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-34-5 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-39-0 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-ethoxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 198413-97-7 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198413-98-8 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17,21-dihydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198413-99-9 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-hydroxy-21-[(methylsulfonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 198414-43-6 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-bromo-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 198413-96-6P 198413-97-7P 198413-98-8P
198413-99-9P 198414-00-5P 198414-21-0P
198414-30-1P 198414-38-9P 198414-42-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of progesterone derivs. as antiprogesterone agents)
RN 198413-96-6 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-chloro-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 198414-00-5 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-21-fluoro-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-21-0 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-oxopropyl)-, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-30-1 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-hydroxy-21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 198414-38-9 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-21-ethoxy-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-42-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-bromo-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 198414-40-3P 198414-41-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of progesterone derivs. as antiprogesterational agents)
 RN 198414-40-3 CAPLUS


L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 19-Norpregna-4,9-diene-3,20-dione, 17,21-bis(acetyloxy)-11-[4-(dimethylamino)phenyl]-, 3-oxime, (3E,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 198414-41-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-methoxy-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



=> d ibib ab fqhit 1-20


L8 ANSWER 1 OF 20 MARPAT COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 135:304062 MARPAT
 TITLE: Preparation of 17.alpha.-substituted-11.beta.-substituted-4-aryl and 21-substituted 19-norpregna-4,9-diene-3,20-dione derivatives as new antiprogesterational agents
 INVENTOR(S): Kim, Hyun K.; Blye, Richard P.; Rao, Pannaraju N.; Cessac, James W.; Acosta, Carmie K.; Simmons, Anne Marie
 PATENT ASSIGNEE(S): Secretary of Health and Human Services, USA
 SOURCE: PCT Int. Appl., 171 pp.
 DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001074840	A2	20011011	WO 2001-US8681	20010316
WO 2001074840	A3	20020502		
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001045849	A5	20011015	AU 2001-45849	20010316
EP 1265911	A2	20021218	EP 2001-918812	20010316
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.: US 2000-526855 20000317 WO 2001-US8681 20010316				

AB 19-Norpregna-4,9-diene-3,20-dione derivs. [I; R1 = OMe, SMe, NMe2, NMe, NC4H8, NC5H10, NC4H8O, CHO, CH(OH)Me, C(O)Me, O(CH2)2NMe2, and -O(CH2)2NC5H10; R2 = H, halogen, alkyl, acyl, hydroxy, alkoxy, acyloxy, alkylcarbonate, cyanoalkoxy, S-alkyl, -SCN, S-acyl and -OC(O)R6; R6 = alkyl, alkoxy ester, alkoxy; R3 = alkyl, hydroxy, alkoxy and acyloxy; R4 = H, alkyl; X = O, (substituted) NOH] were prep'd as antiprogesterational agents. The present invention provides methods wherein I were advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat meningiomas; to treat uterine leiomyomas; to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce cervical ripening; to induce labor; and for contraception. Thus, norpregnadienedione deriv. II was prep'd. from 3,3-ethylenedioxy-17.beta.-cyano-17.alpha.-hydroxyestra-5(10),9(11)-diene and 4-bromo-N,N-dimethylaniline in 9 steps which showed 2.79 times the antiprogesterational potency in the antiClauberg test compared to CDB-2914.

MSTR 1

L8 ANSWER 1 OF 20 MARPAT COPYRIGHT 2003 ACS (Continued)




G2 = Ak<(1-12)> (SO)
 G8 = O
 MPL: claim 1

L8 ANSWER 2 OF 20 MARPAT COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 134:208009 MARPAT
 TITLE: Preparation of 17.beta.-acyl-17.alpha.-propynyl-11.beta.-(cyclic amino)aryl steroids and their derivatives having antagonist hormonal properties
 INVENTOR(S): Cook, C. Edgar; Kepler, John A.; O'Reilly, Jill M.
 PATENT ASSIGNEE(S): Research Triangle Institute, USA
 SOURCE: PCT Int. Appl., 70 pp.
 DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001018025	A2	20010315	WO 2000-US24274	20000905
WO 2001018025	A3	20010920		
V: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000071113	A5	20010410	AU 2000-71113	20000905
EP 1208113	A2	20020529	EP 2000-959867	20000905
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003508540	T2	20030304	JP 2001-522248	20000905
NO 2002001037	A	20020405	NO 2002-1037	20020301
PRIORITY APPLN. INFO.: US 1999-389212 19990903 WO 2000-US24274 20000905				

AB The invention is directed to the prep'n. of 17.beta.-acyl-17.alpha.-propynyl steroids of formula I [R1 = heterocycle; R2 = Me, CF3, CH2OH; R3 = H, Me, OMe, OAc, halo; R4 = H, Me, F, Cl; X = O, H2, NOH, NOME] which exhibit potent antiprogesterational activity. Thus, II was prep'd. from 17.beta.-cyano-3,3-(ethanedithyldioxy)-17.alpha.-trimethylsilyloxy-5(10),9(11)-diene in 8 steps. The anti-McGinty assay for antiprogesterational activity shows II to be an exceptionally potent antiprogesterational agent with a marked effect at 0.3 .mu.g dose.

MSTR 1



L8 ANSWER 2 OF 20 MARPAT COPYRIGHT 2003 ACS (Continued)

G1 = phenylene
 G3 = Me
 G5 = 34



G6 = O
 MPL: claim 1
 NTE: and pharmaceutically acceptable salts

L8 ANSWER 3 OF 20 MARPAT COPYRIGHT 2003 ACS


ACCESSION NUMBER: 133:17687 MARPAT
 TITLE: Preparation of 17.beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties
 INVENTOR(S): Cook, C. Edgar; Kepler, John A.; O'Reilly, Jill M.
 PATENT ASSIGNEE(S): Research Triangle Institute, USA
 SOURCE: PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000034306	A1	20000615	WO 1999-US28535	19991203
<p>W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p> <p>RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG</p>				
US 6172052	B1	20010109	US 1998-205395	19981204
CA 2358466	AA	20000615	CA 1999-2358466	19991203
EP 1135403	A1	20010926	EP 1999-964047	19991203
<p>R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO</p>				
NZ 512697	A	20030131	NZ 1999-512697	19991203
PRIORITY APPLN. INFO.:			US 1998-205395	19981204
			WO 1999-US28535	19991203

AB Novel 17.beta.-acyl-17.alpha.-propynyl steroids of formula I [R1 = NMe2, NMe, NH2; R2 = Me, CF3, CH2OH; R3 = H, Me, OMe, OAc; R4 = H, Me, F, Cl; X = O, H2, NOH, NOME] are prepd. which exhibit potent antiprogesterone activity. Thus, II was prepd. from estrone in many steps. The relative progesterone binding activity of II was 313% of promegestone.

MSTR 1

L8 ANSWER 3 OF 20 MARPAT COPYRIGHT 2003 ACS (Continued)



G3 = Me
 G5 = 34

G6 = 34

G6 = O

DER: and pharmaceutically acceptable salts
 MPL: claim 1

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 4 OF 20 MARPAT COPYRIGHT 2003 ACS

ACCESSION NUMBER: 131:199885 MARPAT
 TITLE: Preparation of 20-keto-11.beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties
 INVENTOR(S): Cook, C. Edgar; Kepler, John A.; Zhang, Ping-sheng; Lee, Yue-wei; Tallent, C. Ray
 PATENT ASSIGNEE(S): Research Triangle Institute, USA
 SOURCE: PCT Int. Appl., 95 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9945022	A1	19990910	WO 1999-US3732	19990305
<p>W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p> <p>RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG</p>				
US 6020328	A	20000201	US 1998-35949	19980306
CA 2322862	AA	19990910	CA 1999-2322862	19990305
AU 9928715	A1	19990920	AU 1999-28715	19990305
EP 1060186	A1	20001220	EP 1999-909531	19990305
<p>R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO</p>				
BR 9908598	A	20011002	BR 1999-8598	19990305
JP 2002505334	T2	20020219	JP 2000-534564	19990305
PRIORITY APPLN. INFO.:			US 1998-35949	19980306
			WO 1999-US3732	19990305

AB 20-Keto-11.beta.-arylsteroids of formula I [X = O, (substituted) NOH, H2, OH, etc.; R1 = dialkylamino, imidazolyl, pyrrolyl, piperidino, etc.; R2 = H, halo; R3 = H, Me, halo; R4 = H, acyloxy, (substituted) OH, alkyl, etc.; R5 = H, alkyl, halo, acyloxy, etc.] are prepd. which exhibit potent antiprogesterone activity. Thus, II was prepd. from 17.alpha.-hydroxymethyl-3-methoxy-19-norpregna-1,3,5(10)-trien-20-one and 4-bromo-N,N-dimethylaniline in several steps. The affinity of II for the progesterone hormone receptor was IC50 of 0.7 nM.

MSTR 1A



G2 = phenylene (SO (1) G3)

L8 ANSWER 4 OF 20 MARPAT COPYRIGHT 2003 ACS (Continued)

G14 = 128

G15 = 128

G15 = O

G29 = alkyl(1-4)
 DER: and pharmaceutically acceptable salts

MPL: claim 1

NTE: substitution is restricted; also incorporates claim 3


REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 20 MARPAT COPYRIGHT 2003 ACS

ACCESSION NUMBER: 130:282222 MARPAT
 TITLE: Method for the preparation and pharmaceutical formulation of 11.beta.-benzaldehyde-9.alpha.,10.alpha.-epoxy-estr-4-ene derivatives
 INVENTOR(S): Schubert, Gerd; Ring, Sven; Kaufmann, Guenter; Schneider, Birgitt; Elger, Walter
 PATENT ASSIGNEE(S): Jenapharm G.m.b.H. and Co. K.-G., Germany
 SOURCE: Ger. Offen., 16 pp.
 CODEN: GVXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19745085	A1	19990415	DE 1997-19745085	19971011
EP 909764	A1	19990421	EP 1998-118613	19981001
EP 909764	B1	19990929		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AT 185145	Z	19991015	AT 1998-118613	19981001
PRIORITY APPLN. INFO.: DE 1997-19745085 19971011				
AB 11.beta.-Benzaldehyde-9.alpha.,10.alpha.-epoxy-estr-4-ene derivs., e.g. I (R1 = H, C1-6-alkyl; R2 = H, C1-10-alkyl, aryl, aralkyl, alkylaryl, C1-10-acyl, CONHR4, CO2R4; R3 = H, C1-10-alkyl, aryl, aralkyl, alkylaryl, (CH2)nCH2Y; R4 = H, C1-10-alkyl, aryl, aralkyl, alkylaryl; Y = F, Cl, Br, I, CN, N3, SCN, OR5, SR5; n = 0 - 2; R5 = H, C1-10-alkyl, aryl, aralkyl, alkylaryl, C1-10-acyl), are described. Thus, (E)-I (R1 = R2 = Me, R3 = CH2OMe, Z = H) was prepd. via regioselective epoxidn. of estradienone II (R1 = R2 = Me, R3 = CH2OMe, Z = H) with m-chloroperbenzoic acid in CH2Cl2. (E)-I (R1 = R2 = Me, R3 = CH2OMe, Z = H) showed 88% affinity for the progesterone receptor but only 12% affinity for the glucocorticoid receptor.				

MSTR 2



G8 = 51




L8 ANSWER 6 OF 20 MARPAT COPYRIGHT 2003 ACS


ACCESSION NUMBER: 129:50105 MARPAT
 TITLE: Uses of anti-glucocorticoid compounds for the treatment of psychoses or addictive behaviors
 INVENTOR(S): Oberlander, Claude; Piazza, Pier Vincenzo
 PATENT ASSIGNEE(S): Hoechst Marion Roussel, Fr.; Oberlander, Claude; Piazza, Pier Vincenzo
 SOURCE: FCT Int. Appl., 41 pp.
 CODEN: FIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9826783	A1	19980625	WO 1997-FR2320	19971217
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
FR 2757400	A1	19980626	FR 1996-15649	19961219
FR 2757400	B1	19991217		
AU 9855632	A1	19980715	AU 1998-55632	19971217
EP 892641	A1	19990127	EP 1997-952078	19971217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRIORITY APPLN. INFO.: FR 1996-15649 19961219				
WO 1997-FR2320 19971217				
AB Glucocorticoid antagonists, except mifepristone, are used as dopamine type II receptor antagonists to treat psychotic or addictive behavior. Thus, 17.beta.-hydroxy-10.beta.-[(4-methylphenyl)methyl]-17.alpha.-(1-propynyl)estra-4,9(11)-dien-3-one considerably reduced the response to morphine in vivo.				

MSTR 1



G1 = Ph (SO (1-) G11)
 G3 = 35-13 37-14



G4 = C(O)

L8 ANSWER 5 OF 20 MARPAT COPYRIGHT 2003 ACS (Continued)

G12 = alkyl<(1-10)>
 DER: or pharmaceutically acceptable salts
 MPL: claim 1

L8 ANSWER 6 OF 20 MARPAT COPYRIGHT 2003 ACS (Continued)

G12 = 41

41 C(O)CH2OH

DER: and pharmaceutically acceptable acid addition salts
 MPL: claim 4
 NTE: substitution is restricted

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 20 MARPAT COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 128:188869 MARPAT
 TITLE: Mixed agonists of the progesterone receptor and assays for them
 INVENTOR(S): McDonnell, Donald P.; Wagner, Brandee L.
 PATENT ASSIGNEE(S): Duke University, USA
 SOURCE: PCT Int. Appl., 62 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9805679	A2	19980212	WO 1997-US13754	19970805

V: CA

RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRIORITY APPL. INFO.: US 1996-23206P 19960805
 AB A third class of PR-ligand (i.e. mixed agonist) is identified which induces a progesterone receptor conformation distinct from that induced by a PR agonist or antagonist; the agonists are extra-4,9-dien-3-one derivs. PR mixed agonists exhibit partial agonist activity which is influenced by cell context. These compds. provide useful pharmacol. profiles for treating progesterone related diseases and/or conditions, such as uterine proliferation from estrogen administration, endometriosis, breast cancer, fibroids, endometrial cancer, and brain meningiomas. The agonists can also be used as contraceptives. Assays are provided to screen for PR mixed agonists. Mol. designs are provided to convert a PR antagonist to a PR mixed agonist.

MSTR 1



G2 = 30

G1 = 50

G3 = alkyl<(1-6)> (50)
G9 = 52

L8 ANSWER 7 OF 20 MARPAT COPYRIGHT 2003 ACS (Continued)



MPL: claim 4

L8 ANSWER 8 OF 20 MARPAT COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 127:35892 MARPAT
 TITLE: Preparation of 21-substituted progesterone derivatives as new antiprogesterone agents
 INVENTOR(S): Kim, Hyun K.; Blye, Richard P.; Rao, Pemmaraju N.; Cessac, James W.; Acosta, Carmie K.
 PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA;
 Kim, Hyun K.; Blye, Richard P.; Rao, Pemmaraju N.; Cessac, James W.; Acosta, Carmie K.
 SOURCE: PCT Int. Appl., 65 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9741145	A1	19971106	WO 1997-US7373	19970430

V: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

CA 2253673 AA 19971106 CA 1997-2253673 19970430

AU 9729304 A1 19971119 AU 1997-29304 19970430

AU 710139 B2 19990916

EP 900234 A1 19990310 EP 1997-923523 19970430

EP 900234 B1 20000705

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

AT 194358 E 20000715 AT 1997-923523 19970430

JP 2000509396 T2 20000725 JP 1997-539232 19970430

ES 2152671 T3 20010201 ES 1997-923523 19970430

US 2002025951 A1 20020228 US 1999-180132 19990524


US 2002025951 A1 20020228 US 1996-16628P 19960501

WO 1997-US7373 19970430

PRIORITY APPL. INFO.:
 AB Progesterone derivs. of formula I [R1 = OMe, SMe, NMe2, NMe, CHO, Ac, CHOHCH3; R2 = halo, alkyl, acyl, OH, alkoxy, etc.; R3 = OH, alkyl, alkoxy, acyloxy; R4 = H, alkyl; X = O, (substituted) NOH] are prepd. as antiprogesterone agents. The present invention provides methods wherein the compds. of formula I are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce labor; and for contraception. Thus, II was prepd. from 3,3-ethylenedioxy-17.β.-cyano-17.α.-hydroxyestra-5(10),9(11)-diene and 4-bromo-N,N-dimethylaniline in 9 steps. II showed 2.79 times the antiprogesterone potency in the antiClauberg test compared to CDB-2914.

MSTR 1

L8 ANSWER 8 OF 20 MARPAT COPYRIGHT 2003 ACS (Continued)

G2 = alkyl<(1-12)>
G10 = O
MPL: claim 1

L8 ANSWER 9 OF 20 MARPAT COPYRIGHT 2003 ACS


ACCESSION NUMBER: 124:22540 MARPAT
 TITLE: Pharmaceutical compositions of antigluco-corticoid compounds for treating or preventing symptoms of spontaneous or narcotic-induced withdrawal.
 INVENTOR(S): Petit, Francis; Philibert, Daniel; Ulmann, Andre
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Eur. Pat. Appl., 30 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 676203	A1	19951011	EP 1995-400764	19950406
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
FR 2718354	A1	19951013	FR 1994-4156	19940408
FR 2718354	B1	19960503		
ZA 9502058	A	19960313	ZA 1995-2058	19950313
CA 2146600	AA	19951009	CA 1995-2146600	19950407
FI 9501683	A	19951009	FI 1995-1683	19950407
AU 9516326	A1	19951019	AU 1995-16326	19950407
JP 07278017	A2	19951024	JP 1995-107071	19950407
HU 71468	A2	19951128	HU 1995-1019	19950407
CN 1116929	A	19960221	CN 1995-104015	19950407
			FR 1994-4156	19940408

PRIORITY APPLN. INFO.:

AB Antigluco-corticoid steroids such as mifepristone, onapristone, lilopristone and related steroids are proposed for the prevention or treatment of withdrawal syndromes, either spontaneous or ptd. by narcotics or mixts. of narcotics. These antigluco-corticoids would be useful in the withdrawal from morphinomimetics such as heroin, morphine or methadone as well as cocaine. Pharmacol. activity was demonstrated by the effect of the antigluco-corticoids on the stereotypic behavior of mice in response to narcotics. Spontaneous withdrawal syndrome was induced by administration of the opioid antagonist, naloxone. An antiprogesterone activity of the steroids in their action mechanism was eliminated. Results confirmed the involvement of endogenous glucocorticoids in morphine withdrawal since this is inhibited by antigluco-corticoids or adrenalectomy.

MSTR 2




L8 ANSWER 11 OF 20 MARPAT COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 122:256423 -MARPAT
 TITLE: Antiglucocorticoid steroids for the treatment of anxiety disorders
 INVENTOR(S): Peeters, Bernardus Wynand Machijs Maria
 PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.
 SOURCE: PCT Int. Appl., 25 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9504536	A1	19950216	WO 1994-EP2513	19940728
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KG, KP, KR, KZ, LX, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GN, ML, MR, NE, SN, TD, TG				
AU 9474968	A1	19950228	AU 1994-74968	19940728
AU 687088	B2	19980219		
EP 712311	A1	19960522	EP 1994-924819	19940728
EP 712311	B1	19981007		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09501172	T2	19970204	JP 1995-506200	19940728
AT 171873	E	19981015	AT 1994-924819	19940728
ES 2124905	T3	19990216	ES 1994-924819	19940728
US 5741787	A	19980421	US 1996-581631	19960118
PRIORITY APPLN. INFO.:				
EP 1993-202304 19930804				
EP 1994-924819 19940728				
WO 1994-EP2513 19940728				


AB Antiglucocorticoid steroids are used for the manuf. of a pharmaceutical compn. for the treatment of anxiety disorders. The anxiolytic effect of 11.beta.-(4-dimethylaminophenyl)-17.beta.-hydroxy-17.alpha.-(prop-1-ynyl)-estra-4,9-dien-3-one (RU38486) was demonstrated in animal testing (antagonism of fear-potentiated startle). Prepn. and activity (antagonism of stress-induced hyperthermia) of selected steroids of the invention is also described.

MSTR 1



G7 = 44

L8 ANSWER 11 OF 20 MARPAT COPYRIGHT 2003 ACS (Continued)



G16 = alkylcarbonyl<(1-5)> (SO (1-) G17)
 G18 = 39




MPL: claim 2

L8 ANSWER 12 OF 20 MARPAT COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 116:35156 MARPAT
 TITLE: Preparation and use of antiprogesteronimetics for synchronization of parturition in livestock
 INVENTOR(S): Grandadam, Jean Andre
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Eur. Pat. Appl., 13 pp.
 CODEN: EPKXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 446124	A2	19910911	EP 1991-400594	19910305
EP 446124	A3	19920527		
R: AT, BE, CH, DE, DK, FR, GB, GR, IT, LI, LU, NL, SE				
FR 2659233	A1	19910913	FR 1990-2783	19900306
FR 2659233	B1	19940121		
CA 2037549	AA	19910907	CA 1991-2037549	19910305
AU 9172608	A1	19910912	AU 1991-72608	19910305
AU 642975	B2	19931104		
ZA 9101603	A	19920527	ZA 1991-1603	19910305
JP 04211610	A2	19920803	JP 1991-62496	19910305
RU 2037295	C1	19950619	RU 1991-4895041	19910305
CN 1055665	A	19911030	CN 1991-102108	19910306
HU 59006	A2	19920428	HU 1991-729	19910306
PRIORITY APPLN. INFO.:				
FR 1990-2783 19900306				

AB The title antiprogesteronimetics are I (R1 = C1-18 hydrocarbyl optionally substituted with .gtoreq.1 heteroatoms and bonded to the steroid by a C; R2 = C1-8 hydrocarbyl; X = remainder of 5- and 6-membered ring optionally substituted and optionally unsatd.; C = A = CNOH, oxo (free or blocked as ketal), etc.; B and C together form a double bond or epoxide bridge) and acid addn. salts thereof. Prepn. of 2 I are described. 17.beta.-Hydroxy-11.beta.-(4-dimethylaminophenyl)-17.alpha.-(prop-1-ynyl)estra-4,9-dien-3-one (II) was more effective at synchronizing parturition than cloprostenol when tested in sows. Injectable pharmaceuticals contg. II are disclosed.

MSTR 1C



G1 = 30



G3 = 55-13 57-14

L8 ANSWER 12 OF 20 MARPAT COPYRIGHT 2003 ACS (Continued)



G15 = 61

G1(O)CH2-OH

G4 +G17= O
 DER: and protected derivatives
 DER: and acid addition salts
 MPL: claim 1

L8 ANSWER 13 OF 20 MARPAT COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 115:214857 MARPAT
 TITLE: Injectable microspheres containing antiestrogenic and antiprogesteromimetic steroids
 INVENTOR(S): Cohen, Gerard; Dubois, Jean Luc
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Ger. Offen., 15 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4036425	A1	19910516	DE 1990-4036425	19901115
FR 2654337	A1	19910517	FR 1989-14976	19891115
FR 2654337	B1	19940805		
SE 9003570	A	19910516	SE 1990-3570	19901109
BE 1005511	A4	19930831	BE 1990-1062	19901109
DK 9002709	A	19910516	DK 1990-2709	19901113
CA 2029940	AA	19910516	CA 1990-2029940	19901114
JP 03294229	A2	19911225	JP 1990-306374	19901114
CH 681691	A	19930514	CH 1990-3611	19901114
NL 9002492	A	19910603	NL 1990-2492	19901115
GB 2239798	A1	19910717	GB 1990-24862	19901115
GB 2239798	B2	19931027		
AT 9002313	A	19950415	AT 1990-2313	19901115
AT 400298	B	19951127		

PRIORITY APPLN. INFO.: FR 1989-14976 19891115
 AB Biodegradable microspheres comprise the title steroids (Markush given) and copolymers of lactic acid with glycolic acid. A mixt. of 250 mL aq. 0.3% hydrolyzed PVA soln., 1 g poly(DL-lactic acid-glycolic acid), 17 g CH₂Cl₂, and 0.5 g 17.β-hydroxy-11.β-[(4-(dimethylamino)phenyl)-17.α-(1-propenyl)estra-4,9-dien-3-one] was emulsified, followed by stirring at 22.°C and decreasing pressure (gtoreq. 400 mm Hg) to give microspheres, which were used for the prepn. of injections.

MSTR 1A

G1—G3

G1 = 3




G3 = 24

L8 ANSWER 14 OF 20 MARPAT COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 115:151901 MARPAT
 TITLE: Use of antiprogesteromimetics for stimulating ovulation, and new preparation for use in pharmaceutical compositions
 INVENTOR(S): Grandadam, Jean Andre
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Eur. Pat. Appl., 24 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 417003	A2	19910313	EP 1990-402449	19900906
EP 417003	A3	19911204		
EP 417003	B1	19940629		
R: AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE				
FR 2651435	A1	19910308	FR 1989-11699	19890907
FR 2651435	B1	19940422		
US 5173483	A	19921222	US 1990-578894	19900905
CA 2024728	AA	19910308	CA 1990-2024728	19900906
AU 9062259	A1	19910314	AU 1990-62259	19900907
AU 623805	B2	19920521		
JP 03099015	A2	19910424	JP 1990-236004	19900907
JP 3032258	B2	20000410		


PRIORITY APPLN. INFO.: FR 1989-11699 19890907
 AB Anti-progesteromimetic compds., e.g. I (R1 = C1-18 hydrocarbyl with optionally .gtoreq.1 heteroatoms, bonded to the steroid by a C; R2 = C1-8 hydrocarbyl; X = rest of 5- or 6-membered (substituted) (unsatd.) ring; A:C = oxo (free or in ketal), CH(OH), CH(OR3), CH(OZCR3), etc.; R3 = C1-8 alkyl, C7-15 aralkyl; B and C together form a double bond or epoxide bridge) and their acid and base addn. salts, are used for making pharmaceuticals for stimulating ovulation, e.g. in cows. The compds. of the invention are preferably used following treatment with progesterone or a progesteromimetic, e.g. 3-oxo-17.α-allyl-17.β-hydroxyestra-4,9,11-triene (II). Thus, heifer cows were 1st administered II for 17 days; on the day following the last administration, the animals were injected with 17.β-hydroxy-11.β-[(4-(dimethylaminophenyl)-17.α-(prop-1-enyl)estra-4,9-dien-3-one]. All of the heifers came to heat after a very short delay period, and LH levels rose very rapidly. Prepn. of 12 anti-progesteromimetics is presented.

MSTR 1B



G1 = 85

L8 ANSWER 13 OF 20 MARPAT COPYRIGHT 2003 ACS (Continued)



G5 = 68-26 70-27



G9 = 74

G10 = CH

MPL: claim 6

L8 ANSWER 14 OF 20 MARPAT COPYRIGHT 2003 ACS (Continued)

G5 = 68-26 70-27

G12 = 96

G14 = 98

G14 = 98

G15 = OH

G5 + G6 = O

DER: or acid or base addition salts

MPL: claim 2

NTE: oxo formed by G5 and G6 may be protected as a ketal

L8 ANSWER 15 OF 20 MARPAT COPYRIGHT 2003 ACS


ACCESSION NUMBER: 115:9125 MARPAT
 TITLE: Preparation of .omega.-[([3-oxoestra-4,9-dien-11.beta.-
 yl]phenylamino)alkanoates as antigluco-corticoids
 INVENTOR(S): Moguilewsky, Martine; Nedelec, Lucien; Nique,
 Francois; Philibert, Daniel
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Eur. Pat. Appl., 33 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 414606	A2	19910227	EP 1990-402328	19900822
EP 414606	A3	19910724		
EP 414606	B1	19941102		
FR 2651233	A1	19910301	FR 1989-11173	19890823
FR 2651233	B1	19911213		
CA 2022648	AA	19910224	CA 1990-2022648	19900803
ZA 9006341	A	19910303	ZA 1990-6341	19900810
US 5166146	A	19921124	US 1990-568597	19900816
JP 03090097	A2	19910416	JP 1990-217281	19900820
JP 3026997	B2	20000327		
IL 95451	A1	19950731	IL 1990-95451	19900821
AU 9061189	A1	19910228	AU 1990-61189	19900822
AU 634569	B2	19930225		
HU 54706	A2	19910328	HU 1990-5275	19900822
HU 208154	B	19930830		
ES 2063313	T3	19950101	ES 1990-402328	19900822
CN 1051362	A	19910515	CN 1990-107161	19900823
CN 1033808	B	19970115		
RU 2041236	C1	19950809	RU 1992-5011511	19920518
			FR 1989-11173	19890823

PRIORITY APPL. INFO.:

OTHER SOURCE(S): CASREACT 115:9125
 AB The title compds. [I; R1 = aliph. hydrocarbyl; R2 = H, (un)substituted
 alkyl; R5, R6 = H, alkyl; X = atoms to complete an (un)substituted 5- or
 6- membered ring; Z = (un)saturated CO2H; n = 1-6] were prepd. Thus,
 aminophenylestradienone II (R = R5 = R6 = H) was condensed with BrCH2CO2Me
 to give, after sapon., II (R = CH2CO2Na, R5 = R6 = H) which at 10-6M in
 vitro gave 82% inhibition of uridine incorporation into rat thymocytes.

MSTR 1A



L8 ANSWER 16 OF 20 MARPAT COPYRIGHT 2003 ACS


ACCESSION NUMBER: 114:229227 MARPAT
 TITLE: Preparation of 19-nor 3-oxo steroids with an amine
 substituted 17-chain as antioxidants and
 antiinflammatories: their use as medicines and
 pharmaceutical composition containing them
 INVENTOR(S): Claussner, Andre; Leclaire, Jacques; Nedelec, Lucien;
 Philibert, Daniel
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Eur. Pat. Appl., 29 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 389370	A1	19900926	EP 1990-400784	19900322
EP 389370	B1	19940427		
FR 2644789	A1	19900928	FR 1989-3742	19890322
FR 2644789	B1	19950203		
JP 02273693	A2	19901108	JP 1990-68508	19900320
JP 2848907	B2	19900120		
US 5108996	A	19920428	US 1990-497562	19900321
			FR 1989-3742	19890322


PRIORITY APPL. INFO.:

OTHER SOURCE(S): CASREACT 114:229227
 AB The title compds. [I; R1, R2 = H, Me; R11 = (poly) (hetero)hydrocarbyl; one
 of R17 and R18 is OH or acyloxy and the other is O; Z = alkylene,
 alkenylene, alkynylene; P = (substituted) pyrimidinyl, pyridyl] were
 prepd. via reacting the halo deriva. II or III (X = halo) with the
 appropriate pyrimidinyl or pyridine deriv. IV. Reaction of estradienone V
 [R3 = 3-bromo-1-propynyl; R4 = OH] (prepn. given) was reacted with
 2,4-bis(1-pyrrolidinyl)-6-(1-piperazinyl)pyrimidine (prepn. given) in
 acetone contg. K2CO3 at ambient temp. for 2 h to give V [R3 =
 3-[4-[2,6-bis(1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-1-propynyl; R4
 = OH]. At 5 .times. 10-4 M this inhibited in vitro the formation of
 malonyldialdehyde, a measure of lipid peroxidn., in rat brain homogenate
 by .apprx.47.5%.

MSTR 3



G2 = 97



MPL: claim 13

L8 ANSWER 15 OF 20 MARPAT COPYRIGHT 2003 ACS (Continued)

G3 = phenylene
 G9 = 39-18 37-17

G16-G10-CH2

G10 = (1-2) 45

G11-G5-G12

G13 = 53

G13(O)-CH2-OH

G16 = 68

G13-G8-G13

MPL: claim 1

L8 ANSWER 16 OF 20 MARPAT COPYRIGHT 2003 ACS (Continued)

NTE: the alkylamino and dialkylamino groups in G11 may be interrupted by
 oxygen, sulfur, or nitrogen

L8 ANSWER 17 OF 20 MARPAT COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 113:115677 MARPAT
 TITLE: Preparation of androstanone derivatives as drugs
 INVENTOR(S): Scholz, Stefan; Neef, Guenter; Ottow, Eckhard; Elger, Walter; Beier, Sybille; Chwalisz, Krzysztof
 PATENT ASSIGNEE(S): Schering A.-G., Germany
 SOURCE: Eur. Pat. Appl., 38 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 360369	A1	19900328	EP 1989-250040	19890920
EP 360369	B1	19950503		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DE 3832303	A1	19900412	DE 1988-3832303	19880920
IL 91672	A1	19941229	IL 1989-91672	19890918
WO 9003385	A1	19900405	WO 1989-EP1090	19890920
W: AU, DK, FI, HU, JP, NO, US				
AU 8943049	A1	19900418	AU 1989-43049	19890920
AU 640616	B2	19930902		
ZA 8907191	A	19901031	ZA 1989-7191	19890920
DD 284682	A5	19901121	DD 1989-332836	19890920
HU 56851	A2	19911028	HU 1989-5541	19890920
HU 208151	B	19930830		
JP 04501712	T2	19920326	JP 1989-509963	19890920
JP 2760870	B2	19980604		
AT 122052	E	19950515	AT 1989-250040	19890920
ES 2074073	T3	19950901	ES 1989-250040	19890920
NO 9101102	A	19910319	NO 1991-1102	19910319
DK 9100504	A	19910320	DK 1991-504	19910320
US 5244886	A	19930914	US 1991-663819	19910320
NO 9104772	A	19910319	NO 1991-4772	19911204
PRIORITY APPLN. INFO.:			DE 1988-3832303	19880920
			WO 1989-EP1090	19890920
			NO 1991-1102	19910319

OTHER SOURCE(S): CASREACT 113:115677
 AB The title compds. [I: Z = O, hydroxyimino; LM = bond, or L = H and M = .alpha.-OH; AB = bond and D = H and R1 = heteroaryl; or A = H and BD = CH2 and Z = H2; R3, R4 = tetrahydropyranyloxyalkyl, tetrahydropyranyloxyalkenyl, etc.], useful as antiglucocorticoids, neoplasm inhibitors (esp. for breast cancer), progestogen inhibitors, and antiproliferative agents, were prepd. 3-(Tetrahydropyran-2-yloxy)-1-propyne was lithiated with BuLi in THF-hexane and the product treated with 14.beta.-androstane-17-one II (R3R4 = O) (prepn. given) to give II (R3 = O, R4 = OH) treated with 4N HCl to give I [R1 = OMe, R2 = Me, R3 = (CH2)3OH, BD = CH2, LM = bond, Z = O, A = H] (III). III had higher affinity for the gestagen receptor than the known EP-A 0277676 [11.beta.-(4-(dimethylamino)phenyl)-17.alpha.-hydroxy-17-(3-hydroxypropyl)-14.beta.-estra-4,9-dien-3-one].

MSTR 1A


L8 ANSWER 18 OF 20 MARPAT COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 112:235680 MARPAT
 TITLE: Preparation of 13-alkyl-11.beta.-phenylgonanes as antigestagens and antiglucocorticoids
 INVENTOR(S): Scholz, Stefan; Ottow, Eckhard; Neef, Guenter; Elger, Walter; Beier, Sybille; Chwalisz, Krzysztof
 PATENT ASSIGNEE(S): Schering A.-G., Germany
 SOURCE: Ger. Offen., 22 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3822770	A1	19900104	DE 1988-3822770	19880701
IL 90826	A1	19940624	IL 1989-90826	19890630
CA 1334668	A1	19950307	CA 1989-604596	19890630
EP 349481	A1	19900103	EP 1989-730155	19890703
EP 349481	B1	19951102		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
WO 9000174	A1	19900111	WO 1989-DE443	19890703
W: AU, FI, HU, JP, NO				
AU 8939569	A1	19900123	AU 1989-38568	19890703
AU 644060	B2	19931202		
ZA 8905058	A	19900425	ZA 1989-5058	19890703
DD 287511	A5	19910228	DD 1989-330342	19890703
HU 56114	A2	19910729	HU 1989-4130	19890703
HU 208021	B	19930728		
DD 295638	A5	19911107	DD 1989-341722	19890703
JP 03505727	T2	19911212	JP 1989-507188	19890703
JP 2956776	B2	19991004		
US 5273971	A	19931228	US 1989-374809	19890703
AT 129717	E	19951115	AT 1989-730155	19890703
ES 2080079	T3	19960201	ES 1989-730155	19890703
NO 9005609	A	19910228	NO 1990-5609	19901227
NO 180451	B	19970113		
NO 180451	C	19970423		
US 5446036	A	19950829	US 1993-144474	19931102
FI 9504856	A	19951012	FI 1995-4856	19951012
NO 9600829	A	19910228	NO 1996-829	19960229
PRIORITY APPLN. INFO.:			DE 1988-3822770	19880701
			US 1989-374809	19890703
			WO 1989-DE443	19890703
			NO 1990-5609	19901227
			FI 1990-6441	19901228


AB The title compds. [I: R1 = heterocyclyl, cycloalkyl, cycloalkenyl, alkenyl, etc.; R2 = .alpha.-, .beta.-Me, -Et; R3, R4 = alkoxy, acyl, oxofuryl, alkynyl, etc.; Z = O, NOH], antigestagens and antiglucocorticoids useful for induction of abortion, were prepd. via Grignard reaction of the corresponding 5.alpha.,10.alpha.-epoxy-9(11) unsatd. steroids with p-R1C6H4X (X = halo). Grignard reaction of epoxy steroid II (prepn. given) with p-CH2:CHC6H4X (X = Br, Iodo) gave I [R1 = CH2:CH, R2 = .beta.-Me, R3 = OH, R4 = C.tplbond.CMe, Z = OCH2CMe2CH2O], which was hydrolyzed to give I [Z = O, R1-R4 same as above]. This at 3.0 mg s.c./day induced abortion in 100% of rats tested.

MSTR 1A

L8 ANSWER 17 OF 20 MARPAT COPYRIGHT 2003 ACS (Continued)




G1 = O
 G20 = 45




G28 = alkyl<(1-4)>
 MPL: claim 1

L8 ANSWER 18 OF 20 MARPAT COPYRIGHT 2003 ACS (Continued)



G1 = O
 G4 = 37



G10 = alkyl<(1-4)>
 MPL: claim 1
 NTE: substitution is restricted

L8 ANSWER 19 OF 20 MARPAT COPYRIGHT 2003 ACS


ACCESSION NUMBER: 110:213172 MARPAT
 TITLE: 13(Alpha)-alkylgonanes, their production, and pharmaceutical preparations containing same
 INVENTOR(S): Neef, Guenter; Wischert, Rudolf; Beier, Sybille; Elger, Walter; Henderson, David
 PATENT ASSIGNEE(S): Schering A.-G., Fed. Rep. Ger.
 SOURCE: U.S., 5 pp. Cont. of U.S. Ser. No. 621,308.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4780461	A	19881025	US 1985-810148	19851218
DE 3321826	A1	19841220	DE 1983-3321826	19830615
DE 3413036	A1	19851017	DE 1984-3413036	19840404
DE 3446661	A1	19860619	DE 1984-3446661	19841218
			DE 1983-3321826	19830615
			DE 1984-3413036	19840404
			US 1984-621308	19840615
			DE 1984-3446661	19841218

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): CASREACT 110:213172
 AB 13.alpha.-Alkylgonanes [I; R = C1-4 acyl; X = O, NOH; II; R1 = amino; R2 = H, Me, Et; R3 = (substituted) alkyl; R4 = OH, alkoxy, alkanoyloxy; or R3R4 = Q; R5 = H, alkyl; III; Z = CH2CH2, CH2CMe2CH2], having antigestagenic activity and useful as postcoital contraceptives, or for triggering abortion and menstruation (no data), are prepd. via photochem. epimerization of the 13.beta.-gonanes IV. 11.beta.-(4-Dimethylaminomethyl)-17.alpha.-hydroxy-13.alpha.-methyl-17.beta.-(3-hydroxypropyl)-4,9-gonadien-3-one (V) was acetylated with Ac2O in pyridine to give 11.beta.-(4-dimethylaminomethyl)-17.alpha.-hydroxy-13.alpha.-methyl-17.beta.-(3-acetoxypropyl)-4,9-gonadien-3-one. A tablet was formulated contg. V 10.0, lactose 140.0, corn starch 69.5, polyvinylpyrrolidone 25 2.5, Aerosil 2.0, and Mg stearate 0.5 mg.

MSTR 2



G4 = 59

59(O)-CH2-G11

L8 ANSWER 20 OF 20 MARPAT COPYRIGHT 2003 ACS

ACCESSION NUMBER: 109:170799 MARPAT
 TITLE: Antiprogesteric 11.beta.-aryl-14.beta.-estra-4,9-dien-3-one derivatives, a process for their preparation, and pharmaceuticals containing them
 INVENTOR(S): Loozen, Hubert Jan Jozef
 PATENT ASSIGNEE(S): AKZO N. V., Neth.
 SOURCE: Eur. Pat. Appl., 15 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 277676	A1	19880810	EP 1988-200071	19880118
EP 277676	B1	19920304		
			CA 1339570	19880115
			CA 1988-556625	19880118
			CA 1988-317	19880118
			AT 1988-200071	19880118
			ES 1988-200071	19880118
			FI 1988-257	19880121
			AU 1988-10669	19880121
			DK 1988-304	19880122
			CN 1988-100979	19880122
			JP 1988-12431	19880122
			US 1990-488391	19900227
			NL 1987-157	19870123
			EP 1988-200071	19880118
			US 1988-146895	19880122

PRIORITY APPLN. INFO.:

AB Title steroids I [R1 = monosubstituted homo- or heterocyclic aryl; R2 = C1-4 alkyl; R3, R4 = H, OH, C1-8 acyloxy, C2-8 alkoxyalkyl, C1-8 acyl, C1-12 alkoxy, (un)satd. (un)substituted C1-8 hydrocarbyl; R3R4 = C1-6 alkylidene, or atoms needed to form rings; DELTA.16 optionally present, with R3 or R4 absent], having strong antiprogesteric activity, are prepd. Estrone 3-Me ether was brominated, dehydrobrominated, and hydrogenated to give the isomeric 14.beta.-estrone 3-Me ether. This underwent NaBH4 redn., Birch redn., hydrolysis, and bromination-dehydrobromination to give 17.alpha.-hydroxy-14.beta.-estra-4,9-dien-3-one. The latter was ketalized at the 3-position, oxidized to the 17-one, alkylated at the 17-position by the tetrahydropyranyl ether of propargyl alc., epoxidized to the 5.alpha.,10.alpha.-epoxide, coupled with 4-(Me2N)C6H4MgBr in the presence of CuCl, hydrogenated in the side chain, hydrolyzed and dehydrated, and cyclized in the sidechain by tosylation in pyridine to give (dimethylaminophenyl)dihydrospiro(estradiene-furan)one II. At 1 mg orally, twice daily in pregnant rats on days 6-10, II caused 100% pregnancy interception, but only slightly reversed dexamethasone-induced thymus wt. redn. in rats.

MSTR 18


L8 ANSWER 19 OF 20 MARPAT COPYRIGHT 2003 ACS (Continued)

G11 = OH
 G12 = 66



GGA = 33 <RC (1), RS (1) M5 (1) X6, EC (0-) O (1-) N (0-) S (0)
 OTHERQ, AN (1) N, BD (ALL) SE>
 DER: and acid addition salts
 MPL: claim 18

L8 ANSWER 20 OF 20 MARPAT COPYRIGHT 2003 ACS (Continued)



G1 = biphenyl (SR)
 G6 = 37



GGA = 27 31 <(1-10)>
 GGA = 37 <(1-8)>
 MPL: claim 1

=> d his

(FILE 'HOME' ENTERED AT 15:23:45 ON 04 JUN 2003)

FILE 'REGISTRY' ENTERED AT 15:23:50 ON 04 JUN 2003

L1 STRUCTURE UPLOADED

L2 12 S L1

L3 176 S L1 FULL

FILE 'CAPLUS' ENTERED AT 15:24:45 ON 04 JUN 2003

L4 7 S L3

FILE 'BEILSTEIN' ENTERED AT 15:27:24 ON 04 JUN 2003

L5 0 S L3

L6 0 S L3 FULL

FILE 'MARPAT' ENTERED AT 15:27:43 ON 04 JUN 2003

L7 0 S L3

L8 20 S L3 FULL

=> d his

(FILE 'HOME' ENTERED AT 15:23:45 ON 04 JUN 2003)

FILE 'REGISTRY' ENTERED AT 15:23:50 ON 04 JUN 2003

L1 STRUCTURE UPLOADED

L2 12 S L1

L3 176 S L1 FULL

FILE 'CAPLUS' ENTERED AT 15:24:45 ON 04 JUN 2003

L4 7 S L3

FILE 'BEILSTEIN' ENTERED AT 15:27:24 ON 04 JUN 2003

L5 0 S L3

L6 0 S L3 FULL

FILE 'MARPAT' ENTERED AT 15:27:43 ON 04 JUN 2003

L7 0 S L3

L8 20 S L3 FULL

FILE 'USPATFULL' ENTERED AT 15:30:16 ON 04 JUN 2003

L9 4 S L3

L10 0 S L4 NOT L9

FILE 'CAOLD' ENTERED AT 15:30:35 ON 04 JUN 2003

L11 0 S L3

L10 ANSWER 1 OF 2 USPATFULL

ACCESSION NUMBER: 20014726 USPATFULL
 TITLE: 17.beta.-acyl-17.alpha.-propynyl-11.beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties
 INVENTOR(S): Cook, C. Edgar, Staunton, VA, United States
 Kepler, John A., Raleigh, NC, United States
 O'Reilly, Jill M., Durham, NC, United States
 PATENT ASSIGNEE(S): Research Triangle Institute, Research Triangle Park, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6172052	B1	20010109
APPLICATION INFO.:	US 1998-205395		19981204 (9)
DOCUMENT TYPE:	Patent		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Dees, Jose! G.		
ASSISTANT EXAMINER:	Ozai, Sabiha		
LEGAL REPRESENTATIVE:	Obilon, Spivak, McClelland, Maier & Neustadt, P.C.		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	2216		


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is directed to a novel class of 17.beta.-acyl-17.alpha.-propynyl steroids which exhibit potent antiprogesterational activity.

IT 273209-12-4P 273209-13-5P 273209-14-6P
 273209-30-6P 273209-31-7P 273209-32-8P
 273209-67-9P 273209-68-0P 273209-69-1P
 273209-85-1P 273209-86-2P 273209-87-3P
 273210-36-9P 273210-37-0P 273210-38-1P
 273210-54-1P 273210-55-2P 273210-56-3P
 (prepn. of 17.beta.-acyl-17.alpha.-propynyl-11.beta.-arylsteroids with antiprogesterational activity)

RN 273209-12-4 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione,
 11-[4-(dimethylamino)phenyl]-17-(1-methoxy-
 17-(1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273209-13-5 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione,
 11-[4-(dimethylamino)phenyl]-21-methoxy-

L10 ANSWER 1 OF 2 USPATFULL (Continued)


RN 273209-31-7 USPATFULL
 CN Estr-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-(1-oxopropyl)-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273209-32-8 USPATFULL
 CN Estr-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-(3-hydroxy-1-propynyl)-17-(1-oxopropyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273209-67-9 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(methylamino)phenyl]-17-(1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273209-68-0 USPATFULL


L10 ANSWER 1 OF 2 USPATFULL (Continued)

17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 273209-14-6 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-(3-hydroxy-1-propynyl)-21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273209-30-6 USPATFULL
 CN Estr-4,9-dien-3-one,
 11-[4-(dimethylamino)phenyl]-17-(1-oxopropyl)-17-(1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L10 ANSWER 1 OF 2 USPATFULL (Continued)


19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(methylamino)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273209-69-1 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione,
 17-(3-hydroxy-1-propynyl)-21-methoxy-11-[4-(methylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273209-85-1 USPATFULL
 CN Estr-4,9-dien-3-one, 11-[4-(methylamino)phenyl]-17-(1-oxopropyl)-17-(1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273209-86-2 USPATFULL
 CN Estr-4,9-dien-3-one, 11-[4-(methylamino)phenyl]-17-(1-oxopropyl)-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


L10 ANSWER 1 OF 2 USPATFULL (Continued)

Absolute stereochemistry.




RN 273209-87-3 USPATFULL
 CN Estradiol-4,9-diene-3-one,
 17-(3-hydroxy-1-propynyl)-11-[4-(methylamino)phenyl]-
 17-(1-oxopropyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273210-36-9 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-(1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L10 ANSWER 1 OF 2 USPATFULL (Continued)




RN 273210-55-2 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(methylamino)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273210-56-3 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-17-(3-hydroxy-1-propynyl)-11-[4-(methylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L10 ANSWER 1 OF 2 USPATFULL (Continued)


RN 273210-37-0 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273210-38-1 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-(3-hydroxy-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273210-54-1 USPATFULL
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(methylamino)phenyl]-17-(1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 2 OF 2 USPATFULL

ACCESSION NUMBER: 2000:12791 USPATFULL
 TITLE: 20-keto-11.beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties
 INVENTOR(S): Cook, C. Edgar, Staunton, VA, United States
 Kepler, John A., Raleigh, NC, United States
 Zhang, Ping-sheng, Millbrae, CA, United States
 Lee, Yue-wei, Chapel Hill, NC, United States
 Tallent, C. Ray, Raleigh, NC, United States
 PATENT ASSIGNEE(S): Research Triangle Institute, Research Triangle Park, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6020328		20000201
APPLICATION INFO.:	US 1998-35949		19980306 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Dees, Jose' G.		
ASSISTANT EXAMINER:	Badio, Barbara		
LEGAL REPRESENTATIVE:	Obion, Spivak, McClelland, Maier & Neustadt, P.C.		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 10 Drawing Page(s)		
LINE COUNT:	2399		

OAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is directed to 20-keto-11.beta.-arylsteroids of formula 1:

1: ##STR1## wherein R.sup.1, R.sup.6, R.sup.7, R.sup.9, R.sup.12 and X are as defined by the specification. The compounds exhibit progestational and antiprogestational activities.


IT 240806-28-4P
 (prepn. of 20-keto-11.beta.-arylsteroids with antiprogestational activity)

RN 240806-28-4 USPATFULL
 CN 19,21-Dinorchola-4,9-dien-24-oic acid, 11-[4-(dimethylamino)phenyl]-17-hydroxy-3,20-dioxo-, ethyl ester, (11.beta.)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 240806-27-3
 CHF C32 H41 N O5

Absolute stereochemistry.



09/180,132

L10 ANSWER 2 OF 2 USPATFULL (Continued)

CM 2

CRN 76-05-1
CMF C2 H F3 O2



09/180,132


=> d ibib ab hitstr 1-5

09/180,132

L12 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2001 ACS
 ACCESSION NUMBER: 2001:747811 CAPLUS
 TITLE: Preparation of 17.alpha.-substituted-11.beta.-substituted-4-aryl and 21-substituted 19-norpregna-4,9-diene-3,20-dione derivatives as new antiprogesterational agents
 INVENTOR(S): Kim, Hyun K.; Blye, Richard P.; Rao, Pemmaraju N.; Cessac, James W.; Acosta, Carmie K.; Simmons, Anne Marie
 PATENT ASSIGNEE(S): Secretary of Health and Human Services, USA
 SOURCE: PCT Int. Appl., 171 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001074840	A2	20011011	WO 2001-US8581	20010316
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p> <p>RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CO, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG</p>				
<p>PRIORITY APPL. INFO.: US 2000-526855 A 20000317</p> <p>AB 19-Norpregna-4,9-diene-3,20-dione derivs. [I; R1 = OMe, SMe, NMe2, NHMe, NC4H8, NC5H10, NC4H8O, CHO, CH(OH)Me, C(O)Me, O(CH2)2NMe2, and -O(CH2)2NC5H10; R2 = H, halogen, alkyl, acyl, hydroxy, alkoxy, acyloxy, alkylcarbonate, cyponyloxy, S-alkyl, -SCN, S-acyl and -OC(O)R6; R6 = alkyl, alkoxy ester, alkoxy; R3 = alkyl, hydroxy, alkoxy and acyloxy; R4 = H, alkyl; X = O, (substituted) NOH] were prepd as antiprogesterational agents. The present invention provides methods wherein I were advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat meningiomas; to treat uterine leiomyomas; to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce cervical ripening; to induce labor; and for contraception. Thus, norpregnadienedione deriv. II was prepd. from 3,3-ethylenedioxy-17.beta.-cyano-17.alpha.-hydroxyestra-5(10),9(11)-diene and 4-bromo-N,N-dimethylaniline in 9 steps which showed 2.79 times the antiprogesterational potency in the antiClauberg test compared to CDB-2914.</p> <p>IT INDEXING IN PROGRESS</p> <p>IT 365416-28-OP 365416-50-OP 365416-51-9P 365416-59-7P 365416-60-OP 365416-61-1P 365416-65-5P 365416-67-7P 365416-68-8P 365416-69-9P 365416-70-2P 365416-71-3P 365416-72-4P 365416-73-5P 365416-74-6P 365416-75-7P</p> <p>RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic</p>				

L12 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)




RN 365416-59-7 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 365416-60-0 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 365416-61-1 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.


L12 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of 17.alpha.-substituted-11.beta.-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogesterational agents)
 RN 365416-28-0 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 365416-50-8 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 365416-51-9 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

L12 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)




RN 365416-65-5 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 365416-67-7 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 365416-68-8 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

L12 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)




RN 365416-69-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 365416-70-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 365416-71-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

L12 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)



RN 365416-75-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




IT 198413-96-6P 198413-97-7P 198413-98-8P
198413-99-9P 198414-00-5P 198414-21-0P
198414-30-1P 198414-32-3P 198414-34-5P
198414-38-9P 198414-42-5P 365416-18-8P
365416-19-9P 365416-20-2P 365416-21-3P
365416-22-4P 365416-33-7P 365416-34-8P
365416-35-9P 365416-45-1P 365416-48-4P
365416-49-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of 17.alpha.-substituted-11.beta.-substituted-4-aryl and
21-substituted 19-norpregnadienedione as new antiprogesterational
agents)
RN 198413-96-6 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione,
21-chloro-11-[4-(dimethylamino)phenyl]-
17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)

Absolute stereochemistry.




RN 365416-72-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 365416-73-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 365416-74-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

L12 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)




RN 198413-97-7 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198413-98-8 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17,21-dihydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198413-99-9 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione,
11-[4-(dimethylamino)phenyl]-17-hydroxy-
21-[(methylsulfonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)




RN 198414-00-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione,
 11-[4-(dimethylamino)phenyl]-21-fluoro-
 17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 198414-21-0 CAPLUS
 CN Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-
 oxopropyl)-, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 198414-30-1 CAPLUS

L12 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)




RN 198414-38-9 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione,
 11-[4-(dimethylamino)phenyl]-21-ethoxy-
 17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-42-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-bromo-11-[4-(dimethylamino)phenyl]-
 17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365416-18-8 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

L12 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)


CN 19-Norpregna-4,9-diene-3,20-dione,
 11-[4-(dimethylamino)phenyl]-21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-32-3 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(3-cyclopentyl-1-oxopropoxy)-11-[4-
 (dimethylamino)phenyl]-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-34-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-
 (dimethylamino)phenyl]-21-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)




RN 365416-19-9 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 365416-20-2 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 365416-21-3 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

L12 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)




RN 365416-22-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 365416-33-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 365416-34-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

L12 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)



RN 365416-49-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



IT 365416-23-5P 365416-27-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of 17- α -substituted-11- β -substituted-4-aryl and
21-substituted 19-norpregnadienedione as new antiprogesterational


agents)
RN 365416-23-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 365416-27-9 CAPLUS

L12 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)




RN 365416-35-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 365416-45-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 365416-48-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

L12 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



09/180,132

L12 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2001:489415 CAPLUS

DOCUMENT NUMBER: 135:61476

TITLE: Process for the preparation of 17.alpha.-acetoxy-11.beta.-[4-N,N-(dimethylamino)phenyl]-21-methoxy-19-norpregna-4,9-diene-3,20-dione, intermediates useful in the process, and processes for preparing such intermediates

INVENTOR(S): Kim, Hyun Koo; Rao, Pemmaraju N.; Cessac, James W.; Simmons, Anne Marie

PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA

SOURCE: PCT Int. Appl., 50 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2001047945	A1	20010705	WO 2000-US35479	20001229
---------------	----	----------	-----------------	----------

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LJ, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-173470 P 19991229

OTHER SOURCE(S): CASREACT 135:61476

AB A process for prep. the antiprogesterone agent, 17.alpha.-acetoxy-11.beta.-[4-N,N-(dimethylamino)phenyl]-21-methoxy-19-norpregna-4,9-dien-3,20-dione (I), intermediates useful in the process, and processes for prep. such intermediates was described. I was prepd. via a multistep synthetic sequence starting from cynaohydrin II. The synthetic sequence involved replacing the cyano group of II with a chloroacetyl group and a hydroxyl group; replacing the chloro group of the resulting compd. with an acetoxy group; deacetylating the resulting compd.; selectively ketalizing the resulting compd.; selectively methylating the 21-hydroxy group of the resulting compd.; reducing the 20-keto group of the resulting

compd.; epoxidizing the resulting compd.; introducing a N,N-dimethylaminophenyl group at the 11-position and opening the epoxide; deketalyzing the resulting compd.; selectively oxidizing the 20-hydroxyl group to a keto group; and acetylating the resulting compd.

IT 198414-30-1P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(process for the prep. of 17.alpha.-acetoxy-11.beta.-[4-N,N-(dimethylamino)phenyl]-21-methoxy-19-norpregna-4,9-diene-3,20-dione, intermediates useful in the process, and processes for prep. such intermediates)

RN 198414-30-1 CAPLUS

CN 19-Norpregna-4,9-diene-3,20-dione,

11-[4-(dimethylamino)phenyl]-17-hydroxy-

L12 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:401850 CAPLUS

DOCUMENT NUMBER: 133:17687

TITLE: Preparation of 17.beta.-acyl-17.alpha.-propynyl-11.beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties

INVENTOR(S): Cook, C. Edgar; Kepler, John A.; O'Reilly, Jill M.

PATENT ASSIGNEE(S): Research Triangle Institute, USA

SOURCE: PCT Int. Appl., 70 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2000034306	A1	20000615	WO 1999-US28535	19991203
---------------	----	----------	-----------------	----------

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LJ, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6172052 B1 20010109 US 1998-205395 19981204

EP 1135403 A1 20010926 EP 1999-964047 19991203

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.: US 1998-205395 A 19981204

WO 1999-US28535 W 19991203

OTHER SOURCE(S): MARPAT 133:17687

AB Novel 17.beta.-acyl-17.alpha.-propynyl steroids of formula I [R1 = NMe2, NHMe, NH2; R2 = Me, CF3, CH2OH; R3 = H, Me, OMe, OAc; R4 = H, Me, F, Cl; X = O, H2, NOH, NOME] are prepd. which exhibit potent antiprogesterone activity. Thus, II was prepd. from estrone in many steps. The relative progesterone binding activity of II was 31% of promegestone.

IT 273209-12-4P 273209-14-6P 273209-15-5P 273209-16-6P 273209-17-7P 273209-18-8P 273209-19-9P 273209-20-0P 273209-21-1P 273209-22-2P 273209-23-3P 273209-24-4P 273209-25-5P 273209-26-6P 273209-27-7P 273209-28-8P 273209-29-9P 273209-30-0P 273209-31-1P 273209-32-2P 273209-33-3P 273209-34-4P 273209-35-5P 273209-36-6P 273209-37-7P 273209-38-8P 273209-39-9P 273209-40-0P 273209-41-1P 273209-42-2P 273209-43-3P 273209-44-4P 273209-45-5P 273209-46-6P 273209-47-7P 273209-48-8P 273209-49-9P 273209-50-0P 273209-51-1P 273209-52-2P 273209-53-3P 273209-54-4P 273209-55-5P 273209-56-6P 273209-57-7P 273209-58-8P 273209-59-9P 273209-60-0P 273209-61-1P 273209-62-2P 273209-63-3P 273209-64-4P 273209-65-5P 273209-66-6P 273209-67-7P 273209-68-8P 273209-69-9P 273209-70-0P 273209-71-1P 273209-72-2P 273209-73-3P 273209-74-4P 273209-75-5P 273209-76-6P 273209-77-7P 273209-78-8P 273209-79-9P 273209-80-0P 273209-81-1P 273209-82-2P 273209-83-3P 273209-84-4P 273209-85-5P 273209-86-6P 273209-87-7P 273209-88-8P 273209-89-9P 273209-90-0P 273209-91-1P 273209-92-2P 273209-93-3P 273209-94-4P 273209-95-5P 273209-96-6P 273209-97-7P 273209-98-8P 273209-99-9P 273209-100-0P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 17.beta.-acyl-17.alpha.-propynyl-11.beta.-arylsteroids with antiprogesterone activity)

RN 273209-12-4 CAPLUS

CN 19-Norpregna-4,9-diene-3,20-dione,

11-[4-(dimethylamino)phenyl]-17-methoxy-


17-(1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)

21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 198414-31-2P, 17.alpha.-Acetoxy-11.beta.-[4-N,N-(dimethylamino)phenyl]-21-methoxy-19-norpregna-4,9-dien-3,20-dione
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(process for the prep. of 17.alpha.-acetoxy-11.beta.-[4-N,N-(dimethylamino)phenyl]-21-methoxy-19-norpregna-4,9-diene-3,20-dione, intermediates useful in the process, and processes for prep. such intermediates)

RN 198414-31-2 CAPLUS

CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetoxy)-11-[4-(dimethylamino)phenyl]-21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7

REFERENCE(S): (2) Lewbart, M; US 4511511 A 1985 CAPLUS

(3) Sigma Tau Ind Farmaceuti; EP 0658533 A 1995


CAPLUS (4) Teutsch, G; STEROIDS 1982, V39(6), P607 CAPLUS

(5) Us Health; WO 9741145 A 1997 CAPLUS

(6) Uskokovic, M; US 3496199 A 1970 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT


L12 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)



RN 273209-13-5 CAPLUS

CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-methoxy-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273209-14-6 CAPLUS

CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-(3-hydroxy-1-propynyl)-21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273209-30-6 CAPLUS

CN Estrone-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-(1-oxopropyl)-17-(1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)




RN 273209-31-7 CAPLUS
 CN Estrone-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-(1-oxopropyl)-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273209-32-8 CAPLUS
 CN Estrone-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-(3-hydroxy-1-propynyl)-17-(1-oxopropyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273209-67-9 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(methylamino)phenyl]-17-(1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


L12 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)

Absolute stereochemistry.




RN 273209-86-2 CAPLUS
 CN Estrone-4,9-dien-3-one, 11-[4-(methylamino)phenyl]-17-(1-oxopropyl)-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273209-87-3 CAPLUS
 CN Estrone-4,9-dien-3-one, 11-[4-(methylamino)phenyl]-17-(3-hydroxy-1-propynyl)-17-(1-oxopropyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273210-36-9 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-(1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

L12 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)




RN 273209-68-0 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(methylamino)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273209-69-1 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(methylamino)phenyl]-17-(3-hydroxy-1-propynyl)-21-methoxy-11-[4-(methylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273209-85-1 CAPLUS
 CN Estrone-4,9-dien-3-one, 11-[4-(methylamino)phenyl]-17-(1-oxopropyl)-17-(1-


L12 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)

Absolute stereochemistry.




RN 273210-37-0 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273210-38-1 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-(3-hydroxy-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273210-54-1 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-


L12 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)
(methylamino)phenyl]-17-(1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273210-55-2 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(methylamino)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273210-56-3 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-17-(3-hydroxy-1-propynyl)-11-[4-(methylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1999:576939 CAPLUS
DOCUMENT NUMBER: 131:199885
TITLE: Preparation of 20-keto-11.beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties
INVENTOR(S): Cook, C. Edgar; Kepler, John A.; Zhang, Ping-sheng; Lee, Yue-wei; Tallent, C. Ray
PATENT ASSIGNEE(S): Research Triangle Institute, USA
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9945022	A1	19990910	WO 1999-US3732	19990305
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6020328	A	20000201	US 1998-35949	19980306
AU 9928715	A1	19990920	AU 1999-28715	19990305
EP 1060186	A1	20001220	EP 1999-909531	19990305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9908598	A	20011002	BR 1999-8598	19990305
PRIORITY APPLN. INFO.: US 1998-35949 A 19980306 WO 1999-US3732 W 19990305				

OTHER SOURCE(S): MARPAT 131:199885
AB 20-Keto-11.beta.-arylsteroids of formula I [X = O, (substituted) NOH, H₂, OH, etc.; R1 = dialkylamino, imidazolyl, pyrrolyl, piperidino, etc.; R2 = H, halo; R3 = H, Me, halo; R4 = H, acyloxy, (substituted) OH, alkyl, etc.;

R5 = H, alkyl, halo, acyloxy, etc.] are prepd. which exhibit potent antiprogesterone activity. Thus, II was prepd. from 17.alpha.-hydroxymethyl-3-methoxy-19-norpregna-1,3,5(10)-trien-20-one and 4-bromo-N,N-dimethylaniline in several steps. The affinity of II for the progesterone hormone receptor was IC50 of 0.7 nM.

IT 240806-28-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. of 20-keto-11.beta.-arylsteroids with antiprogesterone activity)

RN 240806-28-4 CAPLUS
CN 19,21-Dinorchols-4,9-dien-24-oic acid, 11-[4-(dimethylamino)phenyl]-17-hydroxy-3,20-dioxo-, ethyl ester, (11.beta.)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 240806-27-3
CMF C32 H41 N O5

L12 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)
REFERENCE COUNT: 6
REFERENCE(S):

- (1) Bouali; US 5981516 A 1999 CAPLUS
- (2) Cook; US 5073548 A 1991 CAPLUS
- (3) Cook; US 6020328 A 2000 CAPLUS
- (4) Grandadam, J; EP 446124 1991 CAPLUS
- (5) Kasch; US 5407928 A 1995 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)
Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



REFERENCE COUNT: 2
REFERENCE(S):

- (1) Scholz; US 5446036 A 1995 CAPLUS
- (2) Teutsch; US 4386085 A 1983 CAPLUS

L12 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1997:740250 CAPLUS

DOCUMENT NUMBER: 127:358992

TITLE: Preparation of 21-substituted progesterone derivatives

as new antiprogesterone agents
 INVENTOR(S): Kim, Hyun K.; Blye, Richard P.; Rao, Pemmaraju N.;
 Cessac, James W.; Acosta, Carmie K.
 PATENT ASSIGNEE(S): United States Dept. of Health and Human Services,
 USA;

Kim, Hyun K.; Blye, Richard P.; Rao, Pemmaraju N.;
 Cessac, James W.; Acosta, Carmie K.
 SOURCE: PCT Int. Appl., 65 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9741145	A1	19971106	WO 1997-US7373	19970430
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LJ, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2253673	AA	19971106	CA 1997-2253673	19970430
AU 9729304	A1	19971119	AU 1997-29304	19970430
AU 710139	B2	19990916		
EP 900234	A1	19990310	EP 1997-923523	19970430
EP 900234	B1	20000705		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, FI				
AT 194358	E	20000715	AT 1997-923523	19970430
JP 2000509396	T2	20000725	JP 1997-539232	19970430
ES 2152671	T3	20010201	ES 1997-923523	19970430
PRIORITY APPLN. INFO.: US 1996-16628 P 19960501				
WO 1997-US7373 W 19970430				


OTHER SOURCE(S): MARPAT 127:358992
 AB Progesterone derivs. of formula I [R1 = OMe, SMe, NMe2, NHMe, CHO, Ac, CHOCH3; R2 = halo, alkyl, acyl, OH, alkoxy, etc.; R3 = OH, alkyl, alkoxy; R4 = H, alkyl; X = O, (substituted) NOH] are prepd. as antiprogesterone agents. The present invention provides methods wherein the compds. of formula I are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce labor; and for contraception. Thus, II was prepd. from 3,3-ethylenedioxy-17-beta-cyano-17.alpha.-hydroxyestra-5(10),9(11)-diene and 4-bromo-N,N-dimethylaniline in 9 steps. II showed

L12 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)




IT 198414-03-0P 198414-05-0P 198414-11-0P
 198414-22-1P 198414-32-3P 198414-33-6P
 198414-34-5P 198414-39-0P 198414-43-6P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of progesterone derivs. as antiprogesterone agents)
 RN 198414-03-8 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-fluoro-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-05-0 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-chloro-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 198414-11-8 CAPLUS

L12 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)
 2.79 times the antiprogesterone potency in the antiClauberg test compared to CDB 2014.


IT 198414-07-2P 198414-09-4P 198414-31-2P
 RL: BAC (Biological activity or effector, except adverse); RCT (Reactant);
 SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of progesterone derivs. as antiprogesterone agents)
 RN 198414-07-2 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17,21-bis(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-09-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetylthio)-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 198414-31-2 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)


CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-(acetylthio)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 198414-22-1 CAPLUS
 CN Estr-4,9-dien-3-one, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-(1-oxopropyl)-, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 198414-32-3 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(3-cyclopentyl-1-oxopropoxy)-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-33-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-(3-cyclopentyl-1-


L12 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)
oxopropoxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-34-5 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-39-0 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-ethoxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)




RN 198413-97-7 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198413-98-8 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17,21-dihydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198413-99-9 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-hydroxy-21-[(methylsulfonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)



RN 198414-43-6 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-bromo-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 198413-96-6P 198413-97-7P 198413-98-8P
198413-99-9P 198414-00-5P 198414-21-0P
198414-30-1P 198414-38-9P 198414-42-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of progesterone derivs. as Antiprogesterone agents)
RN 198413-96-6 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-chloro-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)




RN 198414-00-5 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-21-fluoro-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-21-0 CAPLUS
CN 19-Norpregna-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-oxopropyl)-, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-30-1 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-hydroxy-21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)


09/180,132

L12 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)
Absolute stereochemistry.




RN 198414-38-9 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione,
11-[4-(dimethylamino)phenyl]-21-ethoxy-
17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-42-5 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-bromo-11-[4-(dimethylamino)phenyl]-
17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2001 ACS (Continued)

09/180,132

L15 ANSWER 1 OF 12 MARPAT COPYRIGHT 2001 ACS

ACCESSION NUMBER: 129:50105 MARPAT
 TITLE: Uses of anti-glucocorticoid compounds for the treatment of psychoses or addictive behaviors
 INVENTOR(S): Oberlander, Claude; Piazza, Pier Vincenzo
 PATENT ASSIGNEE(S): Hoechst Marion Roussel, Fr.; Oberlander, Claude; Piazza, Pier Vincenzo
 SOURCE: PCT Int. Appl., 41 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9826783	A1	19980625	WO 1997-FR2320	19971217
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
FR 2757400	A1	19980626	FR 1996-15649	19961219
FR 2757400	B1	19991217		
AU 9855632	A1	19980715	AU 1998-55632	19971217
EP 892641	A1	19990127	EP 1997-952078	19971217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.:

FR 1996-15649 19961219
 WO 1997-FR2320 19971217


AB Glucocorticoid antagonists, except mifepristone, are used as dopamine type II receptor antagonists to treat psychotic or addictive behavior. Thus, 17.β.-(4-methoxy-10.β.-(4-methylphenyl)methyl)-17.α.-(1-propenyl)estra-4,9(11)-dien-3-one considerably reduced the response to morphine in vivo.

MSTR 1



G1 = Ph (SO (1-)) G11)
 G2 = hydrocarbyl<(1-8)>
 G3 = 35-13 37-14

L15 ANSWER 1 OF 12 MARPAT COPYRIGHT 2001 ACS (Continued)



G4 = C(O)
 G11 = alkenyloxy<(2-6)>
 G12 = 41

C(O)CH₂-OH
41

G16 = OH
 DER: and pharmaceutically acceptable acid addition salts
 MPL: claim 4
 NTE: substitution is restricted

L15 ANSWER 2 OF 12 MARPAT COPYRIGHT 2001 ACS

ACCESSION NUMBER: 128:188869 MARPAT
 TITLE: Mixed agonists of the progesterone receptor and assays
 INVENTOR(S): for them
 McDONNELL, Donald P.; WAGNER, Brandee L.
 PATENT ASSIGNEE(S): Duke University, USA
 SOURCE: PCT Int. Appl., 62 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9805679	A2	19980212	WO 1997-US13754	19970805


W: CA
 RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRIORITY APPLN. INFO.:

US 1996-23206 19960805

AB A third class of PR-ligand (i.e. mixed agonist) is identified which induces a progesterone receptor conformation distinct from that induced by a PR agonist or antagonist; the agonists are estra-4,9-dien-3-one derivs. PR mixed agonists exhibit partial agonist activity which is influenced by cell context. These compds. provide useful pharmacol. profiles for treating progesterone related diseases and/or conditions, such as uterine proliferation from estrogen administration, endometriosis, breast cancer, fibroids, endometrial cancer, and brain meningiomas. The agonists can also be used as contraceptives. Assays are provided to screen for PR mixed agonists. Mol. designs are provided to convert a PR antagonist to a PR mixed agonist.

MSTR 1



G2 = 30

C(O)G3

G3 = alkyl<(1-6)> (SO)
 G6 = alkyl<(1-6)> (SO)
 G9 = 52

L15 ANSWER 2 OF 12 MARPAT COPYRIGHT 2001 ACS (Continued)



G10 = COME
 MPL: claim 4

09/180,132


L15 ANSWER 3 OF 12 MARPAT COPYRIGHT 2001 ACS

ACCESSION NUMBER: 124:22540 MARPAT
 TITLE: Pharmaceutical compositions of antigluco-corticoid compounds for treating or preventing symptoms of spontaneous or narcotic-induced withdrawal.
 INVENTOR(S): Petit, Francis; Philibert, Daniel; Ulmann, Andre
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Eur. Pat. Appl., 30 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 676203	A1	19951011	EP 1995-400764	19950406
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
FR 2718354	A1	19951013	FR 1994-4156	19940408
FR 2718354	B1	19960503		
ZA 9502058	A	19960313	ZA 1995-2058	19950313
CA 2146600	AA	19951009	CA 1995-2146600	19950407
FI 9501683	A	19951009	FI 1995-1683	19950407
AU 9516326	A1	19951019	AU 1995-16326	19950407
JP 07278017	A2	19951024	JP 1995-107071	19950407
HU 71468	A2	19951128	HU 1995-1019	19950407
CN 1116929	A	19960221	CN 1995-104015	19950407

PRIORITY APPLN. INFO.:
 AB Antigluco-corticoid steroids such as mifepristone, onapristone, ilopristone and related steroids are proposed for the prevention or treatment of withdrawal syndromes, either spontaneous or ptpd. by narcotics or mixts. of narcotics. These antigluco-corticoids would be useful in the withdrawal from morphinomimetics such as heroin, morphine or methadone as well as cocaine. Pharmacol. activity was demonstrated by the effect of the antigluco-corticoids on the stereotypic behavior of mice in response to narcotic withdrawal syndrome was induced by administration of the opioid antagonist, naloxone. An antiprogesterone activity of the steroids in their action mechanism was eliminated. Results confirmed the involvement of endogenous glucocorticoids in morphine withdrawal since this is inhibited by antigluco-corticoids or adrenalectomy.

MSTR 2



G1 = Ph (SO (1-)) G2)


L15 ANSWER 4 OF 12 MARPAT COPYRIGHT 2001 ACS

ACCESSION NUMBER: 123:218391 MARPAT
 TITLE: Steroids for reducing multidrug resistance to cancer chemotherapeutic agents
 INVENTOR(S): Cohn, Suzanne Bourgeois; Gruol, Donald J.
 PATENT ASSIGNEE(S): Salk Institute for Biological Studies, USA
 SOURCE: PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9517192	A1	19950629	WO 1994-US14624	19941219
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LJ, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9514395	A1	19950710	AU 1995-14395	19941219

PRIORITY APPLN. INFO.:
 AB Certain steroid-like compds. [I: R1 = H; R2 = OR; or R1R2 = O; R = H, lower alkyl, Me3Si; R3 = H, Me, or absent if double bond or epoxide bridge joins C9 and C10; R4 = OR', C4-18 cyclic org. group contg. O, N, P, or Si; R' = lower alkyl, Me3Si; R5 = H, OR; or R5C16C17 form a 3-, 5-, 6-, or 7-membered ring; R6 = C(O)CH3, CH(OH)CH3, C(O)CH2OH, (substituted) hydrocarbyl; R9 = H, halo, or absent if double bond or epoxide bridge joins C9 and C10] are capable of inhibiting the P-glycoprotein-associated efflux pump which is considered responsible for multidrug resistance. Chemotherapy can be enhanced by facilitating the accumulation of drug at the target site, with reduced or eliminated competition by the drug efflux system. Thus RU 38486, an antiprogesterone, at 5 .mu.M facilitated killing of multidrug-resistant S7CD-5 murine thymoma cells by 20 .mu.M puromycin.

MSTR 1B




09/180,132

L15 ANSWER 5 OF 12 MARPAT COPYRIGHT 2001 ACS
 ACCESSION NUMBER: 122:256423 MARPAT
 TITLE: Antiglucocorticoid steroids for the treatment of anxiety disorders
 INVENTOR(S): Peeters, Bernardus Wynand Machijs Maria
 PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.
 SOURCE: PCT Int. Appl., 25 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9504536	A1	19950216	WO 1994-EP2513	19940728
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KG, KP, KR, KZ, LK, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9474968	A1	19950228	AU 1994-74968	19940728
AU 687088	B2	19980219		
EP 712311	A1	19960522	EP 1994-924819	19940728
EP 712311	B1	19981007		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09501172	T2	19970204	JP 1994-506200	19940728
AT 171873	E	19981015	AT 1994-924819	19940728
ES 2124905	T3	19990216	ES 1994-924819	19940728
US 5741787	A	19980421	US 1996-581631	19960118
PRIORITY APPLN. INFO.: EP 1993-202304 19930804 EP 1994-924819 19940728 WO 1994-EP2513 19940728				

AB Antiglucocorticoid steroids are used for the manuf. of a pharmaceutical compn. for the treatment of anxiety disorders. The anxiolytic effect of 11.beta.-(4-dimethylaminophenyl)-17.beta.-hydroxy-17.alpha.-(prop-1-ynyl)-estra-4,9-dien-3-one (RU38486) was demonstrated in animal testing (antagonism of fear-potentiated startle). Prepn. and activity (antagonism of stress-induced hyperthermia) of selected steroids of the invention is also described.

MSTR 1




L15 ANSWER 6 OF 12 MARPAT COPYRIGHT 2001 ACS
 ACCESSION NUMBER: 116:35156 MARPAT
 TITLE: Preparation and use of antiprogestomimetics for synchronization of parturition in livestock
 INVENTOR(S): Grandadam, Jean Andre
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Eur. Pat. Appl., 13 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 446124	A2	19910911	EP 1991-400594	19910305
EP 446124	A3	19920527		
R: AT, BE, CH, DE, DK, FR, GB, GR, IT, LI, LU, NL, SE				
FR 2659233	A1	19910913	FR 1990-2783	19900306
FR 2659233	B1	19940121		
CA 2037549	AA	19910907	CA 1991-2037549	19910305
AU 9172608	A1	19910912	AU 1991-72608	19910305
AU 642975	B2	19931104		
ZA 9101603	A	19920527	ZA 1991-1603	19910305
JP 04211610	A2	19920803	JP 1991-62496	19910305
RU 2037295	C1	19950619	RU 1991-4895041	19910305
CN 1055665	A	19911030	CN 1991-102108	19910306
HU 59006	A2	19920428	HU 1991-729	19910306
PRIORITY APPLN. INFO.: FR 1990-2783 19900306				

AB The title antiprogestomimetics are I (R1 = C1-18 hydrocarbyl optionally substituted with .gtoreq.1 heteroatoms and bonded to the steroid by a C; R2 = C1-8 hydrocarbyl; X = remainder of 5- and 6-membered ring optionally substituted and optionally unsatd.; C = A = CNOH, oxo (free or blocked as ketal), etc.; B and C together form a double bond or epoxide bridge) and acid addn. salts thereof. Prepn. of 2 I are described. 17.beta.-Hydroxy-11.beta.-(4-dimethylaminophenyl)-17.alpha.-(prop-1-ynyl)estra-4,9-dien-3-one (II) was more effective at synchronizing parturition than cloprostenol when tested in sows. Injectable pharmaceuticals contg. II are disclosed.

MSTR 1C




G1 = 30



G2 = hydrocarbyl<(1-8)>
 G3 = 55-13 57-14

L15 ANSWER 5 OF 12 MARPAT COPYRIGHT 2001 ACS (Continued)
 G7 = 44




G10 = alkyl<(1-6)>
 G11 = OH
 G16 = alkylcarbonyl<(1-5)> (SO (1-) G17)
 G18 = 39



MPL: claim 2

L15 ANSWER 6 OF 12 MARPAT COPYRIGHT 2001 ACS (Continued)



G9 = OH
 G15 = 61



G4 +G17= O
 DER: and protected derivatives
 DER: and acid addition salts
 MPL: claim 1

09/180,132

L15 ANSWER 7 OF 12 MARPAT COPYRIGHT 2001 ACS
 ACCESSION NUMBER: 115:214857 MARPAT
 TITLE: Injectable microspheres containing antiestrogenic and
 antiprogesteromic steroids
 INVENTOR(S): Cohen, Gerard; Dubois, Jean Luc
 PATENT ASSIGNEE(S): Roussel UCLAF, Fr.
 SOURCE: Ger. Offen., 15 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4036425	A1	19910516	DE 1990-4036425	19901115
FR 2654337	A1	19910517	FR 1989-14976	19891115
FR 2654337	B1	19940805		
SE 9003570	A	19910516	SE 1990-3570	19901109
SE 9005511	A4	19920810	SE 1990-1065	19901109
DK 9002709	A	19910516	DK 1990-2709	19901113
CA 2029940	A	19910516	CA 1990-2029940	19901114
JP 03294229	A2	19911225	JP 1990-306374	19901114
CH 681961	A	19930514	CH 1990-3611	19901114
NL 9004292	A	19910603	NL 1990-2492	19901115
GB 2239798	A1	19910717	GB 1990-24862	19901115
CH 681979	B2	19931027		
AT 9003113	A	19950415	AT 1990-2313	19901115
AT 4002938	R	19951127		

PRIORITY APPL. INFO.: B 1995/1127 FR 1989-14976 1989/1115
AB Biodegradable microspheres comprise the title steroids (Markush given)
and
copolymers of lactic acid with glycolic acid. A mixt. of 250 mL aq. 0.3%
hydrolyzed PVA soln., 1 g poly(DL-lactic acid-glycolic acid), 17 g
CH₂Cl₂,
and 0.5 g
17.beta.-hydroxy-11.beta.-[4-(dimethylamino)phenyl]-17.alpha.-(1-
propenyl)-5-androst-3-one was stirred at 22.degree. and decreasing pressure (storep.400 mm Hg) to give
microspheres, which were used for the prepn. of injections.

MSTR 1A

G1—G3

G1 - 3



G2 ■ Me
G3 ■ 24


L15 ANSWER 8 OF 12 MARPAT COPYRIGHT 2001 ACS
 ACCESSION NUMBER: 115:151901 MARPAT
 TITLE: Use of antiprogestomimetics for stimulating
 ovulation, and new preparation for use in pharmaceutical
 compositions
 INVENTOR(S): Grandadam, Jean Andre
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Eur. Pat. Appl., 24 pp.
 CODEN: EPXKDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 417003	A2	19910313	EP 1900-402449	19900906
EP 417003	A3	19911204		
EP 417003	B1	19940629		
FR 2651435	BE, CH, DE, DK, ES, GB, IT, LI, LU, NL, SE	19910308	FR 1989-11699	19890907
FR 2651435	A	19940422		
US 5173483	B1	19921222	US 1990-578894	19900905
CA 2047278	AA	19910308	CA 1990-2047278	19900906
AU 9562259	AA	19910314	AU 1990-62259	19900907
JP 23805	A	19920505		
JP 03099015	A	19910424	JP 1990-236004	19900907
JP 0302258	B2	20000410		


PRIORITY APPLM. INFO.: FR 1989-11699 19890907
 AB Anti-progestomimetic compds., e.g. I [R1 = C1-18 hydrocarbyl with optionally g-tetrel-1 heteroatoms, bonded to the steroid by a C, R2 = C1-8 hydrocarbyl; X = rest of 5- or 6-membered (substituted) (unsatd.) ring; R3 = oxo (if 5-membered) or thio (if 6-membered) group; R4 = C1-8 alkyl, C7-15 aralkyl; B and C together form a double bond or epoxide bridge] and their acid and base addn. salts, are used for making pharmaceuticals for stimulating ovulation, e.g. in cows. The compds. of the invention are preferably used following treatment with progesterone

a progestomimetic, e.g. 3-oxo-17.alpha.-allyl-17.beta.-hydroxyestra-4,9,11-triene (11). Thus, heifer cows were 1st administered 11 for 17 days; on the day following the last administration, the animals were injected with 17.beta.-hydroxy-11.beta.-(4-dimethylaminophenyl)-17.alpha.-(prop-1-ynyl)estra-4,9-dien-3-one. All of the heifers came to heat after a very short delay period, and LH levels rose very rapidly. Prepn. of 12 anti-progestomimetics is presented.


MSTR 1B




L15 ANSWER 7 OF 12 MARPAT COPYRIGHT 2001 ACS (Continued)



G5 ■ 68-26 70-27



G9 - 74



G10 ▪ OH
G13 ▪ OH
MPL: claim 6

L15 ANSWER 8 OF 12 MARPAT COPYRIGHT 2001 ACS (Continued)
G1 = 85



G3 = hydrocarbyl<(1-8)>
G10 = COMe
G12 = OH / 96



G14 = 98



G15 ▪ OH
G5 +G6 ▪ O
DER: or acid or base addition salts
MPL: claim 2
NTE: oxo formed by G5 and G6 may be protected as a ketal

09/180,132

L15 ANSWER 9 OF 12 MARPAT COPYRIGHT 2001 ACS

ACCESSION NUMBER: 115:9125 MARPAT

TITLE: Preparation of
 ω -[3-oxoestra-4,9-dien-11,12-yl]phenylamino]alkanoates as antigluccorticoids

INVENTOR(S): Moguilewsky, Martine; Nedelec, Lucien; Nique, Francois; Philibert, Daniel

PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.

SOURCE: Eur. Pat. Appl., 33 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 414606	A2	19910227	EP 1990-402328	19900822
EP 414606	A3	19910724		
EP 414606	B1	19941102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
FR 2651233	A1	19910301	FR 1989-11173	19890823
FR 2651233	B1	19911213		
CA 2022648	AA	19910224	CA 1990-2022648	19900803
ZA 9006341	A	19911030	ZA 1990-6341	19900810
US 5166146	A	19921124	US 1990-568597	19900816
JP 03090097	A2	19910416	JP 1990-217281	19900820
JP 3026997	B2	20000327		
IL 95451	A1	19950731	IL 1990-95451	19900821
AU 9061189	A1	19910228	AU 1990-61189	19900822
AU 634569	B2	19930225		
HU 54706	A2	19910328	HU 1990-5275	19900822
HU 208154	B	19930830		
ES 2063313	T3	19950101	ES 1990-402328	19900822
CN 1051362	A	19910515	CN 1990-107161	19900823
CN 1033808	B	19970115		
RU 2041236	C1	19950809	RU 1992-5011511	19920518

PRIORITY APPL. INFO.:

AB The title compds. [I; R1 = aliph. hydrocarbyl; R2 = H, (un)substituted alkyl; R5, R6 = H, alkyl; X = atoms to complete an (un)substituted 5- or 6-membered ring; Z = (un)satified CO₂H; n = 1-6] were prepd. Thus, aminophenylestradienone II (R = R5 = R6 = H) was condensed with BrCH₂CO₂Me

to give, after sapon., II (R = CH₂CO₂Na, R5 = R6 = H) which at 10-6M in vitro gave 82% inhibition of uridine incorporation into rat thymocytes.

MSTR 2A



L15 ANSWER 10 OF 12 MARPAT COPYRIGHT 2001 ACS

ACCESSION NUMBER: 114:229227 MARPAT

TITLE: Preparation of 19-nor 3-oxo steroids with an amine substituted 17-chain as antioxidants and antiinflammatories: their use as medicines and pharmaceutical composition containing them

INVENTOR(S): Clausner, Andre; Leclaire, Jacques; Nedelec, Lucien; Philibert, Daniel

PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.

SOURCE: Eur. Pat. Appl., 29 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 389370	A1	19900926	EP 1990-400784	19900322
EP 389370	B1	19940427		
R: CH, DE, FR, GB, IT, LI, NL				
FR 2644789	A1	19900928	FR 1989-3742	19890322
FR 2644789	B1	19950203		
JP 02273693	A2	19901108	JP 1990-68508	19900320
JP 2848907	B2	19990120		
US 5108996	A	19920428	US 1990-497562	19900321

PRIORITY APPL. INFO.:

AB The title compds. [I; R1, R2 = H, Me; R11 = (poly) (hetero)hydrocarbyl; one

of R17 and R18 is OH or acyloxy and the other is Q; Z = alkylene, alkenylene, alkynylene; P = (substituted) pyrimidinyl, pyridyl] were prepd. via reacting the halo derivs. II or III (X = halo) with the appropriate pyrimidinyl or pyridine deriv. IV. Reaction of estradienone


V

[R3 = 3-bromo-1-propynyl, R4 = OH] (prepn. given) was reacted with 2,4-bis(1-pyrrolidinyl)-6-(1-piperazinyl)pyrimidine (prepn. given) in acetone contg. K₂CO₃ at ambient temp. for 2 h to give V [R3 = 3-[4-[2,6-bis(1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-1-propynyl;


R4

= OH]. At 5 .times. 10-4 M this inhibited in vitro the formation of malonyldialdehyde, a measure of lipid peroxidn., in rat brain homogenate by approx. 47.5%.

MSTR 3




G2 = 107




L15 ANSWER 9 OF 12 MARPAT COPYRIGHT 2001 ACS (Continued)


G1 = Ak<(1-8)>
 G3 = phenylene
 G4 = alkylamino<(1-12)>
 G9 = 39-18 37-17




G10 = (1-2) 45



G13 = OH / 53



G16 = 68



DER: and protected derivatives
 MPL: claim 7

L15 ANSWER 10 OF 12 MARPAT COPYRIGHT 2001 ACS (Continued)

G4 = OH
 G14 = NMe₂
 MPL: claim 13
 NTE: the alkylamino and dialkylamino groups in G11 may be interrupted by oxygen, sulfur, or nitrogen

09/180,132

L15 ANSWER 11 OF 12 MARPAT COPYRIGHT 2001 ACS
 ACCESSION NUMBER: 111:233356 MARPAT
 TITLE: New 11-aryl steroids useful as antiprogesterins, their preparation, and pharmaceuticals containing them
 INVENTOR(S): De Jongh, Hendrik Paul; Van Vliet, Nicolaas Pieter
 PATENT ASSIGNEE(S): AKZO N. V., Neth.
 SOURCE: Eur. Pat. Appl., 10 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 321010	A1	19890621	EP 1988-202678	19881125
EP 321010	B1	19930203		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
AT 85342	E	19930215	AT 1988-202678	19881125
ES 2053714	T3	19940801	ES 1988-202678	19881125
ZA 8808996	A	19890830	ZA 1988-8996	19881130
AU 8826469	A1	19890615	AU 1988-26469	19881201
AU 613433	B2	19910801		
US 4921845	A	19900501	US 1988-281582	19881208
CA 1301162	A1	19920519	CA 1988-585297	19881208
DK 8806880	A	19890613	DK 1988-6880	19881209
DK 168444	B1	19940328		
FI 8805717	A	19890613	FI 1988-5717	19881209
FI 89056	B	19930430		
FI 89056	C	19930810		
KR 9709592	B1	19970614	KR 1988-16480	19881210
CN 1034731	A	19890816	CN 1988-108484	19881212
CN 1019807	B	19921230		
JP 01211597	A2	19890824	JP 1988-313643	19881212

PRIORITY APPLN. INFO.:

AB Aryl steroids I [R1 = aryl substituted by -NXY; X, Y = H, Cl-4 hydrocarbyl; or XY = C2-6 hydrocarbyl forming 3- to 7-membered ring; R2 = H, OH, acyloxy, alkoxy, (unsatd. Cl-8 hydrocarbyl with -gtoreq.1 OH, oxo, N3, cyano, and/or halo group; R3 = OH, acyloxy, alkoxy, or acyl optionally substituted by OH, alkoxy, acyloxy, or halo; or R2R3 forms ring; R2 noteq. H or OH when R3 = OH; R4 = Me, Et], which are strong antiprogesterins with little or no antigluco-corticoid activity (no data), are prepd. Thus, 7.beta.-methylster-5-(10)-ene-3,17-dione 3,3-di-Me acetal underwent NaBH4 reduct., decarboxylation, bromination/dehydrobromination, reketolization, and epoxidn., to give 5.alpha., 10.alpha.-epoxy-17.beta.-hydroxy-7.beta.-methylster-9(11)-en-3-one 3,3-ethylene acetal. This underwent CuCl-catalyzed coupling with p-(Me2N)C6H4MgBr, Oppenauer oxidn. of 17-OH, alkynylation with THP-OCH2C2.tpbond.CMgBr (THP = tetrahydropyranyl), and deprotection, to give (dimethylaminophenyl)hydroxy(hydroxypropynyl)methylsteradienone II.

MSTR 1


L15 ANSWER 12 OF 12 MARPAT COPYRIGHT 2001 ACS
 ACCESSION NUMBER: 110:213172 MARPAT
 TITLE: 13(Alpha)-alkylgonanes, their production, and pharmaceutical preparations containing same
 INVENTOR(S): Neef, Guenter; Wiechert, Rudolf; Beier, Sybille; Elger, Walter; Henderson, David
 PATENT ASSIGNEE(S): Schering A. G., Fed. Rep. Ger.
 SOURCE: U.S., 5 pp. Cont. of U.S. Ser. No. 621,308.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4780461	A	19881025	US 1985-810148	19851218
DE 3321826	A1	19841220	DE 1983-3321826	19830615
DE 3413036	A1	19851017	DE 1984-3413036	19840404
DE 3446661	A1	19860619	DE 1984-3446661	19841218

PRIORITY APPLN. INFO.:

AB 13.alpha.-Alkylgonanes I; R = Cl-4 acyl; X = O, NOH; II; R1 = amino; R2 = H, Me, Et; R3 = (substituted) alkyl; R4 = OH, alkoxy, alkanoyloxy; or R3R4 = O; R5 = H, alkyl; III; Z = CH2CH2, CH2Me2CH2], having antigestagenic activity and useful as postcoital contraceptives, or for triggering abortion and menstruation (no data), are prepd. via photochem. epimerization of the 13.beta.-gonanes IV. 11.beta.-(4-Dimethylaminomethyl)-17.alpha.-hydroxy-13.alpha.-methyl-17.beta.-(3-hydroxypropyl)-4,9-gonadien-3-one (V) was acetylated with Ac2O in pyridine to give 11.beta.-(4-dimethylaminomethyl)-17.alpha.-hydroxy-13.alpha.-methyl-17.beta.-(3-acetoxypropyl)-4,9-gonadien-3-one. A tablet was formulated contg. V 10.0, lactose 140.0, corn starch 69.5, polyvinylpyrrolidone 25 2.5, Aerosil 2.0, and Mg stearate 0.5 mg.


MSTR 2



G1 = OMe
 G4 = 59

C(O)CH2-G11

L15 ANSWER 11 OF 12 MARPAT COPYRIGHT 2001 ACS (Continued)



G1 = phenylene
 G3 = NH
 G4 = Ak<(1-4)>
 G5 = OH
 G6 = 35

C(O)-G12

G12 = Ak (SO (1-) G10)
 G14 = 42



MPL: claim 1

L15 ANSWER 12 OF 12 MARPAT COPYRIGHT 2001 ACS (Continued)

G8 = OH
 G11 = OH
 G12 = 66



GGA = 33 <RC (1), RS (1) MS (1) X6, EC (0-) O (1-) N (0-) S (0) OTHERQ, AN (1) N, BD (ALL) SE>
 DER: and acid addition salts
 MPL: claim 18